peak-20260930
0000765880false--12-312026Q3P4Yhttp://fasb.org/us-gaap/2026#SecuredOvernightFinancingRateSofrMemberhttp://fasb.org/us-gaap/2026#SecuredOvernightFinancingRateSofrMemberP1Ynone3xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:purepeak:propertypeak:statespeak:extension_optionpeak:joint_ventureutr:bblpeak:renewal_optionpeak:derivative_heldpeak:facilitypeak:obligationpeak:plan_participantpeak:unitpeak:entitypeak:segmentpeak:hospitalpeak:assetpeak:director00007658802026-01-012026-09-3000007658802026-10-3000007658802026-09-3000007658802025-12-3100007658802026-07-012026-09-3000007658802025-07-012025-09-3000007658802025-01-012025-09-300000765880us-gaap:CommonStockMember2026-06-300000765880us-gaap:AdditionalPaidInCapitalMember2026-06-300000765880us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2026-06-300000765880us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-06-300000765880us-gaap:ParentMember2026-06-300000765880us-gaap:NoncontrollingInterestMember2026-06-3000007658802026-06-300000765880us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2026-07-012026-09-300000765880us-gaap:ParentMember2026-07-012026-09-300000765880us-gaap:NoncontrollingInterestMember2026-07-012026-09-300000765880us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-07-012026-09-300000765880us-gaap:CommonStockMember2026-07-012026-09-300000765880us-gaap:AdditionalPaidInCapitalMember2026-07-012026-09-300000765880us-gaap:CommonStockMember2026-09-300000765880us-gaap:AdditionalPaidInCapitalMember2026-09-300000765880us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2026-09-300000765880us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-09-300000765880us-gaap:ParentMember2026-09-300000765880us-gaap:NoncontrollingInterestMember2026-09-300000765880us-gaap:CommonStockMember2025-06-300000765880us-gaap:AdditionalPaidInCapitalMember2025-06-300000765880us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2025-06-300000765880us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-06-300000765880us-gaap:ParentMember2025-06-300000765880us-gaap:NoncontrollingInterestMember2025-06-3000007658802025-06-300000765880us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2025-07-012025-09-300000765880us-gaap:ParentMember2025-07-012025-09-300000765880us-gaap:NoncontrollingInterestMember2025-07-012025-09-300000765880us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-07-012025-09-300000765880us-gaap:CommonStockMember2025-07-012025-09-300000765880us-gaap:AdditionalPaidInCapitalMember2025-07-012025-09-300000765880us-gaap:CommonStockMember2025-09-300000765880us-gaap:AdditionalPaidInCapitalMember2025-09-300000765880us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2025-09-300000765880us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-09-300000765880us-gaap:ParentMember2025-09-300000765880us-gaap:NoncontrollingInterestMember2025-09-3000007658802025-09-300000765880us-gaap:CommonStockMember2025-12-310000765880us-gaap:AdditionalPaidInCapitalMember2025-12-310000765880us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2025-12-310000765880us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310000765880us-gaap:ParentMember2025-12-310000765880us-gaap:NoncontrollingInterestMember2025-12-310000765880us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2026-01-012026-09-300000765880us-gaap:ParentMember2026-01-012026-09-300000765880us-gaap:NoncontrollingInterestMember2026-01-012026-09-300000765880us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-09-300000765880us-gaap:CommonStockMember2026-01-012026-09-300000765880us-gaap:AdditionalPaidInCapitalMember2026-01-012026-09-300000765880us-gaap:CommonStockMember2024-12-310000765880us-gaap:AdditionalPaidInCapitalMember2024-12-310000765880us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2024-12-310000765880us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310000765880us-gaap:ParentMember2024-12-310000765880us-gaap:NoncontrollingInterestMember2024-12-3100007658802024-12-310000765880us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2025-01-012025-09-300000765880us-gaap:ParentMember2025-01-012025-09-300000765880us-gaap:NoncontrollingInterestMember2025-01-012025-09-300000765880us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-09-300000765880us-gaap:CommonStockMember2025-01-012025-09-300000765880us-gaap:AdditionalPaidInCapitalMember2025-01-012025-09-300000765880peak:JanusLivingIncMemberpeak:CommonClassA1Memberus-gaap:IPOMember2026-03-232026-03-230000765880peak:JanusLivingIncMemberus-gaap:IPOMember2026-03-232026-03-230000765880peak:JanusLivingIncMemberpeak:CommonClassA1Memberpeak:FollowOnPublicOfferingMember2026-06-042026-06-040000765880peak:JanusLivingIncMemberpeak:CommonClassA1Memberus-gaap:OverAllotmentOptionMember2026-06-040000765880peak:JanusLivingIncMemberpeak:CommonClassA1Memberus-gaap:OverAllotmentOptionMember2026-06-042026-06-040000765880peak:JanusLivingIncMemberpeak:FollowOnPublicOfferingMember2026-06-042026-06-040000765880peak:JanusLivingIncMemberpeak:CommonClassA1Memberpeak:FollowOnPublicOfferingMember2026-08-122026-08-120000765880peak:JanusLivingIncMemberpeak:FollowOnPublicOfferingMember2026-08-122026-08-120000765880peak:JanusLivingIncMember2026-07-012026-09-300000765880peak:JanusLivingIncMember2026-01-012026-09-300000765880peak:JanusLivingIncMemberpeak:CommonClassA1Member2026-03-232026-03-230000765880peak:JanusLivingOPCommonUnitsMember2026-03-232026-03-230000765880peak:JanusLivingIncMemberpeak:HealthpeakMemberpeak:CommonClassA2Member2026-03-232026-03-230000765880peak:JanusLivingIncMemberus-gaap:CommonStockMember2026-01-012026-09-300000765880peak:SeniorHousingCommunitiesMember2026-03-230000765880peak:SH2019VenturesLLVJVMember2026-01-310000765880peak:SH2019VenturesLLVJVMember2026-01-012026-01-310000765880peak:SH2019VenturesLLVJVMemberpeak:SeniorHousingPropertiesMember2026-01-310000765880peak:SeniorHousingMember2026-01-012026-03-310000765880stpr:GApeak:SeniorHousingPropertiesMember2026-01-012026-03-310000765880stpr:FLpeak:SeniorHousingPropertiesMember2026-01-012026-03-310000765880stpr:WApeak:SeniorHousingPropertiesMember2026-01-012026-03-310000765880stpr:WApeak:SeniorHousingPropertiesMember2026-04-012026-06-300000765880stpr:AZpeak:SeniorHousingPropertiesMember2026-04-012026-06-300000765880stpr:GApeak:SeniorHousingPropertiesMember2026-07-012026-09-300000765880peak:IllinoisIndianaKentuckyMissouriNebraskaAndSouthCarolinaMemberpeak:SeniorHousingPropertiesMember2026-07-012026-09-300000765880peak:Florida1Memberpeak:SeniorHousingPropertiesMember2026-07-012026-09-300000765880peak:NewMexicoAndTexasMemberpeak:SeniorHousingPropertiesMember2026-07-012026-09-300000765880peak:Florida2Memberpeak:SeniorHousingPropertiesMember2026-07-012026-09-300000765880peak:KentuckyAndMissouriMemberpeak:SeniorHousingPropertiesMember2026-07-012026-09-300000765880stpr:ILpeak:SeniorHousingPropertiesMember2026-07-012026-09-300000765880stpr:SCpeak:SeniorHousingPropertiesMember2026-07-012026-09-300000765880stpr:KYpeak:SeniorHousingPropertiesMember2026-07-012026-09-300000765880peak:Colorado1Memberpeak:SeniorHousingPropertiesMember2026-07-012026-09-300000765880peak:Colorado2Memberpeak:SeniorHousingPropertiesMember2026-07-012026-09-300000765880us-gaap:SubsequentEventMemberpeak:SeniorHousingPropertiesMember2026-10-012026-11-030000765880stpr:MApeak:LabLandParcelsMember2026-01-012026-03-310000765880peak:HQPointInvestmentMember2026-09-012026-09-300000765880peak:SanDiegoCaliforniaMemberpeak:LabBuildingsMember2026-01-012026-03-310000765880us-gaap:SubsequentEventMemberstpr:TXpeak:OutpatientMedicalBuildingsMember2026-10-012026-11-030000765880stpr:NYpeak:OutpatientMedicalBuildingsMember2025-02-012025-02-280000765880peak:LabBuildingsMemberstpr:MA2025-02-012025-02-280000765880peak:LabBuildingsMemberpeak:SouthSanFranciscoCaliforniaMember2025-12-012025-12-310000765880peak:SouthSanFranciscoCaliforniaMemberpeak:GatewayPortfolioJVMember2025-12-012025-12-310000765880peak:LabBuildingsMemberpeak:SouthSanFranciscoCaliforniaMemberpeak:GatewayPortfolioJVMember2025-12-012025-12-310000765880peak:GatewayPortfolioJVMember2026-01-012026-01-310000765880peak:LabBuildingsMemberpeak:GatewayPortfolioJVMember2026-01-012026-01-310000765880stpr:GApeak:OutpatientMedicalBuildingsMember2025-01-012025-12-310000765880stpr:ALpeak:OutpatientMedicalBuildingsMember2025-01-012025-12-310000765880peak:DispositionsOf2026Memberpeak:LabBuildingsMember2026-01-012026-03-310000765880peak:DispositionsOf2026Memberpeak:OutpatientMedicalBuildingsMember2026-01-012026-03-310000765880peak:DispositionsOf2026Memberpeak:OutpatientMedicalBuildingsMemberstpr:GA2026-01-012026-03-310000765880peak:DispositionsOf2026Member2026-01-012026-03-310000765880peak:DispositionsOf2026Memberpeak:OutpatientMedicalBuildingsMember2026-04-012026-06-300000765880peak:DispositionsOf2026Memberpeak:SeniorHousingCommunitiesMember2026-04-012026-06-300000765880peak:DispositionsOf2026Member2026-04-012026-06-300000765880us-gaap:SubsequentEventMemberpeak:DispositionsOf2026Memberpeak:LabBuildingsMember2026-10-012026-10-310000765880us-gaap:SubsequentEventMemberpeak:DispositionsOf2026Memberpeak:OutpatientMedicalBuildingsMember2026-10-012026-10-310000765880peak:BrookfieldJVMember2026-07-310000765880peak:BrookfieldJVMember2026-07-012026-07-310000765880peak:DispositionsOf2025Memberpeak:LandParcelMember2025-04-012025-06-300000765880peak:DispositionsOf2025Member2025-04-012025-06-300000765880peak:DispositionsOf2025Memberpeak:OutpatientMedicalBuildingsMember2025-07-012025-09-300000765880peak:DispositionsOf2025Member2025-07-012025-09-300000765880peak:DispositionsOf2025Memberpeak:NineOutpatientMedicalBuildingsMember2025-10-012025-12-310000765880peak:DispositionsOf2025Memberpeak:SixteenOutpatientMedicalBuildingsMember2025-10-012025-12-310000765880peak:DispositionsOf2025Member2025-10-012025-12-310000765880peak:LabBuildingsMemberus-gaap:DiscontinuedOperationsHeldforsaleMember2026-09-300000765880peak:OutpatientMedicalBuildingsMemberus-gaap:DiscontinuedOperationsHeldforsaleMember2026-09-300000765880us-gaap:DiscontinuedOperationsHeldforsaleMember2026-09-300000765880us-gaap:SubsequentEventMemberpeak:OutpatientMedicalBuildingsMemberus-gaap:DiscontinuedOperationsHeldforsaleMember2026-10-012026-10-310000765880peak:LabBuildingsMemberus-gaap:DiscontinuedOperationsHeldforsaleMember2025-12-310000765880peak:OutpatientMedicalBuildingsMemberus-gaap:DiscontinuedOperationsHeldforsaleMember2025-12-310000765880us-gaap:DiscontinuedOperationsHeldforsaleMember2025-12-310000765880peak:LabBuildingsMemberus-gaap:DiscontinuedOperationsHeldforsaleMember2026-01-012026-03-310000765880peak:OutpatientMedicalBuildingsMemberus-gaap:DiscontinuedOperationsHeldforsaleMember2026-04-012026-06-300000765880peak:SecuredMortgageLoansMember2026-09-300000765880peak:SecuredMortgageLoansMember2025-12-310000765880peak:MezzanineLoansMember2026-09-300000765880peak:MezzanineLoansMember2025-12-310000765880peak:OutpatientMedicalBuildingsMember2024-07-012024-07-310000765880peak:TwoOutpatientMedicalBuildingsMember2024-11-012024-11-300000765880peak:OutpatientMedicalBuildingsMember2024-01-012024-12-310000765880peak:OutpatientMedicalBuildingsMember2026-06-012026-06-300000765880peak:OutpatientMedicalBuildingsMemberpeak:SellerFinancingMembersrt:MinimumMember2026-06-300000765880peak:OutpatientMedicalBuildingsMemberpeak:SellerFinancingMembersrt:MaximumMember2026-06-300000765880us-gaap:SubsequentEventMemberpeak:OutpatientMedicalBuildingsMember2026-11-030000765880peak:OutpatientMedicalBuildingsMember2026-07-012026-09-300000765880peak:OutpatientMedicalBuildingsMember2026-01-012026-09-300000765880peak:OutpatientMedicalBuildingsMember2025-07-012025-09-300000765880peak:OutpatientMedicalBuildingsMember2025-01-012025-09-300000765880peak:OutpatientMedicalBuildingsMember2026-09-300000765880peak:OutpatientMedicalBuildingsMember2025-12-310000765880peak:SecuredMortgageLoansMember2024-12-310000765880peak:MezzanineLoansMember2024-12-310000765880peak:SecuredMortgageLoansMember2025-01-012025-12-310000765880peak:MezzanineLoansMember2025-01-012025-12-310000765880peak:SecuredMortgageLoansMember2026-01-012026-09-300000765880peak:MezzanineLoansMember2026-01-012026-09-300000765880peak:SunriseSeniorHousingPortfolioMember2025-08-310000765880peak:OtherSHOPSellerFinancingMemberpeak:SecuredMortgageLoansMember2025-01-310000765880us-gaap:SubsequentEventMemberpeak:OutpatientMedicalBuildingsMemberpeak:MezzanineLoansMember2026-10-310000765880us-gaap:SubsequentEventMemberpeak:OutpatientMedicalBuildingsMemberpeak:MezzanineLoansMember2026-10-012026-10-310000765880us-gaap:SubsequentEventMemberpeak:OutpatientMedicalBuildingsMemberpeak:MezzanineLoansMembersrt:MinimumMember2026-10-310000765880us-gaap:SubsequentEventMemberpeak:OutpatientMedicalBuildingsMemberpeak:MezzanineLoansMembersrt:MaximumMember2026-10-310000765880us-gaap:PerformingFinancingReceivableMemberus-gaap:MortgageReceivablesMember2026-09-300000765880peak:WatchListFinancingReceivableMemberus-gaap:MortgageReceivablesMember2026-09-300000765880peak:WorkoutFinancingReceivableMemberus-gaap:MortgageReceivablesMember2026-09-300000765880us-gaap:MortgageReceivablesMember2026-09-300000765880peak:CurrentPeriodGrossWriteOffsMemberus-gaap:MortgageReceivablesMember2026-09-300000765880peak:CurrentPeriodRecoveriesMemberus-gaap:MortgageReceivablesMember2026-09-300000765880peak:CurrentPeriodNetWriteOffsMemberus-gaap:MortgageReceivablesMember2026-09-300000765880us-gaap:PerformingFinancingReceivableMemberpeak:MezzanineLoansMember2026-09-300000765880peak:WatchListFinancingReceivableMemberpeak:MezzanineLoansMember2026-09-300000765880peak:WorkoutFinancingReceivableMemberpeak:MezzanineLoansMember2026-09-300000765880peak:MezzanineLoansMember2026-09-300000765880peak:CurrentPeriodGrossWriteOffsMemberpeak:MezzanineLoansMember2026-09-300000765880peak:CurrentPeriodRecoveriesMemberpeak:MezzanineLoansMember2026-09-300000765880peak:CurrentPeriodNetWriteOffsMemberpeak:MezzanineLoansMember2026-09-300000765880peak:MezzanineLoansAndOtherMember2025-12-310000765880peak:MezzanineLoansAndOtherMember2024-12-310000765880peak:MezzanineLoansAndOtherMember2026-01-012026-09-300000765880peak:MezzanineLoansAndOtherMember2025-01-012025-12-3100007658802025-01-012025-12-310000765880peak:MezzanineLoansAndOtherMember2026-09-300000765880peak:LabBuildingsMemberpeak:SouthSanFranciscoJVsMember2026-09-300000765880peak:LabBuildingsMemberpeak:SouthSanFranciscoJVsMember2025-12-310000765880peak:LabBuildingsMemberpeak:CallanRidgeJVMember2026-09-300000765880peak:LabBuildingsMemberpeak:CallanRidgeJVMember2025-12-310000765880peak:OutpatientMedicalBuildingsMemberpeak:BXJVIAndIIMember2026-09-300000765880peak:OutpatientMedicalBuildingsMemberpeak:BXJVIAndIIMember2025-12-310000765880peak:LabBuildingsMemberpeak:LabJVMember2026-09-300000765880peak:LabBuildingsMemberpeak:LabJVMember2025-12-310000765880peak:OutpatientMedicalBuildingsMemberpeak:PMAKJVMember2026-09-300000765880peak:OutpatientMedicalBuildingsMemberpeak:PMAKJVMember2025-12-310000765880peak:LabBuildingsMemberpeak:NeedhamLandParcelJVMember2026-09-300000765880peak:LabBuildingsMemberpeak:NeedhamLandParcelJVMember2025-12-310000765880peak:OutpatientMedicalBuildingsMemberpeak:MedicalOfficeJVMember2026-09-300000765880peak:OutpatientMedicalBuildingsMemberpeak:MedicalOfficeJVMember2025-12-310000765880peak:OutpatientMedicalBuildingsMemberpeak:DavisJVMember2026-09-300000765880peak:OutpatientMedicalBuildingsMemberpeak:DavisJVMember2025-12-310000765880peak:SeniorHousingMemberpeak:SWFSHJVMember2026-09-300000765880peak:SeniorHousingMemberpeak:SWFSHJVMember2025-12-310000765880peak:OtherNonReportingSegmentMemberpeak:HQPointInvestmentMember2026-09-300000765880peak:OtherNonReportingSegmentMemberpeak:HQPointInvestmentMember2025-12-310000765880peak:BXJVIAndIIMember2026-09-300000765880peak:MedicalOfficeJVMember2026-09-300000765880peak:SuburbanPropertiesLLCMember2026-09-300000765880peak:MedicalOfficeJVMember2025-12-310000765880peak:HCPVenturesIVLLCMember2025-12-310000765880peak:SuburbanPropertiesLLCMember2025-12-310000765880peak:MedicalOfficeJVMember2026-01-012026-09-300000765880peak:SeniorHousingMemberpeak:SWFSHJVMemberpeak:SWFSHJVMember2025-12-310000765880peak:SeniorHousingMemberpeak:HQPointInvestmentMember2025-12-310000765880peak:SeniorHousingMemberpeak:SWFSHJVMemberpeak:SWFSHJVMember2026-01-310000765880peak:SeniorHousingMemberpeak:SWFSHJVMemberpeak:SWFSHJVMember2026-01-012026-01-310000765880peak:OutpatientMedicalBuildingsMemberpeak:BXJVIAndIIMemberpeak:BXJVIAndIIMember2026-03-310000765880peak:OutpatientMedicalBuildingsMemberpeak:BXJVIAndIIMember2026-03-310000765880peak:OutpatientMedicalBuildingsMemberpeak:BXJVIAndIIMemberpeak:BXJVIAndIIMember2026-03-012026-03-310000765880peak:BXJVIAndIIMember2026-03-310000765880peak:BXJVIAndIIMemberpeak:BXJVIAndIIMember2026-03-310000765880peak:HQPointInvestmentMember2025-12-310000765880peak:HQPointInvestmentMember2026-09-300000765880peak:SouthSanFranciscoJVsMember2025-09-300000765880peak:SouthSanFranciscoJVsMember2025-01-012025-09-300000765880peak:NeedhamLandParcelJVMember2025-01-012025-09-300000765880peak:MeasurementInputTerminalCapitalizationRateMemberus-gaap:FairValueInputsLevel3Member2025-09-300000765880us-gaap:MeasurementInputDiscountRateMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Member2025-09-300000765880us-gaap:MeasurementInputDiscountRateMembersrt:MaximumMemberus-gaap:FairValueInputsLevel3Member2025-09-300000765880srt:WeightedAverageMemberus-gaap:FairValueInputsLevel3Member2025-09-300000765880srt:OtherPropertyMember2026-01-012026-09-300000765880srt:OtherPropertyMember2025-01-012025-12-310000765880peak:OutpatientMedicalMember2026-09-300000765880peak:OutpatientMedicalMember2025-12-310000765880peak:SeniorHousingMember2026-09-300000765880peak:SeniorHousingMember2025-12-310000765880us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMemberpeak:JanusLivingCreditFacilitiesMember2026-03-230000765880us-gaap:LineOfCreditMemberus-gaap:DelayedDrawTermLoanMemberpeak:JanusLivingCreditFacilitiesMember2026-03-230000765880us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMemberpeak:JanusLivingCreditFacilitiesMember2026-03-232026-03-230000765880us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMemberpeak:JanusLivingCreditFacilitiesMember2026-09-300000765880us-gaap:LineOfCreditMemberus-gaap:DelayedDrawTermLoanMemberpeak:JanusLivingCreditFacilitiesMember2026-09-300000765880us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMemberpeak:JanusLivingCreditFacilitiesMember2026-01-012026-09-300000765880us-gaap:LineOfCreditMemberpeak:JanusLivingCreditFacilitiesMember2026-09-300000765880us-gaap:LineOfCreditMemberpeak:JanusLivingCreditFacilitiesMember2026-03-230000765880us-gaap:LineOfCreditMemberpeak:JanusLivingCreditFacilitiesMember2026-03-232026-03-230000765880us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2026-09-300000765880us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2026-01-012026-09-300000765880us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2025-10-012025-10-310000765880us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMemberpeak:VariableRateComponentOneMember2026-01-012026-09-300000765880us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2025-12-310000765880peak:TermLoanAgreementMember2026-02-280000765880us-gaap:LineOfCreditMemberpeak:A2027TermLoanFacilitiesMemberpeak:TermLoanAgreementMember2026-09-300000765880us-gaap:LineOfCreditMemberpeak:A2027TermLoanFacilitiesOneMemberpeak:TermLoanAgreementMember2026-09-300000765880us-gaap:LineOfCreditMemberpeak:A2027TermLoanFacilitiesMemberpeak:TermLoanAgreementMember2026-01-012026-09-300000765880us-gaap:LineOfCreditMemberpeak:A2027TermLoanFacilitiesTwoMemberpeak:TermLoanAgreementMember2026-09-300000765880peak:UnsecuredTermLoanMember2026-09-300000765880us-gaap:LineOfCreditMemberpeak:A2027TermLoanFacilitiesMemberpeak:TermLoanAgreementMember2025-10-012025-10-310000765880peak:TermLoanAgreementMember2026-03-310000765880peak:A2031TermLoanFacilityMemberpeak:UnsecuredDelayedDrawTermLoanMember2026-03-310000765880peak:A2031TermLoanFacilityMemberpeak:UnsecuredDelayedDrawTermLoanMember2026-09-300000765880peak:TermLoanAgreementMember2026-09-300000765880peak:TermLoanAgreementMember2025-12-310000765880us-gaap:SubsequentEventMemberpeak:TermLoanAgreementMember2026-10-310000765880us-gaap:SubsequentEventMemberpeak:A2030TermLoanFacilityMemberpeak:UnsecuredDelayedDrawTermLoanMember2026-10-310000765880us-gaap:SubsequentEventMemberpeak:A2030TermLoanFacilityMemberpeak:UnsecuredDelayedDrawTermLoanMember2026-10-012026-10-310000765880us-gaap:SubsequentEventMemberpeak:A2030TermLoanFacilityMemberpeak:TermLoanAgreementMember2026-11-030000765880us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2026-09-300000765880peak:A2027TermLoanFacilitiesMemberus-gaap:InterestRateSwapMemberpeak:TermLoanAgreementMember2026-09-300000765880peak:UnsecuredTermLoanMemberpeak:A2029TermLoanMember2026-01-012026-09-300000765880peak:SeniorUnsecuredTermLoanMemberpeak:A2029TermLoanMember2026-09-300000765880peak:UnsecuredTermLoanMemberpeak:A2031TermLoanMember2026-01-012026-09-300000765880peak:SeniorUnsecuredTermLoanMemberpeak:A2028TermLoanMember2026-09-300000765880peak:SeniorUnsecuredTermLoanMemberpeak:A2028TermLoanMember2025-10-012025-10-310000765880peak:SeniorUnsecuredTermLoanMemberpeak:A2028TermLoanMembersrt:MinimumMember2026-01-012026-09-300000765880peak:SeniorUnsecuredTermLoanMemberpeak:A2028TermLoanMembersrt:MaximumMember2026-01-012026-09-300000765880peak:SeniorUnsecuredTermLoanMemberpeak:A2028TermLoanMember2026-01-012026-09-300000765880us-gaap:DesignatedAsHedgingInstrumentMemberpeak:SeniorUnsecuredTermLoanMemberus-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberpeak:A2028TermLoanMember2026-09-300000765880peak:A2028TermLoanFacilitiesMemberus-gaap:InterestRateSwapMemberpeak:TermLoanAgreementMember2026-09-300000765880peak:CommercialPaperProgramMember2026-09-300000765880peak:CommercialPaperProgramMember2025-12-310000765880peak:CommercialPaperProgramMember2026-07-012026-09-300000765880peak:CommercialPaperProgramMember2025-07-012025-09-300000765880peak:CommercialPaperProgramMember2026-01-012026-09-300000765880peak:CommercialPaperProgramMember2025-01-012025-09-300000765880peak:CommercialPaperProgramMember2025-01-012025-12-310000765880us-gaap:UnsecuredDebtMember2026-09-300000765880us-gaap:UnsecuredDebtMember2025-12-310000765880us-gaap:UnsecuredDebtMemberpeak:SeniorUnsecuredNotes3.25Member2026-07-150000765880us-gaap:UnsecuredDebtMemberpeak:SeniorUnsecuredNotes5.38Member2025-02-140000765880us-gaap:UnsecuredDebtMemberpeak:SeniorUnsecuredNotes4.75Member2025-08-140000765880us-gaap:UnsecuredDebtMemberpeak:SeniorUnsecuredNotes3.40Member2025-02-030000765880us-gaap:UnsecuredDebtMemberpeak:SeniorUnsecuredNotes4.00Member2025-06-020000765880us-gaap:SecuredDebtMember2026-09-300000765880us-gaap:SecuredDebtMember2025-12-310000765880us-gaap:SecuredDebtMemberpeak:OutpatientMedicalBuildingsMember2026-09-300000765880us-gaap:SecuredDebtMemberpeak:OutpatientMedicalBuildingsMember2025-12-310000765880us-gaap:SecuredDebtMemberpeak:SeniorHousingCommunitiesMember2025-12-310000765880us-gaap:SecuredDebtMember2026-07-012026-09-300000765880us-gaap:SecuredDebtMember2025-07-012025-09-300000765880us-gaap:SecuredDebtMember2026-01-012026-09-300000765880us-gaap:SecuredDebtMember2025-01-012025-09-300000765880peak:SeniorHousingCommunitiesMemberus-gaap:SecuredDebtMember2026-01-012026-09-300000765880peak:SeniorHousingCommunitiesMemberus-gaap:SecuredDebtMember2026-09-300000765880peak:OutpatientMedicalBuildingsMemberus-gaap:SecuredDebtMember2026-01-012026-09-300000765880peak:OutpatientMedicalBuildingsMemberus-gaap:SecuredDebtMember2026-09-300000765880us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2026-09-300000765880peak:OutpatientMedicalBuildingsMemberus-gaap:SecuredDebtMember2025-01-012025-09-300000765880peak:OutpatientMedicalBuildingsMemberus-gaap:SecuredDebtMember2025-03-310000765880us-gaap:LineOfCreditMember2026-09-300000765880us-gaap:CommercialPaperMember2026-09-300000765880us-gaap:LoansPayableMember2026-09-300000765880us-gaap:UnsecuredDebtMemberpeak:DebtInstrumentRedemptionRemainderOfFiscalYearMember2026-09-300000765880us-gaap:SecuredDebtMemberpeak:DebtInstrumentRedemptionRemainderOfFiscalYearMember2026-09-300000765880us-gaap:UnsecuredDebtMemberus-gaap:DebtInstrumentRedemptionPeriodOneMember2026-09-300000765880us-gaap:SecuredDebtMemberus-gaap:DebtInstrumentRedemptionPeriodOneMember2026-09-300000765880us-gaap:UnsecuredDebtMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMember2026-09-300000765880us-gaap:SecuredDebtMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMember2026-09-300000765880us-gaap:UnsecuredDebtMemberus-gaap:DebtInstrumentRedemptionPeriodThreeMember2026-09-300000765880us-gaap:SecuredDebtMemberus-gaap:DebtInstrumentRedemptionPeriodThreeMember2026-09-300000765880us-gaap:UnsecuredDebtMemberus-gaap:DebtInstrumentRedemptionPeriodFourMember2026-09-300000765880us-gaap:SecuredDebtMemberus-gaap:DebtInstrumentRedemptionPeriodFourMember2026-09-300000765880us-gaap:UnsecuredDebtMemberpeak:DebtInstrumentRedemptionPeriodThereafterMember2026-09-300000765880us-gaap:SecuredDebtMemberpeak:DebtInstrumentRedemptionPeriodThereafterMember2026-09-300000765880us-gaap:CommercialPaperMemberpeak:JanusLivingIncMember2026-09-300000765880us-gaap:UnsecuredDebtMembersrt:MinimumMember2026-09-300000765880us-gaap:UnsecuredDebtMembersrt:MaximumMember2026-09-300000765880us-gaap:UnsecuredDebtMember2026-01-012026-09-300000765880us-gaap:SecuredDebtMembersrt:MinimumMember2026-09-300000765880us-gaap:SecuredDebtMembersrt:MaximumMember2026-09-300000765880us-gaap:LetterOfCreditMember2026-01-012026-09-300000765880us-gaap:LetterOfCreditMember2026-09-300000765880us-gaap:IndemnificationGuaranteeMember2026-09-300000765880us-gaap:SubsequentEventMember2026-10-012026-10-010000765880peak:AtTheMarketProgramMember2026-01-012026-09-300000765880srt:MinimumMemberpeak:AtTheMarketProgramMember2026-01-012026-09-300000765880srt:MaximumMemberpeak:AtTheMarketProgramMember2026-01-012026-09-300000765880peak:A2023AtTheMarketProgramMember2026-01-012026-09-300000765880peak:AtTheMarketProgramMember2026-07-012026-09-300000765880peak:AtTheMarketProgramMember2025-07-012025-09-300000765880peak:AtTheMarketProgramMember2025-01-012025-09-300000765880us-gaap:CommonStockMemberpeak:ATMDirectIssuancesMember2026-07-012026-09-300000765880us-gaap:CommonStockMemberpeak:ATMDirectIssuancesMember2026-01-012026-09-300000765880us-gaap:CommonStockMemberpeak:ATMDirectIssuancesMember2025-07-012025-09-300000765880us-gaap:CommonStockMemberpeak:ATMDirectIssuancesMember2025-01-012025-09-300000765880peak:A2024ShareRepurchaseProgramMember2024-07-240000765880peak:A2024ShareRepurchaseProgramMember2025-01-012025-09-300000765880peak:A2024ShareRepurchaseProgramMember2026-01-012026-09-300000765880peak:A2026ShareRepurchaseProgramMember2026-07-300000765880peak:A2026ShareRepurchaseProgramMember2026-07-012026-09-300000765880peak:A2026ShareRepurchaseProgramMember2026-01-012026-09-300000765880peak:A2026ShareRepurchaseProgramMember2025-07-012025-09-300000765880peak:A2026ShareRepurchaseProgramMember2025-01-012025-09-300000765880peak:A2026ShareRepurchaseProgramMember2026-09-300000765880peak:GatewayCrossingJVMember2025-01-012025-12-310000765880peak:GatewayCrossingJVMember2026-01-012026-03-310000765880peak:JanusLivingIncMemberpeak:CommonClassA1Member2026-01-012026-09-300000765880peak:JanusLivingIncMemberpeak:CommonClassA1Member2026-07-012026-09-300000765880peak:PublicInvestorsMemberpeak:JanusLivingIncMember2026-09-300000765880peak:HealthpeakOPMemberus-gaap:NoncontrollingInterestMember2025-01-012025-09-300000765880peak:HealthpeakOPMemberus-gaap:NoncontrollingInterestMember2026-01-012026-09-300000765880peak:JanusLivingOPMemberus-gaap:NoncontrollingInterestMember2026-01-012026-09-300000765880peak:JanusLivingOPMemberus-gaap:NoncontrollingInterestMember2026-09-300000765880peak:DownREITMember2026-09-300000765880peak:DownREITMember2025-12-310000765880peak:DownREITMember2026-07-012026-09-300000765880peak:DownREITMember2026-01-012026-09-300000765880peak:DownREITMember2025-01-012025-09-300000765880peak:DownREITMember2025-07-012025-09-300000765880peak:OtherNonReportingSegmentMemberus-gaap:OperatingSegmentsMember2026-09-300000765880peak:OutpatientMedicalMemberus-gaap:OperatingSegmentsMember2026-07-012026-09-300000765880peak:LabMemberus-gaap:OperatingSegmentsMember2026-07-012026-09-300000765880peak:SeniorHousingMemberus-gaap:OperatingSegmentsMember2026-07-012026-09-300000765880us-gaap:OperatingSegmentsMember2026-07-012026-09-300000765880peak:SeniorHousingMemberus-gaap:OperatingSegmentsMemberus-gaap:NonrelatedPartyMember2026-07-012026-09-300000765880peak:SeniorHousingMemberus-gaap:OperatingSegmentsMemberus-gaap:RelatedPartyMember2026-07-012026-09-300000765880peak:OutpatientMedicalMemberus-gaap:OperatingSegmentsMember2025-07-012025-09-300000765880peak:LabMemberus-gaap:OperatingSegmentsMember2025-07-012025-09-300000765880peak:SeniorHousingMemberus-gaap:OperatingSegmentsMember2025-07-012025-09-300000765880us-gaap:OperatingSegmentsMember2025-07-012025-09-300000765880peak:SeniorHousingMemberus-gaap:OperatingSegmentsMemberus-gaap:NonrelatedPartyMember2025-07-012025-09-300000765880peak:OutpatientMedicalMemberus-gaap:OperatingSegmentsMember2026-01-012026-09-300000765880peak:LabMemberus-gaap:OperatingSegmentsMember2026-01-012026-09-300000765880peak:SeniorHousingMemberus-gaap:OperatingSegmentsMember2026-01-012026-09-300000765880us-gaap:OperatingSegmentsMember2026-01-012026-09-300000765880peak:SeniorHousingMemberus-gaap:OperatingSegmentsMemberus-gaap:NonrelatedPartyMember2026-01-012026-09-300000765880peak:SeniorHousingMemberus-gaap:OperatingSegmentsMemberus-gaap:RelatedPartyMember2026-01-012026-09-300000765880peak:OutpatientMedicalMemberus-gaap:OperatingSegmentsMember2025-01-012025-09-300000765880peak:LabMemberus-gaap:OperatingSegmentsMember2025-01-012025-09-300000765880peak:SeniorHousingMemberus-gaap:OperatingSegmentsMember2025-01-012025-09-300000765880us-gaap:OperatingSegmentsMember2025-01-012025-09-300000765880peak:SeniorHousingMemberus-gaap:OperatingSegmentsMemberus-gaap:NonrelatedPartyMember2025-01-012025-09-300000765880us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMemberus-gaap:CommercialMortgageBackedSecuritiesMember2026-09-300000765880peak:OtherEquityMember2026-09-300000765880peak:OtherEquityMember2025-12-310000765880peak:LabMemberpeak:NeedhamLandParcelJVMember2021-12-310000765880peak:LabMemberpeak:NeedhamLandParcelJVMember2021-12-012021-12-310000765880peak:OtherMemberpeak:OutpatientMedicalMemberpeak:SecuredMortgageLoansMember2025-03-012025-03-310000765880peak:OtherMemberpeak:LabLandParcelsMemberpeak:SecuredMortgageLoansMember2026-01-012026-01-310000765880peak:HQPointInvestmentMember2026-09-300000765880peak:VariableInterestEntityNotPrimaryBeneficiaryEquityInvestmentMember2026-09-300000765880peak:VariableInterestEntityNotPrimaryBeneficiaryInvestmentInJointVentureMember2026-09-300000765880peak:VariableInterestEntityNotPrimaryBeneficiaryLoansReceivableInvestmentsMember2026-09-300000765880peak:BrookfieldJVMember2026-01-012026-09-300000765880peak:VenturesVLLCMember2026-01-012026-09-300000765880peak:MorganStanleyRealEstateInvestmentJVMember2026-01-012026-09-300000765880peak:DownreitPartnershipsMember2026-09-300000765880peak:DownreitPartnershipsMember2025-12-310000765880peak:LabBuildingsMemberpeak:GatewayPortfolioJVMember2026-01-012026-09-300000765880us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2026-09-300000765880us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2025-12-310000765880us-gaap:VariableInterestEntityPrimaryBeneficiaryMemberus-gaap:DiscontinuedOperationsHeldforsaleMember2026-09-300000765880us-gaap:VariableInterestEntityPrimaryBeneficiaryMemberus-gaap:DiscontinuedOperationsHeldforsaleMember2025-12-310000765880us-gaap:CarryingReportedAmountFairValueDisclosureMember2026-09-300000765880us-gaap:EstimateOfFairValueFairValueDisclosureMember2026-09-300000765880us-gaap:CarryingReportedAmountFairValueDisclosureMember2025-12-310000765880us-gaap:EstimateOfFairValueFairValueDisclosureMember2025-12-310000765880us-gaap:DesignatedAsHedgingInstrumentMemberpeak:InterestRateSwap499PayRateMemberus-gaap:CashFlowHedgingMember2026-09-300000765880us-gaap:DesignatedAsHedgingInstrumentMemberpeak:InterestRateSwap499PayRateMemberus-gaap:CashFlowHedgingMember2025-12-310000765880us-gaap:DesignatedAsHedgingInstrumentMemberpeak:InterestRateSwap454PayRateMemberus-gaap:CashFlowHedgingMember2026-09-300000765880us-gaap:DesignatedAsHedgingInstrumentMemberpeak:InterestRateSwap454PayRateMemberus-gaap:CashFlowHedgingMember2025-12-310000765880us-gaap:DesignatedAsHedgingInstrumentMemberpeak:InterestRateSwap260PayRateMemberus-gaap:CashFlowHedgingMember2026-09-300000765880us-gaap:DesignatedAsHedgingInstrumentMemberpeak:InterestRateSwap260PayRateMemberus-gaap:CashFlowHedgingMember2025-12-310000765880us-gaap:DesignatedAsHedgingInstrumentMemberpeak:InterestRateSwap254PayRateMemberus-gaap:CashFlowHedgingMember2026-09-300000765880us-gaap:DesignatedAsHedgingInstrumentMemberpeak:InterestRateSwap254PayRateMemberus-gaap:CashFlowHedgingMember2025-12-310000765880us-gaap:DesignatedAsHedgingInstrumentMemberpeak:InterestRateSwap3.59PayRateMemberus-gaap:CashFlowHedgingMember2026-09-300000765880us-gaap:DesignatedAsHedgingInstrumentMemberpeak:InterestRateSwap3.59PayRateMemberus-gaap:CashFlowHedgingMember2025-12-310000765880us-gaap:DesignatedAsHedgingInstrumentMemberpeak:InterestRateSwap3.59PayRateOneMemberus-gaap:CashFlowHedgingMember2026-09-300000765880us-gaap:DesignatedAsHedgingInstrumentMemberpeak:InterestRateSwap3.59PayRateOneMemberus-gaap:CashFlowHedgingMember2025-12-310000765880us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2026-09-300000765880us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2025-12-310000765880us-gaap:DesignatedAsHedgingInstrumentMemberpeak:InterestRateSwap3.59PayRateTwoMemberus-gaap:CashFlowHedgingMember2026-09-300000765880us-gaap:DesignatedAsHedgingInstrumentMemberpeak:InterestRateSwap3.59PayRateTwoMemberus-gaap:CashFlowHedgingMember2025-12-310000765880us-gaap:DesignatedAsHedgingInstrumentMemberpeak:InterestRateSwap3.59PayRateThreeMemberus-gaap:CashFlowHedgingMember2026-09-300000765880us-gaap:DesignatedAsHedgingInstrumentMemberpeak:InterestRateSwap3.59PayRateThreeMemberus-gaap:CashFlowHedgingMember2025-12-310000765880us-gaap:DesignatedAsHedgingInstrumentMemberpeak:TwoInterestRateSwapInstrumentsMemberus-gaap:CashFlowHedgingMember2026-09-300000765880us-gaap:DesignatedAsHedgingInstrumentMemberpeak:OneInterestRateSwapInstrumentMemberus-gaap:CashFlowHedgingMember2026-09-300000765880us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2024-03-010000765880us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2026-07-012026-09-300000765880us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2025-07-012025-09-300000765880us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2026-01-012026-09-300000765880us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2025-01-012025-09-300000765880us-gaap:DesignatedAsHedgingInstrumentMemberpeak:InterestRateSwap3.56PayRateMemberus-gaap:CashFlowHedgingMember2026-09-300000765880us-gaap:DesignatedAsHedgingInstrumentMemberpeak:InterestRateSwap3.57PayRateMemberus-gaap:CashFlowHedgingMember2026-09-300000765880us-gaap:DesignatedAsHedgingInstrumentMemberpeak:InterestRateSwap3.58PayRateMemberus-gaap:CashFlowHedgingMember2026-09-300000765880us-gaap:DesignatedAsHedgingInstrumentMemberpeak:InterestRateSwap3.60PayRateMemberus-gaap:CashFlowHedgingMember2026-09-300000765880us-gaap:DesignatedAsHedgingInstrumentMemberpeak:InterestRateSwap3.61PayRateMemberus-gaap:CashFlowHedgingMember2026-09-300000765880peak:JanusLivingIncMember2026-01-012026-03-310000765880peak:JanusLivingIncMember2026-03-232026-03-230000765880peak:JanusLivingIncMemberus-gaap:RelatedPartyMember2026-01-012026-09-300000765880peak:JanusLivingIncMemberpeak:ManagementAndServiceFeesBaseFeeLevelOneMemberus-gaap:RelatedPartyMember2026-01-012026-09-300000765880peak:JanusLivingIncMemberpeak:ManagementAndServiceFeesBaseFeeLevelTwoMemberus-gaap:RelatedPartyMember2026-01-012026-09-300000765880peak:JanusLivingIncMemberus-gaap:RelatedPartyMember2026-07-012026-09-300000765880peak:JanusLivingIncMemberus-gaap:RelatedPartyMember2026-01-012026-09-300000765880peak:JanusLivingIncMemberus-gaap:RelatedPartyMember2026-09-300000765880peak:JanusLivingIncMemberus-gaap:RelatedPartyMember2026-03-232026-09-300000765880us-gaap:IPOMemberus-gaap:RelatedPartyMember2026-03-232026-03-230000765880us-gaap:IPOMemberus-gaap:RelatedPartyMember2026-03-23
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2026
or
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from             to             
Commission file number 001-08895
Healthpeak Properties, Inc.
(Exact name of registrant as specified in its charter)
Maryland33-0091377
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
4600 South Syracuse Street, Suite 500
Denver, CO 80237
(Address of principal executive offices) (Zip Code)
(720) 428-5050
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $1.00 par value
DOC
New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐ No ☒
As of October 30, 2026, there were 689,543,752 shares of the registrant’s $1.00 par value common stock outstanding.


Table of Contents
HEALTHPEAK PROPERTIES, INC.
INDEX

2

Table of Contents
PART I. FINANCIAL INFORMATION
Item 1.  Financial Statements (Unaudited)
Healthpeak Properties, Inc.
CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share data)
(Unaudited)
September 30,
2026
December 31,
2025
ASSETS
Real estate:
Buildings and improvements$18,744,157 $16,593,535 
Development costs and construction in progress1,026,355 1,010,657 
Land and improvements3,426,289 3,007,346 
Accumulated depreciation(4,708,201)(4,512,443)
Net real estate18,488,600 16,099,095 
Loans receivable, net of reserves of $8,036 and $11,345
284,203 606,020 
Investments in unconsolidated joint ventures466,114 802,601 
Accounts receivable, net of allowance of $3,994 and $2,018
75,944 78,327 
Cash and cash equivalents514,310 467,457 
Restricted cash91,512 70,245 
Intangible assets917,700 654,516 
Assets held for sale48,042 80,621 
Right-of-use asset393,382 412,198 
Deferred tax assets121,663 111,248 
Goodwill68,529 68,529 
Other assets941,976 885,161 
Total assets$22,411,975 $20,336,018 
LIABILITIES AND EQUITY
Bank line of credit and commercial paper$1,489,500 $1,078,850 
Term loans1,646,725 1,647,113 
Senior unsecured notes6,142,101 6,772,722 
Mortgage debt104,019 349,209 
Intangible liabilities146,688 173,697 
Liabilities related to assets held for sale1,035 11,900 
Lease liability288,386 296,260 
Accounts payable, accrued liabilities, and other liabilities749,010 718,509 
Deferred revenue1,039,166 985,307 
Total liabilities11,606,630 12,033,567 
Commitments and contingencies (Note 10)
Redeemable noncontrolling interests27,431 159,581 
Common stock, $1.00 par value: 1,500,000,000 shares authorized; 689,535,670 and 695,036,731 shares issued and outstanding
689,536 695,037 
Additional paid-in capital13,470,684 12,767,914 
Cumulative dividends in excess of earnings(6,322,342)(5,952,920)
Accumulated other comprehensive income (loss)28,058 (9,937)
Total stockholders’ equity7,865,936 7,500,094 
Public investors of Janus Living, Inc.1,270,543 — 
Joint venture partners1,283,529 295,455 
Non-managing member unitholders357,906 347,321 
Total noncontrolling interests2,911,978 642,776 
Total equity10,777,914 8,142,870 
Total liabilities and equity$22,411,975 $20,336,018 
See accompanying Notes to the Unaudited Consolidated Financial Statements.
3

Table of Contents
Healthpeak Properties, Inc.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(Unaudited)
Three Months Ended
September 30,
Nine Months Ended
September 30,
2026202520262025
Revenues:
 Rental and related revenues $545,390 $539,886 $1,617,180 $1,607,714 
 Resident fees and services 268,300 150,458 685,101 448,240 
 Interest income and other 7,202 15,529 43,142 47,156 
 Total revenues 820,892 705,873 2,345,423 2,103,110 
 Costs and expenses:
 Operating 379,391 291,922 1,036,375 841,246 
 Depreciation and amortization 298,923 262,317 872,047 796,779 
 Interest expense 83,899 76,784 263,471 224,540 
 General and administrative 23,589 19,907 70,697 66,789 
 Transaction costs 9,738 2,420 43,059 18,169 
 Impairments and loan loss reserves (recoveries), net (210)(54)(3,964)(117)
 Total costs and expenses 795,330 653,296 2,281,685 1,947,406 
 Other income (expense):
 Gain (loss) on sales of real estate, net — 11,500 60,657 13,136 
 Gain (loss) on debt extinguishments — — (403)— 
 Other income (expense), net 8,670 1,160 165,215 (9,658)
 Total other income (expense), net 8,670 12,660 225,469 3,478 
 Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures 34,232 65,237 289,207 159,182 
 Income tax benefit (expense)(1,287)1,206 (139)(3,256)
 Equity income (loss) from unconsolidated joint ventures 3,742 (176,291)10,516 (176,691)
 Net income (loss)36,687 (109,848)299,584 (20,765)
 Noncontrolling interests’ share in earnings(19,424)(7,274)(35,870)(21,856)
 Net income (loss) attributable to Healthpeak Properties, Inc. 17,263 (117,122)263,714 (42,621)
 Participating securities’ share in earnings (145)(134)(444)(714)
Net income (loss) applicable to common shares$17,118 $(117,256)$263,270 $(43,335)
Earnings per common share:
Basic$0.02 $(0.17)$0.38 $(0.06)
Diluted$0.02 $(0.17)$0.38 $(0.06)
Weighted average shares outstanding:
Basic689,509 694,930 691,498 696,380 
Diluted689,509 694,930 691,781 696,380 
See accompanying Notes to the Unaudited Consolidated Financial Statements.
4

Table of Contents
Healthpeak Properties, Inc.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(In thousands)
(Unaudited)
Three Months Ended
September 30,
Nine Months Ended
September 30,
2026202520262025
Net income (loss)$36,687 $(109,848)$299,584 $(20,765)
Other comprehensive income (loss):
Net unrealized gains (losses) on derivatives17,450 (3,027)37,774 (37,005)
Change in Supplemental Executive Retirement Plan obligation and other74 71 221 212 
Total other comprehensive income (loss)17,524 (2,956)37,995 (36,793)
Total comprehensive income (loss)54,211 (112,804)337,579 (57,558)
Total comprehensive (income) loss attributable to noncontrolling interests(19,424)(7,274)(35,870)(21,856)
Total comprehensive income (loss) attributable to Healthpeak Properties, Inc.$34,787 $(120,078)$301,709 $(79,414)
See accompanying Notes to the Unaudited Consolidated Financial Statements.
5

Table of Contents
Healthpeak Properties, Inc.
CONSOLIDATED STATEMENTS OF EQUITY AND REDEEMABLE NONCONTROLLING INTERESTS
(In thousands, except per share data)
(Unaudited)
For the three months ended September 30, 2026:
Common StockAdditional Paid-In CapitalCumulative Dividends In Excess Of EarningsAccumulated Other Comprehensive Income (Loss)Total Stockholders’ EquityTotal Noncontrolling InterestsTotal
Equity
Redeemable Noncontrolling Interests
SharesAmount
July 1, 2026689,465 $689,465 $13,273,880 $(6,129,129)$10,534 $7,844,750 $1,625,995 $9,470,745 $27,695 
Net income (loss)— — — 17,263 — 17,263 19,501 36,764 (77)
Other comprehensive income (loss)— — — — 17,524 17,524 — 17,524 — 
Issuance of common stock, net29 29 219 — — 248 — 248 — 
Conversion of non-managing member units to common stock46 46 1,432 — — 1,478 (1,478)— — 
Repurchase of common stock(4)(4)(101)— — (105)— (105)— 
Stock-based compensation— — 1,706 — — 1,706 4,100 5,806 — 
Common dividends ($0.305 per share)
— — — (210,476)— (210,476)— (210,476)— 
Distributions to noncontrolling interests— — — — — — (50,224)(50,224)(187)
Issuance of noncontrolling interests— — — — — — 1,507,632 1,507,632 — 
Reallocation of noncontrolling interests— — 193,548 — — 193,548 (193,548)— — 
September 30, 2026689,536 $689,536 $13,470,684 $(6,322,342)$28,058 $7,865,936 $2,911,978 $10,777,914 $27,431 
For the three months ended September 30, 2025:
Common StockAdditional Paid-In CapitalCumulative Dividends In Excess Of EarningsAccumulated Other Comprehensive Income (Loss)Total Stockholders’ EquityTotal Noncontrolling InterestsTotal
Equity
Redeemable Noncontrolling Interests
SharesAmount
July 1, 2025694,916 $694,916 $12,763,723 $(5,525,520)$(5,019)$7,928,100 $638,737 $8,566,837 $20,104 
Net income (loss)— — — (117,122)— (117,122)7,381 (109,741)(107)
Other comprehensive income (loss)— — — — (2,956)(2,956)— (2,956)— 
Issuance of common stock, net24 24 359 — — 383 — 383 — 
Conversion of non-managing member units to common stock7 7 191 — — 198 (198)— — 
Repurchase of common stock(1)(1)(16)— — (17)— (17)— 
Stock-based compensation— — 1,636 — — 1,636 3,800 5,436 — 
Common dividends ($0.305 per share)
— — — (212,124)— (212,124)— (212,124)— 
Distributions to noncontrolling interests— — — — — — (9,500)(9,500)(165)
Contributions from noncontrolling interests— — — — — — — — 7,154 
Adjustments to redeemable noncontrolling interests— — (823)— — (823)— (823)823 
September 30, 2025694,946 $694,946 $12,765,070 $(5,854,766)$(7,975)$7,597,275 $640,220 $8,237,495 $27,809 
6

Table of Contents
For the nine months ended September 30, 2026:
Common StockAdditional Paid-In CapitalCumulative Dividends In Excess Of EarningsAccumulated Other Comprehensive Income (Loss)Total Stockholders’ EquityTotal Noncontrolling InterestsTotal
Equity
Redeemable Noncontrolling Interests
SharesAmount
January 1, 2026695,037 $695,037 $12,767,914 $(5,952,920)$(9,937)$7,500,094 $642,776 $8,142,870 $159,581 
Net income (loss)— — — 263,714 — 263,714 36,283 299,997 (413)
Other comprehensive income (loss)— — — — 37,995 37,995 — 37,995 — 
Issuance of common stock, net419 419 972 — — 1,391 — 1,391 — 
Conversion of non-managing member units to common stock117 117 3,142 — — 3,259 (3,259)— — 
Repurchase of common stock(6,037)(6,037)(95,629)— — (101,666)— (101,666)— 
Stock-based compensation— — 5,701 — — 5,701 16,380 22,081 — 
Common dividends ($0.915 per share)
— — — (633,136)— (633,136)— (633,136)— 
Distributions to noncontrolling interests— — — — — — (82,050)(82,050)(529)
Contributions from noncontrolling interests— — — — — — — — 760 
Redemption of noncontrolling interest— — — — — — — — (131,968)
Issuance of noncontrolling interests— — — — — — 3,090,432 3,090,432 — 
Reallocation of noncontrolling interests— — 788,584 — — 788,584 (788,584)— — 
September 30, 2026689,536 $689,536 $13,470,684 $(6,322,342)$28,058 $7,865,936 $2,911,978 $10,777,914 $27,431 
For the nine months ended September 30, 2025:
Common StockAdditional Paid-In CapitalCumulative Dividends In Excess Of EarningsAccumulated Other Comprehensive Income (Loss)Total Stockholders’ EquityTotal Noncontrolling InterestsTotal
Equity
Redeemable Noncontrolling Interests
SharesAmount
January 1, 2025699,485 $699,485 $12,847,252 $(5,174,279)$28,818 $8,401,276 $653,738 $9,055,014 $2,610 
Net income (loss)— — — (42,621)— (42,621)22,145 (20,476)(289)
Other comprehensive income (loss)— — — — (36,793)(36,793)— (36,793)— 
Issuance of common stock, net521 521 415 — — 936 — 936 — 
Conversion of non-managing member units to common stock171 171 3,967 — — 4,138 (4,138)— — 
Repurchase of common stock(5,231)(5,231)(91,827)— — (97,058)— (97,058)— 
Stock-based compensation— — 4,958 — — 4,958 9,964 14,922 — 
Common dividends ($0.915 per share)
— — — (637,866)— (637,866)— (637,866)— 
Distributions to noncontrolling interests— — — — — — (28,484)(28,484)(336)
Contributions from noncontrolling interests— — — — — — — — 13,124 
Adjustments to redeemable noncontrolling interests— — 305 — — 305 (13,005)(12,700)12,700 
September 30, 2025694,946 $694,946 $12,765,070 $(5,854,766)$(7,975)$7,597,275 $640,220 $8,237,495 $27,809 
See accompanying Notes to the Unaudited Consolidated Financial Statements.
7

Table of Contents
Healthpeak Properties, Inc.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
Nine Months Ended
September 30,
20262025
Cash flows from operating activities:
Net income (loss)$299,584 $(20,765)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization of real estate, in-place lease, and other intangibles872,047 796,779 
Stock-based compensation amortization expense14,170 10,410 
Stock-based compensation issued as part of initial public offering of Janus Living, Inc.4,872 — 
Amortization of deferred financing costs and debt discounts (premiums)25,879 23,708 
Straight-line rents(35,964)(30,836)
Amortization of above (below) market lease intangibles(19,466)(28,402)
Amortization of non-refundable entrance fees(84,812)(71,813)
Equity loss (income) from unconsolidated joint ventures(10,516)176,691 
Distributions of earnings from unconsolidated joint ventures1,739 16,861 
Deferred income tax expense (benefit)(2,439)(131)
Impairments and loan loss reserves (recoveries), net(3,964)(117)
Loss (gain) on debt extinguishments403 — 
Loss (gain) on sales of real estate, net(60,657)(13,136)
Loss (gain) upon change of control, net(138,343)— 
Casualty-related loss (recoveries), net(5,950)9,825 
Other non-cash items(14,680)(7,826)
Changes in:
Decrease (increase) in accounts receivable and other assets27,222 9,756 
Increase (decrease) in accounts payable, accrued liabilities, and other liabilities(14,204)(18,087)
Increase (decrease) in deferred revenue121,519 104,958 
Net cash provided by (used in) operating activities976,440 957,875 
Cash flows from investing activities:
Acquisitions of real estate and deposits(2,307,282)(43,880)
Joint venture buyout, net(400,902)— 
Development, redevelopment, and other major improvements of real estate(444,091)(547,087)
Leasing costs, tenant improvements, and recurring capital expenditures(103,678)(76,125)
Proceeds from sales of real estate, net146,702 30,839 
Proceeds from the BX JV I and II transaction, net162,801 — 
Investments in unconsolidated joint ventures(3,123)(76,329)
Distributions in excess of earnings from unconsolidated joint ventures23,084 22,745 
Proceeds from insurance recovery13,969 12,214 
Proceeds from sales/principal repayments on loans receivable and other403,839 125,927 
Investments in loans receivable and other(70,297)(77,357)
Net cash provided by (used in) investing activities(2,578,978)(629,053)
Cash flows from financing activities:
Borrowings under bank line of credit and commercial paper21,494,850 9,435,650 
Repayments under bank line of credit and commercial paper(21,084,200)(9,217,525)
Issuances and borrowings of term loans, senior unsecured notes, and mortgage debt— 987,260 
Repayments and repurchases of term loans, senior unsecured notes, and mortgage debt(894,775)(806,492)
Payments for debt extinguishment and deferred financing costs(8,663)(2,604)
Issuance of common stock, net of offering costs796 304 
Repurchase of common stock(101,660)(97,058)
Dividends paid on common stock(632,541)(637,234)
Distributions to and redemption of noncontrolling interests(195,373)(28,820)
Proceeds from Janus Living public offerings, net of underwriting fees 2,107,448 — 
Proceeds from the Brookfield JV transaction1,001,793 — 
Contributions from and issuance of noncontrolling interests760 13,124 
Noncontrolling interest issuance costs(17,777)— 
Net cash provided by (used in) financing activities1,670,658 (353,395)
Net increase (decrease) in cash, cash equivalents, and restricted cash68,120 (24,573)
Cash, cash equivalents, and restricted cash, beginning of period537,702 184,305 
Cash, cash equivalents, and restricted cash, end of period$605,822 $159,732 
See accompanying Notes to the Unaudited Consolidated Financial Statements.
8

Table of Contents
Healthpeak Properties, Inc.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited) 
NOTE 1.  Business
Overview
Healthpeak Properties, Inc., a Standard & Poor’s 500 company, is a Maryland corporation that is organized to qualify as a real estate investment trust (“REIT”) and that, together with its consolidated entities (collectively, “Healthpeak” or the “Company”), owns, operates, and develops high-quality real estate focused on healthcare discovery and delivery in the United States (“U.S.”). Healthpeak® has a diverse portfolio comprised of investments in the following reportable healthcare segments: (i) outpatient medical; (ii) lab; and (iii) senior housing.
The Company’s corporate headquarters are in Denver, Colorado, and it has additional corporate offices in California, Tennessee, Wisconsin, and Massachusetts, and property management offices in several locations throughout the U.S.
The Company is organized as an umbrella partnership REIT (“UPREIT”). Substantially all of the Company’s business is conducted through Healthpeak OP, LLC (“Healthpeak OP”). The Company is the managing member of Healthpeak OP and does not have material assets or liabilities, other than through its investment in Healthpeak OP.
On March 23, 2026, Janus Living, Inc. (“Janus Living”), a pure-play senior housing REIT, and the only U.S. publicly traded REIT whose portfolio is owned and operated under the REIT Investment Diversification and Empowerment Act of 2007 (“RIDEA”) or similar structures, completed its initial public offering (the “Janus Living IPO”) to become a public company. In connection with the Janus Living IPO, 48,300,000 shares of Janus Living’s Class A-1 common stock were issued to public investors, generating total gross proceeds of $966 million, less $65 million of fees paid to the underwriters.
On June 4, 2026, an additional 25,000,000 shares of Janus Living’s Class A-1 common stock were issued to public investors following the completion of a public offering (the “Janus Living June Follow-On Offering”). As part of the Janus Living June Follow-On Offering, Janus Living granted the underwriters a 30-day option to purchase up to an additional 3,750,000 shares of Janus Living’s Class A-1 common stock, which was exercised in full on June 22, 2026. The Janus Living June Follow-On Offering generated total gross proceeds of $719 million, less $28 million of fees paid to the underwriters.
On August 12, 2026, an additional 18,400,000 shares of Janus Living’s Class A-1 common stock were issued to public investors following the completion of a public offering (the “Janus Living August Follow-On Offering,” collectively with the Janus Living June Follow-On Offering, the “Janus Living Follow-On Offerings”). The Janus Living August Follow-On Offering generated total gross proceeds of $534 million, which included the exercise in full of the underwriters’ option to purchase additional shares, less $19 million of fees paid to the underwriters.
During the three and nine months ended September 30, 2026, the Company recognized interest on invested cash of $8 million and $19 million, respectively, related to interest earned on proceeds from the Janus Living IPO and Janus Living Follow-On Offerings.
In connection with the Janus Living IPO, through a series of formation transactions, the Company transferred, directly or indirectly, cash plus senior housing real estate communities and certain parcels of land for future development to Janus Living. As a result of these transactions, the Company received 138,816,246 shares of Janus Living’s Class A-1 common stock and 75,917,780 common units in the Janus Living OP, LLC (“Janus Living OP”), Janus Living’s operating subsidiary. In connection with these formation transactions, the Company also purchased shares of Janus Living’s Class A-2 common stock in an amount equivalent to the common units of Janus Living OP that the Company holds following completion of the formation transactions described above, for aggregate consideration of approximately $760 thousand. Janus Living’s Class A-2 common stock are not entitled to receive any dividends or distributions, but were issued to provide Healthpeak with voting rights that correspond to its common units. As of September 30, 2026, Healthpeak’s ownership of the Janus Living Class A-1 and Class A-2 common shares, together with the Company’s ownership of common units of Janus Living OP, provides Healthpeak with voting and economic rights of 69.2% of Janus Living. Janus Living is externally managed by Healthpeak Investment Management, LLC, an indirect subsidiary of the Company, and is consolidated by Healthpeak.
9

Table of Contents
NOTE 2.  Summary of Significant Accounting Policies
Basis of Presentation
The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information. Management is required to make estimates and assumptions in the preparation of financial statements in conformity with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from management’s estimates.
The consolidated financial statements include the accounts of Healthpeak Properties, Inc., its wholly owned subsidiaries, joint ventures (“JVs”) that it controls, and variable interest entities (“VIEs”) in which the Company has determined it is the primary beneficiary. Intercompany transactions and balances have been eliminated upon consolidation. All adjustments (consisting of normal recurring adjustments) necessary to present fairly the Company’s financial position, results of operations, and cash flows have been included. Operating results for the three and nine months ended September 30, 2026 are not necessarily indicative of the results that may be expected for the year ending December 31, 2026 or any interim period. The accompanying unaudited interim financial information should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the U.S. Securities and Exchange Commission (“SEC”).
Income Taxes
The Company’s deferred tax assets are netted against deferred tax liabilities on the Consolidated Balance Sheets. The Company is required to evaluate its deferred tax assets for realizability and recognize a valuation allowance, which is recorded against its deferred tax assets, if it is more likely than not that the deferred tax assets will not be realized. The Company considers all available evidence in its determination of whether a valuation allowance for deferred tax assets is required.
In connection with the formation transactions related to the Janus Living IPO, the ownership of six senior housing communities was transferred from a taxable REIT subsidiary to a non-taxable entity. This change in tax status resulted in the derecognition of certain deferred tax assets and liabilities. The net impact of this change in tax status resulted in a net tax benefit of $2 million during the nine months ended September 30, 2026.
Reclassifications
Certain prior period amounts have been reclassified to conform to the current year presentation. On the Consolidated Statements of Cash Flows, the Company elected to separately present the following line items instead of aggregating them into single line items: (i) increase (decrease) in deferred revenue, (ii) increase (decrease) in accounts payable, accrued liabilities, and other liabilities, (iii) amortization of non-refundable entrance fees, and (iv) amortization of above (below) market lease intangibles. These reclassifications had no impact on the Company’s consolidated financial position, results of operations, or cash flows.
Recent Accounting Pronouncements
Not Yet Adopted
Expense Disaggregation. In November 2024, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”), to address requests from investors for more detailed information about the types of expenses in commonly presented expense captions. ASU 2024-03 requires public companies to provide disaggregated disclosure in tabular format in the notes to financial statements of specific expenses, including but not limited to: (i) employee compensation, (ii) depreciation, and (iii) intangible asset amortization. In January 2025, the FASB issued ASU No. 2025-01, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date, which clarifies that the amendments in ASU 2024-03 are effective for public business entities for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. The amendments may be applied either prospectively or retrospectively. Early adoption is also permitted. The Company is evaluating the impact these ASUs will have on its disclosures.
10

Table of Contents
NOTE 3.  Real Estate Investments
2026 Real Estate Investment Acquisitions
SWF JV Buyout
In January 2026, the Company acquired its JV partner’s 46.5% interest in the Sovereign Wealth Fund Senior Housing JV (“SWF SH JV”) for $312 million (the “SWF JV Buyout”). As a result of the SWF JV Buyout, the Company began consolidating the 19 senior housing communities, derecognized its investment in the SWF SH JV, and recognized a gain upon change of control of $46 million, which is recorded in other income (expense), net in the Consolidated Statements of Operations. See Note 7 for further information. The fair value of the senior housing communities was based on a market approach, utilizing an agreed-upon contractual sales price, which is considered to be a Level 3 measurement within the fair value hierarchy.
Subsequent to the completion of this acquisition, the Company entered into agreements to transition the management of certain of these senior housing communities from Brookdale Senior Living (“Brookdale”) to Ciel Senior Living and Pegasus Senior Living (the “operator transition”). In connection with the operator transition, during the three months ended March 31, 2026, the Company incurred a termination fee of $2.5 million to Brookdale, which is recognized within transaction costs on the Consolidated Statements of Operations.
Senior Housing Acquisitions
The following table summarizes senior housing communities acquired during the nine months ended September 30, 2026, excluding the JV Buyout discussed above:
Acquisitions Closed During the
Three Months Ended
StateNumber of PropertiesPurchase Price
(in millions)
March 31, 2026
Georgia2$240 
Florida3119 
Washington141 
June 30, 2026
Washington153 
Arizona152 
September 30, 2026
Georgia3425 
Various(1)
9398 
Florida4190 
Various(2)
8150
Florida1149
Various(3)
3123
Illinois1105
South Carolina181
Kentucky150
Colorado147
Colorado135
_______________________________________
(1)Includes communities located in Illinois, Indiana, Kentucky, Missouri, Nebraska, and South Carolina.
(2)Includes communities located in New Mexico and Texas.
(3)Includes communities located in Kentucky and Missouri.
The Company completed $432 million of acquisitions subsequent to September 30, 2026, which included seven senior housing communities.
Lab Land Parcel Acquisitions
During the three months ended March 31, 2026, the Company acquired two lab land parcels in Cambridge, Massachusetts for $28 million.
11

Table of Contents
HQ Point Acquisition
In September 2026, the Company paid $105 million to acquire the senior construction loan secured by a two-building lab campus in San Diego, California (“HQ Point”) and subsequently obtained 100% ownership of HQ Point (the “HQ Point Buyout”). Prior to the HQ Point Buyout, the Company held an interest in HQ Point through a preferred equity investment (the “HQ Point Preferred Equity Investment”). As a result of the HQ Point Buyout, during the three months ended September 30, 2026, the Company began consolidating HQ Point and derecognized the HQ Point Preferred Equity Investment. See Note 7 for further information. The fair value of HQ Point was determined using standard valuation methodologies, including market and income approaches, including market comparable data, which are considered to be a Level 3 measurement within the fair value hierarchy.
Westway One Acquisition
Subsequent to September 30, 2026, the Company acquired an outpatient medical building in Houston, Texas for $38 million.
2025 Real Estate Investment Acquisitions
Middletown Medical Portfolio
In February 2025, the Company acquired a portfolio of three outpatient medical buildings in New York for $17 million.
100 Smith Land Parcel
In February 2025, the Company acquired a lab land parcel in Cambridge, Massachusetts for $20 million.
Gateway Crossing Acquisition
In December 2025, the Company completed the acquisition of (i) a lab building for consideration paid, net of discounts and closing costs, of $295 million and (ii) a 50% interest in a JV owning five lab buildings and one other property on the same campus in South San Francisco, California (the “Gateway Crossing JV”) for consideration paid, net of discounts and closing costs, of $132 million. As of December 31, 2025, the Company consolidated the Gateway Crossing JV as it was the managing member and had the ability to control the activities that most significantly impacted the JV’s economic performance (see Note 15). The noncontrolling JV partner had the ability to put its equity interest to the Company after the passage of a predetermined period of time. As such, the noncontrolling interest as of December 31, 2025 was recognized within redeemable noncontrolling interests on the Consolidated Balance Sheets (see Note 11). In January 2026, the Company acquired the remaining 50% interest in the Gateway Crossing JV for consideration paid, net of discounts and closing costs, of $132 million, bringing the Company’s equity ownership in these six buildings to 100%.
Other Outpatient Medical Acquisitions
During the year ended December 31, 2025, the Company acquired nine suites within an outpatient medical building in Atlanta, Georgia for $7 million and acquired an outpatient medical land parcel in Huntsville, Alabama for $7 million.
Development Activities
The Company’s commitments, which are primarily related to development and redevelopment projects and Company-owned tenant improvements, decreased by $23 million to $199 million at September 30, 2026, when compared to December 31, 2025, primarily as a result of construction spend on projects in development and redevelopment, partially offset by commitments on projects placed into redevelopment during the period.
NOTE 4.  Dispositions of Real Estate
2026 Dispositions of Real Estate
During the three months ended March 31, 2026, the Company sold (i) four lab buildings for $68 million, (ii) two outpatient medical buildings for $15 million, and (iii) nine suites within an outpatient medical building in Atlanta, Georgia for $7 million, resulting in total gain on sales of $51 million.
During the three months ended June 30, 2026, the Company sold (i) two outpatient medical buildings for $34 million and (ii) one senior housing community for $23 million, resulting in total gain on sales of $10 million.
In October 2026, the Company sold two outpatient medical buildings for $31 million.
12

Table of Contents
Brookfield JV
In July 2026, the Company formed a JV with an affiliate of Brookfield Asset Management (“Brookfield”). The Company contributed 86 outpatient medical buildings which are diversified across 11 states. Brookfield purchased a non-controlling 49% equity interest in the JV at a gross valuation of approximately $2.1 billion. Under the terms of the agreement, the Company will maintain day-to-day control and management of the assets and will retain a call right for a finite period beginning after year seven to repurchase Brookfield’s interest at a price sufficient to provide Brookfield with a 6.5% net annual rate of return excluding initial transaction expenses.
The Brookfield JV is a VIE under ASC 810, Consolidation, because the Company exercises full responsibility, discretion, and control over the day-to-day management of the Brookfield JV, and Brookfield does not have substantive participating rights or substantive kick-out rights. The Company consolidates the Brookfield JV as it is the primary beneficiary given it has both (i) the power to direct the activities that most significantly affect its economic performance and (ii) the obligation to absorb losses and the right to receive benefits that could potentially be significant to the Brookfield JV. See Note 15 for further information.
The Brookfield JV transaction was accounted for as an issuance of a noncontrolling interest in a consolidated subsidiary without a loss of control. Brookfield’s initial capital contribution was recognized as a noncontrolling interest within the Consolidated Balance Sheets and the Consolidated Statements of Equity and Redeemable Noncontrolling Interests. Direct and incremental transaction costs are recorded as a reduction of equity offsetting the proceeds raised.
The Company allocates income and loss attributable to the noncontrolling interest taking into account the contractual terms, economic substance, any capital transactions of the Brookfield JV, and Brookfield’s net annual rate of return.
2025 Dispositions of Real Estate
During the three months ended June 30, 2025, the Company sold one outpatient medical land parcel for $4 million, resulting in gain on sale of $3 million.
During the three months ended September 30, 2025, the Company sold two outpatient medical buildings for $27 million, resulting in gain on sales of $12 million.
During the three months ended December 31, 2025, the Company sold (i) seven outpatient medical buildings for $133 million and (ii) a portfolio of 16 outpatient medical buildings for $182 million, resulting in total gain on sales of $57 million.
Held for Sale
As of September 30, 2026, two lab buildings and three outpatient medical buildings were classified as held for sale, with a carrying value of $48 million, primarily comprised of net real estate assets. As of September 30, 2026, liabilities related to the assets held for sale were $1 million, primarily comprised of deferred revenue. Two of these outpatient medical buildings were sold in October 2026. As of December 31, 2025, six lab buildings and two outpatient medical buildings were classified as held for sale, with a carrying value of $81 million, primarily comprised of net real estate assets of $73 million and right-of-use assets of $7 million. As of December 31, 2025, liabilities related to the assets held for sale were $12 million, primarily comprised of lease liabilities of $9 million and deferred revenue of $3 million. Four of these lab buildings were sold during the three months ended March 31, 2026 and one of these outpatient medical buildings was sold during the three months ended June 30, 2026.
Impairments of Real Estate
During the three and nine months ended September 30, 2026 and 2025, the Company did not recognize any impairment charges on its consolidated real estate assets.
NOTE 5.  Leases
Lease Income
The following table summarizes the Company’s lease income (in thousands):
Three Months Ended
September 30,
Nine Months Ended
September 30,
2026202520262025
Fixed income from operating leases$389,168 $392,915 $1,163,333 $1,178,305 
Variable income from operating leases156,222 146,971 453,847 429,409 
13

Table of Contents
Initial Direct Costs
Initial direct costs incurred in connection with successful property leasing are capitalized as deferred leasing costs and classified as investing activities in the Consolidated Statements of Cash Flows. Initial direct costs include only those costs that are incremental to the arrangement and would not have been incurred if the lease had not been obtained. Initial direct costs consist of leasing commissions paid to employees and external third party brokers and lease incentives. Initial direct costs are included in other assets in the Consolidated Balance Sheets and amortized in depreciation and amortization in the Consolidated Statements of Operations using the straight-line method over the lease term. At September 30, 2026 and December 31, 2025, the balance of net initial direct costs were $227 million and $225 million, respectively.
Straight-Line Rents
For operating leases with minimum scheduled rent increases, the Company recognizes income on a straight-line basis over the lease term when collectibility of future minimum lease payments is probable. Recognizing rental income on a straight-line basis results in a difference in the timing of revenue amounts from what is contractually due from tenants. If the Company determines that collectibility of future minimum lease payments is not probable, the accounts receivable and straight-line rent receivable balance is written off and recognized as a decrease in revenue in that period and future revenue recognition is limited to amounts contractually owed and paid. The Company does not resume recognition of income on a straight-line basis unless it determines that collectibility of future payments related to these leases is probable. For the Company’s portfolio of operating leases that are deemed probable of collection but exhibit a certain level of collectibility risk, the Company may also recognize an incremental allowance as a reduction to revenue. At September 30, 2026 and December 31, 2025, straight-line rent receivable, net of allowance, excluding amounts reported in assets held for sale, was $405 million and $373 million, respectively. Straight-line rent receivable is included in other assets in the Consolidated Balance Sheets.
NOTE 6.  Loans Receivable
The following table summarizes the Company’s loans receivable (in thousands):
September 30,
2026
December 31,
2025
Secured loans(1)
$240,963 $583,460 
Mezzanine loans52,192 47,690 
Unamortized discounts and fees(916)(13,785)
Reserve for loan losses(8,036)(11,345)
Loans receivable, net$284,203 $606,020 
_______________________________________
(1)At September 30, 2026 and December 31, 2025, the Company had $59 million and $99 million, respectively, of remaining commitments to fund additional principal on loans for outpatient medical and lab capital expenditure projects.
Outpatient Medical Seller Financing
In conjunction with the sale of 59 outpatient medical buildings for $674 million in July 2024 and two outpatient medical buildings for $23 million in November 2024, the Company provided the buyer with a mortgage loan secured by the real estate sold for $405 million and $14 million, respectively. The remainder of the sales price was received in cash at the time of sales. The seller financing had an initial maturity date of July 2026 plus two 12-month extension options. The Company also received a $1 million loan origination fee in connection with the loan, which is being recognized in interest income over the remaining term of the loan. In connection with this seller financing, the Company reduced the gain on sales of real estate and recognized a mark-to-market discount of $21 million during the year ended December 31, 2024. This discount is based on the difference between the stated interest rate and the corresponding prevailing market rate as of the transaction date. The discount is recognized as interest income over the term of the discounted loan using the effective interest rate method.
In June 2026, the Company received a $399 million partial principal repayment. In connection with this repayment, the Company accelerated recognition of $9 million of non-cash interest income related to the mark-to-market discount and loan fees. Also in June 2026, the borrower elected the first of its two 12-month extension options, extending the maturity date of the remaining outstanding balance. The interest rate on the seller financing increased from 6.0% for the initial term to 6.5% during the optional extension period. Subsequent to the repayment, as of September 30, 2026, the outstanding principal balance was $20 million and was collateralized by eight outpatient medical buildings.
14

Table of Contents
During the three and nine months ended September 30, 2026, the Company recognized $57 thousand and $12 million, respectively, of non-cash interest income related to the amortization of this mark-to-market discount, which includes the accelerated recognition discussed above for the nine months ended September 30, 2026. During the three and nine months ended September 30, 2025, the Company recognized $2 million and $5 million, respectively, of non-cash interest income related to the amortization of this mark-to-market discount. As of September 30, 2026 and December 31, 2025, the unamortized mark-to-market discount was $360 thousand and $12 million, respectively.
Loans Receivable Activity
The following is a summary of the Company’s loans receivable activity for the periods presented (in thousands):
Secured Loans
Mezzanine Loans
Loans receivable as of December 31, 2024$638,482 $50,314 
Add: Advances on and acquisitions of loans receivable87,648 4,756 
Less: Receipts on loans receivable and other reductions(1)
(142,670)(7,380)
Loans receivable as of December 31, 2025583,460 47,690 
Add: Advances on and acquisitions of loans receivable56,502 9,342 
Less: Receipts on loans receivable and other reductions
(398,999)(4,840)
Loans receivable as of September 30, 2026$240,963 $52,192 
_______________________________________
(1)Includes the following: (i) the full early repayment in August 2025 of the $58 million outstanding balance of seller financing provided to the buyer of a portfolio of Senior Housing Operating Property (“SHOP”) facilities in January 2021 and (ii) the full repayment upon maturity in January 2025 of the $48 million outstanding balance of seller financing provided to the buyer of another SHOP portfolio in January 2021. Both of these loans receivable were secured by the buyer’s equity ownership in the properties.
In October 2026, the Company entered into a $20 million mezzanine loan commitment used to finance outpatient medical acquisitions, of which $5 million was funded at closing. The loan matures in 2031 and has a fixed interest rate of 10.0% for the first four years which increases to 10.5% thereafter.
Loans Receivable Internal Ratings
In connection with the Company’s quarterly review process or upon the occurrence of a significant event, loans receivable are reviewed and assigned an internal rating of Performing, Watch List, or Workout. Loans receivable that are deemed Performing meet material contractual obligations, and collection and timing, of all amounts owed is reasonably assured. Watch List loans receivable are defined as loans receivable that do not meet the definition of Performing or Workout. Workout loans receivable are defined as loans receivable in which the Company has determined, based on current information and events, that: (i) it is probable it will be unable to collect all amounts due according to the contractual terms of the agreement, (ii) the borrower is delinquent on making payments under the contractual terms of the agreement, and (iii) the Company has commenced action or anticipates pursuing action in the near term to seek recovery of its investment.
15

Table of Contents
The following table summarizes, by year of origination, the Company’s internal ratings for loans receivable, net of unamortized discounts, fees, and reserves for loan losses, as of September 30, 2026 (in thousands):
Investment Type
Year of Origination(1)
Total
2026
2025
202420232022Prior
Secured loans
Risk rating:
Performing loans$10,540 $67,324 $80,605 $42,756 $34,319 $— $235,544 
Watch list loans— — — — — — — 
Workout loans— — — — — — — 
Total secured loans$10,540 $67,324 $80,605 $42,756 $34,319 $— $235,544 
Current period gross write-offs$— $— $— $— $— $— $— 
Current period recoveries— — — — — — — 
Current period net write-offs$— $— $— $— $— $— $— 
Mezzanine loans
Risk rating:
Performing loans$8,953 $4,290 $14,413 $— $4,096 $16,907 $48,659 
Watch list loans— — — — — — — 
Workout loans— — — — — — — 
Total mezzanine loans$8,953 $4,290 $14,413 $— $4,096 $16,907 $48,659 
Current period gross write-offs$— $— $— $— $— $— $— 
Current period recoveries— — — — — — — 
Current period net write-offs$— $— $— $— $— $— $— 
_______________________________________
(1)Additional fundings under existing loans are included in the year of origination of the initial loan.
Reserve for Loan Losses
The Company evaluates the liquidity and creditworthiness of its borrowers on a quarterly basis to determine whether any updates to the future expected losses recognized upon inception are necessary. The Company’s evaluation considers payment history and current credit status, industry conditions, current economic conditions, forecasted economic conditions, individual and portfolio property performance, credit enhancements, liquidity, and other factors. Future economic conditions are based primarily on near-term economic forecasts from the Federal Reserve and reasonable assumptions for long-term economic trends. The determination of loan losses also considers concentration of credit risk associated with the senior housing, outpatient medical, and lab industries to which its loans receivable relate. The Company’s borrowers furnish property, portfolio, and guarantor/operator-level financial statements, among other information, on a monthly or quarterly basis; the Company utilizes this financial information to calculate the debt service coverages in its assessment of internal ratings that it uses as a primary credit quality indicator. Debt service coverage information is evaluated together with other property, portfolio, and operator performance information, including revenue, expense, net operating income, occupancy, rental rate, reimbursement trends, capital expenditures, and EBITDA (defined as earnings before interest, tax, and depreciation and amortization), underlying collateral value (as applicable), along with other liquidity measures. The Company evaluates, on a quarterly basis or immediately upon a significant change in circumstance, its borrowers’ ability to service their obligations with the Company.
16

Table of Contents
The following table summarizes the Company’s reserve for loan losses (in thousands):
September 30, 2026December 31, 2025
Secured LoansMezzanine LoansTotalSecured LoansMezzanine LoansTotal
Reserve for loan losses, beginning of period$4,750 $6,595 $11,345 $5,574 $4,925 $10,499 
Provision for expected loan losses on funded loans receivable83 (3,228)(3,145)908 2,215 3,123 
Expected loan losses (recoveries) related to loans sold or repaid in full— (164)(164)(1,732)(545)(2,277)
Reserve for loan losses, end of period$4,833 $3,203 $8,036 $4,750 $6,595 $11,345 
Additionally, at September 30, 2026 and December 31, 2025, a liability of $0.5 million and $1.1 million, respectively, related to expected credit losses for unfunded loan commitments was included in accounts payable, accrued liabilities, and other liabilities.
The change in the reserve for expected loan losses during the nine months ended September 30, 2026 is primarily due to (i) changes in operating performance and fair values of the underlying collateral of the Company’s loans receivable and (ii) recoveries related to loan repayments during the nine months ended September 30, 2026, partially offset by reserves recognized on a new and extended secured loan executed during the nine months ended September 30, 2026.
NOTE 7.  Investments in Unconsolidated Joint Ventures
The Company owns interests in the following entities that are accounted for under the equity method (dollars in thousands): 
Carrying Amount
September 30,December 31,
Entity(1)
Segment
Property Count(2)
Ownership %(2)
20262025
South San Francisco JVs(3)
Lab770$285,388 $285,387 
Callan Ridge JVLab23573,456 74,369 
BX JV I and II(4)
Outpatient medical62042,955 — 
Lab JVLab14930,546 31,406 
PMAK JV(2)
Outpatient medical591214,828 21,711 
Needham Land Parcel JV(2)
Lab—3813,960 12,453 
Outpatient Medical JV(5)
Outpatient medical1673,801 7,177 
Davis JVOutpatient medical23461,180 3,530 
SWF SH JV(6)
Senior housing——— 312,709 
HQ Point Preferred Equity Investment(7)
Other——— 53,859 
$466,114 $802,601 
_______________________________________
(1)These entities are not consolidated because the Company does not control, through voting rights or other means, the JVs.
(2)Property counts and ownership percentages are as of September 30, 2026. Land held for development and the properties underlying the PMAK JV are excluded from the Company’s total property count.
(3)Includes multiple unconsolidated lab JVs in South San Francisco, California in which the Company holds a 70% ownership percentage in each JV. The Company is entitled to a preferred return, a promote, and certain fees in exchange for development and asset management services provided to these joint ventures when certain conditions are met. These JVs have been aggregated herein due to similarity of the investments and operations.
(4)Includes two unconsolidated outpatient medical JVs in which the Company holds a 20% ownership percentage in each JV. These JVs have been aggregated herein due to similarity of the investments and operations.
(5)As of September 30, 2026, includes one unconsolidated outpatient medical JV, Suburban Properties, LLC, in which the Company holds a 67% ownership percentage. As of December 31, 2025, included two unconsolidated outpatient medical JVs in which the Company held an ownership percentage as follows: (i) Ventures IV (20%) and (ii) Suburban Properties, LLC (67%). These joint ventures were aggregated herein due to similarity of the investments and operations. During the nine months ended September 30, 2026, the outpatient medical building in the Ventures IV JV was sold, resulting in a $2 million loss on sale recognized within equity income (loss) from unconsolidated joint ventures.
(6)As of December 31, 2025, the Company held a 53.5% ownership interest in the SWF SH JV that was comprised of 19 senior housing communities prior to the SWF SH JV Buyout, as described below.
(7)As of December 31, 2025, the Company held the HQ Point Preferred Equity Investment, a preferred equity investment in two property lab campus in San Diego, California, prior to the HQ Point Buyout, as described below.

17

Table of Contents
SWF SH JV Buyout
As of December 31, 2025, the Company held a 53.5% ownership interest in the SWF SH JV. In January 2026, the Company acquired its JV partner’s 46.5% interest for $312 million, resulting in consolidation of the 19 senior housing communities (see Note 3).
Blackstone (“BX”) JV I and II
In March 2026, the Company sold an 80% interest in six outpatient medical buildings to a third party for net proceeds of $163 million and formed two JVs. Following the transaction, the Company does not control the JVs through its voting rights, resulting in the Company deconsolidating the assets, recognizing its retained 20% investment in the JVs at fair value, and accounting for its investment using the equity method. The fair value of the Company’s retained investment at the time of the transaction was based on a market approach, utilizing an agreed-upon contractual sales price, which is considered to be a Level 3 measurement within the fair value hierarchy. During the nine months ended September 30, 2026, the Company recognized a gain upon change of control of $92 million, which is recognized within other income (expense), net in the Consolidated Statements of Operations.
HQ Point Preferred Equity Investment
In February 2025, the Company made a preferred equity investment in a joint venture that holds a lab campus under development in San Diego, California. This investment is entitled to a preferred return, and the Company committed to fund up to a total investment of $50 million, all of which had been funded as of December 31, 2025.
In September 2026, the Company paid $105 million to acquire the senior construction loan secured by the campus and subsequently obtained 100% ownership of HQ Point, resulting in consolidation of the two lab buildings (see Note 3).
Other-Than-Temporary Impairments
The Company reviews its investments in unconsolidated joint ventures for indicators of impairment on a quarterly basis and records an impairment charge when a decline in the fair value below the carrying value has been determined to be other-than-temporary. During the three months ended September 30, 2025, indicators of impairment were identified related to the cumulative impact of depressed biotechnology capital raising, lower market rents, increased capitalization rates, and oversupply affecting the life science industry. These conditions were a shift since the time of formation of the South San Francisco JVs, a period marked by historically low interest rates coupled with market rents and valuations at or near industry highs when the JV partner acquired its 30% interest. As the South San Francisco JVs at the time included completed and in-process redevelopment properties, these economic conditions resulted in an increase to the timeframe required to reach stabilized occupancy and changes to management’s estimates of market rents upon completion of redevelopment activities. Additionally, there was a shift in development plans of the Needham Land Parcel JV from a life science development to a mixed-use project, resulting in an extended timeline and delayed project commencement.
These circumstances contributed to a sustained decrease in the value of these investments. During the three months ended September 30, 2025, the Company determined that the length of time and extent of the decline in fair values below carrying values represented other-than-temporary impairments. Accordingly, during the three months ended September 30, 2025, the Company recorded impairment charges of $169 million related to its investments in the South San Francisco JVs and $7 million related to its investment in the Needham Land Parcel JV, net of a $2 million income tax benefit. These impairment charges were recognized in equity income (loss) from unconsolidated joint ventures in the Consolidated Statements of Operations. The discounted cash flow models utilized to determine the impairment charges were considered Level 3 measurements within the fair value hierarchy. These discounted cash flow models utilized the following key assumptions: (i) forecasted occupancy and market rents, (ii) a terminal capitalization rate of 6.50%, (iii) discount rates ranging from 7.50% to 8.75%, with a weighted average of 7.95% (weighted by each property’s relative fair value), (iv) expected capital expenditures, and (v) specific to Needham Land Parcel JV, land values based on a comparable sales approach.
18

Table of Contents
NOTE 8.  Intangibles
Intangible assets primarily consist of lease-up intangibles and above market lease intangibles. The following table summarizes the Company’s intangible lease assets (dollars in thousands):
Intangible lease assetsSeptember 30,
2026
December 31,
2025
Gross intangible lease assets(1)
$1,478,559 $1,377,039 
Accumulated depreciation and amortization(2)
(560,859)(722,523)
Intangible assets$917,700 $654,516 
Weighted average remaining amortization period in years45
_______________________________________
(1)As of September 30, 2026 and December 31, 2025, includes $1.44 billion and $1.33 billion, respectively, of gross lease-up intangibles and $38 million and $43 million, respectively, of gross above market lease intangibles.
(2)As of September 30, 2026 and December 31, 2025, includes $543 million and $705 million, respectively, of accumulated depreciation and amortization on lease-up intangibles and $18 million and $17 million, respectively, of accumulated depreciation and amortization on above market lease intangibles.
Intangible liabilities consist of below market lease intangibles. The following table summarizes the Company’s intangible lease liabilities (dollars in thousands):
Intangible lease liabilitiesSeptember 30,
2026
December 31,
2025
Gross intangible lease liabilities$277,873 $316,197 
Accumulated depreciation and amortization(131,185)(142,500)
Intangible liabilities$146,688 $173,697 
Weighted average remaining amortization period in years99
During the nine months ended September 30, 2026, in conjunction with the Company’s acquisitions of real estate, the Company acquired $497 million of intangible assets with a weighted average amortization period at acquisition of three years. Other activity during the nine months ended September 30, 2026 includes the write-off of fully depreciated assets.
During the year ended December 31, 2025, in conjunction with the Company’s acquisitions of real estate, the Company acquired $137 million of intangible assets with a weighted average amortization period at acquisition of seven years and $31 million of intangible liabilities with a weighted average amortization period at acquisition of eight years.
Goodwill
At September 30, 2026 and December 31, 2025, goodwill was allocated to the Company’s segment assets as follows (in thousands):
Segment
September 30,
2026
December 31,
2025
Outpatient medical
$64,680 $64,680 
Senior housing3,849 3,849 
$68,529 $68,529 
NOTE 9.  Debt
Healthpeak OP, the Company’s consolidated operating subsidiary, is the borrower under, and the Company, DOC DR Holdco, and DOC DR OP Sub are the guarantors of, the Revolving Facility, 2027 Term Loans, 2029 Term Loan, 2030 Term Loan, 2031 Term Loan, Commercial Paper Program (each as defined below), and senior unsecured notes issued by the Company. DOC DR OP Sub is the borrower under, and the Company, Healthpeak OP, and DOC DR Holdco are guarantors of, the 2028 Term Loan (as defined below) and certain senior unsecured notes assumed by the Company. Guarantees of senior unsecured notes are full and unconditional and applicable to existing and future senior unsecured notes.
19

Table of Contents
Janus Living Credit Facilities
Concurrent with the completion of the Janus Living IPO, Janus Living entered into a credit agreement that provided for a $500 million revolving credit facility (as amended, the “Janus Living Revolving Credit Facility”) and a $100 million delayed draw term loan facility (the “Janus Living Delayed Draw Term Loan” and, together with the Janus Living Revolving Credit Facility, the “Janus Living Credit Facilities”). The Janus Living Revolving Credit Facility matures in March 2030 with two six-month extension periods available, subject to certain conditions. Borrowings under the Janus Living Revolving Credit Facility bear interest at SOFR plus 105 basis points, based on Janus Living’s current leverage-based pricing grid. Janus Living may utilize the Janus Living Revolving Credit Facility to fund acquisitions and other commitments. In September 2026, Janus Living amended and restated the Janus Living Credit Facilities to increase the Janus Living Revolving Credit Facility commitment to $1.25 billion. The amended and restated Janus Living Credit Facilities also includes an accordion feature that permits the Company to increase the revolving commitments and/or add incremental term loans in an aggregate amount of $500 million, subject to customary requirements, such as obtaining additional lender commitments (the “Janus Living Term Loans”). The amended and restated Janus Living Credit Facilities also terminated the $100 million Janus Living Delayed Draw Term Loan, prior to Janus Living drawing on the Delayed Draw Term Loan. Inclusive of the $500 million accordion option, these changes increased the aggregate amount under the Janus Living Credit Facilities to $1.75 billion. Janus Living pays a facility fee on the entire revolving commitment that is based on its current leverage-based pricing grid, which was 0.15% as of September 30, 2026. As of September 30, 2026, total unamortized debt issuance costs for the Janus Living Credit Facilities were $6 million, which are recognized in other assets on the Consolidated Balance Sheets. As of September 30, 2026, no principal had been drawn on the Janus Living Credit Facilities.
The Janus Living Credit Facilities are subject to certain financial restrictions and other customary requirements, including financial covenants and cross-default provisions to other indebtedness. Among other things, these covenants, using terms defined in the applicable agreement, provide for the following limitations or other requirements on Janus Living: (i) limit the ratio of Enterprise Total Indebtedness to Enterprise Gross Asset Value to 60%; (ii) limit the ratio of Enterprise Secured Debt to Enterprise Gross Asset Value to 40%; (iii) limit the ratio of Enterprise Unsecured Debt to Enterprise Unencumbered Asset Value to 60%; (iv) require a minimum Fixed Charge Coverage Ratio of 1.5 times; (v) require a minimum Consolidated Tangible Net Worth of at least the sum of (x) $2.04 billion as of the end of any fiscal quarter plus (y) an amount equal to 75% of the net proceeds received from any equity offerings after the original closing date of the Credit Facilities; and (vi) require a minimum Unsecured Interest Coverage Ratio of 1.75 times. The Company believes Janus Living was in compliance with each of these covenants at September 30, 2026.
Bank Line of Credit and Term Loans
Revolving Facility
As of September 30, 2026, the Company’s unsecured revolving line of credit facility had aggregate commitments of $3.0 billion and matures on January 19, 2029, which may be further extended pursuant to two six-month extension options, subject to certain customary conditions (the “Revolving Facility”). Borrowings under the Revolving Facility accrue interest at the applicable interest rate benchmark, SOFR, plus a margin that is based on the credit ratings of the Company’s senior unsecured long-term debt. In October 2025, the Company executed an amendment to the Revolving Facility to, among other immaterial changes, remove a 10 basis point adjustment related to SOFR transition from the determination of the margin. The Company also pays a facility fee on the entire revolving commitment that is based on its credit ratings. Based on the Company’s credit ratings at September 30, 2026, the margin on the Revolving Facility was 0.78% and the facility fee was 0.15%. The Revolving Facility includes a feature that allows the Company to increase the borrowing capacity by an aggregate amount of up to $750 million, subject to securing additional commitments. At each of September 30, 2026 and December 31, 2025, the Company had no balance outstanding under the Revolving Facility.
Term Loan Agreement
The Company previously entered into a term loan agreement (as amended or modified, the “Term Loan Agreement”) that provided a maximum incremental borrowing capacity of $1.5 billion. As of September 30, 2026, the Company had borrowed (i) $500 million principal balance (the “2027 Term Loans”), of which $250 million matures on February 22, 2027 with one option to extend for a one-year period subject to certain customary conditions and $250 million matures on August 22, 2027 with no option to extend, and (ii) an aggregate principal amount of $750 million that matures in March 2029 (the “2029 Term Loan”).
In October 2025, the Company executed an amendment to the Term Loan Agreement to remove a 10 basis point adjustment related to SOFR transition from the determination of the margin.
20

Table of Contents
In March 2026, concurrent with the closing of the Janus Living IPO, the Company executed an amendment to the Term Loan Agreement pursuant to which (i) the applicable lenders provided their consent to the Janus Living IPO and the other transactions consummated in connection therewith, (ii) the maximum incremental borrowing capacity under the Term Loan Agreement was increased from $1.5 billion to $2.0 billion, and (iii) the Company obtained senior unsecured delayed draw term loan commitments in an aggregate principal amount of $400 million (the “2031 Term Loan”). The 2031 Term Loan is available to be drawn through December 2026 and matures in March 2031. As of September 30, 2026, the Company had no balance outstanding under the 2031 Term Loan.
As of September 30, 2026, the unused borrowing capacity under the Term Loan Agreement was $750 million. At each of September 30, 2026 and December 31, 2025, the Company had $1.25 billion of loans outstanding under the Term Loan Agreement.
In October 2026, the Company executed an amendment to the Term Loan Agreement pursuant to which (i) the maximum incremental borrowing capacity under the Term Loan Agreement was increased from $2.0 billion to $2.75 billion and (ii) the Company obtained senior unsecured delayed draw term loan commitments in an aggregate principal amount of $500 million (the “2030 Term Loan”). The 2030 Term Loan is available to be drawn through July 2027 and has a stated maturity of four years. As of November 3, 2026, no amount has been drawn under the 2030 Term Loan.
Loans outstanding under the 2027 Term Loans accrue interest at Term SOFR plus a margin that is based on the credit ratings of the Company’s senior unsecured long-term debt. The 2027 Term Loans also include a sustainability-linked pricing component whereby the applicable margin under the 2027 Term Loans may be reduced by 0.01% based on the Company’s achievement of specified sustainability-linked metrics. Based on the Company’s credit ratings as of September 30, 2026, and inclusive of achievement of a sustainability-linked metric, the margin on the 2027 Term Loans was 0.84%.
The Company has two forward-starting interest rate swap instruments that are designated as cash flow hedges (see Note 17). The 2027 Term Loans associated with these interest rate swap instruments are reported as fixed rate debt due to the Company having effectively established a fixed interest rate for the underlying debt instruments. Based on the Company’s credit ratings as of September 30, 2026, the 2027 Term Loans had a blended fixed effective interest rate of 3.65%, inclusive of the impact of these interest rate swap instruments and amortization of the related debt issuance costs.
Loans outstanding under the 2029 Term Loan accrue interest at Daily SOFR plus a margin that is based on the credit ratings of the Company’s senior unsecured long-term debt. Based on the Company’s credit ratings as of September 30, 2026, the margin on the 2029 Term Loan was 0.85%.
The Company has forward-starting interest rate swap instruments that are designated as cash flow hedges (see Note 17). The 2029 Term Loan associated with these interest rate swaps is reported as fixed rate debt due to the Company having effectively established a fixed interest rate for the underlying debt instruments. Based on the Company’s credit ratings as of September 30, 2026, the 2029 Term Loan had a blended fixed effective interest rate of 4.56%, inclusive of the impact of these interest rate swap instruments and amortization of the related debt issuance costs.
Loans outstanding under the 2031 Term Loan accrue interest at Daily SOFR plus a margin that is based on the credit ratings of the Company’s senior unsecured long-term debt. Based on the Company’s credit ratings as of September 30, 2026, the margin on the 2031 Term Loan was 0.80%.
Loans outstanding under the 2030 Term Loan accrue interest at Daily SOFR plus a margin that is based on the credit ratings of the Company’s senior unsecured long-term debt.
As of September 30, 2026, the Company also had assumed senior unsecured term loans in an aggregate principal amount of $400 million (the “2028 Term Loan”) that mature in May 2028. Loans outstanding under the 2028 Term Loan bear interest at an annual rate equal to (i) the applicable margin, plus (ii) Daily SOFR. In October 2025, the Company executed an amendment to the 2028 Term Loan to remove a 10 basis point adjustment related to SOFR transition from the determination of the margin. The applicable margin under the 2028 Term Loan ranges from 0.85% to 1.65% for Daily SOFR loans and is based on the Company’s and Healthpeak OP’s credit ratings. Based on the Company’s and Healthpeak OP’s credit ratings as of September 30, 2026, the margin on the 2028 Term Loan was 0.90%.
The Company has three interest rate swap instruments that are designated as cash flow hedges. The 2028 Term Loan associated with these interest rate swap instruments is reported as fixed rate debt due to the Company having effectively established a fixed interest rate for the underlying debt instruments. Based on DOC DR OP Sub’s credit ratings as of September 30, 2026, the 2028 Term Loan had a blended fixed effective interest rate of 4.35%, inclusive of the impact of these interest rate swap instruments and amortization of the related premium. See also Note 17 for additional information related to these interest rate swap instruments.
21

Table of Contents
The Revolving Facility, 2027 Term Loans, 2028 Term Loan, 2029 Term Loan, 2030 Term Loan, and 2031 Term Loan are subject to certain financial restrictions and other customary requirements, including financial covenants and cross-default provisions to other indebtedness. Among other things, these covenants, using terms defined in the applicable agreement: (i) limit the ratio of Enterprise Total Indebtedness to Enterprise Gross Asset Value to 60%; (ii) limit the ratio of Enterprise Secured Debt to Enterprise Gross Asset Value to 40%; (iii) limit the ratio of Enterprise Unsecured Debt to Enterprise Unencumbered Asset Value to 60%; (iv) require a minimum Fixed Charge Coverage ratio of 1.5 times; and (v) require a minimum Consolidated Tangible Net Worth of $7.7 billion. The Company believes it was in compliance with each of these covenants at September 30, 2026.
Commercial Paper Program
The Company has an unsecured commercial paper program (the “Commercial Paper Program”). Under the terms of the Commercial Paper Program, the Company may issue, from time to time, short-term unsecured notes with varying maturities. Amounts available under the Commercial Paper Program may be borrowed, repaid, and re-borrowed from time to time. At each of September 30, 2026 and December 31, 2025, the maximum aggregate face or principal amount that could be outstanding at any one time was $2.0 billion. Amounts borrowed under the Commercial Paper Program will be sold on terms that are customary for the U.S. commercial paper market and will be at least equal in right of payment with all of the Company’s other unsecured and unsubordinated indebtedness. The Company uses its Revolving Facility as a liquidity backstop for the repayment of short-term unsecured notes issued under the Commercial Paper Program. During the three months ended September 30, 2026 and 2025, the Company recognized $3 million and $2 million, respectively, of interest expense related to fees and amortization of debt issuance costs in connection with its Commercial Paper Program and Revolving Facility. During the nine months ended September 30, 2026 and 2025, the Company recognized $8 million and $7 million, respectively, of interest expense related to fees and amortization of debt issuance costs in connection with its Commercial Paper Program and Revolving Facility. At September 30, 2026, the Company had $1.5 billion notes outstanding under the Commercial Paper Program, with original maturities of approximately 22 days and a weighted average interest rate of 4.17%. At December 31, 2025, the Company had $1.1 billion of notes outstanding under the Commercial Paper Program, with original maturities of approximately 39 days and a weighted average interest rate of 4.02%.
Senior Unsecured Notes
At September 30, 2026 and December 31, 2025, the Company had senior unsecured notes outstanding with an aggregate principal balance of $6.3 billion and $6.9 billion, respectively. The senior unsecured notes contain certain covenants including limitations on debt, maintenance of unencumbered assets, cross-acceleration provisions, and other customary terms. The Company believes it was in compliance with these covenants at September 30, 2026.
During the three and nine months ended September 30, 2026, there were no issuances of senior unsecured notes.
The following table summarizes the Company’s senior unsecured note repayments during the three and nine months ended September 30, 2026 (dollars in thousands):
Repayment Date
Amount
Coupon Rate(1)
Maturity Year
July 15, 2026$650,000 3.25 %2026
_______________________________________
(1)The effective interest rate, which includes amortization of debt discounts and debt issuance costs, was 3.40%.
The following table summarizes the Company’s senior unsecured note issuances for the year ended December 31, 2025 (dollars in thousands):
Issue DateAmount
Coupon Rate(1)
Maturity Year
February 14, 2025$500,000 5.38 %2035
August 14, 2025500,000 4.75 %2033
_______________________________________
(1)The effective interest rate, which includes amortization of debt discounts and debt issuance costs, is 5.56% for the senior unsecured notes issued in February 2025 and 5.02% for the senior unsecured notes issued in August 2025.
22

Table of Contents
The following table summarizes the Company’s senior unsecured note repayments for the year ended December 31, 2025 (dollars in thousands):
Repayment Date
Amount
Coupon Rate(1)
Maturity Year
February 3, 2025$348,194 3.40 %2025
June 2, 2025451,806 4.00 %2025
_______________________________________
(1)The effective interest rate, which includes amortization of debt discounts and debt issuance costs, was 3.58% for the senior unsecured notes repaid in February 2025 and 4.19% for the senior unsecured notes repaid in June 2025.
Mortgage Debt
At September 30, 2026 and December 31, 2025, the Company had $104 million and $349 million, respectively, in aggregate principal of mortgage debt outstanding. At September 30, 2026, this mortgage debt was secured by five outpatient medical buildings, with an aggregate carrying value of $202 million. At December 31, 2025, this mortgage debt was secured by 18 outpatient medical buildings and two senior housing communities, with an aggregate carrying value of $747 million.
Mortgage debt generally requires monthly principal and interest payments, is collateralized by real estate assets, and is non-recourse. Mortgage debt also typically requires maintenance of the assets in good condition, includes conditions to obtain lender consent to enter into or terminate material leases, requires insurance on the assets, requires payment of real estate taxes, restricts transfer of the encumbered assets and repayment of the loan, and prohibits additional liens. Some of the mortgage debt may require tenants or operators to maintain compliance with the applicable leases or operating agreements of such real estate assets.
During the three months ended September 30, 2026 and 2025, the Company made aggregate principal repayments of mortgage debt of $223 thousand and $1 million, respectively. During the nine months ended September 30, 2026 and 2025, the Company made aggregate principal repayments of mortgage debt of $245 million and $6 million, respectively.
Included in the aggregate principal payments of mortgage debt for the nine months ended September 30, 2026 was a $102 million early full principal repayment in January 2026 of mortgage debt secured by two senior housing communities with original maturities in December 2026. In connection with this repayment, the Company paid $1 million of accrued interest and prepayment penalties and recognized a $400 thousand loss on debt extinguishment.
Also included in the aggregate principal payments of mortgage debt for the nine months ended September 30, 2026 was a $142 million full principal repayment of mortgage debt secured by 13 outpatient medical buildings upon maturity in June 2026. The Company had two interest rate swap instruments that were designated as cash flow hedges on this mortgage debt which matured in May 2026 (see Note 17). During the year ended December 31, 2025, the variable rate mortgage debt associated with these interest rate swap instruments was reported as fixed rate debt due to the Company having effectively established a fixed interest rate for the underlying debt instrument.
Included in the aggregate principal payments of mortgage debt for the nine months ended September 30, 2025 was a $4 million full principal repayment of mortgage debt secured by one outpatient medical building that matured in March 2025.
23

Table of Contents
Debt Maturities
The following table summarizes the Company’s stated debt maturities and scheduled principal repayments at September 30, 2026 (dollars in thousands):
Senior Unsecured
Notes(3)
Mortgage
Debt(4)
Year
Bank Line 
of Credit(1)
Commercial Paper(1)(2)
Term LoansAmount
Interest Rate(5)
Amount
Interest Rate(5)
Total
2026$— $— $— $— — %$100,225 5.76 %$100,225 
2027— — 500,000 850,000 3.23 %842 4.57 %1,350,842 
2028— — 400,000 850,000 3.53 %2,775 3.53 %1,252,775 
2029— 1,489,500 750,000 650,000 3.65 %— — %2,889,500 
2030— — — 750,000 3.14 %— — %750,000 
Thereafter— — — 3,150,000 5.08 %— — %3,150,000 
— 1,489,500 1,650,000 6,250,000 103,842 9,493,342 
Premiums, (discounts), and debt issuance costs, net— — (3,275)(107,899)177 (110,997)
$— $1,489,500 $1,646,725 $6,142,101 $104,019 $9,382,345 
_______________________________________
(1)As of September 30, 2026, total unamortized debt issuance costs for the Revolving Facility and Commercial Paper Program were $11 million and total unamortized debt issuance costs for the Janus Living Credit Facilities were $6 million, which are recognized in other assets on the Consolidated Balance Sheets.
(2)Commercial Paper Program borrowings are backstopped by the availability under the Revolving Facility. As such, the Company calculates the weighted average remaining term of its Commercial Paper Program borrowings using the maturity date of the Revolving Facility.
(3)Effective interest rates on the senior unsecured notes range from 1.54% to 6.87% with a weighted average effective interest rate of 4.24% and a weighted average maturity of approximately four years.
(4)Effective interest rates on the mortgage debt range from 3.53% to 6.37% with a weighted average effective interest rate of 5.69% and a weighted average maturity of approximately three months.
(5)Represents the weighted-average effective interest rate as of the end of the applicable period, including amortization of debt premiums (discounts) and debt issuance costs.
Additionally, as of September 30, 2026, the Company had 14 outstanding letter of credit obligations totaling $3 million.
NOTE 10.  Commitments and Contingencies
Legal Proceedings
From time to time, the Company is a party to legal proceedings, lawsuits and other claims that arise in the ordinary course of the Company’s business. The Company is not aware of any legal proceedings or claims that it believes may have, individually or taken together, a material adverse effect on the Company’s financial condition, results of operations, or cash flows. The Company’s policy is to expense legal costs as they are incurred.
DownREITs and Other Partnerships
In connection with the formation of certain limited liability companies (“DownREITs”), members may contribute appreciated real estate to a DownREIT in exchange for DownREIT units. These contributions are generally tax-deferred, so that the pre-contribution gain related to the property is not taxed to the member. However, if a contributed property is later sold by the DownREIT, the unamortized pre-contribution gain that exists at the date of sale is specifically allocated and taxed to the contributing members. In many of the DownREITs, the Company has entered into indemnification agreements with those members who contributed appreciated property into the DownREIT. Under these indemnification agreements, if any of the appreciated real estate contributed by the members is sold by the DownREIT in a taxable transaction within a specified number of years, the Company will reimburse the affected members for the federal and state income taxes associated with the pre-contribution gain that is specially allocated to the affected member under the Internal Revenue Code (“make-whole payments”). These make-whole payments include a tax gross-up provision. As of September 30, 2026, the Company had indemnification agreements on a total of 28 properties within its DownREITs.
24

Table of Contents
Minimum Liquid Reserve (“MLR”)
For the Company’s life plan communities, which are a form of senior housing that offer a full continuum of care and operate under an entrance fee model, state licensing authorities require the Company to maintain MLR balances in escrow accounts based upon certain financial calculations. This requirement mitigates the risk of a community failure, whereby the Company would be obligated to repay the balance of entrance fees to its residents. The reserve balance required by these state licensing authorities at September 30, 2026 was $93 million, which was met through $63 million of restricted cash held in escrow and $30 million of promissory notes. These promissory notes are issued between the Company and certain of its operating subsidiaries, which represents intercompany activity that is eliminated in the Consolidated Financial Statements.
NOTE 11.  Equity and Redeemable Noncontrolling Interests
Dividends
On October 1, 2026, the Company’s Board of Directors declared a monthly common stock cash dividend of $0.10167 per share for each of October, November, and December 2026, payable on October 30, 2026, November 25, 2026, and December 30, 2026, respectively, to stockholders of record as of the close of business on October 19, 2026, November 13, 2026, and December 18, 2026, respectively.
During each of the three months ended September 30, 2026 and 2025, the Company declared and paid common stock cash dividends of $0.305 per share. During each of the nine months ended September 30, 2026 and 2025, the Company declared and paid common stock cash dividends of $0.915 per share.
At-The-Market Equity Offering Program
The Company’s at-the-market equity offering program (the “ATM Program”) was most recently amended in February 2025 to add certain banks as sales agents, a forward seller, and a forward purchaser under the ATM Program. The ATM Program allows for the sale of shares of common stock having an aggregate gross sales price of up to $1.5 billion (i) by the Company through a consortium of banks acting as sales agents or directly to the banks acting as principals or (ii) by a consortium of banks acting as forward sellers on behalf of any forward purchasers pursuant to a forward sale agreement (each, an “ATM forward contract”). The use of ATM forward contracts allows the Company to lock in a share price on the sale of shares at the time the ATM forward contract becomes effective, but defer receiving the proceeds from the sale of shares until a later date.
ATM forward contracts generally have a one- to two-year term. At any time during the term, the Company may settle a forward sale by delivery of physical shares of common stock to the forward seller or, at the Company’s election, in cash or net shares. The forward sale price the Company expects to receive upon settlement of outstanding ATM forward contracts will be the initial forward price established upon the effective date, subject to adjustments for: (i) accrued interest, (ii) the forward purchasers’ stock borrowing costs, and (iii) certain fixed price reductions during the term of the ATM forward contract.
At September 30, 2026, $1.5 billion of the Company’s common stock remained available for sale under the ATM Program.
ATM Forward Contracts
During each of the three and nine months ended September 30, 2026 and 2025, the Company did not utilize the forward provisions under the ATM Program.
ATM Direct Issuances
During each of the three and nine months ended September 30, 2026 and 2025, there were no direct issuances of shares of common stock under the ATM Program.
25

Table of Contents
Share Repurchase Programs
On July 24, 2024, the Company’s Board of Directors approved a share repurchase program (the “2024 Share Repurchase Program”) to supersede and replace the Company’s previous share repurchase program. Under the 2024 Share Repurchase Program, the Company could acquire shares of its common stock in the open market or other similar purchase techniques (including in compliance with the safe harbor provisions of Rule 10b-18 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or pursuant to one or more plans adopted under Rule 10b5-1 promulgated under the Exchange Act), up to an aggregate purchase price of $500 million. Purchases of common stock under the 2024 Share Repurchase Program could be exercised at the Company’s discretion with the timing and number of shares repurchased depending on a variety of factors, including price, corporate and regulatory requirements, and other corporate liquidity requirements and priorities. During the nine months ended September 30, 2025, the Company repurchased 5.09 million shares of its common stock under the 2024 Share Repurchase Program at a weighted average price of $18.50 per share for a total of $94 million. During the nine months ended September 30, 2026, the Company repurchased 5.95 million shares of its common stock under the 2024 Share Repurchase Program at a weighted average price of $16.81 per share for a total of $100 million. The 2024 Share Repurchase Program expired in July 2026.
On July 30, 2026, the Company’s Board of Directors approved a new share repurchase program (the “2026 Share Repurchase Program”) to supersede and replace the 2024 Share Repurchase Program. Upon adoption of the 2026 Share Repurchase Program, no further share repurchases may be made pursuant to the 2024 Share Repurchase Program. Under the 2026 Share Repurchase Program, the Company may acquire shares of its common stock in the open market or other similar purchase techniques (including in compliance with the safe harbor provisions of Rule 10b-18 under the Exchange Act, or pursuant to one or more plans adopted under Rule 10b5-1 promulgated under the Exchange Act), in an amount up to an aggregate purchase price of $500 million. Purchases of common stock under the 2026 Share Repurchase Program may be exercised at the Company’s discretion with the timing and number of shares repurchased depending on a variety of factors, including price, corporate and regulatory requirements, and other corporate liquidity requirements and priorities. The 2026 Share Repurchase Program may be suspended or terminated at any time without prior notice. During the three and nine months ended September 30, 2026, no shares were repurchased under the 2026 Share Repurchase Program. As of September 30, 2026, $500 million of the Company’s common stock remained available for repurchase under the 2026 Share Repurchase Program.
Accumulated Other Comprehensive Income (Loss)
The following table summarizes the Company’s accumulated other comprehensive income (loss) (in thousands):
September 30,
2026
December 31,
2025
Unrealized gains (losses) on derivatives, net$29,664 $(8,110)
Supplemental Executive Retirement Plan minimum liability(1,606)(1,827)
Total accumulated other comprehensive income (loss)$28,058 $(9,937)
The Company has a defined benefit pension plan, known as the Supplemental Executive Retirement Plan, with one plan participant, a former Chief Executive Officer (“CEO”) of the Company who departed in 2003. Changes to the Supplemental Executive Retirement Plan minimum liability are reflected in other comprehensive income (loss).
Noncontrolling Interests
Redeemable Noncontrolling Interests
Arrangements with noncontrolling interest holders are assessed for appropriate balance sheet classification based on the redemption and other rights held by the noncontrolling interest holder. Certain of the Company’s noncontrolling interest holders have the ability to put their equity interests to the Company upon specified events or after the passage of a predetermined period of time (each, a “Put Option”). Each Put Option is payable in cash and subject to changes in redemption value, which is generally based on the underlying property’s fair value. Accordingly, the Company records redeemable noncontrolling interests outside of permanent equity and presents the redeemable noncontrolling interests at the greater of their carrying amount or redemption value at the end of each reporting period. In addition to the rights of the redeemable noncontrolling interest holders, the Company has the ability to buy out the interests of certain noncontrolling interest holders. The values of the redeemable noncontrolling interests are subject to change based on the assessment of redemption value at each redemption date.
As of December 31, 2025, (i) the estimated redemption value of the redeemable noncontrolling interests with currently exercisable Put Options was $14 million, (ii) the estimated redemption value of the redeemable noncontrolling interests that will become exercisable upon completion of the related development projects was $13 million, and (iii) the estimated redemption value of the Gateway Crossing JV (see Note 3) was $132 million.
26

Table of Contents
During the three months ended March 31, 2026, the Company acquired the remaining 50% interest of the Gateway Crossing JV for $132 million, terminating the Put Option of the noncontrolling interest holder. As of September 30, 2026, (i) the estimated redemption value of the redeemable noncontrolling interests with currently exercisable Put Options was $14 million and (ii) the estimated redemption value of the redeemable noncontrolling interests that will become exercisable upon completion of the related development projects was $14 million.
Janus Living - Public Investors
In connection with the Janus Living IPO in March 2026, 48,300,000 shares of Janus Living’s Class A-1 common stock were issued to public investors, generating total gross proceeds of $966 million, less $65 million of fees paid to the underwriters. During the nine months ended September 30, 2026, a portion of these proceeds were utilized to fund certain other offering and transaction-related costs (see Note 20).
On June 4, 2026, an additional 25,000,000 shares of Janus Living’s Class A-1 common stock were issued to public investors following the completion of the Janus Living June Follow-On Offering. As part of the Janus Living June Follow-On Offering, Janus Living granted the underwriters a 30-day option to purchase up to an additional 3,750,000 shares of Janus Living’s Class A-1 common stock, which was exercised in full on June 22, 2026. The Janus Living June Follow-On Offering generated total gross proceeds of $719 million, less $28 million of fees paid to the underwriters. In conjunction with the Janus Living June Follow-On Offering, $1 million of offering costs were incurred and recognized within total noncontrolling interests on the Consolidated Statements of Equity and Redeemable Noncontrolling Interests during the nine months ended September 30, 2026.
On August 12, 2026, an additional 18,400,000 shares of Janus Living’s Class A-1 common stock were issued to public investors following the completion of the Janus Living August Follow-On Offering. The Janus Living August Follow-On Offering generated total gross proceeds of $534 million, which included the exercise in full of the underwriters’ option to purchase additional shares, less $19 million of fees paid to the underwriters. In conjunction with the Janus Living August Follow-On Offering, $2 million of offering costs were incurred and recognized within total noncontrolling interests on the Consolidated Statements of Equity and Redeemable Noncontrolling Interests during the three months ended September 30, 2026.
As of September 30, 2026, Janus Living public investors represent a 30.8% interest in Janus Living, a consolidated subsidiary of Healthpeak, which is calculated by dividing the number of Janus Living's Class A-1 common stock held by public investors by the total outstanding number of shares of Janus Living’s Class A-1 common stock and common units in Janus Living. The Janus Living IPO and Janus Living Follow-On Offerings resulted in an allocation between equity and noncontrolling interests on the Consolidated Statements of Equity and Redeemable Noncontrolling Interests to reflect the change in total net assets and capital structure of the Company.
Healthpeak OP
During each of the nine months ended September 30, 2026 and 2025, certain employees of the Company (“OP Unitholders”) were issued approximately 2 million non-managing member units in Healthpeak OP (“Healthpeak OP Units”), all of which were profits interests in Healthpeak OP. When certain conditions are met, the OP Unitholders have the right to require redemption of part or all of their Healthpeak OP Units for cash or shares of the Company’s common stock, at the Company’s option as managing member of Healthpeak OP. The per unit redemption amount is equal to either one share of the Company’s common stock or cash equal to the fair value of a share of common stock at the time of redemption. The Company classifies the Healthpeak OP Units in permanent equity because it may elect, in its sole discretion, to issue shares of its common stock to OP Unitholders who choose to redeem their Healthpeak OP Units rather than using cash. As of September 30, 2026, there were approximately 6 million Healthpeak OP Units outstanding and 509 thousand had met the criteria for redemption. As of September 30, 2026, the value of the Healthpeak OP Units that had met the criteria for redemption based on the closing stock price on September 30, 2026 was $10 million. As of December 31, 2025, there were approximately 4 million Healthpeak OP Units outstanding and 275 thousand had met the criteria for redemption. As of December 31, 2025, the value of the Healthpeak OP Units that had met the criteria for redemption based on the closing stock price on December 31, 2025 was $4 million.
27

Table of Contents
Janus Living OP
During the nine months ended September 30, 2026, certain employees of the Company (“Janus Living OP Unitholders”) were issued approximately 392 thousand non-managing member units in Janus Living OP, the operating subsidiary of Janus Living, Inc. (“Janus Living OP Units” and together with Healthpeak OP Units, “OP Units”), all of which were profits interests in Janus Living OP. When certain conditions are met, the holders of Janus Living OP Units have the right to require redemption of part or all of their Janus Living OP Units for cash or shares of the Janus Living’s Class A-1 common stock, at Janus Living’s option as managing member of Janus Living OP. The per unit redemption amount is equal to either one share of Janus Living’s Class A-1 common stock or cash equal to the fair value of a share of Janus Living’s Class A-1 common stock at the time of redemption. The Company classifies the Janus Living OP Units in permanent equity because Janus Living may elect, in its sole discretion, to issue shares of Janus Living’s Class A-1 common stock to Janus Living OP Unitholders who choose to redeem their Janus Living OP Units rather than using cash. As of September 30, 2026, none of the Janus Living OP Units met the criteria for redemption.
DownREITs
The non-managing member units of the Company’s DownREITs are exchangeable for an amount of cash approximating the then-current market value of shares of the Company’s common stock or, at the Company’s option, shares of the Company’s common stock (subject to certain adjustments, such as stock splits and reclassifications). Upon exchange of DownREIT units for the Company’s common stock, the carrying amount of the DownREIT units is reclassified to stockholders’ equity. At each of September 30, 2026 and December 31, 2025, there were approximately 11 million DownREIT units (13 million shares of Healthpeak common stock are issuable upon conversion) outstanding in eight DownREIT LLCs, for all of which the Company holds a controlling interest and/or acts as the managing member. At September 30, 2026 and December 31, 2025, the carrying value of the 11 million DownREIT units was $305 million and $307 million, respectively. The market value of the 11 million DownREIT units, based on the closing stock price on September 30, 2026 and December 31, 2025, was $266 million and $215 million, respectively.
NOTE 12.  Earnings Per Common Share
Basic income (loss) per common share (“EPS”) is computed based on the weighted average number of common shares outstanding. Diluted income (loss) per common share is computed based on the weighted average number of common shares outstanding plus the impact of forward equity sales agreements using the treasury stock method, common shares issuable from the assumed conversion of DownREIT units, certain performance restricted stock units, OP Units, and unvested restricted stock units. Only those instruments having a dilutive impact on the Company’s basic income (loss) per share are included in diluted income (loss) per share during the periods presented.
Certain restricted stock units are considered participating securities, because dividend payments are not forfeited even if the underlying award does not vest, and require use of the two-class method when computing basic and diluted earnings per share.
The Company considers the potential dilution resulting from forward agreements under its ATM Program to the calculation of earnings per share. At inception, the agreements do not have an effect on the computation of basic EPS as no shares are delivered until settlement. However, the Company uses the treasury stock method to calculate the dilution, if any, resulting from the forward sales agreements during the period of time prior to settlement. Refer to Note 11 for a discussion of the forward sales agreements, under which there were no sales or settlements during the three and nine months ended September 30, 2026 and 2025.
28

Table of Contents
The following table illustrates the computation of basic and diluted earnings per share (in thousands, except per share amounts):
Three Months Ended
September 30,
Nine Months Ended
September 30,
2026202520262025
Numerator - Basic
Net income (loss)$36,687 $(109,848)$299,584 $(20,765)
Noncontrolling interests’ share in earnings(19,424)(7,274)(35,870)(21,856)
Net income (loss) attributable to Healthpeak Properties, Inc.17,263 (117,122)263,714 (42,621)
Less: Participating securities’ share in earnings
(145)(134)(444)(714)
Net income (loss) applicable to common shares$17,118 $(117,256)$263,270 $(43,335)
Numerator - Dilutive
Net income (loss) applicable to common shares$17,118 $(117,256)$263,270 $(43,335)
Add: distributions on dilutive convertible units and other— — 90 — 
Dilutive net income (loss) available to common shares$17,118 $(117,256)$263,360 $(43,335)
Denominator
Basic weighted average shares outstanding689,509 694,930 691,498 696,380 
Dilutive potential common shares - equity awards(1)
— — 2 — 
Dilutive potential common shares - OP Units(2)
— — 281 — 
Diluted weighted average common shares689,509 694,930 691,781 696,380 
Earnings per common share
Basic$0.02 $(0.17)$0.38 $(0.06)
Diluted$0.02 $(0.17)$0.38 $(0.06)
_______________________________________
(1)For all periods presented, represents the dilutive impact of 1 million outstanding equity awards (restricted stock units).
(2)For the three months ended September 30, 2026, all 6 million outstanding Healthpeak OP Units were not included because they were anti-dilutive. For the nine months ended September 30, 2026, represents the dilutive impact of 6 million outstanding Healthpeak OP Units. For each of the three and nine months ended September 30, 2025, all 4 million outstanding Healthpeak OP Units were not included because they were anti-dilutive.
For each of the three and nine months ended September 30, 2026 and 2025, all 13 million shares issuable upon conversion of DownREIT units were not included because they were anti-dilutive.
29

Table of Contents
NOTE 13.  Segment Disclosures
The Company’s operating segments, based on how its chief operating decision maker (“CODM”), the President and CEO, evaluates the business and allocates resources, are as follows: (i) outpatient medical, (ii) lab, (iii) senior housing, (iv) loans receivable, (v) a preferred equity investment, and (vi) three other properties. The Company’s reportable segments, as determined in accordance with ASC 280, Segment Reporting, are as follows: (i) outpatient medical, (ii) lab, and (iii) senior housing. The loans receivable, preferred equity investment, and three other properties are non-reportable segments that have been presented on a combined basis within the Notes to the Consolidated Financial Statements herein. The accounting policies of the segments are the same as those described in Note 2 to the Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the SEC, as updated by Note 2 in these financial statements.
For the outpatient medical and lab segments, the CODM evaluates performance based on property adjusted net operating income (“Adjusted NOI”). Adjusted NOI is used to evaluate performance because it provides relevant and useful information by reflecting only income and operating expense items that are incurred at the property level and presenting it on an unlevered basis. NOI is defined as real estate revenues (inclusive of rental and related revenues and resident fees and services, and exclusive of interest income), less property level operating expenses. Adjusted NOI is calculated as NOI after eliminating the effects of straight-line rents, amortization of market lease intangibles, termination fees, operator transition costs, and actuarial reserves for insurance claims that have been incurred but not reported. NOI and Adjusted NOI exclude all other financial statement amounts included in net income (loss).
NOI and Adjusted NOI are calculated as NOI and Adjusted NOI, respectively, from consolidated properties, plus the Company’s share of NOI and Adjusted NOI from unconsolidated joint ventures (calculated by applying the Company’s economic share for the period), less noncontrolling interests’ share of NOI and Adjusted NOI from consolidated joint ventures (calculated by applying the Company’s economic share for the period). Management utilizes its share of NOI and Adjusted NOI in assessing its performance as the Company has various joint ventures that contribute to its performance.
In connection with the Janus Living IPO, beginning in the first quarter of 2026, the CODM evaluates performance for the senior housing segment based on net income (loss).
Segment assets consist of real estate assets, intangible assets, and right-of-use assets. Non-segment assets consist of assets in the Company’s other non-reportable segments and corporate non-segment assets. Corporate non-segment assets consist primarily of corporate assets, including cash and cash equivalents, restricted cash, accounts receivable, other assets, and real estate assets held for sale. Reportable segment asset information is not provided to the CODM as the CODM does not use segment asset information to evaluate the business and allocate resources.
30

Table of Contents
The following table summarizes financial information for the reportable segments for the three months ended September 30, 2026 (in thousands):
Outpatient MedicalLabSenior HousingTotal
Total revenues$314,752 $223,870 $268,300 
Operating expenses(1)
(107,000)(75,058)
Healthpeak’s share of unconsolidated joint venture NOI5,652 5,865 
Noncontrolling interests’ share of consolidated joint venture NOI(20,700)— 
NOI - outpatient medical and lab192,704 154,677 
Adjustments to NOI(2)
(8,432)(13,809)
Adjusted NOI - outpatient medical and lab$184,272 $140,868 $325,140 
Senior housing net income (loss):
Compensation and property management(122,831)
Food(11,712)
Real estate taxes(8,045)
Repairs and maintenance(8,825)
Utilities(11,418)
Other segment items(3)
(30,588)
Depreciation and amortization(78,682)
General and administrative(1,527)
General and administrative - related party management fee(3,779)
Interest expense(486)
Transaction costs(3,400)
Other income (expense), net8,276 
Income tax benefit (expense)(891)
Senior housing net income (loss)$(5,608)(5,608)
Reconciling items:
Plus: Adjustments to NOI(2)
22,241 
Other non-reportable revenues6,768 
Interest income and other7,202 
Other non-reportable operating expenses(3,914)
Depreciation and amortization(220,241)
Interest expense(83,413)
General and administrative(18,283)
Transaction costs(6,338)
Impairments and loan loss reserves, net210 
Other income (expense), net394 
Less: Healthpeak’s share of unconsolidated joint venture NOI - outpatient medical and lab(11,517)
Plus: Noncontrolling interests’ share of consolidated joint venture NOI - outpatient medical20,700 
Plus: Income tax benefit (expense) - senior housing891 
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures$34,232 
_______________________________________
(1)See reconciliation of significant expense categories for outpatient medical and lab below.
(2)Represents straight-line rents, amortization of market lease intangibles, net, actuarial reserves for insurance claims that have been incurred but not reported, and termination fees. Includes the Company’s share of income (loss) generated by unconsolidated joint ventures and excludes noncontrolling interests’ share of earnings generated by consolidated joint ventures.
(3)Other segment items for senior housing include: (i) cleaning and supplies, (ii) insurance, (iii) marketing, and (iv) other expenses.
31

Table of Contents
The following table summarizes the Company’s significant expense categories for the outpatient medical and lab reportable segments for the three months ended September 30, 2026 (in thousands):
Outpatient MedicalLab
Compensation and property management$15,887 $9,330 
Real estate taxes23,677 22,472 
Repairs and maintenance19,521 10,658 
Utilities21,074 18,188 
Other segment items(1)
26,841 14,410 
Operating expenses$107,000 $75,058 
_______________________________________
(1)Other segment items for outpatient medical and lab include: (i) cleaning expense, (ii) ground rent expense, (iii) insurance expense, (iv) roads and grounds expense, (v) security expense, and (vi) other expense.
32

Table of Contents
The following table summarizes financial information for the reportable segments for the three months ended September 30, 2025 (in thousands):
Outpatient MedicalLabSenior HousingTotal
Total revenues$320,903 $213,325 $150,458 
Operating expenses(1)
(110,431)(64,352)
Healthpeak’s share of unconsolidated joint venture NOI4,440 4,605 
Noncontrolling interests’ share of consolidated joint venture NOI(6,569)— 
NOI - outpatient medical and lab208,343 153,578 
Adjustments to NOI(2)
(10,300)(15,520)
Adjusted NOI - outpatient medical and lab$198,043 $138,058 $336,101 
Senior housing net income (loss):
Compensation and property management(71,809)
Food(6,855)
Real estate taxes(4,073)
Repairs and maintenance(5,461)
Utilities(6,278)
Other segment items(3)
(19,434)
Depreciation and amortization(30,885)
General and administrative(2,267)
Interest expense(950)
Other income (expense), net(450)
Income tax benefit (expense)(1,576)
Equity income (loss) from unconsolidated joint ventures992 
Senior housing net income (loss)$1,412 1,412 
Reconciling items:
Plus: Adjustments to NOI(2)
25,820 
Other non-reportable revenues5,658 
Interest income and other15,529 
Other non-reportable operating expenses(3,229)
Depreciation and amortization(231,432)
Interest expense(75,834)
General and administrative(17,640)
Transaction costs(2,420)
Impairments and loan loss reserves, net54 
Gain (loss) on sales of real estate, net11,500 
Other income (expense), net1,610 
Less: Healthpeak’s share of unconsolidated joint venture NOI - outpatient medical and lab(9,045)
Plus: Noncontrolling interests’ share of consolidated joint venture NOI - outpatient medical6,569 
Plus: Income tax benefit (expense) - senior housing1,576 
Less: Equity income (loss) from unconsolidated joint ventures - senior housing(992)
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures$65,237 
_______________________________________
(1)See reconciliation of significant expense categories for outpatient medical and lab below.
(2)Represents straight-line rents, amortization of market lease intangibles, net, actuarial reserves for insurance claims that have been incurred but not reported, and termination fees. Includes the Company’s share of income (loss) generated by unconsolidated joint ventures and excludes noncontrolling interests’ share of earnings generated by consolidated joint ventures.
(3)Other segment items for senior housing include: (i) cleaning and supplies, (ii) insurance, (iii) marketing, and (iv) other expenses.
33

Table of Contents
The following table summarizes the Company’s significant expense categories for the outpatient medical and lab reportable segments for the three months ended September 30, 2025 (in thousands):
Outpatient MedicalLab
Compensation and property management$15,043 $8,484 
Real estate taxes25,068 19,500 
Repairs and maintenance17,000 8,966 
Utilities21,168 14,855 
Other segment items(1)
32,152 12,547 
Operating expenses$110,431 $64,352 
_______________________________________
(1)Other segment items for outpatient medical and lab include: (i) cleaning expense, (ii) ground rent expense, (iii) insurance expense, (iv) roads and grounds expense, (v) security expense, and (vi) other expense.
34

Table of Contents
The following table summarizes financial information for the reportable segments for the nine months ended September 30, 2026 (in thousands):
Outpatient MedicalLabSenior HousingTotal
Total revenues$943,640 $652,793 $685,101 
Operating expenses(1)
(316,740)(211,461)
Healthpeak’s share of unconsolidated joint venture NOI16,078 18,113 
Noncontrolling interests’ share of consolidated joint venture NOI(34,840)(54)
NOI - outpatient medical and lab608,138 459,391 
Adjustments to NOI(2)
(27,484)(34,890)
Adjusted NOI - outpatient medical and lab$580,654 $424,501 $1,005,155 
Senior housing net income (loss):
Compensation and property management(314,444)
Food(30,281)
Real estate taxes(21,091)
Repairs and maintenance(23,196)
Utilities(28,264)
Other segment items(3)
(79,527)
Depreciation and amortization(186,553)
General and administrative(5,819)
General and administrative - related party management fee(6,579)
Interest expense(1,187)
Transaction costs(26,188)
Gain (loss) on sales of real estate, net3,884 
Gain (loss) upon change of control, net(4)
46,270 
Gain (loss) on debt extinguishments(403)
Other income (expense), net25,557 
Income tax benefit (expense)(267)
Equity income (loss) from unconsolidated joint ventures111 
Senior housing net income (loss)$37,124 37,124 
Reconciling items:
Plus: Adjustments to NOI(2)
62,374 
Other non-reportable revenues20,747 
Interest income and other43,142 
Other non-reportable operating expenses(11,371)
Depreciation and amortization(685,494)
Interest expense(262,284)
General and administrative(58,299)
Transaction costs(16,871)
Impairments and loan loss reserves, net3,964 
Gain (loss) on sales of real estate, net56,773 
Other income (expense), net93,388 
Less: Healthpeak’s share of unconsolidated joint venture NOI - outpatient medical and lab(34,191)
Plus: Noncontrolling interests’ share of consolidated joint venture NOI - outpatient medical and lab34,894 
Plus: Income tax benefit (expense) - senior housing267 
Less: Equity income (loss) from unconsolidated joint ventures - senior housing(111)
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures$289,207 
_______________________________________
(1)See reconciliation of significant expense categories for outpatient medical and lab below.
(2)Represents straight-line rents, amortization of market lease intangibles, net, actuarial reserves for insurance claims that have been incurred but not reported, and termination fees. Includes the Company’s share of income (loss) generated by unconsolidated joint ventures and excludes noncontrolling interests’ share of earnings generated by consolidated joint ventures.
(3)Other segment items for senior housing include: (i) cleaning and supplies, (ii) insurance, (iii) marketing, and (iv) other expenses.
(4)Gain (loss) upon change of control, net, is recognized in other income (expense), net, in the Consolidated Statements of Operations.
35

Table of Contents
The following table summarizes the Company’s significant expense categories for the outpatient medical and lab reportable segments for the nine months ended September 30, 2026 (in thousands):
Outpatient MedicalLab
Compensation and property management$47,115 $27,920 
Real estate taxes72,136 66,097 
Repairs and maintenance56,553 29,992 
Utilities58,260 44,142 
Other segment items(1)
82,676 43,310 
Operating expenses$316,740 $211,461 
_______________________________________
(1)Other segment items for outpatient medical and lab include: (i) cleaning expense, (ii) ground rent expense, (iii) insurance expense, (iv) roads and grounds expense, (v) security expense, and (vi) other expense.
36

Table of Contents
The following table summarizes financial information for the reportable segments for the nine months ended September 30, 2025 (in thousands):
Outpatient MedicalLabSenior HousingTotal
Total revenues$950,135 $640,123 $448,240 
Operating expenses(1)
(315,136)(181,412)
Healthpeak’s share of unconsolidated joint venture NOI13,193 11,199 
Noncontrolling interests’ share of consolidated joint venture NOI(20,983)— 
NOI - outpatient medical and lab627,209 469,910 
Adjustments to NOI(2)
(32,959)(42,844)
Adjusted NOI - outpatient medical and lab$594,250 $427,066 $1,021,316 
Senior housing net income (loss):
Compensation and property management(213,558)
Food(20,080)
Real estate taxes(12,905)
Repairs and maintenance(15,181)
Utilities(17,660)
Other segment items(3)
(56,234)
Depreciation and amortization(94,875)
General and administrative(7,781)
Interest expense(2,847)
Other income (expense), net(11,781)
Income tax benefit (expense)(4,777)
Equity income (loss) from unconsolidated joint ventures3,452 
Senior housing net income (loss)$(5,987)(5,987)
Reconciling items:
Plus: Adjustments to NOI(2)
75,803 
Other non-reportable revenues17,456 
Interest income and other47,156 
Other non-reportable operating expenses(9,080)
Depreciation and amortization(701,904)
Interest expense(221,693)
General and administrative(59,008)
Transaction costs(18,169)
Impairments and loan loss reserves, net117 
Gain (loss) on sales of real estate, net13,136 
Other income (expense), net2,123 
Less: Healthpeak’s share of unconsolidated joint venture NOI - outpatient medical and lab(24,392)
Plus: Noncontrolling interests’ share of consolidated joint venture NOI - outpatient medical20,983 
Plus: Income tax benefit (expense) - senior housing4,777 
Less: Equity income (loss) from unconsolidated joint ventures - senior housing(3,452)
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures$159,182 
_______________________________________
(1)See reconciliation of significant expense categories for outpatient medical and lab below.
(2)Represents straight-line rents, amortization of market lease intangibles, net, actuarial reserves for insurance claims that have been incurred but not reported, and termination fees. Includes the Company’s share of income (loss) generated by unconsolidated joint ventures and excludes noncontrolling interests’ share of earnings generated by consolidated joint ventures.
(3)Other segment items for senior housing include: (i) cleaning and supplies, (ii) insurance, (iii) marketing, and (iv) other expenses.
37

Table of Contents
The following table summarizes the Company’s significant expense categories for the outpatient medical and lab reportable segments for the nine months ended September 30, 2025 (in thousands):
Outpatient MedicalLab
Compensation and property management$43,901 $25,071 
Real estate taxes73,455 57,510 
Repairs and maintenance46,586 24,526 
Utilities56,586 35,965 
Other segment items(1)
94,608 38,340 
Operating expenses$315,136 $181,412 
_______________________________________
(1)Other segment items for outpatient medical and lab include: (i) cleaning expense, (ii) ground rent expense, (iii) insurance expense, (iv) roads and grounds expense, (v) security expense, and (vi) other expense.
The following table summarizes the Company’s revenues by reportable segment (in thousands):
Three Months Ended
September 30,
Nine Months Ended
September 30,
Segment2026202520262025
Outpatient medical
$314,752 $320,903 $943,640 $950,135 
Lab
223,870 213,325 652,793 640,123 
Senior housing
268,300 150,458 685,101 448,240 
Total revenues for reportable segments
806,922 684,686 2,281,534 2,038,498 
Total revenues for other non-reportable
6,768 5,658 20,747 17,456 
Interest income and other7,202 15,529 43,142 47,156 
Total revenues$820,892 $705,873 $2,345,423 $2,103,110 
NOTE 14.  Supplemental Cash Flow Information
The following table provides supplemental cash flow information (in thousands):
Nine Months Ended September 30,
20262025
Supplemental cash flow information:
Interest paid, net of capitalized interest$273,084 $219,686 
Income taxes paid (refunded), net5,208 2,089 
Capitalized interest57,715 63,541 
Supplemental schedule of non-cash investing and financing activities:
Accrued construction costs$144,906 $164,460 
Increase in ROU asset in exchange for new lease liability related to operating leases1,561 7,049 
Noncash lease consideration13,000 — 
Net noncash impact from the consolidation of properties previously held in an unconsolidated joint venture371,731 — 
Retained equity method investment from BX JV I and II transactions, net (see Note 7)43,378 — 
Accrued distributions to noncontrolling interests19,180 — 
Noncash noncontrolling interests issuance costs1,029 — 
38

Table of Contents
The following table summarizes cash, cash equivalents, and restricted cash (in thousands):
Nine Months Ended September 30,
20262025
Beginning of period:
Cash and cash equivalents$467,457 $119,818 
Restricted cash70,245 64,487 
Cash, cash equivalents, and restricted cash$537,702 $184,305 
End of period:
Cash and cash equivalents$514,310 $91,038 
Restricted cash91,512 68,694 
Cash, cash equivalents, and restricted cash$605,822 $159,732 
Cash and Cash Equivalents
The Company maintains its cash and cash equivalents at financial institutions insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000 per institution. As of September 30, 2026 and December 31, 2025, the account balances at certain institutions exceeded the FDIC insurance coverage.
NOTE 15.  Variable Interest Entities
Operating Subsidiary
Healthpeak OP is the Company’s operating subsidiary and a limited liability company that has governing provisions that are the functional equivalent of a limited partnership. The Company holds a membership interest in Healthpeak OP, acts as the managing member of Healthpeak OP, and exercises full responsibility, discretion, and control over the day-to-day management of Healthpeak OP. Because the noncontrolling interests in Healthpeak OP do not have substantive liquidation rights, substantive kick-out rights without cause, or substantive participating rights, the Company has determined that Healthpeak OP is a VIE. The Company, as managing member, has the power to direct the core activities of Healthpeak OP that most significantly affect Healthpeak OP’s performance, and through its interest in Healthpeak OP, has both the right to receive benefits from and the obligation to absorb losses of Healthpeak OP. Accordingly, the Company is the primary beneficiary of Healthpeak OP and consolidates Healthpeak OP. As the Company conducts its business and holds its assets and liabilities through Healthpeak OP, the total consolidated assets and liabilities, income (losses), and cash flows of Healthpeak OP represent substantially all of the total consolidated assets and liabilities, including the consolidated and unconsolidated entities discussed in this Note 15, income (losses), and cash flows of the Company.
Unconsolidated Variable Interest Entities
The Company has investments in certain unconsolidated VIEs. The Company determined it is not the primary beneficiary of and therefore does not consolidate these VIEs because it does not have the ability to control the activities that most significantly impact their economic performance. Except for the Company’s equity interest in the unconsolidated joint ventures, as more fully discussed below, it has no formal involvement in these VIEs beyond its investments.
LLC Investment. The Company holds a limited partner ownership interest in an unconsolidated LLC (“LLC Investment”) that has been identified as a VIE. The Company’s involvement in the entity is limited to its equity investment as a limited partner and it does not have any substantive participating rights or kick-out rights over the general partner and given its rights and ownership percentage, the Company has virtually no influence or control. The assets and liabilities of the entity primarily consist of three hospitals as well as senior housing real estate. Any assets generated by the entity may only be used to settle its contractual obligations (primarily capital expenditures and debt service payments).
Other Equity Investments. The Company holds limited partner interests in funds that make venture capital investments in various early-stage technology solutions and certain other investments (the “Other Equity Investments”). At September 30, 2026 and December 31, 2025, the Company’s total investments aggregated $19 million and $3 million, respectively. As of September 30, 2026, the Company had an aggregate remaining commitment of $11 million related to certain of its Other Equity Investments. The Other Equity Investments have been identified as VIEs as (i) they do not have any substantive participating rights or kick-out rights over the general partner or (ii) due to insufficient equity at risk. The assets and liabilities of the entities primarily consist of its capital investments. If applicable, all future investments will be funded with capital contributions from the Company and other limited partners in accordance with their respective commitments.
39

Table of Contents
Needham Land Parcel JV. In December 2021, the Company acquired a 38% interest in a lab development joint venture in Needham, Massachusetts for $13 million. Current equity at risk is not sufficient to finance the joint venture’s activities. The assets and liabilities of the entity primarily consist of real estate and debt service obligations. Any assets generated by the entity may only be used to settle its contractual obligations (primarily development costs and debt service payments).
Loans Receivable Investments. In March 2025, the Company entered into an agreement to provide aggregate financing of $41 million to fund the development of an outpatient medical building in Dallas, Texas. In January 2026, the Company entered into and funded a $10 million loan secured by a lab land parcel. The borrower entities for these investments meet the criteria of a VIE in accordance with ASC 810, Consolidation, and the Company is not the primary beneficiary of the borrowers.
HQ Point Preferred Equity Investment. As of December 31, 2025, the Company had a preferred equity investment in a joint venture that held a lab campus under development in San Diego, California, in which the Company had funded the entirety of its $50 million investment. Current equity at risk was not sufficient to finance the entity’s activities. The assets and liabilities of the entity primarily consisted of real estate and debt service obligations. Any assets generated by the entity could only be used to settle its contractual obligations (primarily development costs and debt service payments). During the three months ended September 30, 2026, the Company completed the HQ Point Buyout, after which HQ Point is 100% owned by the Company. As such, the HQ Point Preferred Equity Investment is no longer a VIE as of September 30, 2026.
The classification of the related assets and the maximum loss exposure as a result of the Company’s involvement with VIEs at September 30, 2026 was as follows (in thousands):
VIE TypeAsset Type
Maximum Loss
Exposure and
Carrying Amount(1)
LLC Investment and Other Equity InvestmentsOther assets$34,240 
Needham Land Parcel JVInvestments in unconsolidated joint ventures13,960 
Loans Receivable InvestmentsLoans receivable, net37,688 
_______________________________________
(1)The Company’s maximum loss exposure represents the aggregate carrying amount of such investments.
As of September 30, 2026, the Company had not provided, and is not required to provide, financial support through a liquidity arrangement or otherwise, to its unconsolidated VIEs, including under circumstances in which it could be exposed to further losses (e.g., cash shortfalls).
Consolidated Variable Interest Entities
The Company’s consolidated total assets and total liabilities at September 30, 2026 and December 31, 2025 include certain assets of VIEs that can only be used to settle the liabilities of the related VIE. The VIE creditors do not have recourse to the Company.
Janus Living OP. Janus Living holds a membership interest in Janus Living OP, acts as the managing member of Janus Living OP, and exercises full responsibility, discretion, and control over the day-to-day management of Janus Living OP. Because certain noncontrolling interests in Janus Living OP do not have substantive liquidation rights, substantive kick-out rights without cause, or substantive participating rights, the Company has determined that Janus Living OP is a VIE. Janus Living, Inc., as managing member, has the power to direct the core activities of Janus Living OP that most significantly affect Janus Living OP’s performance, and through its interest in Janus Living OP, has both the right to receive benefits from and the obligation to absorb losses of Janus Living OP. Accordingly, Janus Living, Inc. is the primary beneficiary of Janus Living OP and consolidates Janus Living OP. The assets of Janus Living OP primarily consist of senior housing properties (net real estate), entrance fee receivables, and cash and cash equivalents; its obligations primarily consist of non-refundable entrance fees and capital expenditures for the properties. Assets generated by Janus Living OP may only be used to settle its contractual obligations.
Brookfield JV. The Company holds a 51% ownership interest in the Brookfield JV, which owns and leases outpatient medical buildings. The Brookfield JV is a VIE because the Company exercises full responsibility, discretion, and control over the day-to-day management of the Brookfield JV, and Brookfield does not have substantive participating rights or substantive kick-out rights. The Company consolidates the Brookfield JV as it is the primary beneficiary given it has both (i) the power to direct the activities that most significantly affect its economic performance and (ii) the obligation to absorb losses and the right to receive benefits that could potentially be significant to the Brookfield JV. The assets of the Brookfield JV primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; its obligations primarily consist of capital expenditures for the properties. Assets generated by the Brookfield JV may only be used to settle its contractual obligations.
40

Table of Contents
Ventures V, LLC. The Company holds a 51% ownership interest in and is the managing member of a joint venture entity formed in October 2015 that owns and leases outpatient medical buildings (“Ventures V”). The Company classifies Ventures V as a VIE due to the non-managing member lacking substantive participation rights in the management of Ventures V or kick-out rights over the managing member. The Company consolidates Ventures V as the primary beneficiary because it has the ability to control the activities that most significantly impact the VIE’s economic performance. The assets of Ventures V primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; its obligations primarily consist of capital expenditures for the properties. Assets generated by Ventures V may only be used to settle its contractual obligations.
MSREI JV. The Company holds a 51% ownership interest in, and is the managing member of, a joint venture entity formed in August 2018 that owns and leases outpatient medical buildings (the “MSREI JV”). The MSREI JV is a VIE due to the non-managing member lacking substantive participation rights in the management of the joint venture or kick-out rights over the managing member. The Company consolidates the MSREI JV as the primary beneficiary because it has the ability to control the activities that most significantly impact the VIE’s economic performance. The assets of the MSREI JV primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; its obligations primarily consist of capital expenditures for the properties. Assets generated by the MSREI JV may only be used to settle its contractual obligations.
DownREITs.  As of September 30, 2026 and December 31, 2025, the Company held a controlling ownership interest in and was the managing member of eight DownREITs. The Company classifies the DownREITs as VIEs due to the non-managing members lacking substantive participation rights in the management of the DownREITs or kick-out rights over the managing member. The Company consolidates the DownREITs as the primary beneficiary because it has the ability to control the activities that most significantly impact these VIEs’ economic performance. The assets of the DownREITs primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; their obligations primarily consist of capital expenditures for the properties, debt service payments, and with respect to DOC DR OP Sub, certain guarantees. Assets generated by the DownREITs (primarily from tenant rents) may only be used to settle their contractual obligations (primarily from debt service and capital expenditures).
Other Consolidated Real Estate Partnerships. The Company holds a controlling ownership interest in and is the general partner (or managing member) of multiple partnerships that own and lease real estate assets (the “Partnerships”). The Company classifies the Partnerships as VIEs due to the limited partners (non-managing members) lacking substantive participation rights in the management of the Partnerships or kick-out rights over the general partner (managing member). The Company consolidates the Partnerships as the primary beneficiary because it has the ability to control the activities that most significantly impact these VIEs’ economic performance. The assets of the Partnerships primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; their obligations primarily consist of debt service payments and capital expenditures for the properties. Assets generated by the Partnerships (primarily from tenant rents) may only be used to settle their contractual obligations (primarily from debt service and capital expenditures).
Gateway Crossing JV. As of December 31, 2025, the Company held a 50% ownership interest in and was the managing member of the Gateway Crossing JV, a joint venture that owned and leased lab and other buildings. The Company classified the Gateway Crossing JV as a VIE due to the non-managing member lacking substantive participation rights in the management of the Gateway Crossing JV or kick-out rights over the managing member. The Company consolidated the Gateway Crossing JV as the primary beneficiary because it had the ability to control the activities that most significantly impacted the VIE’s economic performance. The assets of the Gateway Crossing JV primarily consisted of leased properties (net real estate), rents receivable, and cash and cash equivalents; its obligations primarily consisted of capital expenditures for the properties. Assets generated by the Gateway Crossing JV were only used to settle its contractual obligations. During the three months ended March 31, 2026, the Company acquired the remaining 50% interest in the Gateway Crossing JV, bringing the Company’s ownership interest to 100%. As such, the Gateway Crossing JV is no longer a VIE as of September 30, 2026.
41

Table of Contents
Total assets and total liabilities include VIE assets and liabilities, excluding those of Healthpeak OP, as follows (in thousands):
September 30,
2026
December 31,
2025
Assets
Buildings and improvements$9,337,618 $4,697,185 
Development costs and construction in progress306,933 190,603 
Land and improvements1,097,335 532,374 
Accumulated depreciation(1,869,357)(930,916)
Net real estate8,872,529 4,489,246 
Loans receivable, net181,285 552,113 
Investments in unconsolidated joint ventures38,637 25,241 
Accounts receivable, net44,141 24,823 
Cash and cash equivalents398,169 56,660 
Restricted cash88,984 3,141 
Intangible assets747,089 473,011 
Assets held for sale(1)
4,025 35,244 
Right-of-use asset273,456 266,135 
Deferred tax assets116,024 121 
Goodwill54,350 50,501 
Other assets339,430 138,265 
Total assets$11,158,119 $6,114,501 
Liabilities
Term loans$400,936 $401,339 
Senior unsecured notes1,181,632 1,168,508 
Mortgage debt103,544 245,735 
Intangible liabilities65,668 76,593 
Liabilities related to assets held for sale(1)
— 11,798 
Lease liability206,117 193,441 
Accounts payable, accrued liabilities, and other liabilities526,084 144,106 
Deferred revenue803,466 61,432 
Total liabilities $3,287,447 $2,302,952 
_______________________________________
(1)As of September 30, 2026, there was one outpatient medical building that was classified as held for sale, which was sold in October 2026, and primarily included net real estate of $4 million. As of December 31, 2025, relates to four assets classified as held for sale, which were sold during the nine months ended September 30, 2026. The assets held for sale as of December 31, 2025 primarily included: (i) net real estate of $27 million and (ii) right-of-use assets of $7 million. The liabilities related to assets held for sale as of December 31, 2025 primarily included: (i) lease liabilities of $9 million and (ii) deferred revenue of $2 million.
42

Table of Contents
NOTE 16.  Fair Value Measurements
The table below summarizes the carrying amounts and fair values of the Company’s financial instruments either recorded or disclosed on a recurring basis (in thousands):
September 30, 2026(3)
December 31, 2025(3)
Carrying
Value
Fair ValueCarrying
Value
Fair Value
Loans receivable, net(2)
$284,203 $290,947 $606,020 $620,575 
Interest rate swap assets(2)
29,908 29,908 5,626 5,626 
Bank line of credit and commercial paper(2)
1,489,500 1,489,500 1,078,850 1,078,850 
Term loans(2)
1,646,725 1,646,725 1,647,113 1,647,113 
Senior unsecured notes(1)
6,142,101 5,918,687 6,772,722 6,813,448 
Mortgage debt(2)
104,019 103,526 349,209 347,291 
Interest rate swap liabilities(2)
— — 9,635 9,635 
_______________________________________
(1)Level 1: Fair value is calculated based on quoted prices in active markets.
(2)Level 2: For loans receivable, net, interest rate swap instruments, and mortgage debt, fair value is based on standardized pricing models in which significant inputs or value drivers are observable in active markets. For bank line of credit, commercial paper, and term loans, the carrying values are a reasonable estimate of fair value because the borrowings are primarily based on market interest rates and the Company’s credit rating.
(3)During the nine months ended September 30, 2026 and year ended December 31, 2025, there were no material transfers of financial assets or liabilities within the fair value hierarchy.
NOTE 17.  Derivative Financial Instruments
The Company uses derivative instruments to mitigate the effects of interest rate fluctuations on specific forecasted transactions as well as recognized financial obligations or assets. Utilizing derivative instruments allows the Company to manage the risk of fluctuations in interest rates and their related potential impact on future earnings and cash flows. The Company does not use derivative instruments for speculative or trading purposes. At September 30, 2026, a one percentage point increase or decrease in the underlying interest rate curve would result in a corresponding increase or decrease in the fair value of the derivative instruments by up to $25 million.
43

Table of Contents
The following table summarizes the Company’s interest rate swap instruments (in thousands):
Fair Value(2)
Date Entered(1)
Maturity DateHedge DesignationNotional AmountPay RateReceive RateSeptember 30,
2026
December 31,
2025
Interest rate swap assets:
April 2022May 2026Cash flow$51,100 4.99 %
USD-SOFR w/ -5 Day Lookback + 2.50%
$— $193 
April 2022May 2026Cash flow91,000 4.54 %
USD-SOFR w/ -5 Day Lookback + 2.05%
— 344 
August 2022February 2027Cash flow250,000 2.60 %1 mo. USD-SOFR CME Term1,426 2,109 
August 2022August 2027Cash flow250,000 2.54 %1 mo. USD-SOFR CME Term4,000 2,980 
May 2023(3)
May 2028Cash flow400,000 3.59 %USD-SOFR w/ -5 Day Lookback6,265 — 
January 2024(4)
February 2029Cash flow750,000 3.59 %USD-SOFR w/ -5 Day Lookback18,217 — 
      Total interest rate swap assets
$29,908 $5,626 
Interest rate swap liabilities:
May 2023(3)
May 2028Cash flow$400,000 3.59 %USD-SOFR w/ -5 Day Lookback$— $(3,021)
January 2024(4)
February 2029Cash flow750,000 3.59 %USD-SOFR w/ -5 Day Lookback— (6,614)
      Total interest rate swap liabilities$— $(9,635)
_____________________________
(1)Represents interest rate swap instruments that hedge fluctuations in interest payments on variable rate debt by converting the interest rates to fixed interest rates. The changes in fair value of designated derivatives that qualify as cash flow hedges are recorded in accumulated other comprehensive income (loss) on the Consolidated Balance Sheets.
(2)Derivative assets are recorded at fair value in other assets and derivative liabilities are recorded at fair value in accounts payable, accrued liabilities, and other liabilities on the Consolidated Balance Sheets.
(3)Includes two interest rate swap instruments each with notional amounts of $110 million and one interest rate swap instrument with a notional amount of $180 million. The aggregate fair value upon acquisition of these interest rate swap instruments in March 2024 was $7 million, which was recognized within other assets on the Consolidated Balance Sheets and is being amortized into interest expense on the Consolidated Statements of Operations over the terms of the related interest rate swap instruments. During each of the three months ended September 30, 2026 and 2025, the Company recognized $0.4 million of related amortization into interest expense. During each of the nine months ended September 30, 2026 and 2025, the Company recognized $1 million of related amortization into interest expense.
(4)Includes the following: (i) two interest rate swap instruments each with a pay rate of 3.56% and $50 million notional amount; (ii) three interest rate swap instruments each with a pay rate of 3.57% and $50 million notional amount; (iii) one interest rate swap instrument with a pay rate of 3.58% and $100 million notional amount; (iv) five interest rate swap instruments each with a pay rate of 3.60% and $50 million notional amount; and (v) three interest rate swap instruments each with a pay rate of 3.61% and $50 million notional amount.
NOTE 18. Accounts Payable, Accrued Liabilities, and Other Liabilities
The following table summarizes the Company’s accounts payable, accrued liabilities, and other liabilities (in thousands):
September 30,
2026
December 31,
2025
Refundable entrance fees$224,788 $221,147 
Accrued construction costs144,906 144,524 
Accrued interest53,710 89,202 
Other accounts payable and accrued liabilities325,606 263,636 
Accounts payable, accrued liabilities, and other liabilities$749,010 $718,509 
44

Table of Contents
NOTE 19. Deferred Revenue
The following table summarizes the Company’s deferred revenue, excluding deferred revenue related to assets classified as held for sale (in thousands):
September 30,
2026
December 31, 2025
Non-refundable entrance fees$712,221 $669,528 
Other deferred revenue(1)
326,945 315,779 
Deferred revenue$1,039,166 $985,307 
_______________________________________
(1)Other deferred revenue is primarily comprised of prepaid rent, deferred rent, and tenant-funded tenant improvements owned by the Company. During the three and nine months ended September 30, 2026, the Company recognized amortization related to other deferred revenue of $12 million and $34 million, respectively. During the three and nine months ended September 30, 2025, the Company recognized amortization related to other deferred revenue of $13 million and $37 million, respectively. The amortization of other deferred revenue is included in rental and related revenues on the Consolidated Statements of Operations.
Life Plan Entrance Fees
During the three and nine months ended September 30, 2026, the Company collected non-refundable entrance fees of $47 million and $122 million, respectively, and recognized amortization of $30 million and $85 million, respectively. Also during the nine months ended September 30, 2026, the Company acquired a property which had $5 million of non-refundable entrance fees. During the three and nine months ended September 30, 2025, the Company collected non-refundable entrance fees of $37 million and $108 million, respectively, and recognized amortization of $24 million and $72 million, respectively. The amortization of non-refundable entrance fees is included within resident fees and services on the Consolidated Statements of Operations.
For certain qualified residents of the life plan communities in the Company’s senior housing segment, the Company may offer to provide a deferral of the upfront cash entrance fee requirements so that they are able to move into a community while still continuing the process of selling their previous home. These entrance fee receivables are due upon sale of the resident’s previous home. At September 30, 2026 and December 31, 2025, the Company had $70 million and $73 million, respectively, of entrance fee receivables, which are recognized in other assets on the Consolidated Balance Sheets.
NOTE 20. Related Party Transactions
In connection with the completion of the Janus Living IPO, Healthpeak and/or certain of its direct or indirect subsidiaries entered into certain related party transactions with Janus Living. The various agreements entered into between Healthpeak and Janus Living in connection with the Janus Living IPO and their related impact to the Consolidated Financial Statements are summarized below.
Formation Transactions
As more fully described in Note 1, Healthpeak and Janus Living consummated a series of formation transactions in connection with the Janus Living IPO. In connection with the Janus Living IPO and these formation transactions, during the three months ended March 31, 2026, Janus Living incurred $16 million of transaction costs, recognized within transaction costs on the Consolidated Statements of Operations. Additionally, during the three months ended March 31, 2026, Janus Living incurred $8 million of offering costs in addition to fees paid to the underwriters in connection with the Janus Living IPO. These costs were recognized within total noncontrolling interests on the Consolidated Statements of Equity and Redeemable Noncontrolling Interests. Certain of these offering and transaction costs were initially paid by Healthpeak and reimbursed by Janus Living in accordance with the Healthpeak Management Agreement (defined below).
Equity Awards
In connection with the Janus Living IPO, certain of Healthpeak’s directors and executive officers received equity award grants from Janus Living, either as fully vested shares of Janus Living’s Class A-1 common stock, or as time-based or performance-based equity awards to acquire shares of Janus Living’s Class A-1 common stock subject to the satisfaction of vesting conditions. Of the $16 million of transaction costs discussed above, $5 million relates to stock-based compensation expense recognized on the fully vested awards issued to directors, executive officers, and employees of Healthpeak and Janus Living in connection with the Janus Living IPO. In addition, certain of Healthpeak’s directors and executive officers entered into indemnification agreements with Janus Living in connection with the Janus Living IPO.
45

Table of Contents
Management Agreement
An indirect subsidiary of Healthpeak (the “Manager”) entered into a management agreement with Janus Living (“Healthpeak Management Agreement”). Pursuant to the Healthpeak Management Agreement, Janus Living agreed to pay the Manager a management fee (“Janus Living Management Fee”) for services rendered to Janus Living equal to $10 million plus or minus the cumulative effect of an annual amount of 0.5% of (i) the gross book value (as determined in accordance with GAAP) of any investment that is the subject of an acquisition, or disposition or (ii) the increase in the gross book value of any investment that was the subject of a capital deployment, in each case, since January 1, 2026; provided, that (A) if Janus Living’s investments have a gross book value in excess of $10.0 billion but less than $20.0 billion as of the determination of a management fee adjustment amount pursuant to the terms of the Healthpeak Management Agreement, such 0.5% will be decreased by 0.1% for each dollar of gross book value of any investment that was the subject of an acquisition or disposition or increase in the gross book value of any investment that was the subject of a capital deployment in excess of $10.0 billion but less than $20.0 billion, and (B) if Janus Living’s investments have a gross book value in excess of $20.0 billion as of the determination of a management fee adjustment amount pursuant to the terms of the Healthpeak Management Agreement, such 0.5% will be decreased by 0.15% for each dollar of gross book value of any investment that was the subject of an acquisition or disposition, or increase in gross book value of any investment that was the subject of a capital deployment, that is in excess of $20.0 billion. The management fee will be payable in cash but will be reduced by the stock-based compensation expense recognized in connection with the grant of annual equity awards to employees of the Manager under the Janus Living, Inc. 2026 Equity Plan (“Manager Equity Awards”). The Healthpeak Management Agreement has an initial term of three years from the date of the completion of the Janus Living IPO with annual renewals unless terminated by Janus Living or the Manager pursuant to the terms of the Healthpeak Management Agreement. Janus Living will also reimburse the Manager for documented third-party expenses incurred by the Manager in providing services under the Healthpeak Management Agreement, including expenses related to legal, accounting, due diligence and other services. Expenses will be reimbursed in cash on a quarterly or monthly basis, at the Manager’s election.
During the three and nine months ended September 30, 2026, Healthpeak received $4.5 million and $8 million, respectively, of the Janus Living Management Fee in cash and $266 thousand and $554 thousand, respectively, in the form of Manager Equity Awards. The remaining $585 thousand of the Janus Living Management Fee earned but not yet paid as of September 30, 2026 was recognized as a receivable and eliminated upon consolidation.
In addition to the Janus Living Management Fee due from Janus Living as discussed above, as of September 30, 2026, Healthpeak had $99 thousand due from Janus Living, primarily related to third-party expenses initially paid by Healthpeak that are reimbursable under the Healthpeak Management Agreement. These amounts were recognized as a receivable and eliminated upon consolidation and are non-interest bearing and settled in cash in the ordinary course of business.
Exclusivity Agreement
Healthpeak entered into an exclusivity agreement with Janus Living, pursuant to which Healthpeak and Janus Living agreed that during the term of the management agreement, neither Healthpeak nor Janus Living, nor any of Healthpeak’s or Janus Living’s respective affiliates, will engage in, sponsor, own, operate, manage, or otherwise participate in a competing business.
Stockholders Agreement
Healthpeak entered into a stockholders agreement with Janus Living pursuant to which, among other rights, Healthpeak will have the right to designate a certain number of directors to Janus Living’s Board of Directors based on its ownership threshold in Janus Living. Two of Healthpeak’s directors, Mr. Brinker and Ms. Sandstrom, serve on Janus Living’s Board of Directors pursuant to this agreement.
Purchases in the Reserved Share Program
In connection with the Janus Living IPO, an aggregate of 216 thousand shares of Janus Living’s Class A-1 common stock were purchased by certain of Healthpeak’s and Janus Living’s directors and executive officers through a reserved share program. All purchases of Janus Living’s Class A-1 common stock in the reserved share program were at the Janus Living IPO price of $20.00 per Class A-1 common share.
46

Table of Contents
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
All references in this report to “Healthpeak,” the “Company,” “we,” “us,” or “our” mean Healthpeak Properties, Inc., together with its consolidated subsidiaries. Unless the context suggests otherwise, references to “Healthpeak Properties, Inc.” mean the parent company without its subsidiaries.
Cautionary Language Regarding Forward-Looking Statements
Statements in this Quarterly Report on Form 10-Q that are not historical factual statements are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements include, among other things, statements regarding our and our officers’ intent, belief or expectation as identified by the use of words such as “may,” “will,” “project,” “expect,” “believe,” “intend,” “anticipate,” “seek,” “target,” “forecast,” “plan,” “potential,” “estimate,” “could,” “would,” “should” and other comparable and derivative terms or the negatives thereof. Forward-looking statements reflect our current expectations and views about future events and are subject to risks and uncertainties that could cause actual results, including our future financial condition and results of operations, to differ materially from those expressed or implied by any forward-looking statements. You are urged to carefully review the disclosures we make concerning risks and uncertainties that may affect our business and future financial performance.
Forward-looking statements are based on certain assumptions and analysis made in light of our experience and perception of historical trends, current conditions and expected future developments as well as other factors that we believe are appropriate under the circumstances. While forward-looking statements reflect our good faith belief and assumptions we believe to be reasonable based upon current information, we can give no assurance that our expectations or forecasts will be attained. Further, we cannot guarantee the accuracy of any such forward-looking statement contained in this Quarterly Report on Form 10-Q, and you should not place undue reliance on these forward-looking statements, which speak only as of the date of this report. Except as required by law, we do not undertake, and hereby disclaim, any obligation to update any forward-looking statements, which speak only as of the date on which they are made.
As more fully set forth under Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, principal risks and uncertainties that may cause our actual results to differ materially from the expectations contained in the forward-looking statements include, among other things:
•changes to regulatory, funding, staffing, trade, and other policies and actions by the U.S. political administration;
•macroeconomic trends that may increase borrowing, construction, labor, and other operating costs;
•changes within the life science industry, and significant regulation, funding requirements, and uncertainty faced by our lab tenants;
•factors adversely affecting our tenants’ or borrowers’ ability to meet their financial and other contractual obligations to us;
•the insolvency or bankruptcy of one or more of our major tenants or borrowers;
•our concentration of real estate investments in the healthcare property sector, which makes us more vulnerable to a downturn in that specific sector than if we invested across multiple sectors;
•the illiquidity of real estate investments;
•our ability to identify and secure new or replacement tenants;
•our property development, redevelopment, and tenant improvement risks, which can render a project less profitable or unprofitable and delay or prevent its undertaking or completion;
•the ability of the hospitals on whose campuses our outpatient medical buildings are located and their affiliated healthcare systems to remain competitive or financially viable;
•the failure of our tenants and borrowers to comply with federal, state, and local laws and regulations, including resident health and safety requirements, as well as licensure, certification, and inspection requirements;
•compliance with the Americans with Disabilities Act and fire, safety, and other regulations;
•the requirements of, or changes to, governmental reimbursement programs such as Medicare or Medicaid;
•economic conditions, natural disasters, weather, and other conditions that negatively affect geographic areas where we have concentrated investments;
•uninsured or underinsured losses, which could result in a significant loss of capital invested in a property, lower than expected future revenues, and unanticipated expenses;
•our use of joint ventures may limit our returns on and our flexibility with jointly owned investments;
•our use of rent escalators or contingent rent provisions in our leases;
47

Table of Contents
•competition for suitable healthcare properties to grow our investment portfolio;
•our ability to exercise rights on collateral securing our real estate-related loans;
•any requirement that we recognize reserves, allowances, credit losses, or impairment charges;
•investment of substantial resources and time in transactions that are not consummated;
•our ability to successfully integrate or operate acquisitions and/or internalize property management;
•the potential impact of unfavorable resolution of litigation or disputes and resulting rising liability and insurance costs;
•environmental compliance costs and liabilities associated with our real estate investments;
•environmental, social, and governance (“corporate impact”) and sustainability commitments and changing requirements, as well as stakeholder expectations;
•epidemics, pandemics, or other infectious diseases, and health and safety measures intended to reduce their spread;
•our past participation in the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) Provider Relief Fund and other Covid-related stimulus and relief programs;
•laws or regulations prohibiting eviction of our tenants;
•human capital risks, including the loss or limited availability of our key personnel;
•our reliance on information technology and any material failure, inadequacy, interruption, or security failure of that technology;
•the use of, or inability to use, artificial intelligence by us, our tenants, our vendors, and our investors;
•volatility, disruption, or uncertainty in the financial markets;
•increased interest rates and borrowing costs, which could impact our ability to refinance existing debt, sell properties, and conduct investment activities;
•cash available for distribution to stockholders and our ability to make dividend distributions at expected levels;
•the availability of external capital on acceptable terms or at all;
•an increase in our level of indebtedness;
•covenants in our debt instruments, which may limit our operational flexibility, and breaches of these covenants;
•volatility in the market price and trading volume of our common stock;
•adverse changes in our credit ratings;
•the Janus Living IPO (as defined below) may not achieve the intended benefits;
•our economic exposure to shifts in the price of Janus Living common stock and our ability to control the assets and activities of Janus Living;
•potential conflicts of interest in our relationship with Janus Living;
•our ability to maintain our qualification as a real estate investment trust (“REIT”);
•our taxable REIT subsidiaries being subject to corporate level tax;
•tax imposed on any net income from “prohibited transactions”;
•changes to U.S. federal income tax laws, and potential deferred and contingent tax liabilities from corporate acquisitions;
•calculating non-REIT tax earnings and profits distributions;
•tax protection agreements that may limit our ability to dispose of certain properties and may require us to maintain certain debt levels;
•ownership limits in our charter that restrict ownership in our stock, and provisions of Maryland law and our charter that could prevent a transaction that may otherwise be in the interest of our stockholders;
•conflicts of interest between the interests of our stockholders and the interests of holders of Healthpeak OP, LLC (“Healthpeak OP”) common units;
•provisions in the operating agreement of Healthpeak OP and other agreements that may delay or prevent unsolicited acquisitions and other transactions; and
•our status as a holding company of Healthpeak OP.
48

Table of Contents
Important Information Regarding Our Disclosure to Investors
We may use our website (www.healthpeak.com) and our LinkedIn account (https://www.linkedin.com/company/healthpeak) to communicate with our investors and disclose company information. The information disclosed through those channels may be considered to be material, so investors should monitor them in addition to our press releases, Securities and Exchange Commission (“SEC”) filings, and public conference calls and webcasts. The contents of our website or social media channels referenced herein are not incorporated by reference into this Quarterly Report on Form 10-Q.
Overview
The information set forth in this Item 2 is intended to provide readers with an understanding of our financial condition, changes in financial condition and results of operations and should be read in conjunction with the Consolidated Financial Statements and accompanying Notes. We will discuss and provide our analysis in the following order:
•Executive Summary
•Market Trends and Uncertainties
•Company Highlights
•Dividends
•Results of Operations
•Liquidity and Capital Resources
•Non-GAAP Financial Measures Reconciliations
•Critical Accounting Estimates
Executive Summary
Healthpeak Properties, Inc. is a Standard & Poor’s (“S&P”) 500 company that owns, operates, and develops high-quality real estate focused on healthcare discovery and delivery in the United States (“U.S.”). Our company was originally founded in 1985. We are organized as an umbrella partnership REIT (“UPREIT”). We hold substantially all of our assets and conduct our operations through our operating subsidiary, Healthpeak OP, a consolidated subsidiary of which we are the managing member. We are a Maryland corporation and qualify as a self-administered REIT. We are headquartered in Denver, Colorado, with additional corporate offices in California, Tennessee, Wisconsin, and Massachusetts and property management offices in several locations throughout the U.S.
We have a diversified portfolio of high-quality healthcare properties across three core asset classes of outpatient medical, lab, and senior housing real estate. Under the outpatient medical and lab segments, we own, operate, and develop outpatient medical buildings, hospitals, and lab buildings. Under the senior housing segment, our properties are operated through RIDEA or similar structures. We have other non-reportable segments that are comprised primarily of: (i) loans receivable, (ii) a preferred equity investment, and (iii) three other properties. These non-reportable segments have been presented on a combined basis herein.
On March 23, 2026, Janus Living, Inc. (“Janus Living”) completed its initial public offering (the “Janus Living IPO”) to become a public company. In connection with the Janus Living IPO, 48,300,000 shares of Janus Living’s Class A-1 common stock were issued to public investors, generating total gross proceeds of $966 million, less $65 million of fees paid to the underwriters.
In connection with the Janus Living IPO, through a series of formation transactions, we transferred, directly or indirectly, cash plus senior housing real estate communities and certain parcels of land for future development to Janus Living. As a result of these transactions, we received 138,816,246 shares of Janus Living’s Class A-1 common stock and 75,917,780 common units in the Janus Living OP, LLC (“Janus Living OP”), Janus Living’s operating subsidiary. In connection with these formation transactions, we also purchased shares of Janus Living’s Class A-2 common stock in an amount equivalent to the common units of Janus Living OP that we hold following completion of the formation transactions described above, for aggregate consideration of approximately $760 thousand. Janus Living’s Class A-2 common stock are not entitled to receive any dividends or distributions, but were issued to provide us with voting rights that correspond to our common units.
On June 4, 2026, an additional 25,000,000 shares of Janus Living’s Class A-1 common stock were issued to public investors following the completion of a public offering (the “Janus Living June Follow-On Offering”). As part of the Janus Living June Follow-On Offering, Janus Living granted the underwriters a 30-day option to purchase up to an additional 3,750,000 shares of Janus Living’s Class A-1 common stock, which was exercised in full on June 22, 2026. The Janus Living June Follow-On Offering generated total gross proceeds of $719 million, less $28 million of fees paid to the underwriters.
49

Table of Contents
On August 12, 2026, an additional 18,400,000 shares of Janus Living’s Class A-1 common stock were issued to public investors following the completion of a public offering (the “Janus Living August Follow-On Offering,” collectively with the Janus Living June Follow-On Offering, the “Janus Living Follow-On Offerings”). The Janus Living August Follow-On Offering generated total gross proceeds of $534 million, which included the exercise in full of the underwriters’ option to purchase additional shares, less $19 million of fees paid to the underwriters.
As of September 30, 2026, our ownership of the Janus Living Class A-1 and Class A-2 common shares, together with our ownership of common units of Janus Living OP, provides us with voting and economic rights of 69.2% of Janus Living. Janus Living is externally managed by Healthpeak Investment Management, LLC, one of our indirect subsidiaries, and is consolidated by us.
At September 30, 2026, our portfolio of investments, including properties in certain of our unconsolidated joint ventures, consisted of interests in 726 properties: (i) Outpatient medical – 506 properties; (ii) Lab – 143 properties; (iii) Senior housing – 74 properties; and (iv) Other non-reportable – 3 properties. The following table summarizes information for our reportable segments for the three months ended September 30, 2026 (dollars in thousands):
Segment
NOI by
Reportable Segment(1)
Adjusted NOI by Reportable Segment(1)
Outpatient medical$192,704 $184,272 
Lab154,677 140,868 
Senior housing53,158 53,655 
_______________________________________
(1)For outpatient medical and lab, see Note 13 to the Consolidated Financial Statements for a reconciliation of NOI and Adjusted NOI by reportable segment to income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures. For senior housing, see “Non-GAAP Financial Measures Reconciliations” below for a reconciliation of NOI and Adjusted NOI to senior housing net income (loss). See our Segment Analysis below for additional information.
For a description of our significant activities during the three and nine months ended September 30, 2026, see “Item 2, Management’s Discussion and Analysis of Financial Condition and Results of Operations—Company Highlights” in this report.
Business Strategy
Our strategy is to own, operate, and develop high-quality real estate focused on healthcare discovery and delivery. We manage our real estate portfolio for the long-term to maximize risk-adjusted returns and support the growth of our dividends. Our strategy consists of four core elements:
(i)Our real estate: Our portfolio consists of high-quality properties in desirable locations. Our portfolio is primarily focused on outpatient medical and lab buildings, favorable sectors that benefit from the universal desire for improved health, as well as, through our economic interest in Janus Living, life plan community and senior housing facilities, which benefit from favorable demographic trends. We have built scale and fostered deep industry relationships, two unique factors that provide us with a competitive advantage.
(ii)Our financials: We maintain a strong investment-grade balance sheet with ample liquidity as well as long-term fixed-rate debt financing with staggered maturities to reduce our exposure to interest rate volatility and refinancing risk.
(iii)Our partnerships: We work with leading pharmaceutical, biotechnology, and medical device companies, as well as healthcare delivery systems, specialty physician groups, and other healthcare service providers and senior housing operators and managers, to meet their real estate needs. We provide high-quality property management services to encourage tenants to renew, expand, and relocate into our properties, which drives increased occupancy, rental rates, and property values.
(iv)Our platform: We have a people-first culture that we believe attracts, develops, and retains top talent. We continually strive to create and maintain an industry-leading platform, with systems and tools that allow us to effectively and efficiently manage our assets and investment activity.
Market Trends and Uncertainties
Our operating results have been and will continue to be impacted by global and national economic and market conditions generally and by the local economic conditions where our properties are located.
50

Table of Contents
We continuously monitor the effects of domestic and global events on our operations and financial position, and on the operations and financial position of our tenants, operators, and borrowers, to enable us to remain responsive and adaptable to the dynamic changes in our operating environment. These events include, but are not limited to, the following, any of which could negatively impact our business: inflation; recession; increases in interest rates; challenges in the financial markets; availability of private capital and funding in the life science industry; and actions by the U.S. political administration and regulatory agencies that affect healthcare policy, life science research and innovation, labor supply, procurement and construction costs, and general economic conditions (such as budget reconciliation actions, tariff actions, changes in healthcare regulation, decreases in government funding and staffing, and immigration reform).
To the extent our tenants and/or operators have experienced, or will experience, increased costs, liquidity constraints, and financing difficulties due to the foregoing macroeconomic and market conditions, they may be unable or unwilling to make payments or perform their obligations when due, and occupancy of our properties could be adversely affected.
In addition, uncertainty in public and private equity and fixed income markets and elevated interest rates have directly led to increased costs and limitations on the availability of capital to us. These uncertainties have recently been exacerbated by an increase in the target federal funds rate in September 2026, persistent inflation, and global market pressures, which have led to higher interest rates. Elevated interest rates have impacted and could continue to adversely impact our borrowing costs, the fair value of our fixed rate instruments, transaction volume, and real estate values generally, including our real estate.
We have also been affected by increased costs relating to tenant improvements and construction, which, together with higher costs of capital and tariff actions (or potential tariff actions), have adversely affected, and in the future may adversely affect, construction starts and the expected yields on our capital projects, including our developments and redevelopments.
See Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 for additional discussion of the risks posed by macroeconomic conditions, as well as the uncertainties we and our tenants, operators, and borrowers may face as a result.
Company Highlights
Janus Living IPO and Follow-On Offerings
•In March 2026, the Janus Living IPO was completed, including the sale of 48,300,000 shares of its Class A-1 common stock at a price of $20.00 per share. The Janus Living IPO generated total gross proceeds of $966 million, less $65 million of fees paid to the underwriters. See Note 1 to the Consolidated Financial Statements for additional information.
•We received 138,816,246 shares of Janus Living’s Class A-1 common stock and 75,917,780 common units in the Janus Living OP, Janus Living’s operating subsidiary. We also purchased shares of Janus Living’s Class A-2 common stock in an amount equivalent to the common units of Janus Living OP.
•On June 4, 2026, an additional 25,000,000 shares of Janus Living’s Class A-1 common stock were issued to public investors following the completion of a public offering (the “Janus Living June Follow-On Offering”). As part of the Janus Living June Follow-On Offering, Janus Living granted the underwriters a 30-day option to purchase up to an additional 3,750,000 shares of Janus Living’s Class A-1 common stock, which was exercised in full on June 22, 2026. The Janus Living June Follow-On Offering generated total gross proceeds of $719 million, less $28 million of fees paid to the underwriters.
•On August 12, 2026, an additional 18,400,000 shares of Janus Living’s Class A-1 common stock were issued to public investors following the completion of a public offering (the “Janus Living August Follow-On Offering,” collectively with the Janus Living June Follow-On Offering, the “Janus Living Follow-On Offerings”). The Janus Living August Follow-On Offering generated total gross proceeds of $534 million, which included the exercise in full of the underwriters’ option to purchase additional shares, less $19 million of fees paid to the underwriters.
Real Estate Transactions
•In January 2026, we acquired our joint venture partner’s 46.5% interest in the SWF SH JV for $312 million (the “SWF JV Buyout”).
•During the three months ended March 31, 2026, we acquired two lab land parcels for net proceeds of $28 million.
•During the three months ended March 31, 2026, we sold an 80% interest in six outpatient medical buildings to a third party for net proceeds of $163 million (“BX JV I and II”).
51

Table of Contents
•In July 2026, we formed a JV with an affiliate of Brookfield Asset Management (“Brookfield”). We contributed 86 outpatient medical buildings which are diversified across 11 states. Brookfield purchased a non-controlling 49% equity interest in the JV at a gross valuation of approximately $2.1 billion. Under the terms of the agreement, we will maintain day-to-day control and management of the assets and will retain a call right for a finite period beginning after year seven to repurchase Brookfield’s interest at a price sufficient to provide Brookfield with a 6.5% net annual rate of return excluding initial transaction expenses.
•In September 2026, we paid $105 million to acquire the senior construction loan secured by a two-building lab campus in San Diego, California and subsequently obtained 100% ownership of the campus (the “HQ Point Buyout”).
•During the nine months ended September 30, 2026, we acquired 41 senior housing communities for an aggregate purchase price of $2.26 billion.
•During the nine months ended September 30, 2026, we sold (i) four lab buildings for $68 million, (ii) four outpatient medical buildings for $49 million, (iii) one senior housing community for $23 million, and (iv) nine suites within an outpatient medical building in Atlanta, Georgia for $7 million.
•Subsequent to September 30, 2026, we (i) completed $432 million of senior housing acquisitions, which included seven senior housing communities and (ii) we acquired an outpatient medical building in Houston, Texas for $38 million.
•Subsequent to September 30, 2026, we sold two outpatient medical buildings for $31 million.
Development and Redevelopment Activities
•During the nine months ended September 30, 2026, the following projects were placed in service: (i) two lab redevelopment projects with total project costs of $103 million, (ii) a portion of six lab redevelopment projects with total project costs of $94 million, (iii) a portion of two lab development projects with total project costs of $30 million, and (iv) a portion of two outpatient medical development projects with total project costs of $14 million.
Financing Activities
•In January 2026, we made a $102 million early full principal repayment of mortgage debt secured by two senior housing communities with original maturities in December 2026.
•In March 2026, concurrent with the closing of Janus Living IPO, we entered into a $400 million five-year unsecured term loan (the “2031 Term Loan”) as an incremental facility under our existing term loan agreement. As of September 30, 2026, no principal was outstanding on the 2031 Term Loan.
•In March 2026, concurrent with the closing of Janus Living IPO, Janus Living entered into a credit agreement consisting of a $500 million revolving credit facility (as amended, the “Janus Living Revolving Credit Facility”) maturing in March 2030 bearing interest at SOFR plus 105 basis points and a $100 million delayed draw term loan (the “Janus Living Delayed Draw Term Loan” and, together with the Janus Living Revolving Credit Facility, the “Janus Living Credit Facilities”).
•In April 2026, we repurchased 5.95 million shares of our common stock under the 2024 Share Repurchase Program at a weighted average price of $16.81 per share for a total of $100 million.
•In June 2026, we repaid $142 million of mortgage debt secured by a portfolio of 13 outpatient medical buildings upon maturity.
•In July 2026, we repaid $650 million aggregate principal amount of 3.25% senior unsecured notes with an effective interest rate of 3.40% at maturity.
•In September 2026, we amended and restated the Janus Living Credit Facilities to increase the Janus Living Revolving Credit Facility commitment to $1.25 billion. The amended and restated Janus Living Credit Facilities also includes an accordion feature that permits us to increase the revolving commitments and/or add incremental term loans in an aggregate amount of $500 million, subject to customary requirements, such as obtaining additional lender commitments (the “Janus Living Term Loans”). The amended and restated Janus Living Credit Facilities also terminated the $100 million Janus Living Delayed Draw Term Loan, prior to Janus Living drawing on the Delayed Draw Term Loan. Inclusive of the $500 million accordion option, these changes increased the aggregate amount under the Janus Living Credit Facilities to $1.75 billion. As of September 30, 2026, there were no outstanding borrowings under the Janus Living Credit Facilities.
52

Table of Contents
•In October 2026, we executed an amendment to our term loan agreement pursuant to which (i) the maximum incremental borrowing capacity was increased to $2.75 billion and (ii) we entered into a $500 million four-year unsecured delayed draw term loan (the “2030 Term Loan”) as an incremental facility. As of November 3, 2026, no amount has been drawn under the 2030 Term Loan.
Other Activities
•In June 2026, we received a $399 million partial principal repayment of a seller financing loan receivable secured by outpatient medical buildings.
Dividends
The following table summarizes our common stock cash dividends declared in 2026:
Declaration DateRecord DateAmount Per Share
Dividend Payment Date
January 4January 16$0.10167January 30
January 4February 130.10167February 27
January 4March 170.10167March 31
April 6April 170.10167April 30
April 6May 180.10167May 29
April 6June 150.10167June 26
July 9July 200.10167July 31
July 9August 170.10167August 28
July 9September 140.10167September 25
October 1October 190.10167October 30
October 1November 130.10167November 25
October 1December 180.10167December 30
Results of Operations
We evaluate our business and allocate resources among our operating segments: (i) outpatient medical, (ii) lab, (iii) senior housing, (iv) loans receivable, (v) a preferred equity investment, and (vi) three other properties. Our reportable segments, as determined in accordance with ASC 280, Segment Reporting, are as follows: (i) outpatient medical, (ii) lab, and (iii) senior housing. Under the outpatient medical and lab segments, we own, operate, and develop outpatient medical buildings, hospitals, and lab buildings. Our senior housing properties are operated through RIDEA or similar structures. The loans receivable, preferred equity investment, and the three other properties are non-reportable segments that have been presented on a combined basis herein. Our CODM, the President and CEO, evaluates performance for our outpatient medical and lab segments based upon property adjusted net operating income (“Adjusted NOI”). For our senior housing segment, our CODM evaluates performance based on net income and Adjusted NOI. The accounting policies of the segments are the same as those described in the summary of significant accounting policies in Note 2 to the Consolidated Financial Statements in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the SEC, as updated by Note 2 to the Consolidated Financial Statements herein.
53

Table of Contents
Non-GAAP Financial Measures
NOI and Adjusted NOI
NOI and Adjusted NOI are non-U.S. generally accepted accounting principles (“GAAP”) supplemental financial measures used to evaluate the operating performance of real estate. NOI is defined as real estate revenues (inclusive of rental and related revenues and resident fees and services, and exclusive of interest income), less property level operating expenses. Adjusted NOI is calculated as NOI after eliminating the effects of straight-line rents, amortization of market lease intangibles, termination fees, operator transition costs, and actuarial reserves for insurance claims that have been incurred but not reported. NOI and Adjusted NOI exclude all other financial statement amounts included in net income (loss) as presented in Note 13 to the Consolidated Financial Statements. NOI and Adjusted NOI are calculated as NOI and Adjusted NOI, respectively, from consolidated properties, plus our share of NOI and Adjusted NOI from unconsolidated joint ventures (calculated by applying our economic share for the period), less noncontrolling interests’ share of NOI and Adjusted NOI from consolidated joint ventures (calculated by applying our economic share for the period). We utilize our share of NOI and Adjusted NOI in assessing our performance as we have various joint ventures that contribute to our performance. Our share of NOI and Adjusted NOI should not be considered a substitute for, and should only be considered together with and as a supplement to, our financial information presented in accordance with GAAP. Our pro rata share information is prepared on a basis consistent with the comparable consolidated amounts, is intended to reflect our proportionate economic interest in the operating results of properties in our portfolio and is calculated by applying our economic share for the period. We do not control the unconsolidated joint ventures, and the pro rata presentations of reconciling items included in NOI and Adjusted NOI do not represent our legal claim to such items. The joint venture members or partners are entitled to profit or loss allocations and distributions of cash flows according to the joint venture agreements, which provide for such allocations generally according to their invested capital.
The presentation of pro rata information has limitations, which include, but are not limited to, the following: (i) the amounts shown on the individual line items were derived by applying our overall economic share determined when applying the equity method of accounting and do not necessarily represent our legal claim to the assets and liabilities, or the revenues and expenses and (ii) other companies in our industry may calculate their pro rata interest differently, limiting the usefulness as a comparative measure. Because of these limitations, the pro rata financial information should not be considered independently or as a substitute for our financial statements as reported under GAAP. We compensate for these limitations by relying primarily on our GAAP financial statements, using the pro rata financial information as a supplement.
Adjusted NOI is oftentimes referred to as “Cash NOI.” Management believes NOI and Adjusted NOI are important supplemental measures because they provide relevant and useful information by reflecting only income and operating expense items that are incurred at the property level and present them on an unlevered basis. We use Adjusted NOI to make decisions about resource allocations, to assess and compare property level performance, and to evaluate our Same-Store (“SS”) performance, as described below. We believe that net income (loss) is the most directly comparable GAAP measure to NOI and Adjusted NOI. NOI and Adjusted NOI should not be viewed as alternative measures of operating performance to net income (loss) as defined by GAAP since they do not reflect various excluded items. Further, our definitions of NOI and Adjusted NOI may not be comparable to the definitions used by other REITs or real estate companies, as they may use different methodologies for calculating NOI and Adjusted NOI.
Certain of our operating segments are reportable segments for which we disclose Adjusted NOI by reportable segment. For further information, including information reconciling our NOI and Adjusted NOI for our outpatient medical and lab reportable segments to our income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures, refer to Note 13 to the Consolidated Financial Statements. For information reconciling our NOI and Adjusted NOI for our senior housing segment to our net income (loss), refer to “Non-GAAP Financial Measures Reconciliations” below.
Operating expenses generally relate to leased outpatient medical and lab buildings, as well as senior housing facilities. We generally recover all or a portion of our leased outpatient medical and lab property expenses through tenant recoveries, which are recognized within rental and related revenues.
Same-Store NOI and Same-Store Adjusted NOI
Same-Store NOI and Same-Store Adjusted NOI information allows our investors, analysts, and us to evaluate the performance of our property portfolio under a consistent population by eliminating changes in the composition of our portfolio of properties, excluding properties within the other non-reportable segments. We include properties from our consolidated portfolio, as well as properties owned by our unconsolidated joint ventures, in NOI and Adjusted NOI (see NOI and Adjusted NOI definitions above for further discussion regarding our use of pro-rata share information and its limitations). Same-Store Adjusted NOI excludes amortization of deferred revenue from tenant-funded improvements and certain non-property specific operating expenses that are allocated to each operating segment on a consolidated basis.
54

Table of Contents
Properties are included in Same-Store once they are fully operating for the entirety of the comparative periods presented. A property is removed from Same-Store when it is classified as held for sale, sold, placed into redevelopment, experiences a casualty event or has a planned operator transition that significantly impacts operations, or a significant tenant relocates from a Same-Store property to a Non-Same-Store property and that change results in a corresponding increase in revenue. We do not report Same-Store metrics for our other non-reportable segments.
For a reconciliation of Same-Store to total portfolio NOI and Adjusted NOI and other relevant disclosures by segment, refer to our Segment Analysis below.
Nareit FFO. Funds from Operations (“FFO”) applicable to common shares, as defined by the National Association of Real Estate Investment Trusts (“Nareit”), is net income (loss) applicable to common shares (computed in accordance with GAAP), excluding gains or losses from sales of depreciable property, including any current and deferred taxes directly associated with sales of depreciable property, impairments of, or related to, depreciable real estate or land held for development, plus real estate-related depreciation and amortization, and adjustments to compute our share of Nareit FFO from joint ventures. Adjustments for joint ventures are calculated to reflect our pro rata share of both our consolidated and unconsolidated joint ventures. We reflect our share of Nareit FFO for unconsolidated joint ventures by applying our economic share for the period to the applicable reconciling items on an entity by entity basis. For consolidated joint ventures in which we do not own 100%, we reflect our share of the equity by adjusting our Nareit FFO to remove the third-party economic share of the applicable reconciling items based on economic share for the applicable periods. Our pro rata share information is prepared on a basis consistent with the comparable consolidated amounts, is intended to reflect our proportionate economic interest in the operating results of properties in our portfolio and is calculated by applying our economic share for the period. We do not control the unconsolidated joint ventures, and the pro rata presentations of reconciling items included in Nareit FFO do not represent our legal claim to such items. The joint venture members or partners are entitled to profit or loss allocations and distributions of cash flows according to the joint venture agreements, which provide for such allocations generally according to their invested capital.
The presentation of pro rata information has limitations, which include, but are not limited to, the following: (i) the amounts shown on the individual line items were derived by applying our overall economic share determined when applying the equity method of accounting and do not necessarily represent our legal claim to the assets and liabilities, or the revenues and expenses and (ii) other companies in our industry may calculate their pro rata interest differently, limiting the usefulness as a comparative measure. Because of these limitations, the pro rata financial information should not be considered independently or as a substitute for our financial statements as reported under GAAP. We compensate for these limitations by relying primarily on our GAAP financial statements, using the pro rata financial information as a supplement.
We believe Nareit FFO applicable to common shares and diluted Nareit FFO applicable to common shares are important supplemental non-GAAP measures of operating performance for a REIT. Because the historical cost accounting convention used for real estate assets utilizes straight-line depreciation (except on land), such accounting presentation implies that the value of real estate assets diminishes predictably over time. Since real estate values instead have historically risen and fallen with market conditions, presentations of operating results for a REIT that use historical cost accounting for depreciation could be less informative. The term Nareit FFO was designed by the REIT industry to address this issue.
Nareit FFO does not represent cash generated from operating activities in accordance with GAAP, is not necessarily indicative of cash available to fund cash needs and should not be considered an alternative to net income (loss). We compute Nareit FFO in accordance with the current Nareit definition; however, other REITs may report Nareit FFO differently or have a different interpretation of the current Nareit definition from ours. For a reconciliation of net income (loss) applicable to common shares to Nareit FFO applicable to common shares and other relevant disclosures, refer to “Non-GAAP Financial Measures Reconciliations” below.
FFO as Adjusted. In addition, we present Nareit FFO applicable to common shares on an adjusted basis before the impact of non-comparable items including, but not limited to, transaction, merger, and restructuring-related costs, other impairments (recoveries) and other losses (gains), prepayment costs (benefits) associated with early retirement or payment of debt, litigation costs (recoveries), casualty-related charges (recoveries), deferred tax asset valuation allowances, and changes in tax legislation (“FFO as Adjusted”). These adjustments are net of tax, when applicable, and are reflective of our share of our joint ventures. Adjustments for joint ventures are calculated to reflect our pro rata share of both our consolidated and unconsolidated joint ventures. We reflect our share of FFO as Adjusted for unconsolidated joint ventures by applying our economic share for the period to the applicable reconciling items on an entity by entity basis. We reflect our share for consolidated joint ventures in which we do not own 100% of the equity by adjusting our FFO as Adjusted to remove the third-party economic share of the applicable reconciling items based on economic share for the applicable periods. We do not control the unconsolidated joint ventures, and the pro rata presentations of reconciling items included in FFO as Adjusted do not represent our legal claim to such items. The joint venture members or partners are entitled to profit or loss allocations and distributions of cash flows according to the joint venture agreements, which provide for such allocations generally according to their invested capital.
55

Table of Contents
The presentation of pro rata information has limitations, which include, but are not limited to, the following: (i) the amounts shown were derived by applying our overall economic share determined when applying the equity method of accounting and do not necessarily represent our legal claim to the assets and liabilities or the revenues and expenses; and (ii) other companies in our industry may calculate their pro rata interest differently, limiting the usefulness as a comparative measure. Because of these limitations, the pro rata financial information should not be considered independently or as a substitute for our financial statements as reported under GAAP. We compensate for these limitations by relying primarily on our GAAP financial statements, using the pro rata financial information as a supplement.
Transaction, merger, and restructuring-related costs include expenses incurred as a result of mergers, acquisitions, operator transitions, severance, and other investment pursuit costs. Prepayment costs (benefits) associated with early retirement of debt include the write-off of unamortized deferred financing fees, or additional costs, expenses, discounts, make-whole payments, penalties or premiums incurred as a result of early retirement or payment of debt. Other impairments (recoveries) and other losses (gains) include interest income associated with early and partial repayments of loans receivable and other losses or gains associated with non-depreciable assets including goodwill, loans receivable, and investments in equity securities. Management believes that FFO as Adjusted provides a meaningful supplemental measurement of our FFO run-rate and is frequently used by analysts, investors, and other interested parties in the evaluation of our performance as a REIT. At the same time that Nareit created and defined its FFO measure for the REIT industry, it also recognized that “management of each of its member companies has the responsibility and authority to publish financial information that it regards as useful to the financial community.” We believe stockholders, potential investors, and financial analysts who review our operating performance are best served by an FFO run-rate earnings measure that includes certain other adjustments to net income (loss), in addition to adjustments made to arrive at the Nareit defined measure of FFO. FFO as Adjusted is used by management in analyzing our business and the performance of our properties and we believe it is important that stockholders, potential investors, and financial analysts understand this measure used by management. We use FFO as Adjusted to: (i) evaluate our performance in comparison with expected results and results of previous periods, relative to resource allocation decisions, (ii) evaluate the performance of our management, (iii) budget and forecast future results to assist in the allocation of resources, (iv) assess our performance as compared with similar real estate companies and the industry in general, and (v) evaluate how a specific potential investment will impact our future results. Other REITs or real estate companies may use different methodologies for calculating an adjusted FFO measure, and accordingly, our FFO as Adjusted may not be comparable to those reported by other REITs. For a reconciliation of net income (loss) applicable to common shares to FFO as Adjusted applicable to common shares and other relevant disclosure, refer to “Non-GAAP Financial Measures Reconciliations” below.
56

Table of Contents
Comparison of the Three and Nine Months Ended September 30, 2026 to the Three and Nine Months Ended September 30, 2025
Overview
The following table summarizes results for the three months ended September 30, 2026 and 2025(1) (in thousands):
Three Months Ended September 30,
20262025Change
Net income (loss) applicable to common shares$17,118 $(117,256)$134,374 
Nareit FFO applicable to common shares296,789 318,155 (21,366)
FFO as Adjusted applicable to common shares304,888 318,750 (13,862)
_______________________________________
(1)For the reconciliation of non-GAAP financial measures, see “Non-GAAP Financial Measures Reconciliations” below.
Net income (loss) applicable to common shares increased primarily as a result of the following:
•a decrease in other-than-temporary impairment charges, which were recognized in 2025 related to two lab unconsolidated joint ventures;
•an increase in Adjusted NOI generated from our senior housing segment related to: (i) acquisitions of senior housing communities in 2026, (ii) increased occupancy, (iii) increased rates for resident fees, and (iv) the SWF JV Buyout;
•an increase in Adjusted NOI generated from our lab segment related to: (i) acquisitions of real estate in 2025 and 2026, (ii) development and redevelopment projects placed in service during 2025 and 2026, and (iii) new leasing activity during 2025 and 2026 (including the impact to straight-line rents); partially offset by: (i) dispositions of real estate in 2026, (ii) assets placed into development and redevelopment in 2025, and (iii) lower occupancy;
•interest earned on proceeds from the Janus Living IPO and Janus Living Follow-On Offerings; and
•casualty-related recoveries.
The increase in net income (loss) applicable to common shares was partially offset by:
•an increase in depreciation related to: (i) acquisitions of real estate in 2025 and 2026, including the SWF JV Buyout, and (ii) development and redevelopment projects placed in service during 2025 and 2026;
•a decrease in Adjusted NOI generated from our outpatient medical segment related to: (i) dispositions of real estate in 2026 and 2025, (ii) assets placed into development and redevelopment in 2025 and 2026, and (iii) lower occupancy, partially offset by: (i) development and redevelopment projects placed in service during 2025 and 2026 and (ii) new leasing activity during 2025 and 2026 (including the impact to straight-line rents);
•an increase in noncontrolling interests’ share in earnings as a result of the Brookfield JV, partially offset by third-party noncontrolling interest holders’ share of net loss from Janus Living;
•a decrease in gain on sales of real estate, net as a result of no dispositions of real estate during the three months ended September 30, 2026;
•a decrease in interest income related to principal repayments on loans receivable in 2025 and 2026;
•an increase in transaction costs related to (i) investment pursuit costs and (ii) transition costs associated with senior housing operators;
•an increase in interest expense related to: (i) higher borrowings under the commercial paper program and (ii) the issuance of $500 million aggregate principal amount of 4.75% senior unsecured notes due 2033, which closed in August 2025, partially offset by: (i) the repayment of $650 million aggregate principal amount of 3.25% senior unsecured notes in July 2026, (ii) the early repayment of $102 million aggregate principal of mortgage debt secured by two senior housing communities in January 2026; and (iii) the repayment of $142 million aggregate principal amount of mortgage debt secured by 13 outpatient medical buildings in June 2026; and
•an increase in general and administrative expenses related to: (i) incremental stand-alone public company general and administrative expenses for Janus Living and (ii) higher compensation.
Nareit FFO applicable to common shares decreased primarily as a result of the aforementioned events impacting net income (loss) applicable to common shares, except for the following, which are excluded from Nareit FFO applicable to common shares:
•other-than-temporary impairment charges;
•depreciation and amortization expense; and
57

Table of Contents
•gain on sales of real estate.
FFO as Adjusted applicable to common shares decreased primarily as a result of the aforementioned events impacting Nareit FFO applicable to common shares, except for the following, which are excluded from FFO as Adjusted applicable to common shares:
•transaction and restructuring-related costs; and
•casualty-related losses (recoveries).
The following table summarizes results for the nine months ended September 30, 2026 and 2025 (in thousands):
Nine Months Ended September 30,
20262025Change
Net income (loss) applicable to common shares$263,270 $(43,335)$306,605 
Nareit FFO applicable to common shares912,759 940,418 (27,659)
FFO as Adjusted applicable to common shares938,269 965,087 (26,818)
Net income (loss) applicable to common shares increased primarily as a result of the following:
•a decrease in other-than-temporary impairment charges, which were recognized in 2025 related to two lab unconsolidated joint ventures;
•an increase in gain upon change of control related to: (i) the sale of an 80% interest in six outpatient medical buildings to a third-party in March 2026 and (ii) the SWF JV Buyout in January 2026;
•an increase in gain on sales of real estate due to fewer real estate dispositions during the nine months ended September 30, 2025;
•an increase in Adjusted NOI generated from our senior housing segment related to: (i) acquisitions of senior housing communities in 2026, (ii) increased occupancy, (iii) increased rates for resident fees, and (iv) the SWF JV Buyout;
•interest earned on proceeds from the Janus Living IPO and Janus Living Follow-On Offerings;
•casualty-related recoveries;
•an increase in loan loss recoveries under the current expected credit losses model related to: (i) macroeconomic conditions and (ii) recoveries related to loans repaid during 2025 and 2026, partially offset by new and extended secured loans executed in 2025 and 2026; and
•a decrease in income tax expense as a result of: (i) the tax benefit from the derecognition of certain deferred tax assets and liabilities related to the change in tax status of certain entities in connection with the Janus Living IPO and (ii) the tax benefit recognized in connection with the disposition of a senior housing community in June 2026, partially offset by the tax expense from an increase in operating income associated with our senior housing communities.
The increase in net income (loss) applicable to common shares was partially offset by:
•an increase in depreciation related to: (i) acquisitions of real estate in 2025 and 2026, including the SWF JV Buyout, and (ii) development and redevelopment projects placed in service during 2025 and 2026;
•an increase in interest expense related to: (i) higher borrowings under the commercial paper program, (ii) the issuance of $500 million aggregate principal amount of 4.75% senior unsecured notes due 2033, which closed in August 2025, and (iii) the issuance of $500 million aggregate principal amount of 5.38% senior unsecured notes due 2035, which closed in February 2025, partially offset by: (i) the repayment of $650 million aggregate principal amount of 3.25% senior unsecured notes in July 2026, (ii) the early repayment of $102 million aggregate principal of mortgage debt secured by two senior housing communities in January 2026, (iii) the repayment of $142 million aggregate principal amount of mortgage debt secured by 13 outpatient medical buildings in June 2026, (iv) the repayment of $348 million aggregate principal amount of 3.40% senior unsecured notes in February 2025, and (v) the repayment of $452 million aggregate principal amount of 4.00% senior unsecured notes in June 2025;
•an increase in transaction costs incurred related to: (i) investment pursuit costs, (ii) transition costs associated with senior housing operators, and (iii) costs incurred for the Janus Living IPO;
•a decrease in Adjusted NOI generated from our outpatient medical and lab segments related to: (i) dispositions of real estate in 2026 and 2025, (ii) assets placed into development and redevelopment in 2025 and 2026, and (iii) lower occupancy, partially offset by: (i) acquisitions of real estate in 2025 and 2026, (ii) development and redevelopment projects placed in service during 2025 and 2026, and (iii) new leasing activity during 2025 and 2026 (including the impact to straight-line rents);
58

Table of Contents
•an increase in noncontrolling interests’ share in earnings as a result of the Brookfield JV, partially offset by third-party noncontrolling interest holders’ share of net loss from Janus Living;
•a decrease in interest income related to principal repayments on loans receivable in 2025 and 2026, partially offset by: (i) secured loans funded in 2025 and 2026 and (ii) the accelerated recognition of a mark-to-market discount resulting from a partial principal repayment on loans receivable in 2026; and
•an increase in general and administrative expenses related to: (i) incremental stand-alone public company general and administrative expenses for Janus Living and (ii) higher compensation.
Nareit FFO decreased primarily as a result of the aforementioned events impacting net income (loss) applicable to common shares, except for the following, which are excluded from Nareit FFO:
•other-than-temporary impairment charges;
•gains upon change of control;
•depreciation and amortization expense;
•gain on sales of real estate; and
•taxes associated with real estate dispositions;
FFO as Adjusted decreased primarily as a result of the aforementioned events impacting Nareit FFO, except for the following, which are excluded from FFO as Adjusted:
•casualty-related losses (recoveries);
•transaction and restructuring-related costs;
•valuation allowances on deferred tax assets; and
•other impairments (recoveries).
Segment Analysis
The following tables provide selected operating information for our Same-Store and total property portfolio for each of our reportable segments. For the three months ended September 30, 2026, our Same-Store consists of 600 properties representing properties fully operating on or prior to July 1, 2025 and that remained in operation through September 30, 2026. For the nine months ended September 30, 2026, our Same-Store consists of 593 properties representing properties fully operating on or prior to January 1, 2025 and that remained in operation through September 30, 2026. See “Non-GAAP Financial Measures” for additional information. Our total property portfolio consisted of 726 and 703 properties at September 30, 2026 and 2025, respectively.
59

Table of Contents
Outpatient Medical
The following table summarizes results at and for the three months ended September 30, 2026 and 2025 (dollars and square feet in thousands, except per square foot data):
Same-Store
Total Portfolio(1)
Three Months Ended September 30,Three Months Ended September 30,
20262025Change20262025Change
Rental and related revenues$299,537 $299,517 $20 $314,752 $320,903 $(6,151)
Operating expenses(101,295)(101,835)540 (107,000)(110,431)3,431 
Healthpeak’s share of unconsolidated joint venture NOI5,145 4,235 910 5,652 4,440 1,212 
Noncontrolling interests’ share of consolidated joint venture NOI(22,415)(25,280)2,865 (20,700)(6,569)(14,131)
NOI180,972 176,637 4,335 192,704 208,343 (15,639)
Adjustments to NOI(2)
(7,730)(8,620)890 (8,432)(10,300)1,868 
Adjusted NOI$173,242 $168,017 $5,225 184,272 198,043 (13,771)
Less: Non-SS Adjusted NOI(11,030)(30,026)18,996 
SS Adjusted NOI$173,242 $168,017 $5,225 
Adjusted NOI % change3.1%
Property count(3)
482482506528
End of period occupancy(4)
91.7%91.7%91.2%91.7%
Average occupancy(4)
91.5%91.8%90.1%91.2%
Average occupied square feet31,29731,32232,20733,044
Average annual rent per occupied square foot(5)
$39$38$41$42
Average annual base rent per occupied square foot(6)
$29$28$30$32
___________________________________
(1)Total Portfolio includes results of operations from disposed properties through the disposition date.
(2)Represents adjustments we make to calculate Adjusted NOI in accordance with our definition of Adjusted NOI, which is used by our CODM to evaluate performance of our outpatient medical and lab reportable segments. See Note 13 to the Consolidated Financial Statements for further information, including information reconciling our Adjusted NOI for the outpatient medical and lab reportable segments to income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures. Refer also to “Non-GAAP Financial Measures” above for the definition of Adjusted NOI.
(3)From our third quarter 2025 presentation of Same-Store, we added: (i) three stabilized acquisitions and (ii) two developments placed in service, and we removed: (i) 27 buildings that were sold, (ii) five buildings that were placed into redevelopment, and (iii) three assets that were classified as held for sale. Additionally, 92 assets were contributed to joint ventures and are reported at share.
(4)Total Portfolio occupancy excludes any of the following: (i) developments, (ii) significant redevelopments, (iii) newly completed properties under lease-up, and (iv) properties held for sale.
(5)Average annual rent is total revenues less termination fees and non-cash revenue adjustments (i.e., straight-line rents, amortization of market lease intangibles, and deferred revenues).
(6)Base rent does not include tenant recoveries, additional rents in excess of floors, and non-cash revenue adjustments (i.e., straight-line rents, amortization of market lease intangibles, and deferred revenues).
Same-Store Adjusted NOI increased primarily as a result of the following:
•mark-to-market lease renewals;
•annual rent escalations;
•increased percentage-based rents; and
•lower operating expenses, including savings from our internalization of property management.
Total Portfolio Adjusted NOI decreased primarily as a result of the following Non-Same-Store impacts, partially offset by the aforementioned increases to Same-Store:
•decreased Adjusted NOI from our 2025 and 2026 dispositions, including formation of the Brookfield JV and BX JV I and II; partially offset by
•increased occupancy in former development properties that have been placed into service.
60

Table of Contents
The following table summarizes results at and for the nine months ended September 30, 2026 and 2025 (dollars and square feet in thousands, except per square foot data):
Same-Store
Total Portfolio(1)
Nine Months Ended September 30,Nine Months Ended September 30,
20262025Change20262025Change
Rental and related revenues$893,712 $881,574 $12,138 $943,640 $950,135 $(6,495)
Operating expenses(297,351)(288,286)(9,065)(316,740)(315,136)(1,604)
Healthpeak’s share of unconsolidated joint venture NOI14,509 12,797 1,712 16,078 13,193 2,885 
Noncontrolling interests’ share of consolidated joint venture NOI(71,394)(77,148)5,754 (34,840)(20,983)(13,857)
NOI539,476 528,937 10,539 608,138 627,209 (19,071)
Adjustments to NOI(2)
(23,582)(26,818)3,236 (27,484)(32,959)5,475 
Adjusted NOI$515,894 $502,119 $13,775 580,654 594,250 (13,596)
Less: Non-SS Adjusted NOI(64,760)(92,131)27,371 
SS Adjusted NOI$515,894 $502,119 $13,775 
Adjusted NOI % change2.7 %
Property count(3)
478 478 506 528 
End of period occupancy(4)
91.6 %91.7 %91.2 %91.7 %
Average occupancy(4)
91.5 %92.2 %88.7 %91.6 %
Average occupied square feet31,150 31,368 32,425 33,155 
Average annual rent per occupied square foot(5)
$39 $37 $42 $42 
Average annual base rent per occupied square foot(6)
$29 $28 $31 $32 
___________________________________
(1)Total Portfolio includes results of operations from disposed properties through the disposition date.
(2)Represents adjustments we make to calculate Adjusted NOI in accordance with our definition of Adjusted NOI, which is used by our CODM to evaluate performance of our outpatient medical and lab reportable segments. See Note 13 to the Consolidated Financial Statements for further information, including information reconciling our Adjusted NOI for the outpatient medical and lab reportable segments to income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures. Refer also to “Non-GAAP Financial Measures” above for the definition of Adjusted NOI.
(3)From our third quarter 2025 presentation of Same-Store, we added: (i) two stabilized developments placed in service, and we removed: (i) 27 buildings that were sold, (ii) five buildings that were placed into redevelopment, and (iii) three assets that were classified as held for sale. Additionally, 92 assets were contributed to joint ventures and are reported at share.
(4)Total Portfolio occupancy excludes any of the following: (i) developments, (ii) significant redevelopments, (iii) newly completed properties under lease-up, and (iv) properties held for sale.
(5)Average annual rent is total revenues less termination fees and non-cash revenue adjustments (i.e., straight-line rents, amortization of market lease intangibles, and deferred revenues).
(6)Base rent does not include tenant recoveries, additional rents in excess of floors, and non-cash revenue adjustments (i.e., straight-line rents, amortization of market lease intangibles, and deferred revenues).
Same-Store Adjusted NOI increased primarily as a result of the following:
•mark-to-market lease renewals;
•annual rent escalations; and
•increased percentage-based rents; partially offset by
•higher operating expenses, net of savings from our internalization of property management.
Total Portfolio Adjusted NOI decreased primarily as a result of the following Non-Same-Store impacts, partially offset by the aforementioned increases to Same-Store:
•decreased Adjusted NOI from our 2025 and 2026 dispositions, including formation of the Brookfield JV and BX JV I and II; partially offset by
•increased Adjusted NOI from our 2025 acquisitions; and
•increased occupancy in former development properties that have been placed into service.
61

Table of Contents
Lab
The following table summarizes results at and for the three months ended September 30, 2026 and 2025 (dollars and square feet in thousands, except per square foot data):
Same-Store
Total Portfolio(1)
Three Months Ended September 30,Three Months Ended September 30,
20262025Change20262025Change
Rental and related revenues$167,331 $173,271 $(5,940)$223,870 $213,325 $10,545 
Operating expenses(50,884)(49,382)(1,502)(75,058)(64,352)(10,706)
Healthpeak’s share of unconsolidated joint venture NOI2,936 2,942 (6)5,865 4,605 1,260 
NOI119,383 126,831 (7,448)154,677 153,578 1,099 
Adjustments to NOI(2)
(5,792)(12,391)6,599 (13,809)(15,520)1,711 
Adjusted NOI$113,591$114,440$(849)140,868 138,058 2,810 
Less: Non-SS Adjusted NOI(27,277)(23,618)(3,659)
SS Adjusted NOI$113,591 $114,440 $(849)
Adjusted NOI % change(0.7)%
Property count(3)
103103143139
End of period occupancy(4)
90.6%92.7%85.9%93.4%
Average occupancy(4)
90.8%95.9%85.7%93.8%
Average occupied square feet7,1857,5269,7589,017
Average annual rent per occupied square foot(5)
$93$89$92$92
Average annual base rent per occupied square foot(6)
$66$64$67$69
___________________________________
(1)Total Portfolio includes results of operations from disposed properties through the disposition date.
(2)Represents adjustments we make to calculate Adjusted NOI in accordance with our definition of Adjusted NOI, which is used by our CODM to evaluate performance of our outpatient medical and lab reportable segments. See Note 13 to the Consolidated Financial Statements for further information, including information reconciling our Adjusted NOI for the outpatient medical and lab reportable segments to income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures. Refer also to “Non-GAAP Financial Measures” above for the definition of Adjusted NOI.
(3)From our third quarter 2025 presentation of Same-Store, we added: (i) four stabilized redevelopments placed in service, and we removed: (i) two buildings that were placed into redevelopment and (ii) one asset that experienced a significant tenant relocation.
(4)Refer to “Non-GAAP Financial Measures” above for the definition of Same-Store. Total Portfolio occupancy excludes any of the following: (i) developments, (ii) significant redevelopments, (iii) newly completed properties under lease-up, and (iv) properties held for sale.
(5)Average annual rent is total revenues less termination fees and non-cash revenue adjustments (i.e., straight-line rents, amortization of market lease intangibles, and deferred revenues).
(6)Base rent does not include tenant recoveries, additional rents in excess of floors, and non-cash revenue adjustments (i.e., straight-line rents, amortization of market lease intangibles, and deferred revenues).
Same-Store Adjusted NOI decreased primarily as a result of the following:
•lower occupancy; and
•higher operating expenses; partially offset by
•annual rent escalations.
Total Portfolio Adjusted NOI increased primarily as a result of increased Adjusted NOI from acquisitions in 2025 and 2026, partially offset by the aforementioned decreases to Same-Store.
62

Table of Contents
The following table summarizes results at and for the nine months ended September 30, 2026 and 2025 (dollars and square feet in thousands, except per square foot data):
Same-Store
Total Portfolio(1)
Nine Months Ended September 30,Nine Months Ended September 30,
20262025Change20262025Change
Rental and related revenues$488,856 $520,199 $(31,343)$652,793 $640,123 $12,670 
Operating expenses(143,978)(139,745)(4,233)(211,461)(181,412)(30,049)
Healthpeak’s share of unconsolidated joint venture NOI7,095 6,907 188 18,113 11,199 6,914 
Noncontrolling interests’ share of consolidated joint venture NOI— — — (54)— (54)
NOI351,973 387,361 (35,388)459,391 469,910 (10,519)
Adjustments to NOI(2)
(13,157)(34,707)21,550 (34,890)(42,844)7,954 
Adjusted NOI$338,816$352,654$(13,838)424,501 427,066 (2,565)
Less: Non-SS Adjusted NOI(85,685)(74,412)(11,273)
SS Adjusted NOI$338,816 $352,654 $(13,838)
Adjusted NOI % change(3.9)%
Property count(3)
100100143139
End of period occupancy(4)
90.5%92.5%85.9%93.4%
Average occupancy(4)
90.4%96.6%86.4%95.9%
Average occupied square feet7,0747,5199,6619,262
Average annual rent per occupied square foot(5)
$92$89$91$90
Average annual base rent per occupied square foot(6)
$67$65$67$68
___________________________________
(1)Total Portfolio includes results of operations from disposed properties through the disposition date.
(2)Represents adjustments we make to calculate Adjusted NOI in accordance with our definition of Adjusted NOI, which is used by our CODM to evaluate performance of our outpatient medical and lab reportable segments. See Note 13 to the Consolidated Financial Statements for further information, including information reconciling our Adjusted NOI for the outpatient medical and lab reportable segments to income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures. Refer also to “Non-GAAP Financial Measures” above for the definition of Adjusted NOI.
(3)From our third quarter 2025 presentation of Same-Store, we added: (i) three stabilized redevelopments placed in service, and we removed: (i) two buildings that were placed into redevelopment and (ii) one asset that experienced a significant tenant relocation.
(4)Refer to “Non-GAAP Financial Measures” above for the definition of Same-Store. Total Portfolio occupancy excludes any of the following: (i) developments, (ii) significant redevelopments, (iii) newly completed properties under lease-up, and (iv) properties held for sale.
(5)Average annual rent is total revenues less termination fees and non-cash revenue adjustments (i.e., straight-line rents, amortization of market lease intangibles, and deferred revenues).
(6)Base rent does not include tenant recoveries, additional rents in excess of floors, and non-cash revenue adjustments (i.e., straight-line rents, amortization of market lease intangibles, and deferred revenues).
Same-Store Adjusted NOI decreased primarily as a result of the following:
•lower occupancy; and
•higher operating expenses; partially offset by
•annual rent escalations.
Total Portfolio Adjusted NOI decreased primarily as a result of the aforementioned decreases to Same-Store, which were partially offset by increased Adjusted NOI from acquisitions in 2025 and 2026.
63

Table of Contents
Senior Housing
The following table summarizes results at and for the three months ended September 30, 2026 and 2025 (dollars in thousands, except per unit data):
Same-Store
Total Portfolio
Three Months Ended September 30,Three Months Ended September 30,
20262025Change20262025Change
Resident fees and services$165,203 $150,458 $14,745 $268,300 $150,458 $117,842 
Operating expenses(119,147)(113,870)(5,277)(193,419)(113,910)(79,509)
Healthpeak’s share of unconsolidated joint venture NOI— — — — 5,639 (5,639)
Noncontrolling interests’ share of consolidated NOI(1)
(14,185)(11,269)(2,916)(21,723)— (21,723)
NOI31,871 25,319 6,552 53,158 42,187 10,971 
Adjustments to NOI(2)
— — — 497 (22)519 
Adjusted NOI$31,871 $25,319 $6,552 53,655 42,165 11,490 
Plus (less): Non-SS adjustments(21,784)(16,846)(4,938)
SS Adjusted NOI$31,871 $25,319 $6,552 
Adjusted NOI % change25.9 %
Property count(3)
15157434
Average occupancy(4)
89.7%86.7%86.5%85.8%
Average occupied units(5)
6,3116,12110,7187,597
RevPOR per month(6)
$8,726$8,193$7,421$7,588
___________________________________
(1)Subsequent to the closing of the Janus Living IPO and Janus Living Follow-On Offerings, public investors in Janus Living represent the 30.8% noncontrolling interests’ share of the senior housing reportable segment. To enhance comparability, Same-Store NOI has been adjusted to reflect the noncontrolling interests’ share of consolidated NOI for all periods presented.
(2)Represents adjustments we make to calculate Adjusted NOI in accordance with our definition of Adjusted NOI. Refer to “Non-GAAP Financial Measures” above for the definition of Adjusted NOI. For the senior housing reportable segment, refer also to “Non-GAAP Financial Measures Reconciliations” below for a reconciliation of NOI and Adjusted NOI to net income (loss).
(3)From our third quarter 2025 presentation of Same-Store, no properties were added or removed.
(4)Refer to “Non-GAAP Financial Measures” above for the definition of Same-Store. Total Portfolio occupancy excludes any of the following: (i) developments, (ii) significant redevelopments, (iii) newly completed properties under lease-up, and (iv) properties held for sale.
(5)Represents average occupied units as reported by the operators for the three-month period.
(6)Represents revenues (including our share of revenues from unconsolidated joint ventures) per average occupied unit for the applicable period divided by a factor of three. Excludes newly developed assets, assets sold, acquired or converted to a new operating structure during the relevant period, assets in redevelopment, assets that are held for sale, and assets that experienced a casualty event that significantly impacted operations.
Same-Store Adjusted NOI increased primarily as a result of the following:
•increased rates for resident fees; and
•higher occupancy; partially offset by
•higher costs of labor, operator management fees, utilities, real estate taxes, and other operating expenses.
Total Portfolio Adjusted NOI increased primarily as a result of the aforementioned impacts to Same-Store and the following Non-Same-Store impacts:
•increased Adjusted NOI from senior housing communities acquired during 2026; and
•increased Adjusted NOI from the JV Buyout.
64

Table of Contents
The following table summarizes results at and for the nine months ended September 30, 2026 and 2025 (dollars in thousands, except per unit data):
Same-StoreTotal Portfolio
Nine Months Ended September 30,Nine Months Ended September 30,
20262025Change20262025Change
Resident fees and services$486,825 $448,240 $38,585 $685,101 $448,240 $236,861 
Operating expenses(353,096)(335,505)(17,591)(496,803)(335,618)(161,185)
Healthpeak’s share of unconsolidated joint venture NOI— — — 748 17,794 (17,046)
Noncontrolling interests’ share of consolidated NOI(1)
(41,188)(34,723)(6,465)(34,611)— (34,611)
NOI92,541 78,012 14,529 154,435 130,416 24,019 
Adjustments to NOI(2)
— (583)583 497 (899)1,396 
Adjusted NOI$92,541 $77,429 $15,112 154,932 129,517 25,415 
Plus (less): Non-SS adjustments(62,391)(52,088)(10,303)
SS Adjusted NOI$92,541 $77,429 $15,112 
Adjusted NOI % change19.5 %
Property count(3)
15 15 74 34 
Average occupancy(4)
88.9 %86.3 %86.0 %85.3 %
Average occupied units(5)
6,275 6,093 8,688 7,555 
RevPOR per month(6)
$8,620 $8,173 $7,598 $7,584 
___________________________________
(1)Subsequent to the closing of the Janus Living IPO and Janus Living Follow-On Offerings, public investors in Janus Living represent the 30.8% noncontrolling interests’ share of the senior housing reportable segment. To enhance comparability, Same-Store NOI has been adjusted to reflect the noncontrolling interests’ share of consolidated NOI for all periods presented.
(2)Represents adjustments we make to calculate Adjusted NOI in accordance with our definition of Adjusted NOI. Refer to “Non-GAAP Financial Measures” above for the definition of Adjusted NOI. For the senior housing reportable segment, refer also to “Non-GAAP Financial Measures Reconciliations” below for a reconciliation of NOI and Adjusted NOI to net income (loss).
(3)From our third quarter 2025 presentation of Same-Store, no properties were added or removed.
(4)Refer to “Non-GAAP Financial Measures” above for the definition of Same-Store. Total Portfolio occupancy excludes any of the following: (i) developments, (ii) significant redevelopments, (iii) newly completed properties under lease-up, and (iv) properties held for sale.
(5)Represents average occupied units as reported by the operators for the nine-month period.
(6)Represents revenues (including our share of revenues from unconsolidated joint ventures) per average occupied unit for the applicable period divided by a factor of nine. Excludes newly developed assets, assets sold, acquired or converted to a new operating structure during the relevant period, assets in redevelopment, assets that are held for sale, and assets that experienced a casualty event that significantly impacted operations.
Same-Store Adjusted NOI increased primarily as a result of the following:
•increased rates for resident fees; and
•higher occupancy; partially offset by
•higher costs of labor, operator management fees, utilities, repairs and maintenance, real estate taxes, food, and other operating expenses.
Total Portfolio Adjusted NOI increased primarily as a result of the aforementioned impacts to Same-Store and the following Non-Same-Store impacts:
•increased Adjusted NOI from senior housing communities acquired during 2026; and
•increased Adjusted NOI from the JV Buyout.
65

Table of Contents
Other Income and Expense Items
The following table summarizes the results of our other income and expense items for the three and nine months ended September 30, 2026 and 2025 (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
20262025Change20262025Change
Interest income and other$7,202 $15,529 $(8,327)$43,142 $47,156 $(4,014)
Depreciation and amortization298,923 262,317 36,606 872,047 796,779 75,268 
Interest expense83,899 76,784 7,115 263,471 224,540 38,931 
General and administrative23,589 19,907 3,682 70,697 66,789 3,908 
Transaction costs9,738 2,420 7,318 43,059 18,169 24,890 
Impairments and loan loss reserves (recoveries), net(210)(54)(156)(3,964)(117)(3,847)
Gain (loss) on sales of real estate, net— 11,500 (11,500)60,657 13,136 47,521 
Gain (loss) on debt extinguishments— — — (403)— (403)
Other income (expense), net8,670 1,160 7,510 165,215 (9,658)174,873 
Income tax benefit (expense)(1,287)1,206 (2,493)(139)(3,256)3,117 
Equity income (loss) from unconsolidated joint ventures3,742 (176,291)180,033 10,516 (176,691)187,207 
Noncontrolling interests’ share in earnings(19,424)(7,274)(12,150)(35,870)(21,856)(14,014)
Interest income and other
Interest income and other decreased for the three and nine months ended September 30, 2026 primarily as a result of principal repayments on loans receivable in 2025 and 2026, partially offset by secured loans funded in 2025 and 2026. During the nine months ended September 30, 2026, the decrease in interest income and other was also partially offset by the accelerated recognition of a mark-to-market discount resulting from a partial principal repayment on loans receivable in 2026.
Depreciation and amortization
Depreciation and amortization expense increased for the three and nine months ended September 30, 2026 primarily as a result of: (i) acquisitions of real estate in 2025 and 2026, including the SWF JV Buyout, and (ii) development and redevelopment projects placed in service during 2025 and 2026, partially offset by: (i) dispositions of real estate in 2025 and 2026 and (ii) assets placed into development and redevelopment in 2025 and 2026.
Interest expense
Interest expense increased for the three and nine months ended September 30, 2026 primarily as a result of: (i) higher borrowings under the commercial paper program and (ii) the issuance of $500 million aggregate principal amount of 4.75% senior unsecured notes due 2033, which closed in August 2025, partially offset by: (i) the repayment of $650 million aggregate principal amount of 3.25% senior unsecured notes in July 2026, (ii) the early repayment of $102 million aggregate principal of mortgage debt secured by two senior housing communities in January 2026, and (iii) the repayment of $142 million aggregate principal amount of mortgage debt secured by 13 outpatient medical buildings in June 2026. Interest expense further increased for the nine months ended September 30, 2026 as a result of the issuance of $500 million aggregate principal amount of 5.38% senior unsecured notes due 2035, which closed in February 2025, partially offset by: (i) the repayment of $348 million aggregate principal amount of 3.40% senior unsecured notes in February 2025 and (ii) the repayment of $452 million aggregate principal amount of 4.00% senior unsecured notes in June 2025.
General and administrative
General and administrative expenses increased for the three and nine months ended September 30, 2026 primarily as a result of: (i) incremental stand-alone public company general and administrative expenses for Janus Living and (ii) higher compensation.
Transaction costs
Transaction costs increased for the three months ended September 30, 2026 primarily as a result of: (i) investment pursuit costs and (ii) transition costs associated with senior housing operators. Transaction costs further increased for the nine months ended September 30, 2026 primarily as a result of costs incurred for the Janus Living IPO.
66

Table of Contents
Impairments and loan loss reserves (recoveries), net
Loan loss recoveries increased for the three and nine months ended September 30, 2026 as a result of an increase in loan loss recoveries under the current expected credit losses model, which is primarily due to: (i) macroeconomic conditions and (ii) recoveries related to loans repaid during 2025 and 2026, partially offset by new and extended secured loans executed in 2025 and 2026.
Gain (loss) on sales of real estate, net
Gain on sales of real estate, net decreased during the three months ended September 30, 2026 as a result of no dispositions of real estate during the three months ended September 30, 2026 as compared to the gain on sale of two outpatient medical buildings sold during the three months ended September 30, 2025. Gain on sales of real estate, net increased during the nine months ended September 30, 2026 as a result of: (i) four lab buildings, (ii) four outpatient medical buildings, (iii) nine suites within an outpatient medical building, and (iv) one senior housing community, which were sold during the nine months ended September 30, 2026 as compared to (i) one outpatient medical land parcel and (ii) two outpatient medical buildings (as discussed above), which were sold during the nine months ended September 30, 2025. Refer to Note 4 to the Consolidated Financial Statements for additional information regarding dispositions of real estate and the associated gain (loss) on sales recognized.
Gain (loss) on debt extinguishments
Loss on debt extinguishment increased for the nine months ended September 30, 2026 as a result of the early repayment of $102 million aggregate principal of mortgage debt secured by two senior housing communities in January 2026, with original maturities of December 2026.
Other income (expense), net
Other income increased for the three and nine months ended September 30, 2026 as a result of interest earned on proceeds from the Janus Living IPO and the Janus Living Follow-On Offerings. Other income further increased for the nine months ended September 30, 2026 primarily as a result of: (i) a $92 million gain upon change of control related to the sale of an 80% interest in six outpatient medical buildings to a third-party in March 2026, (ii) a $46 million gain upon change of control related to the SWF JV Buyout in January 2026, (iii) casualty-related recoveries in 2026, and (iv) casualty-related losses associated with Hurricane Milton during the nine months ended September 30, 2025.
Income tax benefit (expense)
Income tax expense decreased for the nine months ended September 30, 2026 primarily as a result of: (i) the tax benefit from the derecognition of certain deferred tax assets and liabilities related to the change in tax status of certain entities in connection with the Janus Living IPO and (ii) the tax benefit recognized in connection with the disposition of a senior housing community in June 2026. Other activity during the three and nine months ended September 30, 2026 includes the net impact of operations of our senior housing communities and changes in actuarial reserves for insurance claims that have been incurred but not reported.
Equity income (loss) from unconsolidated joint ventures
Equity income from unconsolidated joint ventures increased for the three and nine months ended September 30, 2026 primarily as a result of other-than-temporary impairment charges on two lab unconsolidated joint ventures, the South San Francisco JVs and the Needham Land Parcel JV, recognized in 2025.
Noncontrolling interests’ share in earnings
Noncontrolling interests’ share in earnings increased for the three and nine months ended September 30, 2026 primarily as a result of the Brookfield JV, partially offset by third-party noncontrolling interest holders’ share of net loss from Janus Living.
67

Table of Contents
Liquidity and Capital Resources
We anticipate that our cash flows from operations, available cash balances, and cash from our various financing activities will be adequate for the next 12 months and for the foreseeable future for purposes of: (i) funding recurring operating expenses; (ii) meeting debt service requirements; and (iii) satisfying funding of distributions to our stockholders and noncontrolling interest members. Distributions are made using a combination of cash flows from operations, funds available under our bank line of credit (the “Revolving Facility”) and commercial paper program, proceeds from the sale of properties, and other sources of cash available to us.
In addition to funding the activities above, our principal liquidity needs for the next 12 months are to:
•fund capital expenditures, including tenant improvements and leasing costs;
•fund future acquisition, transactional, and development and redevelopment activities; and
•fund loans receivable and other investment commitments.
Our longer term liquidity needs include the items listed above as well as meeting debt service requirements.
We anticipate satisfying these future needs using one or more of the following:
•cash flows from operations;
•sale of, or exchange of ownership interests in, properties or other investments;
•borrowings under our Revolving Facility and commercial paper program;
•issuance of additional debt, including unsecured notes, term loans, and mortgage debt; and/or
•issuance of common or preferred stock or its equivalent, including sales of common stock under the ATM Program (as defined below).
Our ability to access the capital markets impacts our cost of capital and ability to refinance maturing indebtedness, as well as our ability to fund future acquisitions and development through the issuance of additional securities or secured debt. Changes in general market and economic conditions as well as credit ratings impact our ability to access capital and directly impact our cost of capital. Our 2029 Term Loan, our 2027 Term Loans, our 2028 Term Loan, our 2030 Term Loan, our 2031 Term Loan, and our Revolving Facility accrue interest at the Secured Overnight Financing Rate (“SOFR”) plus a margin that is based on the credit ratings of our senior unsecured long-term debt. We also pay a facility fee on the entire commitment under our Revolving Facility that depends upon our credit ratings. As of October 30, 2026, we had long-term credit ratings of Baa1 from Moody’s and BBB+ from S&P Global, and short-term credit ratings of P-2 from Moody’s and A-2 from S&P Global. The Janus Living Credit Facilities accrue interest at SOFR plus a margin, and the Janus Living Revolving Credit Facility is subject to a facility fee, in each case based on Janus Living’s leverage ratio.
A downgrade in credit ratings by Moody’s or S&P Global may have a negative impact on (i) the interest rates of our Revolving Facility, 2027 Term Loans, 2028 Term Loan, 2029 Term Loan, 2030 Term Loan, and 2031 Term Loan, (ii) the facility fees for our Revolving Facility, and (iii) the pricing of notes issued under our commercial paper program and senior unsecured notes. While a downgrade in our credit ratings would adversely impact our cost of borrowing, we believe we would continue to have access to the unsecured debt markets, and we could also seek to enter into one or more secured debt financings, issue additional securities, including under our ATM Program, or dispose of certain assets to fund future operating costs, capital expenditures, or acquisitions, although no assurances can be made in this regard. Refer to “Market Trends and Uncertainties” above for a more comprehensive discussion of the potential impact of economic and market conditions on our business.
Changes in Material Cash Requirements and Off-Balance Sheet Arrangements
Debt. Our material cash requirements related to debt decreased by $466 million to $9.4 billion at September 30, 2026, when compared to our cash requirements at December 31, 2025, primarily as a result of a (i) $102 million full principal repayment of mortgage debt secured by two senior housing communities in January 2026, (ii) $142 million full repayment of mortgage debt secured by 13 outpatient medical buildings in June 2026, and (iii) $650 million full principal repayment of senior unsecured notes in July 2026, partially offset by a $411 million increase in notes outstanding under our commercial paper program. See Note 9 to the Consolidated Financial Statements for additional information about our debt commitments.
Development and redevelopment commitments. Our material cash requirements related to development and redevelopment projects and Company-owned tenant improvements decreased by $23 million to $199 million at September 30, 2026, when compared to December 31, 2025, primarily as a result of construction spend on projects in development and redevelopment, partially offset by commitments on projects placed into redevelopment during the period.
68

Table of Contents
Construction and other loan commitments. Our material cash requirements to provide additional principal on loans for redevelopment and capital expenditure projects decreased by $40 million to $59 million at September 30, 2026, when compared to December 31, 2025. This decrease was the result of additional fundings on existing commitments for construction loans during the nine months ended September 30, 2026. Subsequent to September 30, 2026, we entered into a $20 million mezzanine loan commitment used to finance outpatient medical acquisitions, of which $5 million was funded at closing. See Note 6 to the Consolidated Financial Statements for additional information.
Other investment commitments. As of September 30, 2026, we had venture capital investments, certain of which have an aggregate remaining funding commitment of $11 million, which is expected to be funded over the next six years.
Minimum Liquid Reserve (“MLR”). The MLR required by state licensing authorities decreased by $2 million to $93 million at September 30, 2026, when compared to the MLR required at December 31, 2025, as a result of a decrease of $22 million in the promissory note requirement, partially offset by an increase of $20 million in the restricted cash requirement. See Note 10 to the Consolidated Financial Statements for additional information about our MLR requirements.
Redeemable noncontrolling interests. Our material cash requirements related to redeemable noncontrolling interests decreased by $132 million to $27 million at September 30, 2026, when compared to December 31, 2025. The decrease was primarily the result of our acquisition of the remaining 50% interest in the Gateway Crossing joint venture for $132 million, terminating the Put Option of the noncontrolling interest holder. Additionally, the values of redeemable noncontrolling interests are subject to change based on the assessment of redemption value at each redemption date. As of September 30, 2026, the estimated redemption value of the redeemable noncontrolling interests that have met the conditions for redemption is $14 million. The estimated redemption value of the redeemable noncontrolling interests that will meet the conditions for redemption upon completion of the related development projects is $14 million. See Note 11 to the Consolidated Financial Statements for additional information.
Distribution and dividend requirements. Our dividend policy on our common stock is to distribute a percentage of our cash flow to ensure that we meet the dividend requirements of the Internal Revenue Code of 1986, as amended (the “Code”), relative to maintaining our REIT status, while still allowing us to retain cash to fund capital improvements and other investment activities. Under the Code, REITs may be subject to certain federal income and excise taxes on undistributed taxable income. We paid monthly common stock cash dividends of $0.10167 per share during the three months ended September 30, 2026. Our future common stock cash dividends, if and as declared, may vary and will be determined by the Board based upon the circumstances prevailing at the time, including our financial condition.
Off-balance sheet arrangements. We own interests in certain unconsolidated joint ventures as described in Note 7 to the Consolidated Financial Statements. Four of these joint ventures have aggregate mortgage debt of $945 million, of which our share is $222 million. Our risk of loss is limited to our investment in the applicable joint venture. Additionally, as of September 30, 2026, we had 14 outstanding letter of credit obligations totaling $3 million.
Except as described above, there have been no other material changes, outside of the ordinary course of business, during the nine months ended September 30, 2026 to the material cash requirements or material off-balance sheet arrangements disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025 under “Material Cash Requirements” and “Off-Balance Sheet Arrangements” in “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.”
69

Table of Contents
Cash Flow Summary
The following summary discussion of our cash flows is based on the Consolidated Statements of Cash Flows and is not meant to be an all-inclusive discussion of the changes in our cash flows for the periods presented below.
The following table sets forth changes in cash flows (in thousands):
Nine Months Ended September 30,
20262025Change
Net cash provided by (used in) operating activities$976,440 $957,875 $18,565 
Net cash provided by (used in) investing activities(2,578,978)(629,053)(1,949,925)
Net cash provided by (used in) financing activities1,670,658 (353,395)2,024,053 
Operating Cash Flows
Our cash flows from operations are dependent upon the occupancy levels of our buildings, rental rates on leases, our tenants’ performance on their lease obligations, the level of operating expenses, and other factors. Our net cash provided by operating activities increased $19 million for the nine months ended September 30, 2026 compared to the nine months ended September 30, 2025 primarily as a result of: (i) an increase in Adjusted NOI from acquisitions of real estate in 2025 and 2026, (ii) developments and redevelopments placed in service during 2025 and 2026, (iii) annual rent increases, and (iv) new leasing and renewal activity. The increase in net cash provided by operating activities was partially offset by: (i) an increase in transaction costs as a result of the Janus Living IPO and transition costs associated with senior housing operators, (ii) an increase in cash paid for interest, (iii) a decrease in Adjusted NOI from dispositions of real estate in 2025 and 2026, and (iv) a decrease in Adjusted NOI from buildings undergoing development and redevelopment in 2025 and 2026.
Investing Cash Flows
Our cash flows from investing activities are generally used to fund acquisitions, loans receivable, developments, and redevelopments of real estate, net of proceeds received from sales of real estate and repayments on loans receivable. Our net cash used in investing activities increased $1.9 billion for the nine months ended September 30, 2026 compared to the nine months ended September 30, 2025 primarily as a result of an increase in cash used for real estate asset acquisitions, including the SWF JV Buyout and the HQ Point Buyout. The increase in net cash used in investing activities was partially offset by: (i) an increase in net repayments on loans receivable in 2026, (ii) an increase in proceeds from the BX I JV and II transaction, (iii) an increase in proceeds from sales of real estate, (iv) a decrease in cash used for development, redevelopment, and capital expenditures on our real estate, (v) a decrease in cash used for investments in unconsolidated joint ventures, and (vi) an increase in proceeds received from insurance recoveries.
Financing Cash Flows
Our cash flows from financing activities are generally impacted by issuances and/or repurchases of equity, borrowings and repayments under our bank line of credit and commercial paper program, senior unsecured notes, term loans, and mortgage debt, and dividends paid to common shareholders. Our net cash provided by financing activities increased $2.0 billion for the nine months ended September 30, 2026 compared to the nine months ended September 30, 2025 primarily as a result of the following: (i) proceeds from the Janus Living IPO and Janus Living Follow-On Offerings, net of underwriting fees and other offering costs, (ii) proceeds from the Brookfield JV transaction, (iii) higher net borrowings under the commercial paper program, (iv) a decrease in repayments of senior unsecured notes, and (v) a decrease in dividends paid on common stock, primarily as a result of repurchases of common stock under our share repurchase program. The increase in net cash provided by financing activities was partially offset by: (i) a decrease in proceeds received from the issuance of senior unsecured notes, (ii) an increase in distributions to noncontrolling interests, (iii) an increase in repayments of mortgage debt, (iv) a decrease in contributions from noncontrolling interests in 2026, and (v) higher repurchases of common stock under our share repurchase program.
70

Table of Contents
Debt
In January 2026, we made a $102 million early full principal repayment of mortgage debt secured by two senior housing communities with original maturities in December 2026. In March 2026, concurrent with the closing of Janus Living IPO, we executed the $400 million 2031 Term Loan, which was undrawn as of September 30, 2026. Also in March 2026, concurrent with the closing of the Janus Living IPO, Janus Living entered into a credit agreement that provides for a revolving credit facility, which was amended and restated in September 2026, has a maximum commitment of $1.25 billion, and was undrawn as of September 30, 2026. Janus Living may utilize its revolving credit facility to fund acquisitions and other commitments.
In June 2026, we made a $142 million full repayment of mortgage debt secured by 13 outpatient medical buildings upon maturity. In July 2026, we repaid $650 million aggregate principal amount of 3.25% senior unsecured notes with an effective interest rate of 3.40% at maturity. In October 2026, we executed an amendment to our term loan agreement pursuant to which (i) the maximum incremental borrowing capacity was increased to $2.75 billion and (ii) we obtained loan commitments for the $500 million 2030 Term Loan. As of November 3, 2026, no amount has been drawn under the 2030 Term Loan.
See Note 9 to the Consolidated Financial Statements for additional information about our outstanding debt.
Approximately 83% and 95% of our consolidated debt was fixed rate debt as of September 30, 2026 and 2025, respectively. At September 30, 2026, our fixed rate debt and variable rate debt had weighted average effective interest rates of 4.24% and 4.27%, respectively. At September 30, 2025, our fixed rate debt and variable rate debt had weighted average effective interest rates of 4.20% and 4.79%, respectively. As of September 30, 2026, we had the following swapped to fixed rates through interest rate swap instruments: (i) the $750 million 2029 Term Loan, (ii) the $500 million 2027 Term Loans, and (iii) the $400 million 2028 Term Loan. These interest rate swap instruments are designated as cash flow hedges. For purposes of classification of the amounts above, variable rate debt with a derivative financial instrument designated as a cash flow hedge is reported as fixed rate debt due to us having effectively established a fixed interest rate for the underlying debt instrument. For a more detailed discussion of our interest rate risk, see “Quantitative and Qualitative Disclosures About Market Risk” in Item 3 below.
Supplemental Guarantor Information
Healthpeak OP is the issuer of senior unsecured notes that were offered and sold on a registered basis under the Securities Act. The obligations of Healthpeak OP to pay principal, premiums, if any, and interest on such senior unsecured notes are guaranteed on a full and unconditional basis by the Company, DOC DR Holdco, LLC, one of our wholly owned subsidiaries (“DOC DR Holdco”), and DOC DR, LLC, a wholly owned subsidiary of Healthpeak OP (“DOC DR OP Sub”). Additionally, DOC DR OP Sub is the issuer of certain senior unsecured notes assumed by Healthpeak. See Note 9 to the Consolidated Financial Statements for more information. The obligations of DOC DR OP Sub to pay principal, premiums, if any, and interest on such senior unsecured notes are guaranteed on a full and unconditional basis by the Company, Healthpeak OP, and DOC DR Holdco.
Subsidiary issuers of obligations guaranteed by the parent are not required to provide separate financial statements, provided that the parent guarantee is “full and unconditional”, the subsidiary obligor is a consolidated subsidiary of the parent company, the guaranteed security is debt or debt-like, and consolidated financial statements of the parent company have been filed. Accordingly, separate consolidated financial statements of Healthpeak OP, DOC DR Holdco, and DOC DR OP Sub have not been presented.
As permitted under Rule 13-01 of Regulation S-X, we have excluded the summarized financial information for the Company, Healthpeak OP, DOC DR Holdco, and DOC DR OP Sub because the Company, Healthpeak OP, DOC DR Holdco, and DOC DR OP Sub have no material assets, liabilities, or operations other than the debt financing activities described in the first paragraph of Note 9 to the Consolidated Financial Statements and their investments in non-guarantor subsidiaries, and management believes such summarized financial information would be repetitive and would not provide incremental value to investors.
Equity
At September 30, 2026, we had 690 million shares of common stock outstanding, equity totaled $10.8 billion, and our equity securities had a market value of $14.0 billion.
At-The-Market Program
Our at-the-market equity offering program (the “ATM Program”) allows for the sale of shares of common stock having an aggregate gross sales price of up to $1.5 billion. In addition to the issuance and sale of shares of our common stock, we may also enter into one or more forward sales agreements (each, an “ATM forward contract”) with sales agents for the sale of our shares of common stock under our ATM Program.
71

Table of Contents
During the three and nine months ended September 30, 2026, we did not utilize the forward provisions under the ATM Program or otherwise issue any shares of our common stock under the ATM Program.
At September 30, 2026, $1.5 billion of our common stock remained available for sale under the ATM Program. Actual future sales of our common stock will depend upon a variety of factors, including but not limited to market conditions, the trading price of our common stock, and our capital needs. We have no obligation to sell any shares under our ATM Program.
See Note 11 to the Consolidated Financial Statements for additional information about our ATM Program.
Noncontrolling Interests
Public Investors of Janus Living, Inc. In connection with the Janus Living IPO in March 2026, 48,300,000 shares of Class A-1 common stock were issued to public investors, generating total gross proceeds of $966 million, less $65 million of fees paid to the underwriters. In connection with the Janus Living Follow-On Offerings, an aggregate of 47,150,000 shares of Janus Living’s Class A-1 common stock were issued to public investors. The Janus Living June Follow-On Offering generated total gross proceeds of $719 million, less $28 million of fees paid to the underwriters. The Janus Living August Follow-On Offering generated total gross proceeds of $534 million, which included the exercise in full of the underwriter’s option to purchase additional shares, less $19 million of fees paid to the underwriters. As of September 30, 2026, these public investors represent a 30.8% interest in Janus Living, a consolidated subsidiary of Healthpeak.
Healthpeak OP. During the nine months ended September 30, 2026, certain of our employees (“Healthpeak OP Unitholders”) were issued approximately 2 million noncontrolling, non-managing member units in Healthpeak OP (“Healthpeak OP Units”). When certain conditions are met, the Healthpeak OP Unitholders have the right to require redemption of part or all of their Healthpeak OP Units for cash or shares of our common stock, at our option as managing member of Healthpeak OP. The per unit redemption amount is equal to either one share of our common stock or cash equal to the fair value of a share of common stock at the time of redemption. We classify the Healthpeak OP Units in permanent equity because we may elect, in our sole discretion, to issue shares of our common stock to Healthpeak OP Unitholders who choose to redeem their Healthpeak OP Units rather than using cash. As of September 30, 2026, there were approximately 6 million Healthpeak OP Units outstanding, and 509 thousand had met the criteria for redemption.
Janus Living OP. During the nine months ended September 30, 2026, certain of our employees (“Janus Living OP Unitholders”) were issued approximately 392 thousand non-managing member units in Janus Living OP, the operating subsidiary of Janus Living, Inc. (“Janus Living OP Units”), all of which were profits interests in Janus Living OP. The per unit redemption amount is equal to either one share of Janus Living’s Class A-1 common stock or cash equal to the fair value of a share of Janus Living’s Class A-1 common stock at the time of redemption. We classify the Janus Living OP Units in permanent equity because Janus Living may elect, in its sole discretion, to issue shares of Janus Living’s Class A-1 common stock to Janus Living OP Unitholders who choose to redeem their Janus Living OP Units rather than using cash. As of September 30, 2026, none of the Janus Living OP Units met the criteria for redemption.
DownREITs. At September 30, 2026, non-managing members held an aggregate of approximately 11 million units in eight limited liability companies for which we hold controlling interests and/or are the managing member. The DownREIT units are exchangeable for an amount of cash approximating the then-current market value of shares of our common stock or, at our option, shares of our common stock. At September 30, 2026, the outstanding DownREIT units were convertible into approximately 13 million shares of our common stock.
Share Repurchase Program
On July 30, 2026, our Board of Directors approved a share repurchase program (the “2026 Share Repurchase Program”) to replace our prior share repurchase program approved in July 2024 (the “2024 Share Repurchase Program”). Under the 2026 Share Repurchase Program, we may acquire shares of our common stock in the open market or other similar purchase techniques (including in compliance with the safe harbor provisions of Rule 10b-18 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or pursuant to one or more plans adopted under Rule 10b5-1 promulgated under the Exchange Act), in an amount up to an aggregate purchase price of $500 million. Purchases under the 2026 Share Repurchase Program may be exercised at our discretion with the timing and number of shares repurchased depending on a variety of factors, including price, corporate and regulatory requirements, and other corporate liquidity requirements and priorities. The 2026 Share Repurchase Program may be suspended or terminated at any time without prior notice.
During the nine months ended September 30, 2026, we repurchased 5.95 million shares of our common stock under the 2024 Share Repurchase Program at a weighted average price of $16.81 per share for a total of $100 million. During the three and nine months ended September 30, 2026, no shares were repurchased under the 2026 Share Repurchase Program. As of September 30, 2026, $500 million of our common stock remained available for repurchase under the 2026 Share Repurchase Program.
72

Table of Contents
Shelf Registration
On February 8, 2024, the Company and Healthpeak OP jointly filed a prospectus with the SEC as part of a registration statement on Form S-3, using an automatic shelf registration process. This shelf registration statement expires on February 8, 2027 and at or prior to such time, we expect to file a new shelf registration statement. On February 5, 2025, the Company and Healthpeak OP jointly filed a post-effective amendment to the shelf registration statement to add certain subsidiaries of the Company as co-registrants and register their guarantees of the debt securities of the Company and/or Healthpeak OP as additional securities that may be offered under the prospectus included in the shelf registration statement. Under the “shelf” process, we may sell any combination of the securities described in the prospectus through one or more offerings. The securities described in the prospectus include future offerings of: (i) the Company’s common stock, preferred stock, depositary shares, warrants, debt securities, and guarantees by the Company and certain of its subsidiaries of debt securities issued by Healthpeak OP, and (ii) Healthpeak OP’s debt securities and guarantees by Healthpeak OP and certain other subsidiaries of the Company of debt securities issued by the Company.
73

Table of Contents
Non-GAAP Financial Measures Reconciliations
The following is a reconciliation from net income (loss) applicable to common shares, the most directly comparable financial measure calculated and presented in accordance with GAAP, to Nareit FFO and FFO as Adjusted applicable to common shares (in thousands). For a reconciliation of Same-Store to total portfolio NOI and Adjusted NOI and other relevant disclosures by segment, refer to our Segment Analysis above.
Three Months Ended
September 30,
Nine Months Ended
September 30,
2026202520262025
Net income (loss) applicable to common shares$17,118 $(117,256)$263,270 $(43,335)
Real estate related depreciation and amortization298,923 262,317 872,047 796,779 
Healthpeak’s share of real estate related depreciation and amortization from unconsolidated joint ventures 7,564 12,574 22,420 37,304 
Noncontrolling interests’ share of real estate related depreciation and amortization(26,816)(3,807)(46,939)(12,686)
Loss (gain) on sales of depreciable real estate, net— (11,500)(60,657)(13,136)
Healthpeak’s share of loss (gain) on sales of depreciable real estate, net, from unconsolidated joint ventures — — 1,793 — 
Noncontrolling interests’ share of gain (loss) on sales of depreciable real estate, net— — 973 — 
Loss (gain) upon change of control, net(1)
— — (138,343)— 
Taxes associated with real estate dispositions— — (1,805)(335)
Impairments (recoveries) of real estate, net(2)
— 175,827 — 175,827 
Nareit FFO applicable to common shares296,789 318,155 912,759 940,418 
Distributions on dilutive convertible units and other4,336 4,551 13,257 13,735 
Diluted Nareit FFO applicable to common shares$301,125 $322,706 $926,016 $954,153 
Impact of adjustments to Nareit FFO:
Transaction, merger, and restructuring-related costs(3)
$8,379 $2,420 $36,681 $18,169 
Other impairments (recoveries) and other losses (gains), net(4)
(210)(54)(3,964)125 
Loss (gain) on debt extinguishments— — 302 — 
Casualty-related charges (recoveries), net(5)
(70)(1,771)(4,451)6,375 
Recognition (reversal) of valuation allowance on deferred tax assets(6)
— — (3,058)— 
Total adjustments$8,099 $595 $25,510 $24,669 
FFO as Adjusted applicable to common shares$304,888 $318,750 $938,269 $965,087 
Distributions on dilutive convertible units and other4,330 4,551 13,235 13,715 
Diluted FFO as Adjusted applicable to common shares$309,218 $323,301 $951,504 $978,802 
Other operating data:
Amortization of deferred financing costs and debt discounts (premiums)$8,616 $7,981 $25,879 $23,708 
Non-refundable entrance fee sales in excess of (less than) the related GAAP amortization16,710 12,711 37,331 36,449 
Stock-based compensation amortization expense4,412 4,046 13,265 10,410 
Deferred income taxes930 (179)4,032 4,989 
AFFO capital expenditures(37,617)(27,261)(103,678)(76,125)
Straight-line rents(12,876)(14,282)(35,964)(30,836)
Amortization of above (below) market lease intangibles, net(6,562)(8,105)(19,466)(28,402)
Other items(7)
(3,909)(1,687)(9,571)(1,303)
Refer to footnotes on the next page.
74

Table of Contents
_______________________________________
(1)The nine months ended September 30, 2026 includes a gain upon change of control related to (i) the acquisition of the remaining 46.5% interest in the SWF SH JV which held 19 senior housing properties and (ii) the disposition of an 80% interest in six outpatient medical buildings to a third-party. These gains upon change of control are included in other income (expense), net in the Consolidated Statements of Operations.
(2)The three and nine months ended September 30, 2025 include other-than-temporary impairment charges on certain unconsolidated real estate joint ventures, which are recognized in equity income (loss) from unconsolidated joint ventures in the Consolidated Statements of Operations.
(3)The three and nine months ended September 30, 2026 and 2025 include investment pursuit costs. The three and nine months ended September 30, 2026 includes transition costs associated with senior housing operators and the nine months ended September 30, 2026 includes costs related to the Janus Living IPO. The three and nine months ended September 30, 2025 include costs related to the merger with Physicians Realty Trust, which are primarily comprised of severance, legal, accounting, tax, information technology, and other costs of combining operations with Physicians Realty Trust.
(4)The three and nine months ended September 30, 2026 and 2025 include reserves and (recoveries) for expected loan losses recognized in impairments and loan loss reserves (recoveries), net in the Consolidated Statements of Operations.
(5)Casualty-related charges (recoveries), net are recognized in other income (expense), net, equity income (loss) from unconsolidated joint ventures, and noncontrolling interests’ share in earnings in the Consolidated Statements of Operations.
(6)The nine months ended September 30, 2026 includes the income tax impact related to the change in tax status of certain entities in connection with the Janus Living IPO.
(7)Primarily includes: (i) amortization of deferred revenue, (ii) noncontrolling interests’ share of senior housing entrance fees in excess of (less than) the related GAAP amortization, (iii) noncontrolling interests’ share of Adjusted Funds from Operations (“AFFO”) Capital Expenditures, and (iv) our proportionate share of AFFO capital expenditures and straight-line rents from unconsolidated joint ventures. AFFO Capital Expenditures include costs incurred in our operating portfolio required to maintain the properties in current market condition and generally are recurring in nature.
For a reconciliation of Adjusted NOI for our outpatient medical and lab reportable segments to net income (loss) before income taxes and equity income from unconsolidated joint ventures, see Note 13 to the Consolidated Financial Statements. The following table reconciles net income (loss) of our senior housing reportable segment to NOI and Adjusted NOI for the three and nine months ended September 30, 2026 and 2025 (dollars in thousands):
Three Months Ended
September 30,
Nine Months Ended
September 30,
2026202520262025
Net income (loss)$(5,608)$1,412 $37,124 $(5,987)
Depreciation and amortization78,682 30,885 186,553 94,875 
General and administrative1,527 2,267 5,819 7,781 
General and administrative - related party management fee3,779 — 6,579 — 
Interest expense486 950 1,187 2,847 
Transaction costs3,400 — 26,188 — 
Loss (gain) on sales of real estate, net— — (3,884)— 
Loss (gain) upon change of control, net(1)
— — (46,270)— 
Loss (gain) on debt extinguishments— — 403 — 
Other expense (income), net(8,276)450 (25,557)11,781 
Income tax expense (benefit)891 1,576 267 4,777 
Equity loss (income) from unconsolidated joint venture— (992)(111)(3,452)
Healthpeak’s share of unconsolidated joint venture NOI— 5,639 748 17,794 
Noncontrolling interests’ share of consolidated joint venture NOI(21,723)— (34,611)— 
NOI - senior housing$53,158 $42,187 $154,435 $130,416 
Adjustments to NOI497 (22)497 (899)
Adjusted NOI - senior housing$53,655 $42,165 $154,932 $129,517 
_______________________________________
(1)Recognized in other income (expense), net, in the Consolidated Statements of Operations.
75

Table of Contents
Critical Accounting Estimates
The preparation of financial statements in conformity with U.S. GAAP requires our management to use judgment in the application of critical accounting estimates and assumptions. We base estimates on the best information available to us at the time, our experience and on various other assumptions believed to be reasonable under the circumstances. These estimates could affect our financial position or results of operations. If our judgment or interpretation of the facts and circumstances relating to various transactions or other matters had been different, it is possible that different accounting would have been applied, resulting in a different presentation of our consolidated financial statements. From time to time, we re-evaluate our estimates and assumptions. In the event estimates or assumptions prove to be different from actual results, adjustments are made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. A discussion of accounting estimates that we consider critical in that they may require complex judgment in their application or require estimates about matters that are inherently uncertain is included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 in “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.” During the nine months ended September 30, 2026, we included a new critical accounting estimate as described below:
Valuation of Real Estate Upon Acquisition
For real estate acquisitions accounted for as asset acquisitions, we allocate the acquisition consideration and acquisition costs to the assets acquired and liabilities assumed at fair value as of the acquisition date.
We make estimates as part of our process for allocating acquisition consideration to the various identifiable assets and liabilities based upon the relative fair value of each asset and liability. These fair values are determined using standard valuation methodologies, such as the cost, market, and income approach. These methodologies require various assumptions, including those of a market participant. We utilize available market information in our assessment, such as capitalization and discount rates and comparable sale transactions. The most significant components of our allocations are typically buildings as-if-vacant, land, and lease and in-place resident contract intangibles. In the case of allocating fair value to buildings and in-place resident contract intangibles, our fair value estimates will affect the amount of depreciation and amortization we record over the estimated useful life of each asset acquired. In the case of allocating fair value to in-place leases, we make our best estimates based on our evaluation of the specific characteristics of each tenant’s lease. Factors considered include estimates of carrying costs during hypothetical expected lease-up periods, market conditions, and costs to execute similar leases. Our assumptions affect the amount of future revenue and/or depreciation and amortization expense that we will recognize over the remaining useful life for the acquired in-place leases.
76

Table of Contents
Item 3.  Quantitative and Qualitative Disclosures About Market Risk
Interest Rate Risk. We are exposed to various market risks, primarily from the potential loss arising from adverse changes in interest rates. We use derivative and other financial instruments in the normal course of business to mitigate interest rate risk. We do not use derivative financial instruments for speculative or trading purposes. Derivatives are recorded on the Consolidated Balance Sheets at fair value (see Note 17 to the Consolidated Financial Statements).
To illustrate the effect of movements in the interest rate markets, we performed a market sensitivity analysis on our hedging instruments. We applied various basis point spreads to the underlying interest rate curves of our derivative portfolio in order to determine the change in fair value. At September 30, 2026, a one percentage point increase or decrease in the underlying interest rate curve would result in a corresponding increase or decrease in the fair value of the derivative instruments by up to $25 million.
At September 30, 2026, our exposure to interest rate risk was primarily on our variable rate debt. At September 30, 2026, we had the following swapped to fixed rates through interest rate swap instruments: (i) the $750 million 2029 Term Loan, (ii) the $500 million 2027 Term Loans, and (iii) the $400 million 2028 Term Loan. The interest rate swap instruments are designated as cash flow hedges, with the objective of managing the exposure to interest rate risk by converting the interest rates on our variable rate debt to fixed interest rates. At September 30, 2026, both the fair value and carrying value of the interest rate swap assets were $30 million.
Our remaining variable rate debt at September 30, 2026 was comprised of borrowings under our commercial paper program and certain of our mortgage debt. Interest rate fluctuations will generally not affect our future earnings or cash flows on our fixed rate debt and assets until their maturity or earlier prepayment and refinancing. If interest rates have risen at the time we seek to refinance our fixed rate debt, whether at maturity or otherwise, our future earnings and cash flows could be adversely affected by additional borrowing costs. Conversely, lower interest rates at the time of refinancing may reduce our overall borrowing costs. Interest rate changes will affect the fair value of our fixed rate instruments. At September 30, 2026, a one percentage point increase in interest rates would decrease the fair value of our fixed rate debt by approximately $213 million and a one percentage point decrease in interest rates would increase the fair value of our fixed rate debt by approximately $227 million. Additionally, at September 30, 2026, a one percentage point increase or decrease in interest rates would change the fair value of our fixed rate loans receivable by up to $4 million. These changes would not materially impact earnings or cash flows. Conversely, changes in interest rates on variable rate debt would change our future earnings and cash flows, but not materially impact the fair value of those instruments. Assuming a one percentage point increase in the interest rates related to our variable rate debt, and assuming no other changes in the outstanding balance at September 30, 2026, our annual interest expense would increase by approximately $16 million.
77

Table of Contents
Item 4.  Controls and Procedures
Disclosure Controls and Procedures.  We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
As required by Rules 13a-15(b) and 15d-15(b) of the Exchange Act, we carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2026. Based upon that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of September 30, 2026.
Changes in Internal Control Over Financial Reporting.  There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
78

Table of Contents
PART II. OTHER INFORMATION
Item 1A.  Risk Factors
We have described in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, the primary risk factors that could materially affect our business, financial condition, or future results. There have been no material changes to those risk factors.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
(a)
None.
(b)
None.
(c)
On July 30, 2026, our Board of Directors approved the 2026 Share Repurchase Program to supersede and replace the 2024 Share Repurchase Program. Upon adoption of the 2026 Share Repurchase Program, no further share repurchases may be made pursuant to the 2024 Share Repurchase Program. Under the 2026 Share Repurchase Program, we may acquire shares of our common stock in the open market or other similar purchase techniques (including in compliance with the safe harbor provisions of Rule 10b-18 under the Exchange Act, or pursuant to one or more plans adopted under Rule 10b5-1 promulgated under the Exchange Act), in an amount up to an aggregate purchase price of $500 million. Purchases of common stock under the 2026 Share Repurchase Program may be exercised at our discretion with the timing and number of shares repurchased depending on a variety of factors, including price, corporate and regulatory requirements, and other corporate liquidity requirements and priorities. The 2026 Share Repurchase Program may be suspended or terminated at any time without prior notice. During the three months ended September 30, 2026, no shares were repurchased under the 2026 Share Repurchase Program. At September 30, 2026, $500 million of our common stock remained available for repurchase under the 2026 Share Repurchase Program.
Item 5. Other Information
Insider Trading Arrangements
During the three months ended September 30, 2026, none of our directors or Section 16 officers adopted, modified, or terminated any Rule 10b5-1 trading arrangement or any non-Rule 10b5-1 trading arrangement.
Delayed Draw Term Loan
On October 28, 2026 (the “Closing Date”), the Company, along with Healthpeak OP, DOC DR Holdco, LLC, DOC DR OP Sub and the lenders party thereto and Bank of America, N.A., as administrative agent, executed an amendment to the Term Loan Agreement (the “Amendment”).
Pursuant to the Amendment, Healthpeak OP obtained senior unsecured delayed draw term loan commitments in an aggregate principal amount of $500 million (the “Incremental DDTL Facility”). The Incremental DDTL Facility is available to be drawn through July 2027 and has a stated maturity of four years. Loans outstanding under the Incremental DDTL Facility bear interest at an annual rate equal to (a) the applicable margin, plus (b) at Healthpeak OP’s option, (x) the base rate, (y) a forward-looking term rate based on the secured overnight financing rate as administered by the Federal Reserve Bank of New York (“Term SOFR”) or (z) the daily secured overnight financing rate as administered by the Federal Reserve Bank of New York (“Daily SOFR”), subject to a floor of, in the case of base rate, 1.00% and in the case of Term SOFR and Daily SOFR, 0.00%. The applicable margin under the Incremental DDTL Facility ranges from 0.00% to 0.55% for base rate loans and 0.70% to 1.55% for Term SOFR or Daily SOFR loans, in each case, based on the non-credit enhanced, senior unsecured long-term debt ratings of Healthpeak OP (“Debt Ratings”). Based on Healthpeak OP’s current Debt Ratings, the applicable margin is initially 0.00% for base rate loans and 0.80% for Term SOFR and Daily SOFR loans. The Incremental DDTL Facility is guaranteed by the Company, DOC DR Holdco and DOC DR OP Sub and is subject to customary affirmative and negative covenants.
Additionally, the maximum aggregate borrowing capacity under the Term Loan Agreement was increased from $2.0 billion to $2.75 billion (the “Incremental Increase”). As of the Closing Date after giving effect to the Amendment and including the available commitments under the Incremental DDTL Facility, unused borrowing capacity under the Healthpeak Term Loan Credit Agreement is equal to $1.5 billion.
The foregoing summary of the Amendment is qualified in its entirety by reference to the full text of the Amendment, which is filed herewith as Exhibit 10.1 and is incorporated by reference herein.
79

Table of Contents
Item 6. Exhibits
3.1
3.2
3.3
3.4
3.5
10.1*†
22.1
31.1*
31.2*
32.1**
32.2**
101.INS*XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH*XBRL Taxonomy Extension Schema Document.
101.CAL*XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*XBRL Taxonomy Extension Labels Linkbase Document.
101.PRE*XBRL Taxonomy Extension Presentation Linkbase Document.
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
_______________________________________
*       Filed herewith.
**     Furnished herewith.
†    Certain schedules and exhibits have been omitted from this filing pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted schedule or exhibit to the Securities and Exchange Commission upon request.
80

Table of Contents
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: November 3, 2026Healthpeak Properties, Inc.
/s/ SCOTT M. BRINKER
Scott M. Brinker
President and Chief Executive Officer
(Principal Executive Officer)
/s/ KELVIN O. MOSES
Kelvin O. Moses
Chief Financial Officer
(Principal Financial Officer)
/s/ SHAWN G. JOHNSTON
Shawn G. Johnston
Executive Vice President and
Chief Accounting Officer
(Principal Accounting Officer)
81
EXECUTION VERSION AMENDMENT NO. 6 Dated as of October 28, 2026 to TERM LOAN AGREEMENT Dated as of August 22, 2022 THIS AMENDMENT NO. 6 (this “Amendment”) is made as of October 28, 2026 by and among HEALTHPEAK OP, LLC, a Maryland limited liability company (the “Borrower”), HEALTHPEAK PROPERTIES, INC., a Maryland corporation (the “Parent Guarantor”), DOC DR Holdco, LLC, a Maryland limited liability company (“DOC”), DOC DR, LLC, a Maryland limited liability company (“DOC OP”; collectively, DOC and DOC OP are referred to herein as the “Subsidiary Guarantors” and individually, as a “Subsidiary Guarantor”), the Lenders (including in their respective capacities as “Term A-5 Lenders” and/or “Consenting Lenders,” as indicated on the signature pages hereto) listed on the signature pages hereof and BANK OF AMERICA, N.A., as Administrative Agent (in such capacity, the “Administrative Agent”). WHEREAS, the Borrower, the financial institutions party thereto as lenders, the Administrative Agent and the other parties thereto entered into that certain Term Loan Agreement dated as of August 22, 2022 (as amended by that certain Consent and Amendment No. 1 dated as of February 10, 2023, that certain Consent and Amendment No. 2 and Joinder dated as of March 1, 2024, that certain Amendment No. 3 dated as of December 9, 2024, that certain Amendment No. 4 dated as of October 3, 2025, that certain Amendment No. 5 dated as of March 23, 2026 and as further amended, restated, amended and restated, supplemented or otherwise modified prior to the date hereof, the “Credit Agreement”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings given to them in the Amended Credit Agreement (as defined below); WHEREAS, the Borrower has requested that the Lenders and the Administrative Agent agree to an amendment to the Credit Agreement; WHEREAS, the Borrower has requested, and each of the Lenders identified on the signature pages hereof as a “Consenting Lender” (each individually, a “Consenting Lender” and collectively, the “Consenting Lenders”), constituting the Required Lenders as of the Sixth Amendment Effective Date (as defined below), have agreed, pursuant to and in accordance with Section 10.01 of the Credit Agreement, (i) to increase the amount of the Incremental Term Loans that may be incurred pursuant to Section 2.16 of the Credit Agreement in an amount sufficient to incur the Term A-5 Loans under the Term A-5 Facility from time to time on and/or after the Sixth Amendment Effective Date, plus an additional amount, such that that after giving effect to all Incremental Term Loans, the sum, without duplication, of the aggregate principal amount of the Term A-1 Loans, the Term A-2 Loans, the Term A-3 Loans, the Term A-4 Loans, the Term A-5 Loans and all additional Incremental Term Loans shall not exceed $2,750,000,000 in the aggregate; WHEREAS, the Borrower has requested, and each of the Lenders identified on the signature pages hereof as a “Term A-5 Lender” (each individually, a “Term A-5 Lender” and collectively, the “Term A-5 Lenders”) have agreed to provide, the Term A-5 Facility on the terms set forth in the Amended Credit Agreement, and the Borrower, the Consenting Lenders and the Administrative Agent have agreed to amend the Credit Agreement to effect the making of the Term A-5 Facility on the terms and conditions set forth herein and in the Amended Credit Agreement; and


 
2 WHEREAS, the Borrower, the Administrative Agent and the Consenting Lenders have agreed to make certain other modifications to the Credit Agreement as more fully set forth herein and in the Amended Credit Agreement. NOW, THEREFORE, in consideration of the premises set forth above, the terms and conditions contained herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Loan Parties, the Administrative Agent and Lenders party hereto (including in their capacity as Term A-5 Lenders and/or Consenting Lenders, as applicable) hereby agree to enter into this Amendment. 1. Amendments to the Credit Agreement. (a) Effective as of the Sixth Amendment Effective Date, the parties hereto agree that the Credit Agreement (excluding the Schedules and Exhibits thereto, which shall remain in their current form delivered, subject to Section 1(b) hereof) is hereby amended as set forth in the marked terms on Exhibit A-1 attached hereto (excluding the Schedules and Exhibits thereto, which shall remain in their current form delivered, subject to Section 1(b) hereof, the Credit Agreement as so amended and as supplemented pursuant to Section 1(b) being referred to as the “Amended Credit Agreement”). In Exhibit A-1 hereto, deletions of text in the Amended Credit Agreement are indicated by struck-through text, and insertions of text are indicated by bold, double-underlined text. Exhibit A-2 attached hereto sets forth a clean copy of the Amended Credit Agreement, after giving effect to such amendments and supplements. As so amended and supplemented, the Amended Credit Agreement shall continue in full force and effect. (b) Effective as of the Sixth Amendment Effective Date, the parties hereto agree that: (i) Schedule 2.01 (Commitments and Applicable Percentages) to the Credit Agreement is hereby amended and restated in its entirety in the form attached hereto as Exhibit B. (ii) Exhibit A (Form of Committed Loan Notice) to the Credit Agreement is hereby amended and restated in its entirety in the form attached hereto as Exhibit C. (iii) A new Exhibit D-5 (Form of Term A-5 Note) to the Credit Agreement is hereby added in the form attached hereto as Exhibit D. 2. Term A-5 Facility. On the Sixth Amendment Effective Date, each Term A-5 Lender shall make Term A-5 Commitments available to the Borrower in the amount set forth opposite such Term A-5 Lender’s name on Exhibit B hereto on the terms set forth in the Amended Credit Agreement. 3. Conditions of Effectiveness. The effectiveness of this Amendment and the availability of the Term A-5 Commitments are subject to the satisfaction or waiver of the following conditions precedent (the date of such satisfaction or waiver being the “Sixth Amendment Effective Date”): (a) the Administrative Agent shall have received copies of counterparts of this Amendment duly executed by each Loan Party, the Administrative Agent, the Consenting Lenders constituting the Required Lenders (as defined in the Credit Agreement and as determined immediately prior to giving effect to this Amendment and the Term A-5 Facility) and each of the Term A-5 Lenders; (b) the Administrative Agent shall have received (i) an opinion of Latham & Watkins LLP, New York counsel to the Loan Parties and (ii) an opinion of Ballard Spahr LLP, Maryland counsel to the Loan Parties, each addressed to the Administrative Agent and the Lenders;


 
3 (c) the Administrative Agent shall have received such certificates of resolutions or other action, incumbency certificates and/or other certificates of Responsible Officers as the Administrative Agent may reasonably require evidencing the identity, authority and capacity of each Responsible Officer authorized to act as a Responsible Officer in connection with this Amendment and the other Loan Documents; (d) the Administrative Agent shall have received copies, certified by a Responsible Officer of each Loan Party, of (i) the certificate or articles of incorporation or formation, articles of organization, or other comparable organizational instrument of such Loan Party, (ii) the by-laws or operating agreement (or the equivalent governing documents) of such Loan Party and (iii) all necessary resolutions or other action taken by the board of directors or managers (or the equivalent governing body) of such Loan Party to authorize the execution, delivery and performance of this Amendment by such Loan Party; (e) the Administrative Agent shall have received such documents and certifications as the Administrative Agent may reasonably require to evidence that each Loan Party is validly existing, in good standing and qualified to engage in business in its state of organization and in each jurisdiction where its ownership, lease or operation of properties or the conduct of its business requires such qualification, except to the extent that failure to do so could not reasonably be expected to have a Material Adverse Effect; (f) the Administrative Agent shall have received a certificate executed by a Responsible Officer of the Borrower certifying that, as of the Sixth Amendment Effective Date, (i) no Default or Event of Default exists, and, immediately after giving effect to this Amendment, no Default or Event of Default exists and (ii) the representations and warranties contained in Article V of the Amended Credit Agreement are true and correct in all material respects (or in all respects in the case of a representation or warranty qualified by materiality or Material Adverse Effect), except to the extent that any such representation or warranty specifically refers to an earlier date, in which case they were true and correct in all material respects (or in all respects in the case of a representation or warranty qualified by materiality or Material Adverse Effect, in which case such representation or warranty shall be true and correct in all respects) as of such earlier date; (g) the Borrower shall have provided to the Administrative Agent and the applicable Lender the documentation and other information reasonably requested in writing by the Administrative Agent or such Lender at least five (5) days prior to the Sixth Amendment Effective Date that is required by regulatory authorities applicable to such Lender under applicable “know your customer” and anti-money laundering rules and regulations, including, without limitation, the PATRIOT Act; (h) to the extent that the Borrower qualifies as a “legal entity customer” under the Beneficial Ownership Regulation, the Borrower shall have delivered to the Administrative Agent and any Lender, in each case to the extent reasonably requested by the Administrative Agent or such Lender in writing at least five (5) days prior to the Sixth Amendment Effective Date, a Beneficial Ownership Certification in relation to the Borrower; and (i) the Administrative Agent shall have received payment of all fees and expenses (including fees and expenses of counsel for the Administrative Agent) required to be paid by the Borrower to the Administrative Agent or any Term A-5 Lender on or prior to the Sixth Amendment Effective Date in connection with this Amendment; provided that invoices for such fees and expenses have been presented to the Loan Parties a reasonable period of time (and in any event not less than one (1) Business Day) prior to the Sixth Amendment Effective Date. 4. Representations and Warranties of the Loan Parties. Each Loan Party hereby


 
4 represents and warrants as follows: (a) Each Loan Party (a) is duly organized or formed, validly existing and, where applicable, in good standing under the Laws of the jurisdiction of its incorporation or organization, (b) has all requisite power and authority and all requisite governmental licenses, authorizations, consents and approvals to (i) own its assets and carry on its business and (ii) execute, deliver and perform its obligations under this Amendment, the Amended Credit Agreement and the other Loan Documents to which it is a party and (c) is duly qualified to do business and, where applicable, in good standing under the Laws of each jurisdiction where its ownership, lease or operation of properties or the conduct of its business requires such qualification or license; except in each case referred to in clause (a) (other than with respect to any Loan Party or any Material Subsidiary), clause (b)(i) or clause (c), to the extent that failure to do so could not reasonably be expected to have a Material Adverse Effect. This Amendment has been duly executed and delivered by the duly authorized officers of the Loan Parties, and this Amendment and the Amended Credit Agreement constitute legal, valid and binding obligations of the Loan Parties and are enforceable against the Loan Parties in accordance with their terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium or other laws affecting creditors’ rights generally and subject to general principles of equity, regardless of whether considered in a proceeding in equity or at law. (b) As of the date hereof and after giving effect to the terms of this Amendment, (i) no Default has occurred and is continuing and (ii) the representations and warranties of the Loan Parties contained in the Loan Documents are true and correct in all material respects (except in the case of a representation or warranty qualified by materiality or Material Adverse Effect or similar language, in which case such representation or warranty is true and correct in all respects) on and as of the date hereof, except to the extent that such representations and warranties specifically refer to an earlier date, in which case they are true and correct in all material respects (except in the case of a representation or warranty qualified by materiality or Material Adverse Effect or similar language, in which case such representation or warranty is true and correct in all respects) as of such earlier date. (c) Each Loan Party: (i) reaffirms and admits the validity and enforceability of the Amended Credit Agreement and the other Loan Documents and all of its Obligations thereunder; (ii) as of the date hereof, agrees and admits that it has no valid defenses to or offsets against any of its Obligations to the Administrative Agent and the Lenders under the Amended Credit Agreement and the Notes; and (iii) agrees and acknowledges that all references to the “Obligations” contained in the Loan Documents include the Obligations under the Amended Credit Agreement. 5. Reference to and Effect on the Credit Agreement. (a) Upon the Sixth Amendment Effective Date, each reference to the Credit Agreement in the Amended Credit Agreement or any other Loan Document shall mean and be a reference to the Amended Credit Agreement. (b) Each Loan Document and all other documents, instruments and agreements executed and/or delivered in connection therewith shall remain in full force and effect and are hereby ratified and confirmed. Upon the Sixth Amendment Effective Date, this Amendment shall for all purposes constitute a Loan Document.


 
5 (c) Except with respect to the subject matter hereof, the execution, delivery and effectiveness of this Amendment shall not operate as a waiver of any right, power or remedy of the Administrative Agent or the Lenders, nor constitute a waiver of any provision of the Amended Credit Agreement, the other Loan Documents or any other documents, instruments and agreements executed and/or delivered in connection therewith. (d) This Amendment is not intended by the parties to be, and shall not be construed to be, a substitution or novation of the Obligations outstanding under the Loan Documents, which shall remain in full force and effect, except as modified hereby. 6. Governing Law. This Amendment shall be construed in accordance with and governed by the law of the State of New York. 7. SUBMISSION TO JURISDICTION, WAIVER OF VENUE, SERVICE OF PROCESS, WAIVER OF JURY TRIAL. The jurisdiction, venue, service of process and waiver of jury trial provisions set forth in Sections 10.14 and 10.15 of the Amended Credit Agreement are hereby incorporated by reference, mutatis mutandis. 8. Headings. Section headings in this Amendment are included herein for convenience of reference only and shall not constitute a part of this Amendment for any other purpose. 9. Counterparts; Electronic Execution. This Amendment may be executed by one or more of the parties hereto on any number of separate counterparts, and all of said counterparts taken together shall be deemed to constitute one and the same instrument. Section 10.21 of the Amended Credit Agreement is hereby incorporated by reference, mutatis mutandis. [Signature Pages Follow]


 
Signature Page to Amendment No. 6 to Term Loan Agreement IN WITNESS WHEREOF, this Amendment has been duly executed as of the day and year first above written. HEALTHPEAK OP, LLC, as the Borrower By: HEALTHPEAK PROPERTIES, INC. Its: Managing Member By:/s/ Ankit B. Patadia Name: Ankit B. Patadia Title: Executive Vice President – Finance and Treasurer of Healthpeak Properties, Inc. HEALTHPEAK PROPERTIES, INC., as the Parent Guarantor By:/s/ Ankit B. Patadia Name: Ankit B. Patadia Title: Executive Vice President – Finance and Treasurer of Healthpeak Properties, Inc. DOC DR HOLDCO, LLC, as a Subsidiary Guarantor By: HEALTHPEAK OP, LLC Its: Sole Member By: HEALTHPEAK PROPERTIES, INC. Its: Managing Member By:/s/ Ankit B. Patadia Name: Ankit B. Patadia Title: Executive Vice President – Finance and Treasurer of Healthpeak Properties, Inc.


 
Signature Page to Amendment No. 6 to Term Loan Agreement DOC DR, LLC, as a Subsidiary Guarantor By: DOC DR HOLDCO, LLC, Its: Managing Member By: HEALTHPEAK OP, LLC, Its: Sole Member By: HEALTHPEAK PROPERTIES, INC. Its: Managing Member By:/s/ Ankit B. Patadia Name: Ankit B. Patadia Title: Executive Vice President – Finance and Treasurer of Healthpeak Properties, Inc.


 
Signature Page to Amendment No. 6 to Term Loan Agreement BANK OF AMERICA, N.A., as Administrative Agent By:/s/ Liliana Claar Name: Liliana Claar Title: Vice President


 
Signature Page to Amendment No. 6 to Term Loan Agreement BANK OF AMERICA, N.A., as a Consenting Lender and a Term A-5 Lender By:/s/ Darren Merten Name: Darren Merten Title: Managing Director


 
Signature Page to Amendment No. 6 to Term Loan Agreement JPMORGAN CHASE BANK, N.A., as a Consenting Lender and a Term A-5 Lender By:/s/ Jason Baeten Name: Jason Baeten Title: Executive Director


 
Signature Page to Amendment No. 6 to Term Loan Agreement WELLS FARGO BANK, NATIONAL ASSOCIATION, as a Consenting Lender and a Term A-5 Lender By:/s/ Andrea S. Chen Name: Andrea S. Chen Title: Managing Director


 
Signature Page to Amendment No. 6 to Term Loan Agreement BARCLAYS BANK PLC, as a Consenting Lender and a Term A-5 Lender By:/s/ Charlene Saldanha Name: Charlene Saldanha Title: Director


 
Signature Page to Amendment No. 6 to Term Loan Agreement GOLDMAN SACHS BANK USA, as a Consenting Lender and a Term A-5 Lender By:/s/ Jonathan Dworkin Name: Jonathan Dworkin Title: Authorized Signatory


 
Signature Page to Amendment No. 6 to Term Loan Agreement MORGAN STANLEY BANK, N.A., as a Consenting Lender and a Term A-5 Lender By:/s/ Fred Gonfiantini Name: Fred Gonfiantini Title: Authorized Signatory


 
Signature Page to Amendment No. 6 to Term Loan Agreement ROYAL BANK OF CANADA, as a Consenting Lender and a Term A-5 Lender By:/s/ William Behuniak Name: William Behuniak Title: Authorized Signatory


 
Signature Page to Amendment No. 6 to Term Loan Agreement BNP PARIBAS, as a Consenting Lender and a Term A- 5 Lender By:/s/ John Bosco Name: John Bosco Title: Managing Director By:/s/ Kirby Young Name: Kirby Young Title: Vice President


 
Signature Page to Amendment No. 6 to Term Loan Agreement CAPITAL ONE, N.A., as a Consenting Lender and a Term A-5 Lender By:/s/ Melissa DeVito Name: Melissa DeVito Title: Authorized Signer


 
Signature Page to Amendment No. 6 to Term Loan Agreement CRÉDIT AGRICOLE CORPORATE AND INVESTMENT BANK, as a Consenting Lender and a Term A-5 Lender By:/s/ Jill Wong Name: Jill Wong Title: Director By:/s/ Gordon Yip Name: Gordon Yip Title: Director


 
Signature Page to Amendment No. 6 to Term Loan Agreement THE HUNTINGTON NATIONAL BANK, as a Consenting Lender and a Term A-5 Lender By:/s/ Michael Kinnick Name: Michael Kinnick Title: Managing Director


 
Signature Page to Amendment No. 6 to Term Loan Agreement KEYBANK NATIONAL ASSOCIATION, as a Consenting Lender and a Term A-5 Lender By:/s/ Laura Conway Name: Laura Conway Title: Senior Vice President


 
Signature Page to Amendment No. 6 to Term Loan Agreement M&T BANK, as a Consenting Lender and a Term A-5 Lender By:/s/ Ethan D’Arcangelo Name: Ethan D’Arcangelo Title: Authorized Signatory


 
Signature Page to Amendment No. 6 to Term Loan Agreement MIZUHO BANK, LTD., as a Consenting Lender and a Term A-5 Lender By:/s/ Donna DeMagistris Name: Donna DeMagistris Title: Managing Director


 
Signature Page to Amendment No. 6 to Term Loan Agreement PNC BANK, NATIONAL ASSOCIATION, as a Consenting Lender and a Term A-5 Lender By:/s/ James A. Harmann Name: James A. Harmann Title: Senior Vice President


 
Signature Page to Amendment No. 6 to Term Loan Agreement REGIONS BANK, as a Consenting Lender and a Term A-5 Lender By:/s/ Nicholas R. Frerman Name: Nicholas R. Frerman Title: Senior Vice President


 
Signature Page to Amendment No. 6 to Term Loan Agreement BANCO SANTANDER, S.A., NEW YORK BRANCH, as a Consenting Lender and a Term A-5 Lender By:/s/ Andres Barbosa Name: Andres Barbosa Title: Managing Director By:/s/ Zara Kamal Name: Zara Kamal Title: Executive Director


 
Signature Page to Amendment No. 6 to Term Loan Agreement THE BANK OF NOVA SCOTIA, as a Consenting Lender and a Term A-5 Lender By:/s/ Robb Gass Name: Robb Gass Title: Managing Director


 
Signature Page to Amendment No. 6 to Term Loan Agreement TD BANK, N.A., as a Consenting Lender and a Term A-5 Lender By:/s/ George Skoufis Name: George Skoufis Title: Vice President


 
Signature Page to Amendment No. 6 to Term Loan Agreement TRUIST BANK, as a Consenting Lender and a Term A- 5 Lender By:/s/ Alexandra Korchmar Name: Alexandra Korchmar Title: Vice Director


 
Signature Page to Amendment No. 6 to Term Loan Agreement U.S. BANK NATIONAL ASSOCIATION, as a Consenting Lender and a Term A-5 Lender By:/s/ Travis H. Myers Name: Travis H. Myers Title: Senior Vice President


 
Signature Page to Amendment No. 6 to Term Loan Agreement SCOTIA FINANCING (USA) LLC, as a Consenting Lender By:/s/ Michelle Phillips________ Name: Michelle Phillips Title: President & CEO


 
EXHIBIT A-1 Marked Amended Credit Agreement See attached.


 
EXHIBIT A-2 Clean Amended Credit Agreement See attached.


 
EXHIBIT B Schedule 2.01 (Commitments and Applicable Percentages) See attached.


 
EXHIBIT C Exhibit A (Form of Committed Loan Notice) See attached.


 
EXHIBIT D Exhibit D-5 (Form of Term A-5 Note) See attached.


 
Exhibit A to Amendment No. 56 to Term Loan Agreement TERM LOAN AGREEMENT (as amended, restated, supplemented and otherwise modified through and including that certain Consent and Amendment No. 1 dated as of February 10, 2023, that certain Consent and Amendment No. 2 and Joinder dated as of March 1, 2024, that certain Amendment No. 3 dated as of December 9, 2024, that certain Amendment No. 4 dated as of October 3, 2025, and that certain Amendment No. 5 dated as of March 23, 2026 and that certain Amendment No. 6 dated as of October 28, 2026) Dated as of August 22, 2022 among HEALTHPEAK OP, LLC, as Borrower, HEALTHPEAK PROPERTIES, INC., as Parent Guarantor, THE LENDERS PARTY HERETO FROM TIME TO TIME, and BANK OF AMERICA, N.A., as Administrative Agent With respect to the Term A-1 Facility and Term A-2 Facility: WELLS FARGO BANK, NATIONAL ASSOCIATION, PNC BANK, NATIONAL ASSOCIATION, THE BANK OF NOVA SCOTIA and TRUIST BANK, as Co-Syndication Agents MIZUHO BANK, LTD., REGIONS BANK and TORONTO-DOMINION BANK, as Co-Documentation Agents With respect to the Term A-3 Facility: BARCLAYS BANK PLC, KEYBANK NATIONAL ASSOCIATION and MORGAN STANLEY SENIOR FUNDING, INC., as Co-Syndication Agents CREDIT AGRICOLE CORPORATE AND INVESTMENT BANK, JPMORGAN CHASE BANK, N.A., MIZUHO BANK, LTD. PNC BANK, NATIONAL ASSOCIATION, ROYAL BANK OF CANADA, TD BANK, N.A., TRUIST BANK, U.S. BANK NATIONAL ASSOCIATION and WELLS FARGO BANK, NATIONAL ASSOCIATION, as Co-Documentation Agents With respect to the Term A-4 Facility: JPMORGAN CHASE BANK, N.A. and WELLS FARGO BANK, NATIONAL ASSOCIATION as Co-Syndication Agents BARCLAYS BANK PLC, GOLDMAN SACHS BANK USA, MORGAN STANLEY SENIOR FUNDING, INC. and ROYAL BANK OF CANADA, as Co-Documentation Agents With respect to the Term A-5 Facility: JPMORGAN CHASE BANK, N.A. and WELLS FARGO BANK, NATIONAL ASSOCIATION as Co-Syndication Agents BANCO SANTANDER, S.A., NEW YORK BRANCH, BARCLAYS BANK PLC, BNP PARIBAS, CAPITAL ONE, N.A., CREDIT AGRICOLE CORPORATE AND INVESTMENT BANK, GOLDMAN SACHS BANK USA, THE HUNTINGTON NATIONAL BANK, M&T BANK, MIZUHO BANK, LTD., MORGAN STANLEY BANK, N.A., PNC BANK, NATIONAL ASSOCIATION, ROYAL BANK OF CANADA, T.D. BANK, N.A., THE BANK OF NOVA SCOTIA, TRUIST BANK, U.S. BANK NATIONAL ASSOCIATION, REGIONS BANK and KEYBANK NATIONAL ASSOCIATION, as Senior Managing Agents BOFA SECURITIES, INC. and WELLS FARGO SECURITIES, LLC, as Joint Bookrunners BOFA SECURITIES, INC., WELLS FARGO SECURITIES, LLC, PNC CAPITAL MARKETS LLC, THE BANK OF NOVA SCOTIA, and BOFA SECURITIES, INC., Barclays Bank PLC, KeyBanc Capital Markets, and MORGAN STANLEY SENIOR FUNDING, INC., as Joint Bookrunners BOFA SECURITIES, INC., BARCLAYS BANK PLC, BOFA SECURITIES, INC., JPMORGAN CHASE BANK, N.A., and WELLS FARGO SECURITIES, LLC as Joint Bookrunners BOFA SECURITIES, INC., BOFA SECURITIES, INC., JPMORGAN CHASE BANK, N.A., and WELLS FARGO SECURITIES, LLC as Joint Bookrunners BOFA SECURITIES, INC.,


 
2 TRUIST SECURITIES, INC., as Joint Lead Arrangers CREDIT AGRICOLE CORPORATE AND INVESTMENT BANK, JPMORGAN CHASE BANK, N.A., KEYBANC CAPITAL MARKETS, MORGAN STANLEY SENIOR FUNDING, INC., MIZUHO BANK, LTD., PNC CAPITAL MARKETS LLC, ROYAL BANK OF CANADA, TD BANK, N.A., TRUIST SECURITIES, INC., U.S. BANK NATIONAL ASSOCIATION, and WELLS FARGO SECURITIES, LLC, as Joint Lead Arrangers JPMORGAN CHASE BANK, N.A., and WELLS FARGO SECURITIES, LLC as Joint Lead Arrangers JPMORGAN CHASE BANK, N.A., and WELLS FARGO SECURITIES, LLC as Joint Lead Arrangers


 
i TABLE OF CONTENTS Page Article I DEFINITIONS AND ACCOUNTING TERMSDEFINITIONS AND ACCOUNTING TERMS ............................................................................................ 1 1.01 Defined Terms .................................................................................................................... 1 1.02 Other Interpretive Provisions ........................................................................................ 3840 1.03 Accounting Terms ......................................................................................................... 3940 1.04 Rounding ....................................................................................................................... 3941 1.05 [Reserved] ..................................................................................................................... 3941 1.06 [Reserved] ..................................................................................................................... 3941 1.07 Interest Rates ................................................................................................................. 4041 1.08 Times of Day ................................................................................................................ 4042 Article II THE COMMITMENTS AND CREDIT EXTENSIONS ........................................ 4042 2.01 Committed Loans .......................................................................................................... 4042 2.02 Borrowings and Conversions and Continuations of Loans ........................................... 4143 2.03 [Reserved] ..................................................................................................................... 4345 2.04 [Reserved] ..................................................................................................................... 4345 2.05 [Reserved] ..................................................................................................................... 4345 2.06 Prepayments .................................................................................................................. 4345 2.07 Termination or Reduction of Commitments ................................................................. 4345 2.08 Repayment .................................................................................................................... 4446 2.09 Interest .......................................................................................................................... 4547 2.10 Fees 4547 2.11 Computation of Interest and Fees ................................................................................. 4648 2.12 Evidence of Debt .......................................................................................................... 4648 2.13 Payments Generally; Administrative Agent’s Clawback .............................................. 4649 2.14 Sharing of Payments by Lenders .................................................................................. 4851 2.15 Extension of Term A-2 Maturity Date .......................................................................... 4951 2.16 Incremental Term Loans ............................................................................................... 5052 2.17 [Reserved] ..................................................................................................................... 5355 2.18 Defaulting Lenders ....................................................................................................... 5355 Article III TAXES, YIELD PROTECTION AND ILLEGALITY .......................................... 5456 3.01 Taxes ............................................................................................................................. 5456 3.02 Illegality ........................................................................................................................ 5760 3.03 Inability to Determine Rates ......................................................................................... 5860 3.04 Increased Costs ............................................................................................................. 6062 3.05 Compensation for Losses .............................................................................................. 6164 3.06 Mitigation Obligations; Replacement of Lenders ......................................................... 6264 3.07 Survival ......................................................................................................................... 6265 Article IV CONDITIONS PRECEDENT TO CREDIT EXTENSIONS ................................. 6265 4.01 Conditions to Effectiveness of this Agreement............................................................. 6265 4.02 Conditions to All Credit Extensions after the Closing Date ......................................... 6467


 
ii Article V REPRESENTATIONS AND WARRANTIES ....................................................... 6567 5.01 Existence, Qualification and Power .............................................................................. 6567 5.02 Authorization; No Contravention ................................................................................. 6568 5.03 Governmental Authorization; Other Consents .............................................................. 6668 5.04 Binding Effect ............................................................................................................... 6668 5.05 Financial Statements; No Material Adverse Effect ....................................................... 6668 5.06 Litigation ....................................................................................................................... 6669 5.07 No Default..................................................................................................................... 6769 5.08 Ownership of Property and Valid Leasehold Interests; Liens ...................................... 6769 5.09 Environmental Compliance .......................................................................................... 6769 5.10 Insurance ....................................................................................................................... 6769 5.11 Taxes ............................................................................................................................. 6769 5.12 ERISA Compliance ....................................................................................................... 6770 5.13 Margin Regulations; Investment Company Act; REIT Status ...................................... 6870 5.14 Disclosure ..................................................................................................................... 6871 5.15 Compliance with Laws ................................................................................................. 6971 5.16 Intellectual Property; Licenses, Etc. ............................................................................. 6971 5.17 Use of Proceeds ............................................................................................................ 6972 5.18 Taxpayer Identification Number ................................................................................... 7072 5.19 Sanctions ....................................................................................................................... 7072 5.20 Affected Financial Institution ....................................................................................... 7072 5.21 Anti-Corruption Laws ................................................................................................... 7072 5.22 Solvency........................................................................................................................ 7072 Article VI AFFIRMATIVE COVENANTS ............................................................................. 7073 6.01 Financial Statements ..................................................................................................... 7173 6.02 Certificates; Other Information ..................................................................................... 7174 6.03 Notices .......................................................................................................................... 7375 6.04 Payment of Taxes .......................................................................................................... 7376 6.05 Preservation of Existence, Etc. ..................................................................................... 7476 6.06 Maintenance of Properties ............................................................................................ 7476 6.07 Maintenance of Insurance ............................................................................................. 7476 6.08 Compliance with Laws ................................................................................................. 7477 6.09 Books and Records ....................................................................................................... 7477 6.10 Inspection Rights .......................................................................................................... 7577 6.11 Use of Proceeds ............................................................................................................ 7577 6.12 REIT Status ................................................................................................................... 7577 6.13 Employee Benefits ........................................................................................................ 7577 6.14 Anti-Corruption Laws ................................................................................................... 7578 Article VII NEGATIVE COVENANTS .................................................................................... 7678 7.01 Liens ............................................................................................................................. 7678 7.02 [Reserved] ..................................................................................................................... 7779 7.03 Indebtedness .................................................................................................................. 7780 7.04 Fundamental Changes ................................................................................................... 7880 7.05 Dispositions .................................................................................................................. 7881 7.06 Restricted Payments ...................................................................................................... 7881 7.07 Change in Nature of Business ....................................................................................... 7981


 
iii 7.08 Transactions with Affiliates .......................................................................................... 7981 7.09 Burdensome Agreements .............................................................................................. 8082 7.10 Financial Covenants ...................................................................................................... 8083 7.11 Sanctions ....................................................................................................................... 8183 7.12 Anti-Corruption Laws ................................................................................................... 8183 Article VIII EVENTS OF DEFAULT AND REMEDIES .......................................................... 8184 8.01 Events of Default .......................................................................................................... 8184 8.02 Remedies Upon Event of Default ................................................................................. 8386 8.03 Application of Funds .................................................................................................... 8486 Article IX ADMINISTRATIVE AGENT ................................................................................. 8587 9.01 Appointment and Authority .......................................................................................... 8587 9.02 Rights as a Lender ......................................................................................................... 8587 9.03 Exculpatory Provisions ................................................................................................. 8588 9.04 Reliance by Administrative Agent ................................................................................ 8688 9.05 Delegation of Duties ..................................................................................................... 8689 9.06 Resignation of Administrative Agent ........................................................................... 8689 9.07 Non-Reliance on Administrative Agent, the Arrangers and Other Lenders ................. 8790 9.08 No Other Duties, Etc. .................................................................................................... 8890 9.09 Administrative Agent May File Proofs of Claim .......................................................... 8890 9.10 Recovery of Erroneous Payments ................................................................................. 8991 9.11 Guaranty Matters .......................................................................................................... 8991 Article X MISCELLANEOUS ................................................................................................ 8992 10.01 Amendments, Etc. ......................................................................................................... 8992 10.02 Notices; Effectiveness; Electronic Communication ..................................................... 9295 10.03 No Waiver; Cumulative Remedies ............................................................................... 9497 10.04 Expenses; Indemnity; Damage Waiver ......................................................................... 9597 10.05 Payments Set Aside ...................................................................................................... 9799 10.06 Successors and Assigns .............................................................................................. 97100 10.07 Treatment of Certain Information; Confidentiality ................................................... 101103 10.08 Right of Setoff .......................................................................................................... 102105 10.09 Interest Rate Limitation ............................................................................................ 102105 10.10 Integration; Effectiveness ......................................................................................... 103105 10.11 Survival of Representations and Warranties ............................................................. 103105 10.12 Severability ............................................................................................................... 103106 10.13 Replacement of Lenders ........................................................................................... 103106 10.14 Governing Law; Jurisdiction; Etc. ............................................................................ 104107 10.15 Waiver of Jury Trial .................................................................................................. 105108 10.16 No Advisory or Fiduciary Responsibility ................................................................. 105108 10.17 USA Patriot Act and Beneficial Ownership Regulation Notice ............................... 106108 10.18 Delivery of Signature Page ....................................................................................... 106109 10.19 Judgment Currency ................................................................................................... 106109 10.20 Acknowledgement and Consent to Bail-In of Affected Financial Institutions ......... 107109 10.21 Electronic Execution; Electronic Records; Counterparts .......................................... 107110 10.22 [Reserved] ................................................................................................................. 108110 10.23 Lender Representations ............................................................................................. 108110


 
iv 10.24 Acknowledgement Regarding Any Supported QFCs ............................................... 109111 10.25 Cashless Settlement .................................................................................................. 110112 10.26 Appointment of Borrower ......................................................................................... 110112 10.27 Keepwell ................................................................................................................... 110113 Article XI CONTINUING GUARANTY ............................................................................. 110113 11.01 Guaranty.................................................................................................................... 110113 11.02 Rights of Lenders ...................................................................................................... 111114 11.03 Certain Waivers ........................................................................................................ 111114 11.04 Obligations Independent ........................................................................................... 112114 11.05 Subrogation ............................................................................................................... 112114 11.06 Termination; Reinstatement ...................................................................................... 112115 11.07 Stay of Acceleration .................................................................................................. 112115 11.08 Condition of Borrower .............................................................................................. 112115 Article XII SUBSIDIARY GUARANTOR CONTINUING GUARANTY .......................... 113115 12.01 Guaranty.................................................................................................................... 113115 12.02 Rights of Lenders ...................................................................................................... 113116 12.03 Certain Waivers ........................................................................................................ 113116 12.04 Obligations Independent ........................................................................................... 114117 12.05 Subrogation ............................................................................................................... 114117 12.06 Termination; Reinstatement ...................................................................................... 114117 12.07 Stay of Acceleration .................................................................................................. 115117 12.08 Condition of Borrower .............................................................................................. 115117 12.09 Subordination ............................................................................................................ 115118 12.10 Release of Subsidiary Guarantors ............................................................................. 115118


 
v SCHEDULES 2.01 Commitments and Applicable Percentages 7.09 Burdensome Agreements 10.02 Administrative Agent’s Office; Certain Addresses for Notices EXHIBITS Form of A Committed Loan Notice B [Reserved] C [Reserved] D-1 Term A-1 Note D-2 Term A-2 Note D-3 Term A-3 Note D-4 Term A-4 Note D-5 Term A-5 Note E Compliance Certificate F Assignment and Assumption G Sustainability Metric Annual Certificate


 
TERM LOAN AGREEMENT This TERM LOAN AGREEMENT, dated as of August 22, 2022 (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”), among HEALTHPEAK OP, LLC, a Maryland limited liability company, HEALTHPEAK PROPERTIES, INC., a Maryland corporation, the lending institutions party hereto from time to time (each, a “Lender” and collectively, the “Lenders”), BANK OF AMERICA, N.A., as Administrative Agent, WELLS FARGO BANK, NATIONAL ASSOCIATION, PNC BANK, NATIONAL ASSOCIATION, THE BANK OF NOVA SCOTIA, TRUIST BANK, BARCLAYS BANK PLC, KEYBANK NATIONAL ASSOCIATION, MORGAN STANLEY SENIOR FUNDING, INC. and JPMORGAN CHASE BANK, N.A., as Co-Syndication Agents, and MIZUHO BANK, LTD., REGIONS BANK, CREDIT AGRICOLE CORPORATE AND INVESTMENT BANK, JPMORGAN CHASE BANK, N.A., PNC BANK, NATIONAL ASSOCIATION, ROYAL BANK OF CANADA, TRUIST BANK, U.S. BANK NATIONAL ASSOCIATION, WELLS FARGO BANK, NATIONAL ASSOCIATION, TD BANK, N.A., BARCLAYS BANK PLC, GOLDMAN SACHS BANK USA and MORGAN STANLEY SENIOR FUNDING, INC., as Co-Documentation Agents. WHEREAS, the Borrower has requested that the Lenders provide threefour delayed-draw term loan facilities pursuant to the terms of this Agreement, and the Lenders are willing to do so on the terms and conditions set forth herein. NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained, the parties hereto covenant and agree as follows: ARTICLE I DEFINITIONS AND ACCOUNTING TERMS 1.01 Defined Terms. As used in this Agreement, the following terms shall have the meanings set forth below: “2024 Credit Agreement” means that certain Third Amended and Restated Credit Agreement, dated as of December 9, 2024, among the Borrower, the Guarantor Parties, Bank of America, N.A., as administrative agent, and the lenders and other agents party thereto. “2021 Credit Agreement” means that certain Second Amended and Restated Credit Agreement, dated as of September 20, 2021, among the Borrower, Bank of America, N.A., as administrative agent, L/C issuer and alternative currency fronting lender, and the lenders and other agents party thereto. “Administrative Agent” means Bank of America in its capacity as administrative agent under any of the Loan Documents, or any successor administrative agent. “Administrative Agent’s Office” means the Administrative Agent’s address and, as appropriate, account as set forth on Schedule 10.02, or such other address or account as the Administrative Agent may from time to time notify to the Borrower and the Lenders. “Administrative Questionnaire” means an Administrative Questionnaire in a form supplied by the Administrative Agent. “Affected Financial Institution” means (a) any EEA Financial Institution, or (b) any UK Financial Institution.


 
2 “Affected Loan” has the meaning specified in Section 3.02. “Affiliate” means, with respect to any Person, another Person that directly, or indirectly through one or more intermediaries, Controls or is Controlled by or is under common Control with the Person specified. “Agent Parties” has the meaning specified in Section 10.02(c). “Agents” means the Administrative Agent, the Arrangers, the Co-Syndication Agents and, the Co-Documentation Agents and the Senior Managing Agents. “Aggregate Commitments” means, at any date of determination, the sum of the Aggregate Term A-1 Commitments, the Aggregate Term A-2 Commitments, the Aggregate Term A-3 Commitments and, the Aggregate Term A-4 Commitments and the Aggregate Term A-5 Commitments on such date. “Aggregate Term A-1 Commitments” means the Term A-1 Commitments of all Term A-1 Lenders, which as of the Closing Date are $250,000,000, which may be increased pursuant to Section 2.16 or decreased pursuant to Section 2.07. “Aggregate Term A-2 Commitments” means the Term A-2 Commitments of all Term A-2 Lenders, which as of the Closing Date are $250,000,000, which may be increased pursuant to Section 2.16 or decreased pursuant to Section 2.07. “Aggregate Term A-3 Commitments” means the Term A-3 Commitments of all Term A-3 Lenders, which as of the Second Amendment Effective Date are $750,000,000, which may be increased pursuant to Section 2.16 or decreased pursuant to Section 2.07. “Aggregate Term A-4 Commitments” means the Term A-4 Commitments of all Term A-4 Lenders, which as of the Fifth Amendment Effective Date are $400,000,000, which may be increased pursuant to Section 2.16 or decreased pursuant to Section 2.07. “Aggregate Term A-5 Commitments” means the Term A-5 Commitments of all Term A-5 Lenders, which as of the Sixth Amendment Effective Date are $500,000,000, which may be increased pursuant to Section 2.16 or decreased pursuant to Section 2.07. “Agreement” has the meaning specified in the introductory paragraph hereto. “Agreement Currency” has the meaning specified in Section 10.19. “Anti-Corruption Laws” has the meaning specified in Section 5.21. “Applicable Percentage” means (a) with respect to the Term A-1 Facility for each Term A-1 Lender at any time, subject to adjustment as provided in Section 2.18, a fraction (expressed as a percentage, carried out to the ninth decimal place) of the Term A-1 Facility represented by (i) at any time during the Availability Period in respect of such Term A-1 Facility, the aggregate amount of such Term A-1 Lender’s unused Term A-1 Commitment at such time plus the aggregate outstanding principal amount of such Term A-1 Lender’s Term A-1 Loans at such time, and (ii) thereafter, the aggregate outstanding principal amount of such Term A-1 Lender’s Term A-1 Loans at such time; (b) with respect to the Term A-2 Facility for each Term A-2 Lender at any time, subject to adjustment as provided in Section 2.18, a fraction (expressed as a percentage, carried out to the ninth decimal place) of the Term A-2 Facility represented by (i) at any time during the Availability Period in respect of such Term A-2 Facility, the aggregate amount of


 
3 such Term A-2 Lender’s unused Term A-2 Commitment at such time plus the aggregate outstanding principal amount of such Term A-2 Lender’s Term A-2 Loans at such time and (ii) thereafter, the aggregate outstanding principal amount of such Term A-2 Lender’s Term A-2 Loans at such time; (c) with respect to the Term A-3 Facility for each Term A-3 Lender at any time, subject to adjustment as provided in Section 2.18, a fraction (expressed as a percentage, carried out to the ninth decimal place) of the Term A-3 Facility represented by (i) on the Second Amendment Effective Date, the aggregate amount of such Term A-3 Lender’s Term A-3 Commitment in effect at such time, and (ii) thereafter, the aggregate outstanding principal amount of such Term A-3 Lender’s Term A-3 Loans at such time; (d) with respect to the Term A-4 Facility for each Term A-4 Lender at any time, subject to adjustment as provided in Section 2.18, a fraction (expressed as a percentage, carried out to the ninth decimal place) of the Term A-4 Facility represented by (i) at any time during the Availability Period in respect of such Term A-4 Facility, the aggregate amount of such Term A-4 Lender’s unused Term A-4 Commitment at such time plus the aggregate outstanding principal amount of such Term A-4 Lender’s Term A-4 Loans at such time and (ii) thereafter, the aggregate outstanding principal amount of such Term A-4 Lender’s Term A-4 Loans at such time; and (e) with respect to the Term A-5 Facility for each Term A-5 Lender at any time, subject to adjustment as provided in Section 2.18, a fraction (expressed as a percentage, carried out to the ninth decimal place) of the Term A-5 Facility represented by (i) at any time during the Availability Period in respect of such Term A-5 Facility, the aggregate amount of such Term A-5 Lender’s unused Term A-5 Commitment at such time plus the aggregate outstanding principal amount of such Term A-5 Lender’s Term A-5 Loans at such time and (ii) thereafter, the aggregate outstanding principal amount of such Term A-5 Lender’s Term A-5 Loans at such time; and (f) with respect to any Incremental Term Loan Facility for each Lender thereunder at any time, subject to adjustment as provided in Section 2.18, a fraction (expressed as a percentage, carried out to the ninth decimal place) of such Incremental Term Loan Facility represented by (i) on or prior to the applicable Increase Effective Date, such Lender’s allocated portion of such Incremental Term Loan Facility, and (ii) thereafter, the aggregate outstanding principal amount of such Lender’s Incremental Term Loans under such Incremental Term Loan Facility at such time. The Applicable Percentages of each Lender under the applicable Term Facility or Term Facilities as of the Closing Date are set forth opposite the name of such Lender on Schedule 2.01 or in the Assignment and Assumption or the New Lender Joinder Agreement pursuant to which such Lender becomes a party hereto, as applicable. “Applicable Rate” means, for any Term Loan, from time to time, the number of basis points per annum set forth in the relevant columns of the following table based upon the Debt Rating as set forth immediately below: Pricing Level Debt Ratings (S&P/Moody’s/Fitch) Applicable Rate for Term SOFR Loans (other than under the Term A-4 Facility and the Term A-5 Facility) and, solely with respect to the Term A-3 Facility, Daily SOFR Loans Applicable Rate for Term SOFR Loans and Daily SOFR Loans under the Term A-4 Facility and the Term A-5 Facility Applicable Rate for Base Rate Loans (other than under the Term A- 4 Facility and the Term A-5 Facility) Applicable Rate for Base Rate Loans under the Term A- 4 Facility and the Term A-5 Facility 1 ≥A / ≥A2 / ≥A 75.0 bps 70.0 bps 0 bps 0 bps 2 A- / A3 / A- 80.0 bps 75.0 bps 0 bps 0 bps 3 BBB+ / Baa1 / BBB+ 85.0 bps 80.0 bps 0 bps 0 bps


 
4 Pricing Level Debt Ratings (S&P/Moody’s/Fitch) Applicable Rate for Term SOFR Loans (other than under the Term A-4 Facility and the Term A-5 Facility) and, solely with respect to the Term A-3 Facility, Daily SOFR Loans Applicable Rate for Term SOFR Loans and Daily SOFR Loans under the Term A-4 Facility and the Term A-5 Facility Applicable Rate for Base Rate Loans (other than under the Term A- 4 Facility and the Term A-5 Facility) Applicable Rate for Base Rate Loans under the Term A- 4 Facility and the Term A-5 Facility 4 BBB / Baa2 / BBB 95.0 bps 90.0 bps 0 bps 0 bps 5 BBB- / Baa3 / BBB- 120.0 bps 115.0 bps 20.0 bps 15.0 bps 6 <BBB- / <Baa3 / <BBB- or non-rated 160.0 bps 155.0 bps 60.0 bps 55.0 bps For purposes hereof, the term “Debt Rating” means, as of any date of determination, the rating by S&P, Moody’s or Fitch of the Borrower’s non-credit enhanced, senior unsecured long-term debt; provided that, if at any time when the Borrower has only two (2) Debt Ratings, and such Debt Ratings are split, then: (A) if the difference between such Debt Ratings is one ratings category (e.g., Baa2 by Moody’s and BBB- by S&P or Fitch), the Applicable Rate shall be the rate per annum that would be applicable if the higher of the Debt Ratings were used, and (B) if the difference between such Debt Ratings is two or more ratings categories (e.g., Baa1 by Moody’s and BBB- by S&P or Fitch), the Applicable Rate shall be the rate per annum that would be applicable if the median of the applicable Debt Ratings were used. If at any time when the Borrower has three (3) Debt Ratings, and such Debt Ratings are split, then: (A) if the difference between the highest and the lowest such Debt Ratings is one ratings category (e.g., Baa2 by Moody’s and BBB- by S&P or Fitch), the Applicable Rate shall be the rate per annum that would be applicable if the highest of the Debt Ratings were used, and (B) if the difference between such Debt Ratings is two or more ratings categories (e.g., Baa1 by Moody’s and BBB- by S&P or Fitch), the Applicable Rate shall be the rate per annum that would be applicable if the average of the two (2) highest Debt Ratings were used; provided that, if such average is not a recognized rating category, then the Applicable Rate shall be the rate per annum that would be applicable if the second highest Debt Rating of the three were used. Initially, the Applicable Rate shall be determined based upon the Debt Rating specified in the certificate delivered pursuant to Section 4.01(a)(vi) (or, in the case of (x) Term A-3 Loans, delivered as of the Second Amendment Effective Date pursuant to the Second Amendment and, (y) Term A-4 Loans, delivered as of the Fifth Amendment Effective Date pursuant to the Fifth Amendment and (z) Term A-5 Loans, delivered as of the Sixth Amendment Effective Date pursuant to the Sixth Amendment). Thereafter, each change in the Applicable Rate shall occur on the first Business Day following the effective change in the Debt Rating. Solely with respect to the Term A-1 Facility and the Term A-2 Facility, notwithstanding the foregoing, with respect to any calendar year ending on or after December 31, 2022, if the Borrower delivers a Sustainability Metric Annual Certificate to the Administrative Agent, certifying that the Sustainability Metric as of December 31 of the most recently ended calendar year (the “Specified Test Year”) satisfies the Sustainability Metric Election Threshold for such Specified Test Year, and electing that the Applicable Rate instead be based on the table set forth below (the “Sustainability Metric Pricing Grid”), then the Applicable Rate with respect to each Facility shall be determined based on the relevant columns of the


 
5 Sustainability Metric Pricing Grid for the period commencing on the fifth (5th) Business Day following the date such Sustainability Metric Annual Certificate is delivered to the Administrative Agent by the Borrower until the earlier to occur of (i) the date that is one (1) year after the date the Sustainability Metric Pricing Grid became effective for such period in connection with the delivery of such Sustainability Metric Annual Certificate and (ii) the date that is the fifth (5th) Business Day following the date of delivery by the Borrower of the Sustainability Metric Annual Certificate for the calendar year ending immediately after such Specified Test Year, which subsequent Sustainability Metric Annual Certificate indicates that (A) the Sustainability Metric for the calendar year ending immediately after such Specified Test Year did not satisfy the Sustainability Metric Election Threshold or (B) the Borrower does not elect to apply the Sustainability Metric Pricing Grid for the calendar year ending immediately after such Specified Test Year; provided that it is understood and agreed that (x) if the Sustainability Metric for any calendar year does not satisfy the Sustainability Metric Election Threshold, the Borrower shall not be restricted from making any subsequent election to apply the Sustainability Metric Pricing Grid pursuant to this paragraph if the Sustainability Metric for the calendar year most recently ended prior to such election satisfies the Sustainability Metric Election Threshold, and (y) a Sustainability Metric Annual Certificate electing to apply the Sustainability Metric Pricing Grid pursuant to this paragraph may be delivered at any time by the Borrower so long as the Sustainability Metric for the calendar year most recently ended prior to such election satisfies the Sustainability Metric Election Threshold. If, as a result of (A) the agreement by the Borrower, the Administrative Agent and the Lenders that the Sustainability Metric for any calendar year as reported on any Sustainability Metric Annual Certificate was inaccurate or (B) the Borrower, the Administrative Agent or the Lenders becoming aware of any material inaccuracy in the Sustainability Metric for any calendar year as reported on any Sustainability Metric Annual Certificate (and, in the case of the Administrative Agent or the Lenders becoming aware thereof, written notice thereof has been delivered to the Borrower setting forth in reasonable detail the basis for such determination) (any such event referred to in clause (A) or (B) above, a “Sustainability Metric Annual Certificate Inaccuracy”) and, in each case, the Borrower made an election to apply the Sustainability Metric Pricing Grid pursuant to such Sustainability Metric Annual Certificate and a proper calculation of the Sustainability Metric for such calendar year would not have resulted in any adjustment, or would have resulted in a smaller adjustment, to the Applicable Rate pursuant to the Sustainability Metric Pricing Grid for the relevant period covered by such election, then the Borrower shall immediately and retroactively be obligated to pay to the Administrative Agent for the account of the applicable Lenders promptly (and in any event, within five (5) Business Days) following written demand by the Administrative Agent (or, after the occurrence of an actual or deemed entry of an order for relief with respect to the Borrower under the Bankruptcy Code, immediately, automatically and without further action by the Administrative Agent or any Lender), an amount equal to the excess of the amount of interest that should have been paid for such period (or relevant portion thereof then elapsed in respect of which payments of interest were previously made) over the amount of interest actually paid for such period (or relevant portion thereof). Notwithstanding anything to the contrary herein, unless such amounts shall be due upon the occurrence of an actual or deemed entry of an order for relief with respect to the Borrower under the Bankruptcy Code, (i) any additional amounts required to be paid pursuant to the immediately preceding sentence shall not be due and payable until a written demand is made for such payment by the Administrative Agent, (ii) any nonpayment of such additional amounts prior to or upon such demand for payment by Administrative Agent shall not, whether retroactively or otherwise, (x) constitute a Default or Event of Default or (y) otherwise result in the failure to satisfy any condition precedent to any Credit Extension, a Maturity Date extension pursuant to Section 2.15, or an Increase Effective Date pursuant to Section 2.16, and (iii) none of such additional amounts shall be deemed overdue prior to such a demand or shall accrue interest at the Default Rate prior to such a demand. It is understood and agreed that no Sustainability Metric Annual Certificate Inaccuracy shall, whether retroactively or otherwise, (x) constitute a Default or Event of Default or (y) otherwise result in the failure to satisfy any condition precedent to any Credit Extension, a Maturity Date extension pursuant to Section 2.15, or an Increase Effective Date pursuant to Section 2.16; provided


 
6 that the Borrower complies with the terms of this paragraph with respect to such Sustainability Metric Annual Certificate Inaccuracy. Sustainability Metric Pricing Grid Pricing Level Debt Ratings (S&P/Moody’s/Fitch) Applicable Rate for Term SOFR Loans Applicable Rate for Base Rate Loans 1 ≥A / ≥A2 / ≥A 74.0 bps 0 bps 2 A- / A3 / A- 79.0 bps 0 bps 3 BBB+ / Baa1 / BBB+ 84.0 bps 0 bps 4 BBB / Baa2 / BBB 94.0 bps 0 bps 5 BBB- / Baa3 / BBB- 119.0 bps 19.0 bps 6 <BBB- / <Baa3 / <BBB- or non-rated 159.0 bps 59.0 bps “Approved Fund” means any Fund that is administered or managed by (a) a Lender, (b) an Affiliate of a Lender or (c) an entity or an Affiliate of an entity that administers or manages a Lender. “Arrangers” means each institution identified as a “Joint Lead Arranger” or a “Joint Bookrunner” on the cover pages to this Agreement (solely with respect to the applicable Term Facility), and to the extent for which such institution is so identified on the cover pages to this Agreement. “Assignee Group” means two or more Eligible Assignees that are Affiliates of one another or two or more Approved Funds managed by the same investment advisor. “Assignment and Assumption” means an assignment and assumption entered into by a Lender and an Eligible Assignee (with the consent of any party whose consent is required by Section 10.06(b)), and accepted by the Administrative Agent, in substantially the form of Exhibit F or any other form (including electronic documentation generated by use of an electronic platform) approved by the Administrative Agent. “Attributable Indebtedness” means, on any date, (a) in respect of any Financing Lease of any Person, the capitalized amount thereof that would appear on a balance sheet of such Person prepared as of such date in accordance with GAAP, and (b) in respect of any Synthetic Lease Obligation, the capitalized amount of the remaining lease payments under the relevant lease that would appear on a balance sheet of such Person prepared as of such date in accordance with GAAP if such lease were accounted for as a Financing Lease. “Audited Financial Statements” means the audited consolidated balance sheet of the Parent Guarantor and its Subsidiaries for the fiscal year ended December 31, 2023, and the related consolidated statements of income or operations, shareholders’ equity and cash flows for such fiscal year of the Parent Guarantor and its Subsidiaries, including the notes thereto.


 
7 “Availability Period” means (a) in respect of the Term A-1 Facility, the period from and including the Closing Date to and including the earlier of (i) February 17, 2023, and (ii) the date of termination of the Aggregate Commitments pursuant to Section 8.02; (b) in respect of the Term A-2 Facility, the period from and including the Closing Date to and including the earlier of (i) February 17, 2023, and (ii) the date of termination of the Aggregate Commitments pursuant to Section 8.02; and (c) in respect of the Term A-4 Facility, the period from and including the Fifth Amendment Effective Date to and including the earlier of (i) December 18, 2026, and (ii) the date of termination of the Aggregate Commitments pursuant to Section 8.02.; and (d) in respect of the Term A-5 Facility, the period from and including the Sixth Amendment Effective Date to and including the earlier of (i) July 23, 2027, and (ii) the date of termination of the Aggregate Commitments pursuant to Section 8.02. “Bail-In Action” means the exercise of any Write-Down and Conversion Powers by the applicable Resolution Authority in respect of any liability of an Affected Financial Institution. “Bail-In Legislation” means, (a) with respect to any EEA Member Country implementing Article 55 of Directive 2014/59/EU of the European Parliament and of the Council of the European Union, the implementing law, rule, regulation or requirement for such EEA Member Country from time to time which is described in the EU Bail-In Legislation Schedule, and (b) with respect to the United Kingdom, Part I of the United Kingdom Banking Act 2009 (as amended from time to time) and any other law, regulation or rule applicable in the United Kingdom relating to the resolution of unsound or failing banks, investment firms or other financial institutions or their affiliates (other than through liquidation, administration or other insolvency proceedings). “Bank of America” means Bank of America, N.A. and its successors. “Bankruptcy Code” means the Bankruptcy Reform Act of 1978, as heretofore and hereafter amended, as codified at 11 U.S.C. § 101 et seq., and the rules and regulations promulgated thereunder, or any successor provision thereto. “Base Rate” means for any day a fluctuating rate of interest per annum equal to the highest of (a) the Federal Funds Rate plus ½ of 1%, (b) the rate of interest in effect for such day as publicly announced from time to time by Bank of America as its “prime rate,” (c) Term SOFR (as defined in clause (b) of the definition thereof) plus 1% and (d) 1.00%. The “prime rate” is a rate set by Bank of America based upon various factors including Bank of America’s costs and desired return, general economic conditions and other factors, and is used as a reference point for pricing some loans, which may be priced at, above, or below such announced rate. Any change in such prime rate announced by Bank of America shall take effect at the opening of business on the day specified in the public announcement of such change. If at any time of determination, the Base Rate is being used as an alternate rate of interest pursuant to Section 3.03 hereof, then the Base Rate at such time shall be the greater of clauses (a), (b) and (d) above and shall be determined without reference to clause (c) above. “Base Rate Loan” means a Loan that bears interest based on the Base Rate. All Base Rate Loans shall be denominated in Dollars. “Beneficial Ownership Certification” means a certification regarding beneficial ownership required by the Beneficial Ownership Regulation. “Beneficial Ownership Regulation” means 31 C.F.R. § 1010.230. “Benefit Plan” means any of (a) an “employee benefit plan” (as defined in ERISA) that is subject to Title I of ERISA, (b) a “plan” as defined in and subject to Section 4975 of the Code or (c) any Person


 
8 whose assets include (for purposes of ERISA Section 3(42) or otherwise for purposes of Title I of ERISA or Section 4975 of the Code) the assets of any such “employee benefit plan” or “plan.” “Borrower” means Healthpeak OP, LLC, a Maryland limited liability company. “Borrower Materials” has the meaning specified in Section 6.02. “Borrowing” means (a) a Committed Borrowing or (b) a borrowing consisting of simultaneous Incremental Term Loans of a specific tranche of the same Type, of the same Class, and, in the case of Term SOFR Loans, having the same Interest Period made by each of the Lenders of such Class pursuant to Section 2.16, as the context may require. “Borrowing Date” means, with respect to any Term Loan, any date on or after the Closing Date on which the applicable conditions set forth in Article IV are satisfied or waived and any Term Loans are made to the Borrower pursuant to Section 2.01, which day shall be a Business Day occurring during the Availability Period for the applicable Term Facility. “Boundary Property” means any building that is part of the Borrower’s portfolio of assets under management and that the Borrower identifies internally as under the Borrower’s operational control. For purposes of this definition, such operational control shall mean that the Borrower or any of its Controlled Subsidiaries maintains, provides service to, and/or has the authority to implement operating policies with respect to energy usage, water usage and/or waste disposal, in any such case, for all or any portion of such building. Any reference herein to the square footage of a Boundary Property shall be a reference to the proportional percentage of total square footage of such Boundary Property that is under the Borrower’s operational control with respect to such Boundary Property. “Business Day” means any day other than a Saturday, Sunday or other day on which commercial banks are authorized to close under the Laws of, or are in fact closed in, the State of California or the State of New York or the state where the Administrative Agent’s Office is located. “Change in Law” means the occurrence, after the Closing Date, and with respect to any Person in particular, after the date such Person becomes a party to this Agreement, of any of the following: (a) the adoption or taking effect of any law, rule, regulation or treaty, (b) any change in any law, rule, regulation or treaty or in the administration, interpretation, implementation or application thereof by any Governmental Authority or (c) the making or issuance of any request, rule, guideline or directive (whether or not having the force of law) by any Governmental Authority; provided that notwithstanding anything herein to the contrary, (x) the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines or directives thereunder or issued in connection therewith or in the implementation thereof and (y) all requests, rules, guidelines or directives promulgated by the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the United States or foreign regulatory authorities, in each case pursuant to Basel III, shall in each case be deemed to be a “Change in Law,” regardless of the date enacted, adopted, issued or implemented. “Change of Control” means an event or series of events by which: (a) any “person” or “group” (as such terms are used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, but excluding any employee benefit plan of such person or its subsidiaries, and any person or entity acting in its capacity as trustee, agent or other fiduciary or administrator of any such plan) becomes the “beneficial owner” (as defined in Rules 13d-3 and 13d-5 under the Securities Exchange Act of 1934, except that a person or group shall be deemed to


 
9 have “beneficial ownership” of all securities that such person or group has the right to acquire, whether such right is exercisable immediately or only after the passage of time (such right, an “option right”)), directly or indirectly, of thirty-five percent (35%) or more of the equity securities of the Parent Guarantor (which equity securities have ordinary voting powers to elect a majority of the members of the board of directors or equivalent governing body of the Parent Guarantor (irrespective of whether at such time stock of any other class or classes shall have or might have voting power by reason of the happening of any contingency)) on a fully-diluted basis (and taking into account all such securities that such person or group has the right to acquire pursuant to any option right) and the Borrower shall not have repaid all of the outstanding Obligations in full in cash (other than contingent Obligations that are not then due and payable) and terminated the Aggregate Commitments within forty-five (45) days after such “person” or “group” shall have become the “beneficial owner” of such percentage of such stock; (b) during any period of twelve (12) consecutive months, a majority of the members of the board of directors or other equivalent governing body of the Parent Guarantor cease to be composed of individuals (i) who were members of that board or equivalent governing body on the first day of such period, (ii) whose election or nomination to that board or equivalent governing body was approved or recommended by individuals referred to in clause (i) above constituting at the time of such election or nomination at least a majority of that board or equivalent governing body or (iii) whose election or nomination to that board or other equivalent governing body was approved or recommended by individuals referred to in clauses (i) and (ii) above constituting at the time of such election or nomination at least a majority of that board or equivalent governing body; or (c) the Parent Guarantor shall, at any time, cease to Control the Borrower. “Class” (a) when used with respect to any Loan or Borrowing, refers to whether such Loan, or the Loans comprising such Borrowing, are Committed Term A-1 Loans, Committed Term A-2 Loans, Committed Term A-3 Loans, Committed Term A-4 Loans, Committed Term A-5 Loans or a specific tranche of Incremental Term Loans, (b) when used with respect to any Lender, refers to whether such Lender has any (i) Term A-1 Commitment or Term A-1 Loan, (ii) Term A-2 Commitment or Term A-2 Loan, (iii) Term A-3 Commitment or Term A-3 Loan, (iv) Term A-4 Commitment or Term A-4 Loan or, (v) Term A-5 Commitment or Term A-5 Loan or (vi) Incremental Term Loan of a specific tranche or commitment to make an Incremental Term Loan of a specific tranche, and (c) when used with respect to any Commitment, refers to whether such Commitment is a Term A-1 Commitment, a Term A-2 Commitment, a Term A-3 Commitment, a Term A-4 Commitment, a Term A-5 Commitment or a commitment to make an Incremental Term Loan of a specific tranche. “Closing Date” means the first date all the conditions precedent in Section 4.01 are satisfied or waived in accordance with Section 10.01. “CME” means CME Group Benchmark Administration Limited. “Co-Documentation Agent” means (a) with respect to the Term A-1 Facility and the Term A-2 Facility, each of Mizuho Bank, Ltd., Regions Bank, and Toronto-Dominion Bank, (b) with respect to the Term A-3 Facility each of Credit Agricole Corporate and Investment Bank, JPMorgan Chase Bank, N.A., Mizuho Bank, Ltd., PNC Bank, National Association, Royal Bank of Canada, TD Bank, N.A., Truist Bank, U.S. Bank National Association and Wells Fargo Bank, National Association, and (c) with respect to the Term A-4 Facility, Barclays Bank PLC, Goldman Sachs Bank USA, Morgan Stanley Senior Funding, Inc. and Royal Bank of Canada, in each case, in their capacities as Co-Documentation Agents.


 
10 “Co-Syndication Agent” means each of Wells Fargo, PNC Bank, National Association, The Bank of Nova Scotia, Truist Bank, Barclays Bank PLC, KeyBank National Association and Morgan Stanley Senior Funding, Inc., in their capacities as Co-Syndication Agents. “Code” means the Internal Revenue Code of 1986, as amended. “Commitment” means a Term A-1 Commitment, a Term A-2 Commitment, a Term A-3 Commitment or, a Term A-4 Commitment or a Term A-5 Commitment, as the context may require. “Committed Borrowing” means a borrowing consisting of simultaneous Committed Loans of the same Type, of the same Class, and, in the case of Term SOFR Loans, having the same Interest Period made by each of the Lenders of such Class pursuant to Section 2.01. “Committed Loan” means a Committed Term A-1 Loan, a Committed Term A-2 Loan, a Committed Term A-3 Loan or, a Committed Term A-4 Loan or a Committed Term A-5 Loan, as the context may require. “Committed Loan Notice” means a notice from the Borrower to the Administrative Agent of (a) a Borrowing, (b) a conversion of Loans of the same Class from one Type to another Type, or (c) a continuation of Term SOFR Loans, pursuant to Section 2.02(a), which, if in writing, shall be substantially in the form of Exhibit A or such other form as may be approved by the Administrative Agent (including any form on an electronic platform or electronic transmission system as shall be approved by the Administrative Agent), appropriately completed and signed by a Responsible Officer of the Borrower. “Committed Term A-1 Loan” has the meaning specified in Section 2.01(a). “Committed Term A-2 Loan” has the meaning specified in Section 2.01(b). “Committed Term A-3 Loan” has the meaning specified in Section 2.01(c). “Committed Term A-4 Loan” has the meaning specified in Section 2.01(d). “Committed Term A-5 Loan” has the meaning specified in Section 2.01(e). “Communication” means this Agreement, any other Loan Document and any document, amendment, approval, consent, information, notice, certificate, request, statement, disclosure or authorization related to any Loan Document. “Compliance Certificate” means a certificate substantially in the form of Exhibit E. “Conforming Changes” means, with respect to the use, administration of or any conventions associated with SOFR or any proposed Successor Rate or Term SOFR, as applicable, any conforming changes to the definitions of “Base Rate,” “Daily SOFR,” “Daily Simple SOFR,” “SOFR,” “Term SOFR,” “Term SOFR Screen Rate,” and “Interest Period,” timing and frequency of determining rates and making payments of interest and other technical, administrative or operational matters (including, for the avoidance of doubt, the definitions of “Business Day” and “U.S. Government Securities Business Day,” timing of borrowing requests or prepayment, conversion or continuation notices, and the applicability and length of lookback periods) as may be appropriate, in the discretion of the Administrative Agent (after consultation in good faith with the Borrower), to reflect the adoption and implementation of such applicable rate(s) and to permit the use and administration thereof by the Administrative Agent in a manner substantially consistent with market practice (or, if the Administrative Agent determines that adoption of any portion of


 
11 such market practice is not administratively feasible or that no market practice for the administration of such rate exists, in such other manner of administration as the Administrative Agent (after consultation in good faith with the Borrower) determines is reasonably necessary in connection with the administration of this Agreement and any other Loan Document). “Consolidated Intangible Assets” means, as of any date of determination, an amount equal to the Intangible Assets of the Group on a consolidated basis. “Consolidated Shareholders’ Equity” means, as of any date of determination, consolidated shareholders’ equity of the Group, as determined in accordance with GAAP. “Consolidated Tangible Net Worth” means, as of any date of determination, for the Group on a consolidated basis, an amount equal to (a) Consolidated Shareholders’ Equity on such date plus (b) accumulated depreciation and amortization, determined on a consolidated basis in accordance with GAAP, on such date, minus (c) Consolidated Intangible Assets on such date. “Contractual Obligation” means, as to any Person, any provision of any security issued by such Person or of any agreement, instrument or other undertaking to which such Person is a party or by which it or any of its property is bound. “Control” means the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of a Person, whether through the ability to exercise voting power, by contract or otherwise. “Controlling” and “Controlled” have meanings correlative thereto. “Covered Party” has the meaning specified in Section 10.24. “Credit Extension” means a Borrowing. “Daily Simple SOFR” means, with respect to any applicable determination date, SOFR published on such date on the Federal Reserve Bank of New York’s website (or any successor source). “Daily SOFR” means the rate per annum equal to SOFR determined for any day pursuant to the definition thereof. Any change in Daily SOFR shall be effective from and including the date of such change without further notice. If the rate as so determined would be less than 0.00%, such rate shall be deemed to be 0.00% for purposes of this Agreement. “Daily SOFR Loan” means a Term A-3 Loan or, a Term A-4 Loan or a Term A-5 Loan, as the context may require, in each case that bears interest at a rate based on Daily SOFR. “Debt Rating” has the meaning specified in the definition of “Applicable Rate.” “Debtor Relief Laws” means the Bankruptcy Code of the United States, and all other liquidation, conservatorship, bankruptcy, assignment for the benefit of creditors, moratorium, rearrangement, receivership, insolvency, reorganization, or similar debtor relief Laws of the United States or other applicable jurisdictions from time to time in effect and affecting the rights of creditors generally. “Default” means any event or condition that constitutes an Event of Default or that, with the giving of any notice, the passage of time, or both, would be an Event of Default. “Default Rate” means an interest rate equal to (i) the Base Rate plus (ii) the Applicable Rate, if any, applicable to Base Rate Loans plus (iii) 2% per annum; provided, however, that, with respect to a Daily


 
12 SOFR Loan or a Term SOFR Loan, the Default Rate shall be an interest rate equal to the interest rate (including any Applicable Rate) otherwise applicable to such Loan plus 2% per annum. “Defaulting Lender” means, subject to Section 2.18(b), any Lender that, as reasonably determined by the Administrative Agent, (a) has failed to (i) perform any of its funding obligations hereunder, including in respect of its Loans, within two (2) Business Days of the date required to be funded by it hereunder, unless such Lender notifies the Administrative Agent and the Borrower in writing that such failure is the result of such Lender’s good faith determination that a condition precedent to funding (each of which conditions precedent, together with any applicable default, shall be specifically identified in such writing) has not been satisfied or (ii) pay to the Administrative Agent or any other Lender any other amount required to be paid by it hereunder within two (2) Business Days of the date when due, (b) has notified the Borrower or the Administrative Agent that it does not intend to comply with its funding obligations or has made a public statement to that effect with respect to its funding obligations hereunder (unless such notice or public statement states that such position is based on such Lender’s good faith determination that a condition precedent (each of which conditions precedent, together with any applicable default, shall be specifically identified in such notice or public statement) to funding a Loan under this Agreement cannot be satisfied) or generally under other agreements in which it commits to extend credit, (c) has failed, within three (3) Business Days after written request by the Administrative Agent or the Borrower, to confirm in writing in a manner satisfactory to the Administrative Agent and the Borrower that it will comply with its funding obligations hereunder (provided that such Lender shall cease to be a Defaulting Lender pursuant to this clause (c) upon receipt of such written confirmation by the Administrative Agent and the Borrower), or (d) has, or has a direct or indirect parent company that has, (i) become the subject of a proceeding under any Debtor Relief Law, (ii) had a receiver, conservator, trustee, administrator, assignee for the benefit of creditors or similar Person charged with reorganization or liquidation of its business or assets or a custodian appointed for it, (iii) taken any action in furtherance of, or indicated its consent to, approval of or acquiescence in any such proceeding or appointment or (iv) become the subject of a Bail-In Action; provided that a Lender shall not be a Defaulting Lender solely by virtue of the ownership or acquisition of any equity interest in that Lender or any direct or indirect parent company thereof by a Governmental Authority so long as such ownership interest does not result in or provide such Lender with immunity from the jurisdiction of courts within the United States or from the enforcement of judgments or writs of attachment on its assets or permit such Lender (or such Governmental Authority) to reject, repudiate, disavow or disaffirm any contracts or agreements made with such Lender. Any determination by the Administrative Agent that a Lender is a Defaulting Lender under one or more of clauses (a) through (d) above, and of the effective date of such status, shall be conclusive and binding absent manifest error, and such Lender shall be deemed to be a Defaulting Lender (subject to Section 2.18(b)) as of the date established therefor by the Administrative Agent in a written notice of such determination, which shall be delivered by the Administrative Agent to the Borrower and each other Lender promptly following such determination. “Delaware Divided LLC” means any Delaware LLC that has been formed upon consummation of a Delaware LLC Division. “Delaware LLC” means any limited liability company organized or formed under the laws of the State of Delaware. “Delaware LLC Division” means the statutory division of any Delaware LLC into two or more Delaware LLCs pursuant to Section 18-217 of the Delaware Limited Liability Company Act. “Designated Jurisdiction” means any country, region or territory to the extent that such country, region or territory itself is the target of comprehensive Sanctions (as of the FifthSixth Amendment Effective Date, Cuba, Iran, North Korea, Syria, the Crimea, Zaporizhzhia and Kherson regions of Ukraine, the so-called Donetsk People’s Republic, and the so-called Luhansk People’s Republic).


 
13 “Development Property” means any real property in which the development and construction with respect thereto are not complete. “Disclosed Matters” means any event, circumstance, condition or other matter expressly disclosed in the reports and other documents furnished to or filed with the SEC by the Parent Guarantor, the Borrower or any of their Subsidiaries and that are publicly available on or prior to the FifthSixth Amendment Effective Date. “Disposition” or “Dispose” means the sale, transfer or assignment (including any sale and leaseback transaction) of any property by any Person, including any sale, assignment, transfer or other disposal, with or without recourse, of any notes or accounts receivable or any rights and claims associated therewith and including any disposition of property to a Delaware Divided LLC pursuant to a Delaware LLC Division, in any case other than sales or other dispositions of assets in the ordinary course of business. “DOC” means DOC DR Holdco, LLC, a Maryland limited liability company. “DOC OP” means DOC DR, LLC, a Maryland limited liability company. “DOC Credit Agreement” means that certain Third Amended and Restated Credit Agreement dated as of September 24, 2021 by and among DOC DR, LLC (as successor to Physicians Realty L.P.), as borrower, DOC DR Holdco, LLC (as successor to Physicians Realty Trust), as guarantor, the lenders party thereto and KeyBank National Association, as administrative agent (as amended by that certain First Amendment to Third Amended and Restated Credit Agreement dated as of March 31, 2023, as amended by that certain Second Amendment to Third Amended and Restated Credit Agreement dated as of May 24, 2023, as amended by that certain Consent and Third Amendment to Third Amended and Restated Credit Agreement dated as of February 21, 2024, as amended by that certain Fourth Amendment to Third Amended and Restated Credit Agreement, dated as of December 9, 2024, as amended by that certain Fifth Amendment to Third Amended and Restated Credit Agreement dated as of October 1, 2025, as amended by that certain Sixth Amendment to Third Amended and Restated Credit Agreement dated on or around March 23, 2026) and as may be further amended, restated, supplemented or otherwise modified and in effect from time to time. “DOC Debt” means, collectively, all obligations under the DOC Credit Agreement and the DOC Notes, together with any credit agreement(s) or other agreements, notes, offering memoranda, instruments or other documents evidencing indebtedness incurred to refinance or replace any of the foregoing. “DOC Notes” means those certain notes issued from time to time under that certain Senior Indenture, dated as of March 7, 2017 among DOC (as successor to Physicians Realty Trust, a Maryland real estate investment trust), DOC OP (as successor to Physicians Realty L.P., a Delaware limited partnership) and U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association), as trustee, as supplemented by that certain First Supplemental Indenture, dated as of March 7, 2017, that certain Second Supplemental Indenture, dated as of December 1, 2017, that certain Third Supplemental Indenture, dated as of October 13, 2021, that certain Fourth Supplemental Indenture, dated as of March 1, 2024 and as may be further as amended, supplemented, or otherwise modified from time to time. “Dollar” and “$” mean lawful money of the United States. “EBITDA” means, for any period, for a Person and its Subsidiaries on a consolidated basis, an amount equal to, without duplication, the Net Income of such Person and its Subsidiaries for such period plus (a) the following to the extent deducted in calculating such Net Income: (i) Interest Expense of such


 
14 Person and its Subsidiaries for such period, (ii) the provision for Federal, state, local and foreign taxes on or measured by income of such Person and its Subsidiaries for such period (whether or not payable during that period), (iii) depreciation and amortization expense for such period and (iv) expenses of such Person and its Subsidiaries reducing such Net Income during such period which do not represent a cash expenditure in such period or any prior or future period and minus (b) (i) all items of such Person and its Subsidiaries increasing Net Income for such period which do not represent a cash receipt in such period or any prior or future period and (ii) any addition to EBITDA pursuant to clause (a)(ii) above taken or payable during such period to the extent added to EBITDA in any prior or future period. “EEA Financial Institution” means (a) any credit institution or investment firm established in any EEA Member Country which is subject to the supervision of an EEA Resolution Authority, (b) any entity established in an EEA Member Country which is a parent of an institution described in clause (a) of this definition, or (c) any financial institution established in an EEA Member Country which is a Subsidiary of an institution described in clause (a) or (b) of this definition and is subject to consolidated supervision with its parent. “EEA Member Country” means any of the member states of the European Union, Iceland, Liechtenstein, and Norway. “EEA Resolution Authority” means any public administrative authority or any Person entrusted with public administrative authority of any EEA Member Country (including any delegee) having responsibility for the resolution of any EEA Financial Institution. “Electronic Copy” shall have the meaning specified in Section 10.21. “Electronic Record” and “Electronic Signature” shall have the meanings assigned to them, respectively, by 15 USC §7006, as it may be amended from time to time. “Eligible Assignee” means any Person that meets the requirements to be an assignee under Sections 10.06(b)(iii), (v), (vi) and (vii) (subject to such consents, if any, as may be required under Section 10.06(b)(iii)). “Enterprise EBITDA” means, for any period, the sum of (a) EBITDA of the Group on a consolidated basis for such period plus (b) without duplication, the Borrower’s Pro Rata Share of EBITDA of each Material Joint Venture for such period. “Enterprise Fixed Charges” means, for any period, with respect to the Group on a consolidated basis, the sum of, without duplication, (a) Enterprise Interest Expense paid in cash during such period plus (b) Scheduled Principal Payments during such period plus (c) cash dividends and distributions in respect of preferred stock of the Group during such period (but excluding (i) redemption payments or charges in connection with the redemption of preferred stock and (ii) amounts paid to the Parent Guarantor, the Borrower or any of their respective Subsidiaries); provided that Enterprise Fixed Charges shall not include (i) any amounts with respect to any Intercompany Indebtedness, (ii) gains and losses from unwinding or break-funding of Swap Contracts, (iii) write-offs of unamortized deferred financing fees, (iv) prepayment fees, premiums and penalties, and (v) other unusual or non-recurring items as are reasonably acceptable to the Administrative Agent and the Required Lenders. “Enterprise Gross Asset Value” means, as of any date of determination, the sum of (a) Gross Asset Value of the Group on a consolidated basis plus (b) without duplication, the Borrower’s Pro Rata Share of Gross Asset Value of each Material Joint Venture; provided that (i) without duplication, for purposes of calculating the Leverage Ratio, Enterprise Gross Asset Value shall not include the aggregate amount of


 
15 unrestricted cash and cash equivalents deducted in the calculation of Enterprise Total Indebtedness pursuant to the first proviso of the definition of “Enterprise Total Indebtedness”, and (ii) for purposes of any determination of Enterprise Gross Asset Value (x) to the extent the amount of Enterprise Gross Asset Value attributable to Joint Ventures would exceed 25% of Enterprise Gross Asset Value, such excess shall be excluded (it being understood and agreed, that for purposes of this clause (x) the Loan Parties’ Investment in any Joint Venture will be valued at book value as shown on the consolidated balance sheet of the Parent Guarantor, as determined in accordance with GAAP), and (y) to the extent the amount of Enterprise Gross Asset Value attributable to Development Properties would exceed 35% of Enterprise Gross Asset Value, such excess shall be excluded. “Enterprise Interest Expense” means, for any period, the sum of (a) Interest Expense of the Group on a consolidated basis for such period plus (b) without duplication, the Borrower’s Pro Rata Share of Interest Expense of each Material Joint Venture for such period. “Enterprise Secured Debt” means, as of any date of determination, that portion of Enterprise Total Indebtedness that is subject to a Lien (other than Permitted Specified Liens); provided that in no event shall the Obligations under the Janus Credit Agreement constitute “Enterprise Secured Debt” solely as a result of any security interest granted to the Administrative Agent thereunder or any L/C Issuer thereunder, solely in any Cash Collateral or any account or other property, including proceeds thereof, established for the purpose of securing obligations in respect of Letters of Credit, exchange rate fluctuations or otherwise to the extent required pursuant to any of the cash collateralization provisions of the Janus Credit Agreement (each of the foregoing defined terms as defined therein). “Enterprise Total Indebtedness” means, as of any date of determination, an amount equal to, without duplication, (a) Indebtedness of the Group on a consolidated basis outstanding on such date, plus (b) without duplication, the Borrower’s Pro Rata Share of Indebtedness of each Material Joint Venture outstanding on such date; provided that for purposes of calculating the Leverage Ratio, (x) clause (a) shall be reduced by the aggregate amount of (i) all unrestricted cash and cash equivalents of the Group and (ii) escrow and other deposits to the extent available on such date for the repayment of any of the Indebtedness included in the calculation of clause (a) above up to an amount in the aggregate for this clause (x) not to exceed the aggregate amount of Indebtedness reflected in clause (a) above maturing in the immediately succeeding 24 months and (y) clause (b) shall be reduced by the aggregate amount of (i) all unrestricted cash and cash equivalents of each such applicable Material Joint Venture and (ii) escrow and other deposits to the extent available on such date for the repayment of any of the Indebtedness included in the calculation of clause (b) above up to an amount in the aggregate for this clause (y) not to exceed the aggregate amount of Indebtedness reflected in clause (b) above maturing in the immediately succeeding 24 months; provided, further, that Enterprise Total Indebtedness shall not include accounts payable, intracompany debt, dividends and distributions declared but not payable, security deposits, accrued liabilities or prepaid rent, each as defined in accordance with GAAP. “Enterprise Unencumbered Asset Value” means, as of any date of determination, the sum of (a) Unencumbered Asset Value of the Group on a consolidated basis plus (b) without duplication, the Borrower’s Pro Rata Share of Unencumbered Asset Value of each Material Joint Venture; provided that for purposes of any determination of Enterprise Unencumbered Asset Value (x) to the extent the amount of Enterprise Unencumbered Asset Value attributable to Joint Ventures would exceed 25% of Enterprise Unencumbered Asset Value, such excess shall be excluded (it being understood and agreed, that for purposes of this clause (x) the Loan Parties’ Investment in any Joint Venture will be valued at book value as shown on the consolidated balance sheet of the Parent Guarantor, as determined in accordance with GAAP), and (y) to the extent the amount of Enterprise Unencumbered Asset Value attributable to Development Properties would exceed 35% of Enterprise Unencumbered Asset Value, such excess shall be excluded.


 
16 “Enterprise Unsecured Debt” means, as of any date of determination, that portion of Enterprise Total Indebtedness that is not Enterprise Secured Debt or a Guarantee of Enterprise Secured Debt. “Environmental Laws” means any and all Federal, state, local, and foreign statutes, laws, regulations, ordinances, rules, judgments, orders, decrees, permits, concessions, grants, franchises, licenses, agreements or governmental restrictions relating to pollution and the protection of the environment or the release of any materials into the environment, including those related to hazardous substances or wastes, air emissions and discharges to waste or public systems. “Environmental Liability” means any liability, contingent or otherwise (including any liability for damages, costs of environmental remediation, fines, penalties or indemnities), of a Loan Party or any of its Subsidiaries directly or indirectly resulting from or based upon (a) violation of any Environmental Law, (b) the generation, use, handling, transportation, storage, treatment or disposal of any Hazardous Materials, (c) exposure to any Hazardous Materials, (d) the release or threatened release of any Hazardous Materials into the environment or (e) any contract, agreement or other consensual arrangement pursuant to which liability is assumed or imposed with respect to any of the foregoing. “Equity Interests” means, with respect to any Person, all of the shares of capital stock of (or other ownership or profit interests in) such Person and all of the warrants or options for the purchase or acquisition from such Person of shares of capital stock of (or other ownership or profit interests in) such Person (but excluding any debt security that is convertible into or exchangeable for capital stock). “ERISA” means the Employee Retirement Income Security Act of 1974. “ERISA Affiliate” means any trade or business (whether or not incorporated) under common control with the Loan Parties within the meaning of Section 414(b) or (c) of the Code (and Sections 414(m) and (o) of the Code for purposes of provisions relating to Section 412 of the Code). “ERISA Event” means (a) a Reportable Event with respect to a Pension Plan; (b) a withdrawal by any Loan Party or any ERISA Affiliate from a Pension Plan subject to Section 4063 of ERISA during a plan year in which it was a substantial employer (as defined in Section 4001 (a)(2) of ERISA) or a cessation of operations that is treated as such a withdrawal under Section 4062(e) of ERISA; (c) a complete or partial withdrawal by any Loan Party or any ERISA Affiliate from a Multiemployer Plan or notification that a Multiemployer Plan is in reorganization; (d) the filing of a notice of intent to terminate, the treatment of a Plan amendment as a termination under Section 4041 or 4041A of ERISA, or the commencement of proceedings by the PBGC to terminate a Pension Plan or Multiemployer Plan; (e) an event or condition which constitutes grounds under Section 4042 of ERISA for the termination of, or the appointment of a trustee to administer, any Pension Plan or Multiemployer Plan; or (f) the imposition of any liability under Title IV of ERISA, other than for PBGC premiums due but not delinquent under Section 4007 of ERISA, upon a Loan Party or any ERISA Affiliate in excess of the Threshold Amount. “ESG Report” means the annual non-financial disclosure substantially similar to the GRI Standards as publicly reported by the Parent Guarantor or the Borrower and published on an Internet or intranet website to which each Lender and the Administrative Agent has or has been granted access free of charge. “EU Bail-In Legislation Schedule” means the EU Bail-In Legislation Schedule published by the Loan Market Association (or any successor person), as in effect from time to time. “Event of Default” has the meaning specified in Section 8.01.


 
17 “Excluded Swap Obligations” means, with respect to any Guarantor Party, any Swap Obligation if, and to the extent that, all or a portion of the Guaranty of such Guarantor Party of, or the grant by such Guarantor Party of a Lien to secure, such Swap Obligation (or any Guarantee thereof) is or becomes illegal under the Commodity Exchange Act or any rule, regulation or order of the Commodity Futures Trading Commission (or the application or official interpretation thereof) by virtue of such Guarantor Party’s failure for any reason to constitute an “eligible contract participant” as defined in the Commodity Exchange Act (determined after giving effect to Section 10.27 and any other “keepwell”, support or other agreement for the benefit of such Guarantor Party and any and all guarantees of the Guarantor Party’s Swap Obligations by other guarantors (if any)) at the time the Guaranty of such Guarantor Party, or grant by such Guarantor Party of a Lien, becomes effective with respect to such Swap Obligation. If a Swap Obligation arises under a Master Agreement governing more than one Swap Contract, such exclusion shall apply only to the portion of such Swap Obligation that is attributable to Swap Contracts for which such Guaranty or Lien is or becomes excluded in accordance with the first sentence of this definition. “Excluded Taxes” means, with respect to the Administrative Agent, any Lender or any other recipient of any payment to be made by or on account of any obligation of any Loan Party hereunder, (a) taxes imposed on or measured by its overall net income (however denominated), and franchise taxes in each case (i) imposed on it (in lieu of net income taxes), by the jurisdiction (or any political subdivision thereof) under the Laws of which such recipient is organized or in which its principal office is located or, in the case of any Lender, in which its applicable Lending Office is located or (ii) that are Other Connection Taxes, (b) any branch profits taxes imposed by the United States or any similar tax imposed by any other jurisdiction in which any Loan Party is located, (c) any backup withholding tax that is required to be withheld from amounts payable to a Lender that has failed to comply with clause (A) of Section 3.01(e)(ii), (d) in the case of a Lender (other than an assignee pursuant to a request by the Borrower under Section 10.13), any Tax that is imposed on amounts payable to such Lender at the time such Lender becomes a party hereto (or designates a new Lending Office) or is attributable to such Lender’s failure or inability (other than as a result of a Change in Law) to comply with Section 3.01(e), except to the extent that such Lender (or its assignor, if any) was entitled, at the time of designation of a new Lending Office (or assignment), to receive additional amounts from the Loan Parties with respect to such withholding tax pursuant to Section 3.01(a) and (e) Taxes imposed under FATCA. “Facility” means the Term A-1 Facility, the Term A-2 Facility, the Term A-3 Facility, the Term A- 4 Facility, the Term A-5 Facility or an Incremental Term Loan Facility, as the context may require. “FASB ASC” means the Accounting Standards Codification of the Financial Accounting Standards Board. “FATCA” means Sections 1471 through 1474 of the Code, as of the Closing Date (or any amended or successor version that is substantively comparable and not materially more onerous to comply with), any current or future regulations or official interpretations thereof, any agreements entered into pursuant to Section 1471(b)(1) of the Code and any fiscal or regulatory legislation, rules or practices adopted pursuant to any intergovernmental agreement, treaty or convention among Governmental Authorities entered into in connection with the implementation of the foregoing. “Federal Funds Rate” means, for any day, the rate per annum calculated by the Federal Reserve Bank of New York based on such day’s federal funds transactions by depository institutions (as determined in such manner as the Federal Reserve Bank of New York shall set forth on its public website from time to time) and published on the next succeeding Business Day by the Federal Reserve Bank of New York as the federal funds effective rate; provided that, if the Federal Funds Rate as so determined would be less than zero, such rate shall be deemed to be zero for purposes of this Agreement.


 
18 “Fifth Amendment” means that certain Amendment No. 5 to Term Loan Agreement dated as of March 23, 2026, by and among the Guarantor Parties, the Borrower, the Lenders party thereto and the Administrative Agent. “Fifth Amendment Effective Date” has the meaning assigned thereto in the Fifth Amendment. “Financing Lease” means, as applied to any Person, any lease of any property by that Person as lessee which, in accordance with GAAP, is required to be accounted for as a financing lease on the balance sheet of that Person. “Fitch” means Fitch Ratings, Inc. and any successor thereto. “Fixed Charge Coverage Ratio” means, on the last day of any fiscal quarter, the ratio of (a) Enterprise EBITDA for the twelve-month period ending on such date to (b) Enterprise Fixed Charges for the twelve-month period ending on such date. “Foreign Lender” means any Lender that is organized under the Laws of a jurisdiction other than that in which the Borrower is a resident for tax purposes. For purposes of this definition, the United States, each State thereof and the District of Columbia shall be deemed to constitute a single jurisdiction. “Form S-11” means the Registration Statement on Form S-11 filed by Janus Parent, as amended as of March 17, 2026. “FRB” means the Board of Governors of the Federal Reserve System of the United States. “Fund” means any Person (other than a natural person or a holding company, investment vehicle or trust for, or owned and operated for the primary benefit of, a natural person) that is (or will be) engaged in making, purchasing, holding or otherwise investing in commercial loans and similar extensions of credit in the ordinary course of its activities. “GAAP” means generally accepted accounting principles in the United States set forth in the opinions and pronouncements of the Accounting Principles Board and the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board or such other principles as may be approved by a significant segment of the accounting profession in the United States, that are applicable to the circumstances as of the date of determination, consistently applied. “Governmental Authority” means the government of the United States or any other nation, or of any political subdivision thereof, whether state or local, and any agency, authority, instrumentality, regulatory body, court, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative powers or functions of or pertaining to government (including any supranational bodies such as the European Union or the European Central Bank). “GRI Standards” means the Global Reporting Initiative Sustainability Reporting Standards (2016) (or successor standards) published by the Global Reporting Initiative. “Gross Asset Value” means, as of any date of determination, an amount equal to (a) all assets of a Person and its Subsidiaries as determined in accordance with GAAP plus (b) all accumulated depreciation and accumulated amortization associated with such assets minus (c) Intangible Assets of such Person and its Subsidiaries. “Group” means the Parent Guarantor, the Borrower and their respective Subsidiaries.


 
19 “Guarantee” means, as to any Person, (a) any obligation, contingent or otherwise, of such Person guaranteeing or having the economic effect of guaranteeing any Indebtedness or other obligation payable or performable by another Person (the “primary obligor”) in any manner, whether directly or indirectly, and including any payment obligation of such Person, direct or indirect, (i) to purchase or pay (or advance or supply funds for the purchase or payment of) such Indebtedness or other obligation, (ii) to purchase or lease property, securities or services for the purpose of assuring the obligee in respect of such Indebtedness or other obligation of the payment or performance of such Indebtedness or other obligation, (iii) to maintain working capital, equity capital or any other financial statement condition or liquidity or level of income or cash flow of the primary obligor so as to enable the primary obligor to pay such Indebtedness or other obligation, or (iv) entered into for the purpose of assuring in any other manner the obligee in respect of such Indebtedness or other obligation of the payment or performance thereof or to protect such obligee against loss in respect thereof (in whole or in part), or (b) any Lien on any assets of such Person securing any Indebtedness or other obligation of any other Person, whether or not such Indebtedness or other obligation is assumed by such Person (or any right, contingent or otherwise, of any holder of such Indebtedness to obtain any such Lien). The amount of any Guarantee shall be deemed to be an amount equal to the stated or determinable amount of the related primary obligation, or portion thereof, in respect of which such Guarantee is made or, if not stated or determinable, the maximum reasonably anticipated liability in respect thereof as determined by the guaranteeing Person in good faith. The term “Guarantee” as a verb has a corresponding meaning. “Guaranteed Obligations” has the meaning specified in Section 11.01 or Section 12.01, as the context may require. “Guarantor” means the Parent Guarantor. “Guarantor Party” means each of the Parent Guarantor and each Subsidiary Guarantor and “Guarantor Parties” means all of them collectively. “Guaranty” means, as the context may require, (a) the Guarantee made by the Parent Guarantor under Article XI in favor of the Administrative Agent and the Lenders or (b) the Guarantee made by each Subsidiary Guarantor under Article XII in favor of the Administrative Agent and the Lenders. “Hazardous Materials” means all explosive or radioactive substances or wastes and all hazardous or toxic substances, wastes or other pollutants, including petroleum or petroleum distillates, asbestos or asbestos-containing materials, polychlorinated biphenyls, radon gas, infectious or medical wastes and all other substances or wastes of any nature regulated pursuant to any Environmental Law. “HMT” has the meaning specified in the definition of “Sanction(s).” “Increase Effective Date” has the meaning specified in Section 2.16(d). “Incremental Term Loan” has the meaning specified in Section 2.16(a). “Incremental Term Loan Amendment” has the meaning specified in Section 2.16(e)(iii). “Incremental Term Loan Facility” means, at any time, any new tranche of term loans established pursuant to Section 2.16 and the aggregate Outstanding Amount of the Incremental Term Loans under such tranche of all Lenders at such time.


 
20 “Indebtedness” means, at any time and with respect to any Person, without duplication, all of the following, whether or not included as indebtedness or liabilities in accordance with GAAP: (a) all obligations of such Person for borrowed money, whether secured or unsecured, and all obligations of such Person evidenced by bonds, debentures, notes, loan agreements or other similar instruments, including, without limitation, recourse and non-recourse mortgage debt; (b) all direct or contingent obligations of such Person arising under letters of credit (including standby and commercial), bankers’ acceptances, bank guaranties, surety bonds and similar instruments; (c) aggregate net obligations of such Person under Swap Contracts; (d) all obligations of such Person to pay the deferred purchase price of property or services (other than (i) trade accounts payable and other accrued obligations in the ordinary course of business and (ii) liabilities with respect to earnouts, reimbursements, true-ups and other similar obligations incurred in connection with the purchase or sale of assets except to the extent such liabilities are required to appear on the balance sheet of such Person prepared in accordance with GAAP); (e) indebtedness (excluding prepaid interest thereon) secured by a Lien on property owned or purchased by such Person (including indebtedness arising under conditional sales or other title retention agreements), whether or not such indebtedness shall have been assumed by such Person or is limited in recourse, to the extent of the value of the property encumbered by such Lien; (f) Financing Leases and Synthetic Lease Obligations; (g) all obligations of such Person to purchase, redeem, retire, defease or otherwise make any payment in respect of any Equity Interest in such Person (other than OP units or LTIP units issued by such Person) at any time prior to the date that is six (6) months after the latest Maturity Date then in effect (other than obligations that can solely be satisfied by delivery of Equity Interests of such Person), valued, in the case of a redeemable preferred interest, at the liquidation preference thereof; and (h) all Guarantees of such Person in respect of any of the foregoing. For all purposes hereof, (i) the amount of any net obligation under any Swap Contract on any date shall be deemed to be the Swap Termination Value thereof as of such date (which shall be a positive number if such amount would be owed by the Parent Guarantor, the Borrower or any of their respective Subsidiaries and a negative number if such amount would be owed to the Parent Guarantor, the Borrower or any of their respective Subsidiaries) and the net obligations under Swap Contracts shall not be less than zero and (ii) the amount of any Financing Lease or Synthetic Lease Obligation as of any date shall be deemed to be the amount of Attributable Indebtedness in respect thereof as of such date. Any liability will be excluded so long as it is (1) secured by a letter of credit issued for the benefit of the Parent Guarantor, the Borrower or any of their respective Subsidiaries in form and substance and from a financial institution reasonably acceptable to the Administrative Agent, but only to the extent neither the Parent Guarantor, the Borrower nor any of their respective Subsidiaries has liability therefor, (2) any obligation (including obligations under so called “sandwich leases”) against which a third party indemnifies the Parent Guarantor, the Borrower or any of their respective Subsidiaries, or guarantees all loss suffered by the Parent Guarantor, the Borrower or any of their respective Subsidiaries on account thereof, to the extent the indemnitor or guarantor has the


 
21 financial wherewithal to satisfy its obligation, or (3) otherwise acceptable as a “Covered Liability” in the reasonable discretion of the Administrative Agent and the Required Lenders. “Indemnified Taxes” means Taxes other than Excluded Taxes. “Indemnitee” has the meaning specified in Section 10.04(b). “Initial Term A-2 Maturity Date” has the meaning specified in Section 2.15(a). “Intangible Assets” means, as of any date of determination, assets of a Person and its Subsidiaries that are classified as intangible assets under GAAP, but excluding interests in real estate that are classified as intangible assets in accordance with GAAP. “Intercompany Indebtedness” means, as of any date, Indebtedness to which the only parties are the Parent Guarantor, the Borrower and/or any of their respective Subsidiaries as of such date and which, if the Parent Guarantor or the Borrower is the borrower with respect to such Indebtedness, is subordinated to the obligations under this Agreement and the other Loan Documents. “Interest Expense” means, for any period, for a Person and its Subsidiaries on a consolidated basis, the sum, without duplication, of all (a) interest expense for such period determined in accordance with GAAP (but excluding, to the extent included in Interest Expense, (i) any charges resulting from settlement of options to repurchase remarketable bonds, (ii) remaining unamortized fees paid pursuant to the 2021 Credit Agreement, and (iii) amortization of deferred financing fees, amortization of debt discounts and swap breakage costs) and (b) interest that is capitalized in such period in accordance with GAAP. “Interest Payment Date” means, (a) as to any Term SOFR Loan, the last day of each Interest Period applicable to such Loan and the applicable Maturity Date; provided, however, that, if any Interest Period for a Term SOFR Loan exceeds three (3) months, then the respective dates that fall every three (3) months after the beginning of such Interest Period shall also be Interest Payment Dates; and (b) as to any Base Rate Loan or Daily SOFR Loan, the last Business Day of each calendar quarter and the applicable Maturity Date. “Interest Period” means, as to each Term SOFR Loan, the period commencing on the date such Term SOFR Loan is disbursed or converted to or continued as a Term SOFR Loan and ending on the numerically corresponding day in the calendar month that is one, three or six months (or, if agreed to by all Lenders, 12 months) thereafter (in each case, subject to availability), as selected by the Borrower in its Committed Loan Notice; provided that: (a) any Interest Period that would otherwise end on a day that is not a Business Day shall be extended to the next succeeding Business Day unless such Business Day falls in another calendar month, in which case such Interest Period shall end on the next preceding Business Day; (b) any Interest Period that begins on the last Business Day of a calendar month (or on a day for which there is no numerically corresponding day in the calendar month at the end of such Interest Period) shall end on the last Business Day of the calendar month at the end of such Interest Period; and (c) no Interest Period shall extend beyond the applicable Maturity Date. “Investment” means, as to any Person, any direct or indirect acquisition or investment by such Person, whether by means of (a) the purchase or other acquisition of capital stock or other securities of another Person, (b) a loan, advance or capital contribution to, Guarantee or assumption of debt of, or


 
22 purchase or other acquisition of any other debt or equity participation or interest in, another Person, including any partnership or joint venture interest in such other Person and any arrangement pursuant to which the investor Guarantees Indebtedness of such other Person, or (c) the purchase or other acquisition (in one transaction or a series of transactions) of assets of another Person that constitute a business unit. For purposes of covenant compliance, the amount of any Investment shall be the amount actually invested, without adjustment for subsequent increases or decreases in the value of such Investment. “IP Rights” has the meaning specified in Section 5.16. “IRS” means the United States Internal Revenue Service. “Janus Credit Agreement” means that certain Amended and Restated Credit Agreement dated as of March 23September 17, 2026 by and among Janus OP, as borrower, Janus Parent, as guarantor, the other subsidiaries of Janus Parent and Janus OP party thereto, as guarantors, the lenders party thereto and Bank of America, N.A., as administrative agent, and as may be further amended, restated, supplemented or otherwise modified and in effect from time to time. “Janus Group” means Janus Parent and each of its direct or indirect Subsidiaries. “Janus IPO” means the underwritten public offering of Equity Interests constituting common stock of Janus Parent, that results in such Equity Interests being traded on the New York Stock Exchange or other nationally-recognized stock exchange and the use of proceeds therefrom, in each case substantially as described in the Form S-11 for such offering. “Janus IPO Transactions” means the Janus IPO and the related transactions (including the “formation transactions” (as defined in the Form S-11)) expressly contemplated by, and consummated in accordance with, the terms of the Form S-11. “Janus Management Agreement” means that certain Management Agreement, dated as of March 23, 2026, by and among the Janus Parent, Janus OP, and Healthpeak Investment Management, LLC (the “Healthpeak Manager”) under which Janus Parent and Janus OP shall have engaged the Healthpeak Manager to provide day-to-day management services and advice with respect to the management of the Janus Group’s operations and properties, substantially in the form provided to the Administrative Agent prior to the Fifth Amendment Effective Date, as amended or otherwise modified from time to time to the extent such amendments and modifications are not reasonably expected to have a Material Adverse Effect (“Permitted Amendment”). “Janus OP” means Janus Living OP, LLC, a Maryland limited liability company. “Janus Parent” means Janus Living, Inc., a Maryland corporation. “Joint Venture” means any Person in which the Borrower, directly or indirectly, has an ownership interest but does not consolidate the assets or income of such Person in preparing its consolidated financial statements. “Judgment Currency” has the meaning specified in Section 10.19. “Laws” means, collectively, all international, foreign, Federal, state and local statutes, treaties, rules, guidelines, regulations, ordinances, codes, executive orders and administrative or judicial precedents or authorities, including the interpretation or administration thereof by any Governmental Authority charged with the enforcement, interpretation or administration thereof, and all applicable administrative


 
23 orders, directed duties, requests, licenses, authorizations and permits of, and agreements with, any Governmental Authority, in each case whether or not having the force of law. “Lender” has the meaning specified in the introductory paragraph hereto. The term “Lender” may also be used to refer to a Term A-1 Lender, a Term A-2 Lender, a Term A-3 Lender, a Term A-4 Lender, a Term A-5 Lender or a Lender of an Incremental Term Loan, as the context may require. “Lender Related Party” has the meaning specified in Section 10.04(d). “Lending Office” means, as to any Lender, the office or offices of such Lender or its Affiliates described as such in such Lender’s Administrative Questionnaire, or such other office or offices as a Lender may from time to time notify the Borrower and the Administrative Agent. “Leverage Ratio” means, on the last day of any fiscal quarter, the ratio of (a) Enterprise Total Indebtedness outstanding on such date to (b) Enterprise Gross Asset Value as of such date. “Lien” means any mortgage, pledge, hypothecation, assignment, deposit arrangement, encumbrance, lien (statutory or other), charge, or preference, priority or other security interest or preferential arrangement in the nature of a security interest of any kind or nature whatsoever (including any conditional sale or other title retention agreement, any easement, right of way or other encumbrance on title to real property, and any financing lease having substantially the same economic effect as any of the foregoing). “Loan” means an extension of credit by a Lender to the Borrower under Article II in the form of a Committed Loan or an Incremental Term Loan of any tranche. “Loan Documents” means this Agreement, each Note and any Sustainability Metric Annual Certificate. “Loan Parties” means, collectively, the Borrower and each Guarantor Party. “Master Agreement” has the meaning specified in the definition of “Swap Contract.” “Material Adverse Effect” means a material adverse effect on (a) the business, operations, properties or financial condition of the Group, taken as a whole, (b) the ability of the Loan Parties to perform any of their material obligations under the Loan Documents, or (c) the rights of or remedies available to the Administrative Agent and the Lenders under the Loan Documents. “Material Group” has the meaning specified in the definition of “Material Subsidiary.” “Material Joint Venture” means a Joint Venture in which the Borrower has made a net equity investment of $15,000,000 or greater. For purposes of this definition, the Borrower’s aggregate Investment in a Joint Venture will be valued at book value as shown on the consolidated balance sheet of the Borrower, as determined in accordance with GAAP. “Material Recourse Indebtedness” means any Indebtedness of the Parent Guarantor, the Borrower and/or any of their respective Subsidiaries (other than Indebtedness under the Loan Documents and Indebtedness under Swap Contracts) that (a) does not constitute Non-Recourse Indebtedness, and (b) individually or in the aggregate, has a principal amount (including, without duplication, undrawn committed or available amounts and amounts owing to all creditors under any combined or syndicated credit arrangement) of more than the Threshold Amount.


 
24 “Material Subsidiary” means each Subsidiary or any group of Subsidiaries (i) which, as of the most recent fiscal quarter of the Parent Guarantor or the Borrower, as applicable, for the period of four consecutive fiscal quarters then ended, for which financial statements have been delivered pursuant to Section 6.01 (or, prior to the delivery of such financial statements for the fiscal year ending December 31, 2024, for the period of four consecutive fiscal quarters ended September 30, 2024), contributed greater than $100,000,000 of Enterprise EBITDA for such period or (ii) which contributed greater than $300,000,000 of Enterprise Gross Asset Value as of such date. A group of Subsidiaries (a “Material Group”) each of which is not otherwise a Material Subsidiary (defined in the foregoing sentence) shall constitute a Material Subsidiary if the group taken as a single entity satisfies the requirements of the foregoing sentence. “Maturity Date” means (a) with respect to the Term A-1 Facility, the Term A-1 Maturity Date, (b) with respect to the Term A-2 Facility, the Term A-2 Maturity Date, (c) with respect to the Term A-3 Facility, the Term A-3 Maturity Date, (d) with respect to the Term A-4 Facility, the Term A-4 Maturity Date, (e) with respect to the Term A-5 Facility, the Term A-5 Maturity Date and/or (ef) with respect to any tranche of Incremental Term Loans, subject to Section 2.16(e)(iii), the date set forth in the applicable Incremental Term Loan Amendment as the “Maturity Date” for such tranche of Incremental Term Loans, in each case, as the context may require. “Maximum Rate” has the meaning specified in Section 10.09. “Moody’s” means Moody’s Investors Service, Inc. and any successor thereto. “Mortgage Lien” means any Lien that encumbers a real property owned by a Person other than Permitted Specified Liens. “Multiemployer Plan” means any employee benefit plan of the type described in Section 4001(a)(3) of ERISA, to which a Loan Party or any ERISA Affiliate makes or is obligated to make contributions, or during the preceding five plan years, has made or been obligated to make contributions. “Negative Pledge” means any provision of a document, instrument or agreement (other than this Agreement or any other Loan Document) that is binding on a Loan Party or any Wholly-Owned Subsidiary and prohibits the creation or assumption of any Lien on any assets of such Person to secure the Obligations; provided, however, that a provision conditioning a Person’s ability to encumber its assets upon the maintenance of one or more specified ratios shall not constitute a Negative Pledge so long as such provision does not generally prohibit the encumbrance of such Person’s assets or the encumbrance of specific assets. “Net Income” means, for any period, for a Person and its Subsidiaries on a consolidated basis, the net income of such Person and its Subsidiaries for such period as determined in accordance with GAAP (without giving effect to (i) any net after tax gains or losses attributable to sales of non-current assets out of the ordinary course of business and write-downs of non-current assets in anticipation of losses to the extent they have decreased net income, and (ii) gains and losses from dispositions of depreciable real estate investments, impairment charges, the early extinguishment of debt and transaction costs of acquisitions not permitted to be capitalized pursuant to GAAP and other non-recurring items, including, without limitation, charges resulting from settlement of options to repurchase remarketable bonds and other similar charges). “New Lender Joinder Agreement” has the meaning specified in Section 2.16(c). “Non-Recourse Indebtedness” of a Person means any Indebtedness of such Person, the recourse for which is limited to the asset or assets securing such Indebtedness (and, if applicable, in the event such Person owns no assets other than real estate that secures such Indebtedness and assets incident to ownership of such real estate (e.g., personal property) and has no other Indebtedness, to such Person and/or such


 
25 Person’s Equity Interests), other than in respect of environmental liabilities, fraud, misrepresentation and other similar matters. “Notes” means, collectively, the Term Notes and any promissory notes made by the Borrower evidencing any Incremental Term Loans in a form agreed between the Borrower and the Administrative Agent, as the context may require, and “Note” means any of them individually. “Obligations” means all advances to, and debts, liabilities, obligations, covenants and duties of any Loan Party arising under any Loan Document or otherwise with respect to any Loan, whether direct or indirect (including those acquired by assumption), absolute or contingent, due or to become due, now existing or hereafter arising and including interest and fees that accrue after the commencement by or against any Loan Party or any Affiliate thereof of any proceeding under any Debtor Relief Laws naming such Person as the debtor in such proceeding, regardless of whether such interest and fees are allowed claims in such proceeding; provided that, without limiting the foregoing, the Obligations of any Guarantor Party shall exclude any Excluded Swap Obligations with respect to such Guarantor Party. “OFAC” means the Office of Foreign Assets Control of the United States Department of the Treasury. “Organization Documents” means, (a) with respect to any corporation, the certificate or articles of incorporation and the bylaws (or equivalent or comparable constitutive documents with respect to any non-U.S. jurisdiction); (b) with respect to any limited liability company, the certificate or articles of formation or organization and operating agreement; and (c) with respect to any partnership, joint venture, trust or other form of business entity, the partnership, joint venture or other applicable agreement of formation or organization and any agreement, instrument, filing or notice with respect thereto filed in connection with its formation or organization with the applicable Governmental Authority in the jurisdiction of its formation or organization and, if applicable, any certificate or articles of formation or organization of such entity. “Other Connection Taxes” means, with respect to any Recipient, Taxes imposed as a result of a present or former connection between such Recipient and the jurisdiction imposing such Tax (other than connections arising from such Recipient having executed, delivered, become a party to, performed its obligations under, received payments under, received or perfected a security interest under, engaged in any other transaction pursuant to or enforced any Loan Document, or sold or assigned an interest in any Loan or Loan Document). “Other Taxes” means all present or future stamp, court, documentary intangible, recording, filing or similar taxes or any other excise or property taxes, charges or similar levies arising from any payment made hereunder or under any other Loan Document or from the execution, delivery or enforcement of, or otherwise with respect to, this Agreement or any other Loan Document except any such taxes that are Other Connection Taxes imposed with respect to an assignment (other than an assignment made pursuant to Section 3.06 or Section 10.13). “Outstanding Amount” means, with respect to Loans of one or more Class(es) on any date, the aggregate outstanding principal amount thereof after giving effect to any borrowings and prepayments or repayments of Loans of such Class(es) occurring on such date. “Overnight Rate” means, for any day, the greater of (i) the Federal Funds Rate and (ii) an overnight rate determined by the Administrative Agent in accordance with banking industry rules on interbank compensation.


 
26 “Parent Guarantor” means Healthpeak Properties, Inc., a Maryland corporation. “Participant” has the meaning specified in Section 10.06(d). “Participant Register” has the meaning specified in Section 10.06(d). “Patriot Act” has the meaning specified in Section 10.17. “PBGC” means the Pension Benefit Guaranty Corporation. “Pension Plan” means any “employee pension benefit plan” (as such term is defined in Section 3(2) of ERISA), other than a Multiemployer Plan, that is subject to Title IV of ERISA and is sponsored or maintained by a Loan Party or any ERISA Affiliate or to which a Loan Party or any ERISA Affiliate contributes or has an obligation to contribute, or in the case of a multiple employer or other plan described in Section 4064(a) of ERISA, has made contributions at any time during the immediately preceding five plan years. “Permitted Specified Liens” means Liens permitted under Section 7.01(c) – (h), (j) – (m) and (o) – (q). “Person” means any natural person, corporation, limited liability company, trust, joint venture, association, company, partnership, Governmental Authority or other entity. “Plan” means any “employee benefit plan” (as such term is defined in Section 3(3) of ERISA) established by a Loan Party or, with respect to any such plan that is subject to Section 412 of the Code or Title IV of ERISA, any ERISA Affiliate. “Platform” has the meaning specified in Section 6.02. “Pro Forma Basis” means, for purposes of determining any financial covenant hereunder, that the subject transaction shall be deemed to have occurred as of the first day of the period of four (4) consecutive fiscal quarters ending as of the end of the most recent fiscal quarter for which annual or quarterly financial statements shall have been delivered in accordance with the provisions of this Agreement. Further, for purposes of making calculations on a “Pro Forma Basis” hereunder, (a) in the case of a Disposition, (i) income statement items (whether positive or negative) attributable to the property, entities or business units that are the subject of such Disposition shall be excluded to the extent relating to any period prior to the date of the subject transaction, and (ii) Indebtedness paid or retired in connection with the subject transaction shall be deemed to have been paid and retired as of the first day of the applicable period; (b) in the case of an acquisition, development or redevelopment, (i) income statement items (whether positive or negative) attributable to the property, entities or business units that are the subject of such acquisition, development or redevelopment shall be included to the extent relating to any period prior to the date of the subject transaction, and (ii) Indebtedness incurred in connection with the subject transaction shall be deemed to have been incurred as of the first day of the applicable period (and interest expense shall be imputed for the applicable period utilizing the actual interest rates thereunder or, if actual rates are not ascertainable, assuming prevailing interest rates hereunder) and (c) in the case of the issuance or exercise of Equity Interests, Indebtedness paid or retired in connection therewith shall be deemed to have been paid and retired as of the first day of the applicable period. “Pro Rata Share” means (a) with respect to the EBITDA, Net Income, Interest Expense, Gross Asset Value and Unencumbered Asset Value of each Joint Venture, the Borrower’s direct or indirect percentage ownership interest in such Joint Venture and (b) with respect to the Indebtedness of each Joint


 
27 Venture (i) if the Indebtedness is recourse to the Parent Guarantor, the Borrower or any of their respective Subsidiaries, the amount of such Indebtedness that is recourse to the Parent Guarantor, the Borrower or such Subsidiary and (ii) if the Indebtedness is not recourse to the Parent Guarantor, the Borrower or any of their respective Subsidiaries, the Borrower’s percentage ownership interest in such Joint Venture. “PTE” means a prohibited transaction class exemption issued by the U.S. Department of Labor, as any such exemption may be amended from time to time. “Public Lender” has the meaning specified in Section 6.02. “QFC Credit Support” has the meaning specified in Section 10.24. “Qualified ECP Guarantor” means, at any time, each Loan Party with total assets exceeding $10,000,000 or that qualifies at such time as an “eligible contract participant” under the Commodity Exchange Act and can cause another Person to qualify as an “eligible contract participant” at such time under Section 1a(18)(A)(v)(II) of the Commodity Exchange Act. “Recipient” means the Administrative Agent and any Lender, as applicable. “Register” has the meaning specified in Section 10.06(c). “REIT” means a real estate investment trust as defined in Sections 856-860 of the Code. “Related Indemnified Party” of an Indemnitee means (a) any trustees, members, administrators, managers, partners, Controlling Person or Controlled Affiliate of such Indemnitee, (b) the respective directors, officers or employees of such Indemnitee or any of its Controlling Persons or Controlled Affiliates and (c) the respective advisors, attorneys, accountants, agents and representatives of such Indemnitee or any of its Controlling Persons or Controlled Affiliates, in the case of this clause (c), acting on behalf of, or at the express instructions of, such Indemnitee, Controlling Person or such Controlled Affiliate. “Related Parties” means, with respect to any Person, such Person’s Affiliates and the partners, directors, officers, employees, agents, trustees, administrators, managers, advisors and representatives of such Person and of such Person’s Affiliates. “Reportable Event” means any of the events set forth in Section 4043(c) of ERISA, other than events for which the thirty (30) day notice period has been waived. “Request for Credit Extension” means, with respect to a Borrowing or a conversion or continuation of any Loan, a Committed Loan Notice. “Required Class Lenders” means, at any time with respect to any Class of Loans (or any Class of commitments to make Loans), Lenders having Total Loan Exposures with respect to such Class representing more than 50% of the Total Loan Exposures of all Lenders of such Class. The Total Loan Exposure of any Defaulting Lender with respect to such Class shall be disregarded in determining Required Class Lenders at any time. “Required Lenders” means, as of any date of determination, Lenders having Total Loan Exposures representing more than 50% of the Total Loan Exposures of all Lenders. The Total Loan Exposure of any Defaulting Lender shall be disregarded in determining Required Lenders at any time.


 
28 “Required Term A-1 Lenders” means, as of any date of determination, Term A-1 Lenders having Total Term A-1 Loan Exposures representing more than 50% of the Total Term A-1 Loan Exposures of all Term A-1 Lenders. The Total Term A-1 Loan Exposure of any Defaulting Lender shall be disregarded in determining Required Term A-1 Lenders at any time. “Required Term A-2 Lenders” means, as of any date of determination, Term A-2 Lenders having Total Term A-2 Loan Exposures representing more than 50% of the Total Term A-2 Loan Exposures of all Term A-2 Lenders. The Total Term A-2 Loan Exposure of any Defaulting Lender shall be disregarded in determining Required Term A-2 Lenders at any time. “Required Term A-3 Lenders” means, as of any date of determination, Term A-3 Lenders having Total Term A-3 Loan Exposures representing more than 50% of the Total Term A-3 Loan Exposures of all Term A-3 Lenders. The Total Term A-3 Loan Exposure of any Defaulting Lender shall be disregarded in determining Required Term A-3 Lenders at any time. “Required Term A-4 Lenders” means, as of any date of determination, Term A-4 Lenders having Total Term A-4 Loan Exposures representing more than 50% of the Total Term A-4 Loan Exposures of all Term A-4 Lenders. The Total Term A-4 Loan Exposure of any Defaulting Lender shall be disregarded in determining Required Term A-4 Lenders at any time. “Required Term A-5 Lenders” means, as of any date of determination, Term A-5 Lenders having Total Term A-5 Loan Exposures representing more than 50% of the Total Term A-5 Loan Exposures of all Term A-5 Lenders. The Total Term A-5 Loan Exposure of any Defaulting Lender shall be disregarded in determining Required Term A-5 Lenders at any time. “Rescindable Amount” has the meaning specified in Section 2.13(b)(ii). “Resolution Authority” means an EEA Resolution Authority or, with respect to any UK Financial Institution, a UK Resolution Authority. “Responsible Officer” means the chief executive officer, president, chief financial officer, each executive vice president and senior vice president, and the treasurer of any Loan Party, and solely for purposes of the delivery of incumbency certificates pursuant to Section 4.01, the secretary or any assistant secretary of a Loan Party or any entity authorized to act on behalf of such Loan Party, and, solely for purposes of notices given pursuant to Article II, any other officer or employee of a Loan Party so designated by any of the foregoing officers in a notice to the Administrative Agent or any other officer or employee of such Loan Party designated in or pursuant to an agreement between such Loan Party and the Administrative Agent. Any document delivered hereunder that is signed by a Responsible Officer shall be conclusively presumed to have been authorized by all necessary corporate, partnership and/or other action on the part of the applicable Loan Party and such Responsible Officer shall be conclusively presumed to have acted on behalf of such Loan Party. “Restricted Payment” means any payment (whether in cash, securities or other property) by the Parent Guarantor, the Borrower or any of their respective Subsidiaries, including any sinking fund or similar deposit, on account of the purchase, redemption, retirement, acquisition, cancellation or termination of any of the Parent Guarantor’s or Borrower’s capital stock or other Equity Interest, or on account of any return of capital to the Parent Guarantor’s or the Borrower’s stockholders, partners or members (or the equivalent Person thereof); provided that dividends to the extent in the form of Equity Interests shall not constitute Restricted Payments.


 
29 “Rolling Base Year Methodology” has the meaning specified in the definition of “Sustainability Metric.” “Rolling Base Year Percentage” has the meaning specified in the definition of “Sustainability Metric.” “S&P” means Standard & Poor’s Financial Services LLC, a subsidiary of S&P Global Inc., and any successor thereto. “Same Day Funds” means immediately available funds. “Sanction(s)” means any international economic or financial sanctions, trade embargoes or similar restrictions, administered or enforced by the United States federal government (including, without limitation, OFAC), the United Nations Security Council, the European Union, His Majesty’s Treasury of the United Kingdom (“HMT”) or other relevant sanctions authority with jurisdiction over any Loan Party. “Scheduled Principal Payment” means, for any period, (a) all regularly scheduled principal payments during such period by the Parent Guarantor and its Subsidiaries with respect to Indebtedness of the Parent Guarantor and its Subsidiaries (other than payments due at final maturity of any tranche of Indebtedness) and (b) without duplication, the Borrower’s Pro Rata Share of all regularly scheduled principal payments during such period with respect to the Indebtedness (other than payments due at final maturity of any tranche of Indebtedness) of each Material Joint Venture. For purposes of determining Scheduled Principal Payments, Indebtedness shall not include accounts payable, intracompany debt, dividends and distributions declared but not payable, security deposits, accrued liabilities or prepaid rent, each as defined in accordance with GAAP. “Scheduled Unavailability Date” has the meaning specified in Section 3.03(b). “Scope 1” means direct greenhouse gas emissions relating to natural gas, transport fuel and refrigerants (or other similar categories) as disclosed in the applicable annual Sustainability Metric Report. “Scope 2” means indirect greenhouse gas emissions relating to purchased electricity and purchased chilled water refrigerants (or other similar categories) as disclosed in the applicable annual Sustainability Metric Report. “SEC” means the Securities and Exchange Commission, or any Governmental Authority succeeding to any of its principal functions. “Second Amendment” means that certain Consent and Amendment No. 2 and Joinder to Term Loan Agreement dated as of March 1, 2024, by and among the Guarantor Parties, the Borrower, the Lenders party thereto and the Administrative Agent. “Second Amendment Effective Date” has the meaning assigned thereto in the Second Amendment. “Secured Debt Ratio” means, on the last day of any fiscal quarter, the ratio of (a) Enterprise Secured Debt outstanding on such date to (b) Enterprise Gross Asset Value as of such date. Notwithstanding anything to the contrary contained herein, for the purposes of this ratio, the aggregate amount of all unrestricted cash and cash equivalents on such date deducted from Enterprise Secured Debt pursuant to the definition of “Enterprise Total Indebtedness” shall exclude the aggregate amount of all unrestricted cash and cash equivalents deducted from Enterprise Unsecured Debt pursuant to the definition of “Enterprise Total Indebtedness” for the purpose of determining the Unsecured Leverage Ratio as of such date.


 
30 “Senior Managing Agent” means, with respect to the Term A-5 Facility, each of Banco Santander, S.A., New York Branch, Barclays Bank PLC, BNP Paribas, Capital One, N.A., Credit Agricole Corporate and Investment Bank, Goldman Sachs Bank USA, The Huntington National Bank, M&T Bank, Mizuho Bank, LTD., Morgan Stanley Bank, N.A., PNC Bank, National Association, Royal Bank of Canada, T.D. Bank, N.A., The Bank of Nova Scotia, Truist Bank, U.S. Bank National Association, Regions Bank and KeyBank National Association, in each case, in their capacities as Senior Managing Agents. “Significant Acquisition” means the acquisition (in one or a series of related transactions) of all or substantially all of the assets or Equity Interests of a Person or any division, line of business or business unit of a Person for an aggregate consideration in excess of $450,000,000. “Sixth Amendment” means that certain Amendment No. 6 to Term Loan Agreement dated as of October 28, 2026, by and among the Guarantor Parties, the Borrower, the Lenders party thereto and the Administrative Agent. “Sixth Amendment Effective Date” has the meaning assigned thereto in the Sixth Amendment. “SOFR” means, with respect to any applicable determination date, the Secured Overnight Financing Rate published on the second U.S. Government Securities Business Day preceding such date by the SOFR Administrator (or a successor administrator of such rate) on the Federal Reserve Bank of New York’s website (or any successor source); provided, however, that, with respect to any Daily SOFR Loan, if such determination date is not a U.S. Government Securities Business Day, then SOFR means such rate that applied on the first U.S. Government Securities Business Day immediately prior thereto. “SOFR Administrator” means the Federal Reserve Bank of New York, as the administrator of SOFR, or any successor administrator of SOFR designated by the Federal Reserve Bank of New York or other Person acting as the SOFR Administrator at such time that is satisfactory to the Administrative Agent. “SOFR Replacement Date” has the meaning specified in Section 3.03(b). “Specified Arrangers” means BofA Securities, Inc. and Wells Fargo Securities, LLC, each in its capacity as a joint lead arranger. “Specified Default” means an Event of Default arising under Section 8.01(a) or 8.01(f). “Specified Representations” means the representations and warranties set forth in the Loan Documents (or otherwise mutually agreed between the Borrower and the applicable Lenders providing any applicable Incremental Term Loans) relating to: corporate existence of each Loan Party and good standing of such Loan Party in its jurisdiction of organization; power and authority, due authorization, execution and delivery and enforceability, in each case, relating to such Loan Party entering into and performance of the Loan Documents; no conflicts with or consents under such Loan Party’s Organization Documents, applicable Law or material contractual obligations (in each case, as they relate to the entering into and performance of the Loan Documents); use of proceeds of the Incremental Term Loans on the relevant Increase Effective Date; solvency of the Loan Parties and their Subsidiaries on a consolidated basis; Federal Reserve margin regulations; the Investment Company Act of 1940; the Patriot Act; OFAC; and Sanctions and Anti-Corruption Laws. “Specified Test Year” has the meaning specified in the definition of “Applicable Rate.”


 
31 “Subsidiary” of a Person means a corporation, partnership, joint venture, limited liability company or other business entity the accounts of which are consolidated with the accounts of such Person in such Person’s consolidated financial statements prepared in accordance with GAAP. Unless otherwise specified, all references herein to a “Subsidiary” or to “Subsidiaries” shall refer to a Subsidiary or Subsidiaries of a Loan Party. “Subsidiary Guarantor” means each of DOC and DOC OP. “Successor Rate” has the meaning specified in Section 3.03(b). “Supported QFC” has the meaning specified in Section 10.24. “Sustainability Assurance Provider” means Cventure LLC, or any replacement sustainability assurance provider thereof as designated from time to time by the Borrower; provided that any such replacement Sustainability Assurance Provider (a) shall be (i) a qualified external reviewer, independent of the Loan Parties and their Subsidiaries, believed in good faith by the Borrower to have relevant expertise, such as an auditor, environmental consultant and/or independent ratings agency or (ii) another firm designated by the Borrower and identified in writing to the Administrative Agent and the Lenders, so long as Lenders constituting the Required Lenders do not object to such designation pursuant to this clause (a)(ii) within five (5) Business Days after notice thereof (setting forth in reasonable detail the basis for such objection), and (b) to the extent relevant to the Sustainability Metric Components, shall apply auditing standards and methodology that are the same as or substantially consistent with the auditing standards and methodology used in the Borrower’s ESG Report for the calendar year ended December 31, 2020, except for any changes to such standards and/or methodology that (x) are not material, (y) are consistent with then generally accepted industry standards or (z) if not so consistent, are proposed by the Borrower and notified in writing to the Administrative Agent and the Lenders, so long as, in the case of this subclause (z), Lenders constituting Required Lenders do not object to such changes within five (5) Business Days after notice thereof (setting forth in reasonable detail the basis for such objection). “Sustainability Metric” means, for any given calendar year (for purposes of this definition, the “subject year”), the percentage change of the Sustainability Metric Components relative to the Sustainability Metric Baseline, which percentage change for any subject year shall be determined and calculated based on the following methodology: (a) the Sustainability Metric Components for such subject year shall be compared year-over-year to the Sustainability Metric Components for the immediately preceding calendar year using a like-for-like rolling baseline year reflecting the Boundary Properties that the Borrower has owned and that were in service for the period of two (2) full consecutive calendar years ending on the last day of such subject year (such methodology described in this clause (a), the “Rolling Base Year Methodology,” and the percentage change of such Sustainability Metric Components for a subject year relative to such Sustainability Metric Components for the immediately preceding calendar year being referred to as the “Rolling Base Year Percentage”, which, for the avoidance of doubt, shall be expressed as a negative percentage in the event such Sustainability Metric Components for such subject year are less than such Sustainability Metric Components for the immediately preceding calendar year); (b) in the case of the Specified Test Year ending December 31, 2022, the Sustainability Metric for such Specified Test Year shall be the percentage equal to the sum of (i) the Rolling Base Year Percentage for such Specified Test Year and (ii) the Rolling Base Year Percentage for the calendar year ended December 31, 2021; and (c) in the case of a Specified Test Year ending after December 31, 2022, the Sustainability Metric for such Specified Test Year shall be the percentage equal to the sum of (i) the Rolling Base Year Percentage for such Specified Test Year and (ii) the Rolling Base Year Percentage for each preceding calendar year ended on or after December 31, 2021.


 
32 “Sustainability Metric Annual Certificate” means a certificate substantially in the form of Exhibit G (or such other form as may be approved by the Administrative Agent), signed by a Responsible Officer, and attaching a copy of the Sustainability Metric Report for the most recently ended calendar year (provided that such a copy shall not be required to be so attached if such Sustainability Metric Report has been published on an Internet or intranet website to which each Lender and the Administrative Agent has or has been granted access free of charge); provided that the Borrower may, but shall not be required to, include a certification regarding whether or not the Sustainability Metric Election Threshold has been satisfied as of December 31 of the then most recently ended calendar year (commencing with the calendar year ending December 31, 2022) in any Compliance Certificate delivered by the Borrower from time to time pursuant to Section 6.02(a), and any Compliance Certificate containing such a certification (and attaching a copy of the applicable Sustainability Metric Report, except to the extent such attachment is not required as described above) shall be deemed to be the Sustainability Metric Annual Certificate for the calendar year most recently ended prior to the delivery of such Compliance Certificate. “Sustainability Metric Annual Certificate Inaccuracy” has the meaning specified in the definition of “Applicable Rate.” “Sustainability Metric Baseline” means the Borrower’s Sustainability Metric Components for the calendar year ended December 31, 2020, as set forth in the applicable Sustainability Metric Report (for the avoidance of doubt, subject to the Rolling Base Year Methodology). “Sustainability Metric Components” means, for any calendar year of the Borrower, the combined Scope 1 and Scope 2 greenhouse gas emissions of the Parent Guarantor, the Borrower and their respective Controlled Subsidiaries for such calendar year (determined in all material respects in conformity with the GRI Standards), less any qualified emissions offsets (including, but not limited to, renewable energy certificates) of the Parent Guarantor, the Borrower and their respective Controlled Subsidiaries during such calendar year, in each case, with respect to the Boundary Properties (subject to the Rolling Base Year Methodology). Qualified emissions offsets include any offsets used to calculate Scope 1 and Scope 2 emissions for reporting emissions in the applicable annual Sustainability Metric Report, including any offsets in which Parent Guarantor, Borrower and/or any of their respective Controlled Subsidiaries has an interest as a result of purchasing environmental attributes of projects other than those owned directly by the Parent Guarantor, the Borrower and/or any of their respective Controlled Subsidiaries. “Sustainability Metric Election Threshold” means, with respect to any Specified Test Year of the Borrower listed in the first column of the table set forth below, the percentage change specified opposite such Specified Test Year in the second column of the table below (such change specified in such column, the “Sustainability Metric Election Threshold”). Specified Test Year ending December 31 of Required Sustainability Metric Reduction 2022 -2.00% 2023 -3.00% 2024 -4.00% 2025 and thereafter -5.00% For purposes hereof, the Sustainability Metric Election Threshold for any Specified Test Year shall be satisfied if the Sustainability Metric for such Specified Test Year is a negative number the absolute value of which is equal to or greater than the absolute value of such Sustainability Metric Election Threshold. “Sustainability Metric Pricing Grid” has the meaning specified in the definition of “Applicable Rate.”


 
33 “Sustainability Metric Report” means an annual report by the Parent Guarantor or the Borrower (it being understood that such annual report for any year may take the form of the annual ESG Report) that sets forth the Sustainability Metric Components for a specific calendar year and with respect to which a verification review of the Scope 1 and Scope 2 emissions reported therein for such calendar year has been conducted by the Sustainability Assurance Provider; provided that, to the extent relevant to such Sustainability Metric Components, the qualified or limited statement of assurance from the Sustainability Assurance Provider that is set forth in, or attached to, such report shall be the same as or substantially similar in all material respects to the statement of the Sustainability Assurance Provider set forth on page 54 of the ESG Report for the calendar year ended December 31, 2020, except for any changes that (x) are with respect to any additional or increased level of assurance or any expanded scope of review, (y) are with respect to accounting standards or methodology, so long as, in the case of this subclause (y), such changes are consistent with the requirements of clause (b) of the definition of “Sustainability Assurance Provider” (without regard to whether such Sustainability Assurance Provider is a replacement Sustainability Assurance Provider) or (z) are proposed by the Borrower and notified in writing to the Administrative Agent and the Lenders, so long as, in the case of this subclause (z), Lenders constituting Required Lenders do not object to such changes within five (5) Business Days after notice thereof (setting forth in reasonable detail the basis for such objection). “Swap Contract” means (a) any and all rate swap transactions, basis swaps, credit derivative transactions, forward rate transactions, commodity swaps, commodity options, forward commodity contracts, equity or equity index swaps or options, bond or bond price or bond index swaps or options or forward bond or forward bond price or forward bond index transactions, interest rate options, forward foreign exchange transactions, cap transactions, floor transactions, collar transactions, currency swap transactions, cross-currency rate swap transactions, currency options, spot contracts, or any other similar transactions or any combination of any of the foregoing (including any options to enter into any of the foregoing), whether or not any such transaction is governed by or subject to any Master Agreement (as defined below), and (b) any and all transactions of any kind, and the related confirmations, which are subject to the terms and conditions of, or governed by, any form of master agreement published by the International Swaps and Derivatives Association, Inc., any International Foreign Exchange Master Agreement, or any other master agreement (any such master agreement, together with any related schedules, a “Master Agreement”), including any such obligations or liabilities under any Master Agreement. “Swap Obligations” means, with respect to any Guarantor Party, any obligation to pay or perform under any agreement, contract or transaction that constitutes a “swap” within the meaning of Section 1a(47) of the Commodity Exchange Act. “Swap Termination Value” means, in respect of any one or more Swap Contracts, after taking into account the effect of any legally enforceable netting agreement relating to such Swap Contracts, (a) for any date on or after the date such Swap Contracts have been closed out and termination value(s) determined in accordance therewith, such termination value(s), and (b) for any date prior to the date referenced in clause (a), the amount(s) determined as the mark-to-market value(s) for such Swap Contracts, as determined based upon one or more mid-market or other readily available quotations provided by any recognized dealer in such Swap Contracts (which may include a Lender or any Affiliate of a Lender). “Synthetic Lease Obligation” means the monetary obligation of a Person under (a) a so-called synthetic, off-balance sheet or tax retention lease or (b) any similar off-balance sheet financing product that is considered borrowed money indebtedness for tax purposes but classified as an operating lease under GAAP.


 
34 “Taxes” means all present or future taxes, levies, imposts, duties, deductions, withholdings (including backup withholding), assessments, fees or other charges imposed by any Governmental Authority, including any interest, additions to tax or penalties applicable thereto. “Term A-1 Borrowing” means a borrowing consisting of simultaneous Term A-1 Loans of the same Type and, in the case of Term SOFR Loans, having the same Interest Period made by each of the Term A-1 Lenders pursuant to Section 2.01(a). “Term A-1 Commitment” means, as to each Term A-1 Lender, its obligation to make Committed Term A-1 Loans to the Borrower pursuant to Section 2.01(a), in an aggregate principal amount which does not exceed the Dollar amount set forth opposite such Lender’s name in the column entitled “Term A-1 Commitment” on Schedule 2.01 or in the Assignment and Assumption or the New Lender Joinder Agreement pursuant to which such Lender becomes a party hereto, as applicable, as such amount may be adjusted from time to time in accordance with this Agreement. “Term A-1 Facility” means, at any time, (a) during the Availability Period in respect of such Facility, the sum of (i) the aggregate amount of the unused Term A-1 Commitments of all Term A-1 Lenders at such time and (ii) the aggregate Outstanding Amount of the Term A-1 Loans of all Term A-1 Lenders at such time and (b) thereafter, the aggregate Outstanding Amount of the Term A-1 Loans of all Term A-1 Lenders at such time. “Term A-1 Lender” means a Lender with a Term A-1 Commitment or an outstanding Committed Term A-1 Loan. “Term A-1 Loan” means any extension of credit under the Term A-1 Facility in the form of a loan by a Term A-1 Lender to the Borrower under Article II. “Term A-1 Loan Exposure” means, as to any Lender at any time, the aggregate Outstanding Amount at such time of its Term A-1 Loans; provided that at any time prior to the end of the Availability Period with respect to the Term A-1 Facility, the Term A-1 Loan Exposure of any Lender shall also include such Lender’s unused Term A-1 Commitment at such time. “Term A-1 Maturity Date” means August 22, 2027 (or, if such date is not a Business Day, the immediately preceding Business Day). “Term A-1 Note” means a promissory note made by the Borrower in favor of a Term A-1 Lender evidencing Term A-1 Loans made by such Lender, substantially in the form of Exhibit D–1. “Term A-2 Borrowing” means a borrowing consisting of simultaneous Term A-2 Loans of the same Type and, in the case of Term SOFR Loans, having the same Interest Period made by each of the Term A-2 Lenders pursuant to Section 2.01(b). “Term A-2 Commitment” means, as to each Term A-2 Lender, its obligation to make Committed Term A-2 Loans to the Borrower pursuant to Section 2.01(b), in an aggregate principal amount which does not exceed the Dollar amount set forth opposite such Lender’s name in the column entitled “Term A-2 Commitment” on Schedule 2.01 or in the Assignment and Assumption or the New Lender Joinder Agreement pursuant to which such Lender becomes a party hereto, as applicable, as such amount may be adjusted from time to time in accordance with this Agreement. “Term A-2 Facility” means, at any time, (a) during the Availability Period in respect of such Facility, the sum of (i) the aggregate amount of the unused Term A-2 Commitments of all Term A-2


 
35 Lenders at such time and (ii) the aggregate Outstanding Amount of the Term A-2 Loans of all Term A-2 Lenders at such time and (b) thereafter, the aggregate Outstanding Amount of the Term A-2 Loans of all Term A-2 Lenders at such time. “Term A-2 Lender” means a Lender with a Term A-2 Commitment or an outstanding Committed Term A-2 Loan. “Term A-2 Loan” means any extension of credit under the Term A-2 Facility in the form of a loan by a Term A-2 Lender to the Borrower under Article II. “Term A-2 Loan Exposure” means, as to any Lender at any time, the aggregate Outstanding Amount at such time of its Term A-2 Loans; provided that at any time prior to the end of the Availability Period with respect to the Term A-2 Facility, the Term A-2 Loan Exposure of any Lender shall also include such Lender’s unused Term A-2 Commitment at such time. “Term A-2 Maturity Date” means February 22, 2027 (or, if such date is not a Business Day, the immediately preceding Business Day), subject to extension in accordance with Section 2.15. “Term A-2 Note” means a promissory note made by the Borrower in favor of a Term A-2 Lender evidencing Term A-2 Loans made by such Lender, substantially in the form of Exhibit D–2. “Term A-3 Borrowing” means a borrowing consisting of simultaneous Term A-3 Loans of the same Type and, in the case of Term SOFR Loans, having the same Interest Period made by each of the Term A-3 Lenders pursuant to Section 2.01(c). “Term A-3 Commitment” means, as to each Term A-3 Lender, its obligation to make Committed Term A-3 Loans on the Second Amendment Effective Date to the Borrower pursuant to Section 2.01(c), in an aggregate principal amount which does not exceed the Dollar amount set forth opposite such Lender’s name in the column entitled “Term A-3 Commitment” on Schedule 2.01. “Term A-3 Facility” means, at any time, the aggregate Outstanding Amount of the Term A-3 Loans of all Term A-3 Lenders at such time. “Term A-3 Lender” means a Lender with a Term A-3 Commitment or an outstanding Committed Term A-3 Loan. “Term A-3 Loan” means any extension of credit under the Term A-3 Facility in the form of a loan by a Term A-3 Lender to the Borrower under Article II. “Term A-3 Loan Exposure” means, as to any Lender at any time, the aggregate Outstanding Amount at such time of its Term A-3 Loans. “Term A-3 Maturity Date” means March 1, 2029 (or, if such date is not a Business Day, the immediately preceding Business Day). “Term A-3 Note” means a promissory note made by the Borrower in favor of a Term A-3 Lender evidencing Term A-3 Loans made by such Lender, substantially in the form of Exhibit D–3. “Term A-4 Borrowing” means a borrowing consisting of simultaneous Term A-4 Loans of the same Type and, in the case of Term SOFR Loans, having the same Interest Period made by each of the Term A-4 Lenders pursuant to Section 2.01(d).


 
36 “Term A-4 Commitment” means, as to each Term A-4 Lender, its obligation to make Committed Term A-4 Loans to the Borrower pursuant to Section 2.01(d), in an aggregate principal amount which does not exceed the Dollar amount set forth opposite such Lender’s name in the column entitled “Term A-4 Commitment” on Schedule 2.01 or in the Assignment and Assumption or the New Lender Joinder Agreement pursuant to which such Lender becomes a party hereto, as applicable, as such amount may be adjusted from time to time in accordance with this Agreement. “Term A-4 Facility” means, at any time, (a) during the Availability Period in respect of such Facility, the sum of (i) the aggregate amount of the unused Term A-4 Commitments of all Term A-4 Lenders at such time and (ii) the aggregate Outstanding Amount of the Term A-4 Loans of all Term A-4 Lenders at such time and (b) thereafter, the aggregate Outstanding Amount of the Term A-4 Loans of all Term A-4 Lenders at such time. “Term A-4 Lender” means a Lender with a Term A-4 Commitment or an outstanding Committed Term A-4 Loan. “Term A-4 Loan” means any extension of credit under the Term A-4 Facility in the form of a loan by a Term A-4 Lender to the Borrower under Article II. “Term A-4 Loan Exposure” means, as to any Lender at any time, the aggregate Outstanding Amount at such time of its Term A-4 Loans; provided that at any time prior to the end of the Availability Period with respect to the Term A-4 Facility, the Term A-4 Loan Exposure of any Lender shall also include such Lender’s unused Term A-4 Commitment at such time. “Term A-4 Maturity Date” means March 23, 2031 (or, if such date is not a Business Day, the immediately preceding Business Day). “Term A-4 Note” means a promissory note made by the Borrower in favor of a Term A-4 Lender evidencing Term A-4 Loans made by such Lender, substantially in the form of Exhibit D–4. “Term A-4 Ticking Fee” has the meaning specified in Section 2.10(c)(i). “Term A-5 Borrowing” means a borrowing consisting of simultaneous Term A-5 Loans of the same Type and, in the case of Term SOFR Loans, having the same Interest Period made by each of the Term A-5 Lenders pursuant to Section 2.01(e). “Term A-5 Commitment” means, as to each Term A-5 Lender, its obligation to make Committed Term A-5 Loans to the Borrower pursuant to Section 2.01(e), in an aggregate principal amount which does not exceed the Dollar amount set forth opposite such Lender’s name in the column entitled “Term A-5 Commitment” on Schedule 2.01 or in the Assignment and Assumption or the New Lender Joinder Agreement pursuant to which such Lender becomes a party hereto, as applicable, as such amount may be adjusted from time to time in accordance with this Agreement. “Term A-5 Facility” means, at any time, (a) during the Availability Period in respect of such Facility, the sum of (i) the aggregate amount of the unused Term A-5 Commitments of all Term A-5 Lenders at such time and (ii) the aggregate Outstanding Amount of the Term A-5 Loans of all Term A-5 Lenders at such time and (b) thereafter, the aggregate Outstanding Amount of the Term A-5 Loans of all Term A-5 Lenders at such time. “Term A-5 Lender” means a Lender with a Term A-5 Commitment or an outstanding Committed Term A-5 Loan.


 
37 “Term A-5 Loan” means any extension of credit under the Term A-5 Facility in the form of a loan by a Term A-5 Lender to the Borrower under Article II. “Term A-5 Loan Exposure” means, as to any Lender at any time, the aggregate Outstanding Amount at such time of its Term A-5 Loans; provided that at any time prior to the end of the Availability Period with respect to the Term A-5 Facility, the Term A-5 Loan Exposure of any Lender shall also include such Lender’s unused Term A-5 Commitment at such time. “Term A-5 Maturity Date” means October 28, 2030 (or, if such date is not a Business Day, the immediately preceding Business Day). “Term A-5 Note” means a promissory note made by the Borrower in favor of a Term A-5 Lender evidencing Term A-5 Loans made by such Lender, substantially in the form of Exhibit D–5. “Term A-5 Ticking Fee” has the meaning specified in Section 2.10(c)(ii). “Term Facility” means the Term A-1 Facility, the Term A-2 Facility, the Term A-3 Facility or, the Term A-4 Facility or the Term A-5 Facility, as the context may require. “Term Loan” means a Term A-1 Loan, a Term A-2 Loan, a Term A-3 Loan or, a Term A-4 Loan or a Term A-5 Loan, as the context may require. “Term Note” means a Term A-1 Note, a Term A-2 Note, a Term A-3 Note or, a Term A-4 Note or a Term A-5 Note, as the context may require. “Term SOFR” means: (a) for any Interest Period with respect to a Term SOFR Loan, the rate per annum equal to the Term SOFR Screen Rate two U.S. Government Securities Business Days prior to the commencement of such Interest Period with a term equivalent to such Interest Period; provided that, if the rate is not published prior to 11:00 a.m. on such determination date then Term SOFR means the Term SOFR Screen Rate on the first U.S. Government Securities Business Day immediately prior thereto for which such rate was published; and (b) for any interest calculation with respect to a Base Rate Loan on any date, the rate per annum equal to the Term SOFR Screen Rate with a term of one month commencing that day; provided that, if the rate is not published prior to 11:00 a.m. on such determination date then Term SOFR means the Term SOFR Screen Rate on the first U.S. Government Securities Business Day immediately prior thereto for which such rate was published; provided that, if Term SOFR determined in accordance with the provisions of either clause (a) or (b) above would otherwise be less than 0.00%, then Term SOFR shall be deemed 0.00% for purposes of this Agreement. “Term SOFR Loan” means a Loan that bears interest at a rate based on clause (a) of the definition of “Term SOFR.” “Term SOFR Screen Rate” means the forward-looking SOFR term rate administered by CME (or any successor administrator satisfactory to the Administrative Agent) and published on the applicable Reuters screen page (or such other commercially available source providing such quotations as may be designated by the Administrative Agent from time to time).


 
38 “Third Amendment” means that certain Amendment No. 3 to Term Loan Agreement dated as of December 9, 2024, by and among the Guarantor Parties, the Borrower, the Lenders party thereto and the Administrative Agent. “Third Amendment Effective Date” has the meaning assigned thereto in the Third Amendment. “Threshold Amount” means $150,000,000. “Ticking Fee” has the meaning specified in Section 2.10(c)means the Term A-4 Ticking Fee or the Term A-5 Ticking Fee, as the context may require. “Total Loan Exposure” means, as to any Lender at any time, (a) in respect of the Term A-1 Facility, the Term A-1 Loan Exposure of such Lender at such time, (b) in respect of the Term A-2 Facility, the Term A-2 Loan Exposure of such Lender at such time, (c) in respect of the Term A-3 Facility, the Term A-3 Loan Exposure of such Lender at such time, (d) in respect of the Term A-4 Facility, the Term A-4 Loan Exposure of such Lender at such time and (e, (e) in respect of the Term A-5 Facility, the Term A-5 Loan Exposure of such Lender at such time and (f) in respect of any Incremental Term Loan Facility, the aggregate Outstanding Amount at such time of its Incremental Term Loans under such Incremental Term Loan Facility; provided that at any time prior to the termination of all commitments to make Incremental Term Loans under such Incremental Term Loan Facility, the Total Loan Exposure in respect of such Incremental Term Loan Facility of any Lender shall also include such Lender’s unused commitment, if any, at such time to make Incremental Term Loans under such Incremental Term Loan Facility. “Treasury Management Agreement” means any treasury, depository or cash management arrangements, services or products, including, without limitation, overdraft services and automated clearinghouse transfers of funds. “Treasury Management Lender” means any Person that, at the time it enters into a Treasury Management Agreement, is a Lender or an Affiliate of a Lender, in its capacity as a party to such Treasury Management Agreement. “Type” means, with respect to a Loan, its character as a Base Rate Loan, a Term SOFR Loan or, solely with respect to the Term A-3 Loans and, the Term A-4 Loans and the Term A-5 Loans, a Daily SOFR Loan. “UK Financial Institution” means any BRRD Undertaking (as such term is defined under the PRA Rulebook (as amended from time to time) promulgated by the United Kingdom Prudential Regulation Authority) or any person subject to IFPRU 11.6 of the FCA Handbook (as amended from time to time) promulgated by the United Kingdom Financial Conduct Authority, which includes certain credit institutions and investment firms, and certain affiliates of such credit institutions or investment firms. “UK Resolution Authority” means the Bank of England or any other public administrative authority having responsibility for the resolution of any UK Financial Institution. “Unencumbered Asset Value” means, for a Person and its Subsidiaries on a consolidated basis, as of any date of determination, the sum of (a) the aggregate net book value, as determined in accordance with GAAP, of all real property of a Person (such Person, an “Unencumbered Pool Entity”) that is not subject to a Mortgage Lien plus (b) all accumulated depreciation and amortization with respect to such real properties plus (c) unrestricted cash and cash equivalents of such Person plus (d) the sum of (i) unencumbered mezzanine and mortgage loan receivables (at the value reflected in the consolidated financial statements of the Parent Guarantor, in accordance with GAAP, as of such date, including the effect


 
39 of any impairment charges) and (ii) unencumbered marketable securities (at the value reflected in the consolidated financial statements of the Parent Guarantor, in accordance with GAAP, as of such date, including the effect of any impairment charges); provided that the items described in this clause (ii) and in the preceding clause (i) shall not be taken into account to the extent that the amounts of such items exceed, in the aggregate, 20% of Unencumbered Asset Value. For purposes of this definition, (1) (x) with respect to the Parent Guarantor and its Subsidiaries, the phrase “not subject to a Mortgage Lien” shall include that all Equity Interests of an Unencumbered Pool Entity, and all Equity Interests of each Subsidiary of the Parent Guarantor that owns, directly or indirectly, any Equity Interests of any Unencumbered Pool Entity, shall be free of any Liens (other than Permitted Specified Liens and any lien securing Intercompany Indebtedness) and (y) “Mortgage Lien” shall not include any lien securing Intercompany Indebtedness, and (2) for the avoidance of doubt, the value of any asset or property subject to Liens on assets of the Parent Guarantor, the Borrower or any of their respective Subsidiaries securing obligations under Swap Contracts shall not be included in the calculation of Unencumbered Asset Value. “Unfunded Pension Liability” means the excess of a Pension Plan’s benefit liabilities under Section 4001(a)(16) of ERISA, over the current value of that Pension Plan’s assets, determined in accordance with the assumptions used for funding the Pension Plan pursuant to Section 412 of the Code for the applicable plan year. “United States” and “U.S.” mean the United States of America. “Unsecured Leverage Ratio” means, on the last day of any fiscal quarter, the ratio of (a) Enterprise Unsecured Debt outstanding on such date to (b) Enterprise Unencumbered Asset Value as of such date. Notwithstanding anything to the contrary contained herein, for the purposes of this ratio, the aggregate amount of all unrestricted cash and cash equivalents on such date deducted from Enterprise Unsecured Debt pursuant to the definition of “Enterprise Total Indebtedness” shall exclude the aggregate amount of all unrestricted cash and cash equivalents deducted from Enterprise Secured Debt pursuant to the definition of “Enterprise Total Indebtedness” for the purpose of determining the Secured Debt Ratio as of such date. “U.S. Government Securities Business Day” means any day except for (a) a Saturday, (b) a Sunday or (c) a day on which the Securities Industry and Financial Markets Association recommends that the fixed income departments of its members be closed for the entire day for purposes of trading in United States government securities. “U.S. Special Resolution Regimes” has the meaning specified in Section 10.24. “Wells Fargo” means Wells Fargo Bank, National Association and its successors. “Wholly-Owned Subsidiary” means any wholly-owned Subsidiary of the Parent Guarantor or the Borrower, as applicable, in each case, that is not a special purpose entity. “Write-Down and Conversion Powers” means, (a) with respect to any EEA Resolution Authority, the write-down and conversion powers of such EEA Resolution Authority from time to time under the Bail- In Legislation for the applicable EEA Member Country, which write-down and conversion powers are described in the EU Bail-In Legislation Schedule, and (b) with respect to the United Kingdom, any powers of the applicable Resolution Authority under the Bail-In Legislation to cancel, reduce, modify or change the form of a liability of any UK Financial Institution or any contract or instrument under which that liability arises, to convert all or part of that liability into shares, securities or obligations of that person or any other person, to provide that any such contract or instrument is to have effect as if a right had been exercised under it or to suspend any obligation in respect of that liability or any of the powers under that Bail-In Legislation that are related to or ancillary to any of those powers.


 
40 1.02 Other Interpretive Provisions. With reference to this Agreement and each other Loan Document, unless otherwise specified herein or in such other Loan Document: (a) The definitions of terms herein shall apply equally to the singular and plural forms of the terms defined. Whenever the context may require, any pronoun shall include the corresponding masculine, feminine and neuter forms. The words “include,” “includes” and “including” shall be deemed to be followed by the phrase “without limitation.” The word “will” shall be construed to have the same meaning and effect as the word “shall.” Unless the context requires otherwise, (i) any definition of or reference to any agreement, instrument or other document (including any Organization Document) shall be construed as referring to such agreement, instrument or other document as from time to time amended, restated, supplemented or otherwise modified (subject to any restrictions on such amendments, restatements, supplements or modifications set forth herein or in any other Loan Document), (ii) any reference herein to any Person shall be construed to include such Person’s successors and assigns, (iii) the words “hereto,” “herein,” “hereof” and “hereunder,” and words of similar import when used in any Loan Document, shall be construed to refer to such Loan Document in its entirety and not to any particular provision thereof, (iv) all references in a Loan Document to Articles, Sections, Exhibits and Schedules shall be construed to refer to Articles and Sections of, and Exhibits and Schedules to, the Loan Document in which such references appear, (v) any reference to any law shall include all statutory and regulatory provisions consolidating, amending replacing or interpreting such law and any reference to any law, rule or regulation shall, unless otherwise specified, refer to such law, rule or regulation as amended, modified or supplemented from time to time, and (vi) the words “asset” and “property” shall be construed to have the same meaning and effect and to refer to any and all tangible and intangible assets and properties, including cash, securities, accounts and contract rights. (b) In the computation of periods of time from a specified date to a later specified date, the word “from” means “from and including”; the words “to” and “until” each mean “to but excluding”; and the word “through” means “to and including.” (c) Section headings herein and in the other Loan Documents are included for convenience of reference only and shall not affect the interpretation of this Agreement or any other Loan Document. (d) Any reference herein to a merger, transfer, consolidation, amalgamation, assignment, sale, disposition or transfer, or similar term, shall be deemed to apply to a division of or by a limited liability company, or an allocation of assets to a series of a limited liability company (or the unwinding of such a division or allocation), as if it were a merger, transfer, consolidation, amalgamation, assignment, sale, disposition or transfer, or similar term, as applicable, to, of or with a separate Person. Any division of a limited liability company shall constitute a separate Person hereunder (and each division of any limited liability company that is a Subsidiary, joint venture or any other like term shall also constitute such a Person or entity). (e) For the avoidance of doubt, the parties intend that the term “Enterprise” refer to financial calculations that cover (i) the Group and (ii) the Borrower’s Pro Rata Share of Material Joint Ventures. 1.03 Accounting Terms. (a) Generally. All accounting terms not specifically or completely defined herein shall be construed in conformity with, and all financial data (including financial ratios and other financial calculations) required to be submitted pursuant to this Agreement shall be prepared in conformity with, GAAP applied on a consistent basis, as in effect from time to time, applied in a manner consistent with that


 
41 used in preparing the Audited Financial Statements, except as otherwise specifically prescribed herein. Notwithstanding the foregoing, for purposes of determining compliance with any covenant (including the computation of any financial covenant) contained herein, Indebtedness of the Parent Guarantor and its Subsidiaries shall be deemed to be carried in accordance with GAAP, excluding the effects of FASB ASC 825 on financial liabilities. Notwithstanding anything to the contrary in the Loan Documents, and notwithstanding any accounting change after January 1, 2019 that would require lease obligations (whether such lease obligations are entered into before or after such date) that would be treated as operating leases to be classified and accounted for as Financing Leases or otherwise reflected on the consolidated balance sheet of the Parent Guarantor and its Subsidiaries, for the purposes of determining compliance with any covenant contained herein, such obligations shall be treated in the same manner as operating leases are treated as of such date without giving effect to any such changes in accounting and shall not constitute Indebtedness or a Financing Leases of the Parent Guarantor or any of its Subsidiaries as a result of such changes in accounting. (b) Changes in GAAP. If at any time any change in GAAP would affect the computation of any financial ratio or requirement set forth in any Loan Document, and either the Borrower or the Required Lenders shall so request, the Administrative Agent, the Lenders and the Borrower shall negotiate in good faith to amend such ratio or requirement to preserve the original intent thereof in light of such change in GAAP (subject to the approval of the Required Lenders and the Borrower); provided that, until so amended, (i) such ratio or requirement shall continue to be computed in accordance with GAAP prior to such change therein and (ii) the Borrower shall provide to the Administrative Agent financial statements and other documents required under this Agreement or as reasonably requested in writing hereunder by the Administrative Agent setting forth a reconciliation between calculations of such ratio or requirement made before and after giving effect to such change in GAAP. 1.04 Rounding. Any financial ratios required to be maintained by the Parent Guarantor pursuant to this Agreement shall be calculated by dividing the appropriate component by the other component, carrying the result to one place more than the number of places by which such ratio is expressed herein and rounding the result up or down to the nearest number (with a rounding-up if there is no nearest number). 1.05 [Reserved]. 1.06 [Reserved]. 1.07 Interest Rates. Except as specifically set forth herein, the Administrative Agent does not warrant, nor accept responsibility, nor shall the Administrative Agent have any liability with respect to the administration, submission or any other matter related to any reference rate referred to herein or with respect to any rate (including, for the avoidance of doubt, the selection of such rate and any related spread or other adjustment) that is an alternative or replacement for or successor to any such rate (including, without limitation, any Successor Rate) (or any component of any of the foregoing) or the effect of any of the foregoing, or of any Conforming Changes. The Administrative Agent and its affiliates or other related entities may engage in transactions or other activities that affect any reference rate referred to herein, or any alternative, successor or replacement rate (including, without limitation, any Successor Rate) (or any component of any of the foregoing) or any related spread or other adjustments thereto, in each case, in a manner adverse to the Borrower. The Administrative Agent may select information sources or services in its reasonable discretion to ascertain any reference rate referred to herein or any alternative, successor or replacement rate (including, without limitation, any Successor Rate) (or any component of any of the foregoing), in each case pursuant to the terms of this Agreement, and shall have no liability to the Borrower, any Lender or any other person or entity for damages of any kind, including direct or indirect, special,


 
42 punitive, incidental or consequential damages, costs, losses or expenses (whether in tort, contract or otherwise and whether at law or in equity), for any error or other action or omission related to or affecting the selection, determination, or calculation of any such rate (or component thereof) provided by any such information source or service. 1.08 Times of Day. Unless otherwise specified, all references herein to times of day shall be references to Eastern time (daylight or standard, as applicable). ARTICLE II THE COMMITMENTS AND CREDIT EXTENSIONS 2.01 Committed Loans. (a) Term A-1 Borrowings. Subject to the terms and conditions set forth herein, each Term A-1 Lender severally agrees to make term loans (each such loan, a “Committed Term A-1 Loan”) to the Borrower in Dollars from time to time, on any Business Day during the Availability Period for the Term A-1 Facility, in an aggregate amount not to exceed such Term A-1 Lender’s Applicable Percentage of the Term A-1 Facility; provided that, there shall be no more than five (5) separate Borrowing Dates on which any Term Loans made pursuant to Section 2.01(a) and/or Section 2.01(b) during the Availability Period with respect to the Term A-1 Facility. Each Term A-1 Borrowing shall consist of Term A-1 Loans made simultaneously by the Term A-1 Lenders in accordance with their respective Applicable Percentage of the Term A-1 Facility. Amounts borrowed under this Section 2.01(a) and repaid or prepaid may not be reborrowed. Term A-1 Loans may be Base Rate Loans or Term SOFR Loans, as further provided herein. (b) Term A-2 Borrowings. Subject to the terms and conditions set forth herein, each Term A-2 Lender severally agrees to make term loans (each such loan, a “Committed Term A-2 Loan”) to the Borrower in Dollars from time to time, on any Business Day during the Availability Period for the Term A-2 Facility, in an aggregate amount not to exceed such Term A-2 Lender’s Applicable Percentage of the Term A-2 Facility; provided that, there shall be no more than five (5) separate Borrowing Dates on which any Term Loans made pursuant to Section 2.01(a) and/or Section 2.01(b) during the Availability Period with respect to the Term A-2 Facility. Each Term A-2 Borrowing shall consist of Term A-2 Loans made simultaneously by the Term A-2 Lenders in accordance with their respective Applicable Percentage of the Term A-2 Facility. Amounts borrowed under this Section 2.01(b) and repaid or prepaid may not be reborrowed. Term A-2 Loans may be Base Rate Loans or Term SOFR Loans, as further provided herein. (c) Term A-3 Borrowings. Subject to the terms and conditions set forth herein, each Term A-3 Lender severally agrees to make term loans (each such loan, a “Committed Term A-3 Loan”) to the Borrower in Dollars on the Second Amendment Effective Date. Each Term A-3 Borrowing shall consist of Term A-3 Loans made simultaneously by the Term A-3 Lenders in accordance with their respective Applicable Percentage of the Term A-3 Facility. Amounts borrowed under this Section 2.01(c) and repaid or prepaid may not be reborrowed. Term A-3 Loans may be Base Rate Loans, Term SOFR Loans or Daily SOFR Loans, as further provided herein. (d) Term A-4 Borrowings. Subject to the terms and conditions set forth herein, each Term A-4 Lender severally agrees to make term loans (each such loan, a “Committed Term A-4 Loan”) to the Borrower in Dollars from time to time, on any Business Day during the Availability Period for the Term A-4 Facility, in an aggregate amount not to exceed such Term A-4 Lender’s Applicable Percentage of the Term A-4 Facility; provided that, there shall be no more than five (5) separate Borrowing Dates on which


 
43 any Term Loans are made pursuant to this Section 2.01(d) during the Availability Period with respect to the Term A-4 Facility. Each Term A-4 Borrowing shall consist of Term A-4 Loans made simultaneously by the Term A-4 Lenders in accordance with their respective Applicable Percentage of the Term A-4 Facility. Amounts borrowed under this Section 2.01(d) and repaid or prepaid may not be reborrowed. Term A-4 Loans may be Base Rate Loans, Term SOFR Loans or Daily SOFR Loans, as further provided herein. (e) Term A-5 Borrowings. Subject to the terms and conditions set forth herein, each Term A-5 Lender severally agrees to make term loans (each such loan, a “Committed Term A-5 Loan”) to the Borrower in Dollars from time to time, on any Business Day during the Availability Period for the Term A-5 Facility, in an aggregate amount not to exceed such Term A-5 Lender’s Applicable Percentage of the Term A-5 Facility; provided that, there shall be no more than five (5) separate Borrowing Dates on which any Term Loans are made pursuant to this Section 2.01(e) during the Availability Period with respect to the Term A-5 Facility. Each Term A-5 Borrowing shall consist of Term A-5 Loans made simultaneously by the Term A-5 Lenders in accordance with their respective Applicable Percentage of the Term A-5 Facility. Amounts borrowed under this Section 2.01(e) and repaid or prepaid may not be reborrowed. Term A-5 Loans may be Base Rate Loans, Term SOFR Loans or Daily SOFR Loans, as further provided herein. 2.02 Borrowings and Conversions and Continuations of Loans. (a) Each Borrowing, each conversion of Loans from one Type to another Type, and each continuation of Term SOFR Loans shall be made upon the Borrower’s irrevocable notice to the Administrative Agent, which may be given by (A) telephone, or (B) a Committed Loan Notice; provided that any telephonic notice must be confirmed immediately by delivery to the Administrative Agent of a Committed Loan Notice. Each such Committed Loan Notice must be received by the Administrative Agent not later than 12:00 Noon (i) two (2) Business Days prior to the requested date of any Borrowing of, conversion to or continuation of Term SOFR Loans or of any conversion of Term SOFR Loans to Base Rate Loans (or, with respect to such a Borrowing of any Incremental Term Loan, such other notice period as may be agreed to in the relevant Incremental Term Loan Amendment), (ii) solely with respect to Term A-3 Loans or, Term A-4 Loans or Term A-5 Loans, on the requested date of any Borrowing of, or conversion to, Daily SOFR Loans or of any conversion of Daily SOFR Loans to Base Rate Loans, and (iii) on the requested date of any Borrowing of Base Rate Loans. Each Borrowing of or conversion to Term SOFR Loans or Daily SOFR Loans, or continuation of Term SOFR Loans, shall be in a principal amount equal to $1,000,000 or a whole multiple of $100,000 in excess thereof. Each Borrowing of or conversion to Base Rate Loans shall be in a principal amount equal to $500,000 or a whole multiple of $100,000 in excess thereof. Each Committed Loan Notice (whether telephonic or written) shall specify (i) whether the Borrower is requesting a Borrowing of Committed Term A-1 Loans, a Borrowing of Committed Term A-2 Loans, a Borrowing of Committed Term A-3 Loans, a Borrowing of Committed Term A-4 Loans, a Borrowing of Committed Term A-5 Loans, a Borrowing of Incremental Term Loans of a specific tranche, a conversion of Loans from one Type to another Type, or a continuation of Term SOFR Loans, (ii) the requested date of the Borrowing, conversion or continuation, as the case may be (which shall be a Business Day), (iii) the principal amount of Loans to be borrowed, converted or continued, (iv) the Type and Class of Loans to be borrowed or to which existing Loans are to be converted, and (v) if applicable, the duration of the Interest Period with respect thereto. If the Borrower fails to specify a Type of Loan in a Committed Loan Notice or if the Borrower fails to give a timely notice requesting a conversion or continuation, then the applicable Loans shall be made as, or converted to, Base Rate Loans; provided, however, that, in the case of a failure to timely request a continuation of Term SOFR Loans, such Loans shall be continued as Term SOFR Loans with an Interest Period of one month (unless an Event of Default exists and is continuing


 
44 at such time and the Administrative Agent has notified the Borrower that the Required Lenders have determined that such a continuation as Term SOFR Loans is not appropriate in accordance with Section 2.02(c)). Any such automatic conversion to Base Rate Loans or Term SOFR Loans with an Interest Period of one month shall be effective as of the last day of the Interest Period then in effect with respect to the applicable Term SOFR Loans. If the Borrower requests a Borrowing of, conversion to, or continuation of Term SOFR Loans in any such Committed Loan Notice, but fails to specify an Interest Period, it will be deemed to have specified an Interest Period of one month. For the avoidance of doubt, Base Rate Loans shall automatically continue as Base Rate Loans and Daily SOFR Loans shall automatically continue as Daily SOFR Loans unless and until such Loans are converted to Term SOFR Loans pursuant to this Section 2.02 or are repaid in accordance with this Agreement, and no Committed Loan Notice shall be required in connection with such continuation. (b) Following receipt of a Committed Loan Notice requesting a Committed Borrowing, the Administrative Agent shall promptly notify each applicable Lender of the amount of its Applicable Percentage of the Committed Loans under the applicable Facility. In the case of a Borrowing, each applicable Lender shall make the amount of its Loan available to the Administrative Agent in Same Day Funds at the Administrative Agent’s Office not later than 1:00 p.m. on the Business Day specified in the applicable Committed Loan Notice. In any event, a Lender may cause any domestic branch or Affiliate to fund or make the amount of its Loan available in accordance with the foregoing provisions. Upon satisfaction or waiver of the applicable conditions set forth in Section 4.02 (or in the case of (x) a Borrowing requested by the Borrower to be made on the Closing Date, the conditions set forth in Section 4.01, or (y) a Borrowing of Incremental Term Loans, the applicable conditions set forth in Section 2.16(e)), the Administrative Agent shall make all funds so received available to the Borrower in like funds as received by the Administrative Agent either by (i) crediting the account of the Borrower on the books of Bank of America with the amount of such funds or (ii) wire transfer of such funds, in each case in accordance with instructions provided to (and reasonably acceptable to) the Administrative Agent by the Borrower. (c) Except as otherwise provided herein, a Term SOFR Loan may be continued or converted only on the last day of an Interest Period for such Term SOFR Loan. During the existence of an Event of Default that is continuing, no Loans may be requested as, converted to or continued as Term SOFR Loans, or, solely with respect to Term A-3 Loans or, Term A-4 Loans or Term A-5 Loans, Daily SOFR Loans, if the Administrative Agent has notified the Borrower that the Required Lenders have determined that such a continuation or conversion is not appropriate. (d) The Administrative Agent shall promptly notify the Borrower and the Lenders of the interest rate applicable to any Interest Period for Term SOFR Loans upon determination of such interest rate. At any time that Base Rate Loans are outstanding, the Administrative Agent shall notify the Borrower and the Lenders of any change in Bank of America’s prime rate used in determining the Base Rate promptly following the public announcement of such change. (e) After giving effect to all Committed Borrowings, all conversions of Committed Loans from one Type to another Type, and all continuations of Committed Loans as the same Type, there shall not be more than (i) six (6) Interest Periods in effect with respect to all Committed Term A-1 Loans, (ii) six (6) Interest Periods in effect with respect to all Committed Term A-2 Loans, (iii) six (6) Interest Periods in effect with respect to all Committed Term A-3 Loans, and (iv) six (6) Interest Periods in effect with respect to all Committed Term A-4 Loans and (v) six (6) Interest Periods in effect with respect to all Committed Term A-5 Loans.


 
45 (f) With respect to SOFR, Daily SOFR or Term SOFR, the Administrative Agent will have the right to make Conforming Changes from time to time and, notwithstanding anything to the contrary herein or in any other Loan Document, any amendments implementing such Conforming Changes will become effective without any further action or consent of any other party to this Agreement or any other Loan Document; provided that, with respect to any such amendment effected, the Administrative Agent shall post each such amendment implementing such Conforming Changes to the Borrower and the Lenders reasonably promptly after such amendment becomes effective. 2.03 [Reserved]. 2.04 [Reserved]. 2.05 [Reserved]. 2.06 Prepayments. The Borrower may, upon notice to the Administrative Agent, at any time or from time to time, voluntarily prepay any Loans of any Class in whole or in part without premium or penalty pursuant to this Section 2.06; provided that (i) such notice must be received by the Administrative Agent not later than 11:00 a.m. (A) two (2) Business Days (or such shorter period as the Administrative Agent shall agree) prior to any date of prepayment of Term SOFR Loans, (B) on the date of prepayment of Daily SOFR Loans and (C) on the date of prepayment of Base Rate Loans; (ii) any prepayment of Term SOFR Loans or Daily SOFR Loans shall be in a principal amount of $1,000,000 or a whole multiple of $100,000 in excess thereof; and (iii) any prepayment of Base Rate Loans shall be in a principal amount of $500,000 or a whole multiple of $100,000 in excess thereof or, in each case, if less, the entire principal amount thereof then outstanding. Each such notice shall specify the date and amount of such prepayment and the Type(s) and Class(es) of Loans to be prepaid and, if Term SOFR Loans are to be prepaid, the Interest Period(s) of such Loans. The Administrative Agent will promptly notify each applicable Lender of its receipt of each such notice, and of the amount of such Lender’s Applicable Percentage of such prepayment of the applicable Class(es) of Loans. If such notice is given by the Borrower, the Borrower shall make such prepayment and the payment amount specified in such notice shall be due and payable on the date specified therein; provided, however, that a notice of voluntary prepayment may state that such notice is conditioned upon an event, such as the effectiveness of other credit facilities, the receipt of the proceeds from the issuance of Equity Interests or other Indebtedness or the receipt of the proceeds from a Disposition, in which case such notice of prepayment may be revoked by the Borrower if such condition is not satisfied. Any prepayment of a Term SOFR Loan or a Daily SOFR Loan shall be accompanied by all accrued interest on the amount prepaid, together with, in the case of any Term SOFR Loan, any additional amounts required pursuant to Section 3.05. Subject to Section 2.18, each prepayment of Loans of any Class made pursuant to this Section 2.06 shall be made ratably among the Lenders of such Class in accordance with their respective Applicable Percentages of such Class of Loans. 2.07 Termination or Reduction of Commitments. (a) Concurrently with the Borrowing of any Term A-1 Loans on any Borrowing Date, the Term A-1 Commitment of each Term A-1 Lender will be permanently reduced on a dollar-for-dollar basis by the principal amount of Term A-1 Loans made by such Term A-1 Lender on such Borrowing Date. Concurrently with the Borrowing of any Term A-2 Loans on any Borrowing Date, the Term A-2 Commitment of each Term A-2 Lender will be permanently reduced on a dollar-for-dollar basis by the principal amount of Term A-2 Loans made by such Term A-2 Lender on such Borrowing Date. Concurrently with the Borrowing of the Term A-3 Loans on the Second Amendment Effective Date, the Term A-3 Commitment of each Term A-3 Lender will be permanently reduced to zero and be terminated. Concurrently with the Borrowing of any Term A-4 Loans on any Borrowing Date, the Term A-4 Commitment of each Term A-4 Lender will be permanently reduced on a dollar-for-dollar basis by the


 
46 principal amount of Term A-4 Loans made by such Term A-4 Lender on such Borrowing Date. Concurrently with the Borrowing of any Term A-5 Loans on any Borrowing Date, the Term A-5 Commitment of each Term A-5 Lender will be permanently reduced on a dollar-for-dollar basis by the principal amount of Term A-5 Loans made by such Term A-5 Lender on such Borrowing Date. (b) Unless previously terminated, (i) the Aggregate Term A-1 Commitments will terminate in full at 5:00 p.m. on the last day of the Availability Period with respect to the Term A-1 Facility, (ii) the Aggregate Term A-2 Commitments will terminate in full at 5:00 p.m. on the last day of the Availability Period with respect to the Term A-2 Facility and, (iii) the Aggregate Term A-4 Commitments will terminate in full at 5:00 p.m. on the last day of the Availability Period with respect to the Term A-4 Facility. and (iv) the Aggregate Term A-5 Commitments will terminate in full at 5:00 p.m. on the last day of the Availability Period with respect to the Term A-5 Facility. (c) The Borrower may, upon notice to the Administrative Agent, terminate the Aggregate Term A-1 Commitments, the Aggregate Term A-2 Commitments or, the Aggregate Term A-4 Commitments or the Aggregate Term A-5 Commitments, or from time to time permanently reduce the Aggregate Term A-1 Commitments, the Aggregate Term A-2 Commitments or, the Aggregate Term A-4 Commitments or the Aggregate Term A-5 Commitments; provided that (i) any such notice shall be received by the Administrative Agent not later than 12:00 Noon five (5) Business Days prior to the date of termination or reduction, and (ii) any such partial reduction shall be in an aggregate amount of $5,000,000 or any whole multiple of $1,000,000 in excess thereof. Each such notice of termination shall specify such election to terminate, the relevant Class(es) of Commitments to be terminated, and the effective date thereof. The Administrative Agent will promptly notify the Lenders of the relevant Class(es) of any such notice of termination or reduction of Commitments of such Class(es). A notice delivered by the Borrower pursuant to this Section 2.07(c) may state that such notice is conditioned upon an event, such as the effectiveness of other credit facilities, the receipt of the proceeds from the issuance of Equity Interests or other Indebtedness or the receipt of the proceeds from a Disposition, in which case such notice may be revoked by the Borrower (by notice to the Administrative Agent on or prior to the specified effective date) if such condition is not satisfied. (d) Any reduction of the Aggregate Term A-1 Commitments pursuant to Section 2.07(b) or (c) shall be applied to the Term A-1 Commitment of each Lender according to its Applicable Percentage of the Term A-1 Facility. Any reduction of the Aggregate Term A-2 Commitments pursuant to Section 2.07(b) or (c) shall be applied to the Term A-2 Commitment of each Lender according to its Applicable Percentage of the Term A-2 Facility. Any reduction of the Aggregate Term A-4 Commitments pursuant to Section 2.07(b) or (c) shall be applied to the Term A-4 Commitment of each Lender according to its Applicable Percentage of the Term A-4 Facility. Any reduction of the Aggregate Term A-5 Commitments pursuant to Section 2.07(b) or (c) shall be applied to the Term A-5 Commitment of each Lender according to its Applicable Percentage of the Term A-5 Facility. 2.08 Repayment. (a) The Borrower shall repay to the Term A-1 Lenders on the Term A-1 Maturity Date, unless accelerated sooner pursuant to Section 8.02, the entire outstanding principal balance of all Committed Term A-1 Loans, together with accrued but unpaid interest, fees and all other sums with respect thereto. (b) The Borrower shall repay to the Term A-2 Lenders on the Term A-2 Maturity Date, unless accelerated sooner pursuant to Section 8.02, the entire outstanding principal balance of all Committed Term A-2 Loans, together with accrued but unpaid interest, fees and all other sums with respect thereto.


 
47 (c) The Borrower shall repay to the Term A-3 Lenders on the Term A-3 Maturity Date, unless accelerated sooner pursuant to Section 8.02, the entire outstanding principal balance of all Committed Term A-3 Loans, together with accrued but unpaid interest, fees and all other sums with respect thereto. (d) The Borrower shall repay to the Term A-4 Lenders on the Term A-4 Maturity Date, unless accelerated sooner pursuant to Section 8.02, the entire outstanding principal balance of all Committed Term A-4 Loans, together with accrued but unpaid interest, fees and all other sums with respect thereto. (e) The Borrower shall repay to the Term A-5 Lenders on the Term A-5 Maturity Date, unless accelerated sooner pursuant to Section 8.02, the entire outstanding principal balance of all Committed Term A-5 Loans, together with accrued but unpaid interest, fees and all other sums with respect thereto. 2.09 Interest. (a) Applicable Interest. Subject to the provisions of Section 2.09(b), (i) each Term SOFR Loan shall bear interest on the outstanding principal amount thereof for each Interest Period applicable thereto at a rate per annum equal to Term SOFR for such Interest Period plus the Applicable Rate; (ii) each Term A-3 Loan or, Term A-4 Loan or Term A-5 Loan that is a Daily SOFR Loan shall bear interest on the outstanding principal amount thereof from the applicable borrowing date at a rate per annum equal to Daily SOFR plus the Applicable Rate; and (iii) each Base Rate Loan shall bear interest on the outstanding principal amount thereof from the applicable borrowing date at a rate per annum equal to the Base Rate plus the Applicable Rate. (b) Default Interest. (i) If any amount of principal of any Loan is not paid when due, whether at stated maturity, by acceleration or otherwise, then upon the request of the Required Lenders, such amount shall thereafter bear interest at a fluctuating interest rate per annum at all times equal to the Default Rate to the fullest extent permitted by applicable Laws. (ii) If any amount (other than principal of any Loan) payable by the Borrower under any Loan Document is not paid when due (without regard to any applicable grace periods), whether at stated maturity, by acceleration or otherwise, then upon the request of the Required Lenders, such amount shall thereafter bear interest at a fluctuating interest rate per annum at all times equal to the Default Rate to the fullest extent permitted by applicable Laws. (iii) Upon the request of the Required Lenders, while any Event of Default exists, (x) the Borrower shall pay interest on the principal amount of all outstanding Obligations hereunder at a fluctuating interest rate per annum at all times equal to the Default Rate to the fullest extent permitted by applicable Laws and (y) any adjustment to the Applicable Rate pursuant to the Sustainability Metric Pricing Grid shall cease to apply. (iv) Accrued and unpaid interest on past due amounts (including interest on past due interest) shall be due and payable upon demand. (c) Interest Payment Date. Interest on each Loan shall be due and payable in arrears on each Interest Payment Date applicable thereto and at such other times as may be specified herein. Interest hereunder shall be due and payable in accordance with the terms hereof before and after judgment, and before and after the commencement of any proceeding under any Debtor Relief Law.


 
48 2.10 Fees. (a) The Borrower shall pay to the Arrangers and the Administrative Agent, as applicable, for their own respective accounts, in Dollars, fees in the amounts and at the times as separately agreed upon in writing between the Borrower, the applicable Arrangers and the Administrative Agent, as applicable. Such fees shall be fully earned when paid and shall not be refundable for any reason whatsoever, absent manifest error. (b) The Borrower shall pay to the Lenders, in Dollars, such fees as shall have been separately agreed upon in writing in the amounts and at the times so specified. Such fees shall be fully earned when paid and shall not be refundable for any reason whatsoever, absent manifest error. (c) Ticking Fees. (i) The Borrower agrees to pay to the Administrative Agent for the account of each Lender with respect to the Term A-4 Facility a ticking fee (the “Term A-4 Ticking Fee”) in Dollars, which, subject to adjustment as provided in Section 2.18, shall accrue at a rate of 0.15% (15.0 basis points) per annum on the actual daily amount of the undrawn Commitments of such Lender under the Term A-4 Facility during the period commencing on July 21, 2026 to but not including the earlier of (x) the final day of the Availability Period with respect to the Term A-4 Facility and (y) the date on which all Commitments under the Term A-4 Facility shall have been terminated. Accrued and unpaid Term A-4 Ticking Fees with respect to the Term A-4 Facility shall be due and payable quarterly in arrears and on the earliest of (i) the date that is the final day of the Availability Period with respect to the Term A-4 Facility and (ii) the date on which any Commitments under the Term A-4 Facility are terminated. (ii) The Borrower agrees to pay to the Administrative Agent for the account of each Lender with respect to the Term A-5 Facility a ticking fee (the “Term A-5 Ticking Fee”) in Dollars, which, subject to adjustment as provided in Section 2.18, shall accrue at a rate of 0.15% (15.0 basis points) per annum on the actual daily amount of the undrawn Commitments of such Lender under the Term A-5 Facility during the period commencing on January 26, 2027 to but not including the earlier of (x) the final day of the Availability Period with respect to the Term A-5 Facility and (y) the date on which all Commitments under the Term A-5 Facility shall have been terminated. Accrued and unpaid Term A-5 Ticking Fees with respect to the Term A-5 Facility shall be due and payable quarterly in arrears and on the earliest of (i) the date that is the final day of the Availability Period with respect to the Term A-5 Facility and (ii) the date on which any Commitments under the Term A-5 Facility are terminated. (iii) All Ticking Fees shall be computed on the basis of a year of 360 days and shall be payable for the actual number of days elapsed (including the first day but excluding the last day). 2.11 Computation of Interest and Fees. All computations of interest for Base Rate Loans (including Base Rate Loans determined by reference to Term SOFR) shall be made on the basis of a year of 365 or 366 days, as the case may be, and actual days elapsed. All other computations of fees and interest shall be made on the basis of a 360-day year and actual days elapsed (which results in more fees or interest, as applicable, being paid than if computed on the basis of a 365-day year). Interest shall accrue on each Loan for the day on which the Loan is made, and shall not accrue on a Loan, or any portion thereof, for the day on which the Loan or such portion is paid; provided that any Loan that is repaid on the same day on which it is made shall, subject to


 
49 Section 2.13(a), bear interest for one day. Each determination by the Administrative Agent of an interest rate or fee hereunder shall be conclusive and binding for all purposes, absent manifest error. 2.12 Evidence of Debt. The Credit Extensions made by each Lender shall be evidenced by one or more accounts or records maintained by such Lender and by the Administrative Agent in the ordinary course of business. The accounts or records maintained by the Administrative Agent and each Lender shall be conclusive absent manifest error of the amount of the Credit Extensions made by the Lenders to the Borrower and the interest and payments thereon. Any failure to so record or any error in doing so shall not, however, limit or otherwise affect the obligation of the Borrower hereunder to pay any amount owing with respect to the Obligations. In the event of any conflict between the accounts and records maintained by any Lender and the accounts and records of the Administrative Agent in respect of such matters, the accounts and records of the Administrative Agent shall control in the absence of manifest error. Upon the request of any Lender made through the Administrative Agent, the Borrower shall execute and deliver to such Lender (through the Administrative Agent) a Note with respect to the applicable Facility, which shall evidence such Lender’s Loans in addition to such accounts or records. Each Lender may attach schedules to its Note(s) and endorse thereon the date, Type (if applicable), amount, and maturity of its Loans and payments with respect thereto. 2.13 Payments Generally; Administrative Agent’s Clawback. (a) General. All payments to be made by the Borrower shall be made without condition or deduction for any counterclaim, defense, recoupment or setoff. Except as otherwise expressly provided herein, all payments by the Borrower hereunder shall be made to the Administrative Agent, for the account of the respective Lenders to which such payment is owed, at the Administrative Agent’s Office in Dollars and in Same Day Funds not later than 2:00 p.m. on the date specified herein. Without limiting the generality of the foregoing, the Administrative Agent may require that any payments due under this Agreement be made in the United States. The Administrative Agent will promptly distribute to each Lender its Applicable Percentage in respect of the relevant Facility (or other applicable share as provided herein) of such payment in like funds as received by wire transfer to such Lender’s Lending Office. All payments received by the Administrative Agent after 2:00 p.m. shall be deemed received on the next succeeding Business Day and any applicable interest or fee shall continue to accrue. If any payment to be made by the Borrower shall come due on a day other than a Business Day, such due date shall be extended to the next following Business Day, and such extension of time shall be reflected in computing interest or fees, as the case may be. (b) (i) Funding by Lenders; Presumption by Administrative Agent. Unless the Administrative Agent shall have received notice from a Lender prior to the proposed date of any Borrowing of Term SOFR Loans or, solely in the case of Term A-3 Loans or, Term A-4 Loans or Term A-5 Loans, Daily SOFR Loans (or, in the case of any Borrowing of Base Rate Loans, prior to 12:00 noon on the date of such Borrowing), that such Lender will not make available to the Administrative Agent such Lender’s share of such Borrowing, the Administrative Agent may assume that such Lender has made such share available on such date in accordance with Section 2.02 (or, in the case of a Borrowing of Base Rate Loans, that such Lender has made such share available in accordance with and at the time required by Section 2.02) and may, in reliance upon such assumption, make available to the Borrower a corresponding amount. In such event, if a Lender has not in fact made its share of the applicable Borrowing available to the Administrative Agent, then the applicable Lender and the Borrower severally agree to pay to the Administrative Agent forthwith on demand (without duplication) such corresponding amount in Same Day Funds with interest thereon, for each day from and including the date such amount is made available to the Borrower to but excluding the date of payment to the Administrative Agent, at (A) in the case of a payment to be made by such Lender, the Overnight Rate plus any administrative, processing or similar fees customarily charged by the Administrative Agent in connection with the foregoing, and (B) in the case of a payment to be made by the Borrower, the interest rate applicable to the Loans constituting such


 
50 Borrowing. If the Borrower and such Lender shall pay such interest to the Administrative Agent for the same or an overlapping period, the Administrative Agent shall promptly remit to the Borrower the amount of such interest paid by the Borrower for such period. In the event the Borrower pays such amount to the Administrative Agent, then such amount shall reduce the principal amount of such Borrowing (subject to the last sentence of this paragraph and any applicable provisions of Section 2.18). If such Lender pays its share of the applicable Borrowing to the Administrative Agent, then the amount so paid shall constitute such Lender’s Loan included in such Borrowing. Any payment by the Borrower shall be without prejudice to any claim the Borrower may have against a Lender that shall have failed to make such payment to the Administrative Agent. (ii) Payments by the Borrower; Presumptions by Administrative Agent. Unless the Administrative Agent shall have received notice from the Borrower prior to the time at which any payment is due to the Administrative Agent for the account of the Lenders of any Class hereunder that the Borrower will not make such payment, the Administrative Agent may assume that the Borrower has made such payment on such date in accordance herewith and may, in reliance upon such assumption, distribute to the Lenders of such Class the amount due. With respect to any payment that the Administrative Agent makes for the account of any of the Lenders hereunder as to which the Administrative Agent determines (which determination shall be conclusive absent manifest error) that any of the following applies (such payment referred to as the “Rescindable Amount”): (1) the Borrower has not in fact made such payment; (2) the Administrative Agent has made a payment in excess of the amount so paid by Borrower (whether or not then owed); or (3) the Administrative Agent has for any reason otherwise erroneously made such payment, then each of the Lenders severally agrees to repay to the Administrative Agent forthwith on demand the Rescindable Amount so distributed to such Lender, in Same Day Funds with interest thereon, for each day from and including the date such amount is distributed to it to but excluding the date of payment to the Administrative Agent, at the Overnight Rate. A notice of the Administrative Agent to any Lender or the Borrower with respect to any amount owing under this Section 2.13(b) shall be conclusive, absent manifest error. (c) Failure to Satisfy Conditions Precedent. If any Lender makes available to the Administrative Agent funds for any Loan to be made by such Lender as provided in the foregoing provisions of this Article II, and such funds are not made available to the Borrower by the Administrative Agent because the conditions to the applicable Credit Extension set forth in Section 4.02 (or in the case of (x) a Borrowing requested by the Borrower to be made on the Closing Date, the conditions set forth in Section 4.01, or (y) a Borrowing of Incremental Term Loans, the applicable conditions set forth in Section 2.16(e)) are not satisfied or waived in accordance with the terms hereof, the Administrative Agent shall return such funds (in like funds as received from such Lender) to such Lender, without interest. (d) Obligations of Lenders Several. The obligations of the Lenders hereunder to make Committed Term A-1 Loans, Committed Term A-2 Loans, Committed Term A-3 Loans and, Committed Term A-4 Loans and Committed Term A-5 Loans and to make payments pursuant to Section 10.04(c) are several and not joint. The failure of any Lender to make any Loan or to make any payment under Section 10.04(c) on any date required hereunder shall not relieve any other Lender of its corresponding obligation to do so on such date, and no Lender shall be responsible for the failure of any other Lender to so make its Loan or to make its payment under Section 10.04(c). (e) Funding Source. Nothing herein shall be deemed to obligate any Lender to obtain the funds for any Loan in any particular place or manner or to constitute a representation by any Lender that it has obtained or will obtain the funds for any Loan in any particular place or manner.


 
51 (f) Insufficient Funds. If at any time insufficient funds are received by and available to the Administrative Agent to pay fully all amounts of principal, interest and fees then due hereunder, such funds shall be applied (i) first, toward payment of interest and fees then due hereunder, ratably among the parties entitled thereto in accordance with the amounts of interest and fees then due to such parties, and (ii) second, toward payment of principal then due hereunder, ratably among the parties entitled thereto in accordance with the amounts of principal then due to such parties. 2.14 Sharing of Payments by Lenders. If any Lender shall, by exercising any right of setoff or counterclaim or otherwise, obtain payment in respect of any principal of or interest on any of the Loans of any Class made by it resulting in such Lender’s receiving payment of a proportion of the aggregate amount of such Loans of such Class and accrued interest thereon greater than its pro rata share thereof as provided herein, then the Lender receiving such greater proportion shall (a) notify the Administrative Agent of such fact, and (b) purchase (for cash at face value) participations in the Loans of the relevant Class(es), or make such other adjustments as shall be equitable, so that the benefit of all such payments shall be shared by the relevant Lenders of the relevant Class(es) ratably in accordance with the aggregate amount of principal of and accrued interest on their respective Loans of the relevant Class(es) or such other amounts owing them under the relevant Facilities, as applicable; provided that: (i) if any such participations are purchased and all or any portion of the payment giving rise thereto is recovered, such participations shall be rescinded and the purchase price restored to the extent of such recovery, without interest; and (ii) the provisions of this Section 2.14 shall not be construed to apply to (x) any payment made by or on behalf of the Borrower pursuant to and in accordance with the express terms of this Agreement (including the application of funds arising from the existence of a Defaulting Lender), (y) [reserved] or (z) any payment obtained by a Lender as consideration for the assignment of or sale of a participation in any of its Commitments or Loans to any assignee or participant, other than an assignment to the Borrower or any Subsidiary thereof (as to which the provisions of this Section 2.14 shall apply). The Borrower consents to the foregoing and agrees, to the extent it may effectively do so under applicable Law, that any Lender acquiring a participation pursuant to the foregoing arrangements may exercise against the Borrower rights of setoff and counterclaim with respect to such participation as fully as if such Lender were a direct creditor of the Borrower in the amount of such participation. 2.15 Extension of Term A-2 Maturity Date. (a) Requests for Extension. The Borrower may, by written notice to the Administrative Agent (who shall promptly notify the Term A-2 Lenders) not earlier than ninety (90) days and not later than thirty (30) days prior to the Term A-2 Maturity Date then in effect (such date, the “Initial Term A-2 Maturity Date”), elect that the Term A-2 Lenders extend the Term A-2 Maturity Date for an additional twelve (12) months after such Initial Term A-2 Maturity Date; provided that the Borrower may not make more than one (1) such election pursuant to this Section 2.15 during the term of this Agreement. (b) Confirmation by Administrative Agent. The Administrative Agent shall confirm receipt of the Borrower’s notice delivered pursuant to Section 2.15(a) no later than the date that is fifteen (15) days prior to the Initial Term A-2 Maturity Date (or, if such date is not a Business Day, on the next preceding Business Day).


 
52 (c) Extension of Term A-2 Maturity Date. If (and only if) the conditions precedent set forth in Section 2.15(d) have been met, then, effective as of the Initial Term A-2 Maturity Date, the Term A-2 Maturity Date shall be extended to the date falling twelve (12) months after the Initial Term A-2 Maturity Date (except that, if such date is not a Business Day, such Term A-2 Maturity Date as so extended shall be the next preceding Business Day). Upon satisfaction of the conditions precedent set forth in Section 2.15(d), as certified by the Borrower to the Administrative Agent in writing, the Administrative Agent shall deliver a copy of such certification to each Term A-2 Lender. (d) Conditions to Effectiveness of Extensions. As a condition precedent to such extension, (i) the Borrower shall deliver to the Administrative Agent a certificate of the Borrower dated as of the Initial Term A-2 Maturity Date signed by a Responsible Officer (x) certifying and attaching the resolutions adopted by the Borrower approving or consenting to such extension and (y) certifying that (1) the representations and warranties contained in Article V and in the other Loan Documents are true and correct in all material respects (except in the case of a representation or warranty qualified by materiality or Material Adverse Effect or similar language, in which case such representation or warranty shall be true and correct in all respects) on and as of the Initial Term A-2 Maturity Date (other than such representations and warranties, which are expressly made only as of the Closing Date or the FifthSixth Amendment Effective Date, as applicable, including but not limited to those set forth in Section 5.05(c) and Section 5.22), except to the extent that any such representation or warranty specifically refers to an earlier date, in which case such representation or warranty was true and correct in all material respects (except in the case of a representation or warranty qualified by materiality or Material Adverse Effect or similar language, in which case such representation or warranty shall have been true and correct in all respects) as of such earlier date, and except that for purposes of this Section 2.15, the representations and warranties contained in subsections (a) and (b) of Section 5.05 shall be deemed to refer to the most recent statements furnished pursuant to subsections (a) and (b), respectively, of Section 6.01 and (2) as of the Initial Term A-2 Maturity Date, and immediately after giving effect to such extension, no Default exists and (ii) the Borrower shall pay to the Term A-2 Lenders on or prior to the Initial Term A-2 Maturity Date a fee (to be shared among the Term A-2 Lenders based upon their Applicable Percentages of the Outstanding Amount of the Term A-2 Loans) equal to the product of (x) 0.125% multiplied by (y) the then Outstanding Amount of the Term A-2 Loans. (e) Conflicting Provisions. This Section 2.15 shall supersede any provisions in Section 2.02(b), 2.14 or 10.01 to the contrary. 2.16 Incremental Term Loans. (a) Request for Incremental Term Loans. From time to time, the Borrower shall have the right to enter into one or more new tranches (or increase an existing tranche) of term loans under this Agreement (each, an “Incremental Term Loan”); provided that (i) subject to the last proviso to clause (e)(i) below, no Default has occurred and is continuing, (ii) each increase or tranche of Incremental Term Loans must be in a minimum amount of $10,000,000 and in integral multiples of $5,000,000 in excess thereof (or such other amounts as are agreed to by the Borrower and the Administrative Agent), and (iii) after giving effect to all such Incremental Term Loans, the sum, without duplication, of the aggregate principal amounts of the Term A-1 Loans, the Term A-2 Loans, the Term A-3 Loans, the Term A-4 Loans, the Term A-5 Loans and all such Incremental Term Loans shall not exceed $2,000,000,0002,750,000,000. At the time of sending such notice to the Administrative Agent of the exercise of such right, the Borrower (in consultation with the Administrative Agent) shall specify the Lenders to be approached to provide all or a portion of such Incremental Term Loan (subject in each case to any requisite consents required under Section 10.06) and the time period within which each such Lender is requested to respond (which time period shall be as mutually agreed between the Borrower and the Administrative Agent).


 
53 (b) Lender Elections to Participate. Each Lender shall notify the Administrative Agent within such time period whether or not it agrees to participate in such new tranche or increase, as the case may be, and, if so, the maximum aggregate principal amount of the proposed Incremental Term Loans that such Lender is offering to provide. Any Lender not responding within such time period shall be deemed to have declined to participate in such new tranche or increase, as the case may be. Any such new tranche or increase shall be syndicated on a best efforts basis and no Lender shall be required to participate in any tranche of Incremental Term Loans to facilitate such tranche or increase. (c) Notification by Administrative Agent; Additional Lenders. The Administrative Agent shall notify the Borrower and each Lender of the Lenders’ responses to each request made hereunder. Subject to the approval of the Administrative Agent (which approval shall not be unreasonably withheld), the Borrower may also invite additional Eligible Assignees to become Lenders pursuant to a joinder agreement in form and substance reasonably satisfactory to the Administrative Agent and its counsel (a “New Lender Joinder Agreement”). (d) Effective Date and Allocations. If any Incremental Term Loan is extended in accordance with this Section 2.16, the Administrative Agent and the Borrower shall determine the effective date (the “Increase Effective Date”) and the final allocation thereof. The Administrative Agent shall promptly notify the Borrower and the Lenders of the final allocation of such Incremental Term Loan and the Increase Effective Date. (e) Conditions to Effectiveness of Incremental Term Loans. As a condition precedent to any Incremental Term Loan: (i) the Borrower shall deliver to the Administrative Agent a certificate of the Borrower dated as of the Increase Effective Date signed by a Responsible Officer (A) certifying and attaching the resolutions adopted by the Borrower approving or consenting to such Incremental Term Loan, and (B) certifying that (1) the representations and warranties contained in Article V and in the other Loan Documents are true and correct in all material respects (except in the case of a representation or warranty qualified by materiality or Material Adverse Effect or similar language, in which case such representation or warranty shall be true and correct in all respects) on and as of the Increase Effective Date (other than such representations and warranties which are expressly made only as of the Closing Date or the FifthSixth Amendment Effective Date, as applicable, including but not limited to those set forth in Section 5.05(c) and Section 5.22), except to the extent that any such representation or warranty specifically refers to an earlier date, in which case such representation or warranty was true and correct in all material respects (except in the case of a representation or warranty qualified by materiality or Material Adverse Effect or similar language, in which case such representation or warranty shall have been true and correct in all respects) as of such earlier date, and except that for purposes of this Section 2.16, the representations and warranties contained in subsections (a) and (b) of Section 5.05 shall be deemed to refer to the most recent statements furnished pursuant to clauses (a) and (b), respectively, of Section 6.01; provided that, in the case of any Incremental Term Loan the proceeds of which are to be used to finance an acquisition (including by means of a merger, amalgamation or consolidation) or other Investment not prohibited by this Agreement (and related transaction costs) the consummation of which is not conditioned on the availability of, or on obtaining, third-party financing or that is otherwise subject to customary “funds certain provisions,” to the extent agreed by the applicable Lenders providing such Incremental Term Loan, the representations and warranties the accuracy of which in all material respects (except in the case of a representation or warranty qualified by materiality or Material Adverse Effect or similar language, in which case such representation or warranty shall be accurate in all respects) are a condition to the funding of such Incremental Term Loan shall be limited to (x) the Specified Representations (or such other


 
54 formulation thereof as may be agreed by the applicable Lenders providing such Incremental Term Loan) and (y) those representations of the acquired company in the applicable acquisition agreement that are material to the interests of the applicable Lenders providing such Incremental Term Loan and which, if breached or inaccurate, would give the Parent Guarantor, the Borrower or any Subsidiary the right to terminate or refuse to close under the applicable acquisition agreement, and (2) as of the Increase Effective Date, and immediately after giving effect to such Incremental Term Loan, no Default or Event of Default exists; provided that, in the case of any Incremental Term Loan the proceeds of which are to be used to finance an acquisition or other Investment not prohibited by this Agreement (and related transaction costs) the consummation of which is not conditioned on the availability of, or on obtaining, third-party financing or that is otherwise subject to customary “funds certain provisions,” to the extent agreed by the applicable Lenders providing such Incremental Term Loan, this condition shall be limited to (x) at the time of the execution and delivery of the applicable acquisition agreement related to such acquisition, no Default shall have occurred and be continuing or shall occur as a result thereof and (y) upon the effectiveness and making of any Incremental Term Loan on the applicable Increase Effective Date, no Specified Default shall have occurred and be continuing or shall occur as a result thereof; (ii) (A) upon the reasonable request of any Lender made at least five (5) days prior to the applicable Increase Effective Date, the Borrower shall have provided to such Lender the documentation and other information so requested by such Lender that satisfies all requirements of regulatory authorities applicable to such Lender and such Lender’s internal policies and procedures in connection with applicable “know your customer” and anti-money-laundering rules and regulations, including, without limitation, the Patriot Act and (B) if the Borrower qualifies as a “legal entity customer” under the Beneficial Ownership Regulation it shall have delivered, to each Lender that so requests at least five (5) days prior to the applicable Increase Effective Date, a Beneficial Ownership Certification in relation to the Borrower; (iii) in the case of any tranche of Incremental Term Loans, such Incremental Term Loans (A) shall rank pari passu in right of payment with the Term Loans and any other outstanding Incremental Term Loans, (B) shall not mature earlier than the latest Maturity Date then in effect (but may have amortization prior to such date so long as the weighted average life to maturity of any Incremental Term Loans shall be no shorter than the remaining weighted average life to maturity of any previously funded and then outstanding Incremental Term Loans (if any) at such time); provided that, notwithstanding the foregoing, any increase pursuant to this Section 2.16 to a then existing tranche of Loans under this Agreement shall have the same Maturity Date as such then existing tranche that is being so increased, and (C) shall be treated substantially the same as (and in any event no more favorably than) the Term Loans and any other outstanding Incremental Term Loans; provided that (1) the terms and conditions applicable to any tranche of Incremental Term Loans maturing after the latest Maturity Date then in effect may provide for material additional or different financial or other covenants or requirements applicable only during periods after such Maturity Date then in effect, (2) the Incremental Term Loans may be priced differently than the Term Loans and any other outstanding Incremental Term Loans and (3) other terms and conditions applicable to Incremental Term Loans may be materially different from those of the Term Loans and any other outstanding Incremental Term Loans to the extent such differences are solely administrative in nature or are terms and conditions reasonably acceptable to the Administrative Agent or that customarily apply to syndicated term loan facilities (as determined in good faith by the board of directors or other equivalent governing body of the Borrower). Incremental Term Loans may be made hereunder pursuant to an amendment or restatement (an “Incremental Term Loan Amendment”) of this Agreement and, as appropriate, the other Loan Documents, executed by the Borrower, each Lender participating in such tranche or increase and the Administrative Agent. The Incremental Term Loan Amendment may, without the consent of


 
55 any other Lenders, effect such amendments to this Agreement and the other Loan Documents as may be necessary or appropriate, in the reasonable opinion of the Administrative Agent, to effect the provisions of this Section 2.16; (iv) the Administrative Agent shall have received a Request for Credit Extension in accordance with the terms hereof; and (v) the Borrower shall provide a Note to any Lender joining on the Increase Effective Date, if requested. (f) Conflicting Provisions. This Section 2.16 shall supersede any provisions in Sections 2.14 or 10.01 to the contrary. (g) Fees. In connection with any Incremental Term Loans pursuant to this Section 2.16, the Borrower shall pay such fees to the Administrative Agent, for its own account and for the benefit of the Lenders participating in such Incremental Term Loans, determined at the time of such funding of such Incremental Term Loans (or such other time specified in the relevant Incremental Term Loan Amendment) and agreed to by the Borrower in writing. (h) Lenders. In connection with any Incremental Term Loans pursuant to this Section 2.16, any new Lender party hereto shall (i) execute such documents and agreements as the Administrative Agent may reasonably request and (ii) in the case of any new Lender that is organized under the laws of a jurisdiction outside of the United States of America, provide to the Administrative Agent, its name, address, tax identification number and/or such other information as shall be necessary for the Administrative Agent to comply with “know your customer” and anti-money laundering rules and regulations, including, without limitation, the Patriot Act. 2.17 [Reserved]. 2.18 Defaulting Lenders. (a) Adjustments. Notwithstanding anything to the contrary contained in this Agreement, if any Lender becomes a Defaulting Lender, then, until such time as that Lender is no longer a Defaulting Lender, to the extent permitted by applicable Law: (i) Waivers and Amendments. That Defaulting Lender’s right to approve or disapprove any amendment, waiver or consent with respect to this Agreement shall be restricted as set forth in Section 10.01 and in the definitions of “Required Class Lenders,” “Required Lenders,” “Required Term A-1 Lenders,” “Required Term A-2 Lenders,” and “Required Term A-3 Lenders,” and “Required Term A-4 Lenders” and “Required Term A-5 Lenders.” (ii) Reallocation of Payments. Any payment of principal, interest, fees or other amounts received by the Administrative Agent for the account of that Defaulting Lender (whether voluntary or mandatory, at maturity, pursuant to Article VIII or otherwise, and including any amounts made available to the Administrative Agent by that Defaulting Lender pursuant to Section 10.08), shall be applied at such time or times as may be determined by the Administrative Agent as follows: first, to the payment of any amounts owing by that Defaulting Lender to the Administrative Agent hereunder; second, as the Borrower may request (so long as no Event of Default exists), to the funding of any Loan in respect of which such Defaulting Lender has failed to fund its portion thereof as required by this Agreement, as determined by the Administrative Agent; third, if so determined by the Administrative Agent and the Borrower, to be held in a non-


 
56 interest bearing deposit account and released in order to satisfy obligations of such Defaulting Lender to fund Loans under this Agreement; fourth, to the payment of any amounts owing to the other Lenders as a result of any judgment of a court of competent jurisdiction obtained by any Lender against such Defaulting Lender as a result of that Defaulting Lender’s breach of its obligations under this Agreement; fifth, so long as no Event of Default exists, to the payment of any amounts owing to the Borrower as a result of any judgment of a court of competent jurisdiction obtained by the Borrower against such Defaulting Lender as a result of such Defaulting Lender’s breach of its obligations under this Agreement; and sixth, to such Defaulting Lender or as otherwise directed by a court of competent jurisdiction; provided that, with respect to this clause sixth, if (x) such payment is a payment of the principal amount of any Loans in respect of which such Defaulting Lender has not fully funded its appropriate share and (y) such Loans were to be made at a time when the conditions set forth in Section 4.02 (or in the case of (A) Loans requested by the Borrower to be made on the Closing Date, the conditions set forth in Section 4.01, or (B) Incremental Term Loans, the applicable conditions set forth in Section 2.16(e)) were satisfied or waived, such payment shall be applied solely to pay the Loans of all non-Defaulting Lenders on a pro rata basis prior to being applied to the payment of any Loans of such Defaulting Lender. Any payments, prepayments or other amounts paid or payable to a Defaulting Lender that are applied (or held) to pay amounts owed by a Defaulting Lender pursuant to this Section 2.18(a)(ii) shall be deemed paid to and redirected by that Defaulting Lender, and each Lender irrevocably consents hereto. (iii) Certain Fees. Such Defaulting Lender shall not be entitled to receive any Ticking Fee on unfunded amounts pursuant to Section 2.10(c) for any period during which that Lender is a Defaulting Lender (and the Borrower shall not be required to pay any Ticking Fee on any unfunded amounts pursuant to Section 2.10(c) that otherwise would have been required to have been paid to such Defaulting Lender during such period). (b) Defaulting Lender Cure. If the Borrower and the Administrative Agent agree in writing in their sole discretion that a Defaulting Lender should no longer be deemed to be a Defaulting Lender, the Administrative Agent will so notify the parties hereto, whereupon as of the effective date specified in such notice and subject to any conditions set forth therein, such Lender will, to the extent applicable, take such actions as the Administrative Agent may determine to be necessary to cause the Loans under each applicable Facility to be held on a pro rata basis by the Lenders of such Facility in accordance with their respective Applicable Percentages of such Facility, whereupon such Lender will cease to be a Defaulting Lender; provided that no adjustments will be made retroactively with respect to fees accrued or payments made by or on behalf of the Borrower while such Lender was a Defaulting Lender; and provided, further, that subject to Section 10.20 and except to the extent otherwise expressly agreed by the affected parties, no change hereunder from Defaulting Lender to Lender will constitute a waiver or release of any claim of any party hereunder arising from such Lender’s having been a Defaulting Lender. ARTICLE III TAXES, YIELD PROTECTION AND ILLEGALITY 3.01 Taxes. (a) Payments Free of Taxes. Any and all payments by or on account of any obligation of any Loan Party hereunder or under any other Loan Document shall be made free and clear of and without reduction or withholding for any Taxes; provided that, if the applicable Loan Party or the Administrative Agent shall be required by applicable Law to withhold or deduct any Taxes, including both United States federal backup withholding and withholding taxes, from any payment, then (A) such Loan Party or the


 
57 Administrative Agent shall withhold or make such deductions as are determined by the Administrative Agent to be required based upon the information and documentation it has received pursuant to Section 3.01(e), (B) the Administrative Agent shall timely pay the full amount withheld or deducted to the relevant Governmental Authority in accordance with the Code and (C) to the extent that the withholding or deduction is made on account of Indemnified Taxes or Other Taxes, the sum payable by the applicable Loan Party shall be increased as necessary so that after any required withholding or the making of all required deductions (including deductions applicable to additional sums payable under this Section 3.01) the Administrative Agent or the applicable Lender, as the case may be, receives an amount equal to the sum it would have received had no such withholding or deduction been made. (b) Payment of Other Taxes by the Loan Parties. Without limiting the provisions of Section 3.01(a), the Loan Parties shall timely pay any Other Taxes to the relevant Governmental Authority in accordance with applicable Law. (c) Tax Indemnification. (i) Without limiting the provisions of Section 3.01(a) or 3.01(b), each of the Loan Parties shall, and does hereby, jointly and severally, indemnify the Administrative Agent and each Lender, and shall make payment in respect thereof, within ten (10) Business Days after demand therefor, for the full amount of any Indemnified Taxes or Other Taxes (including Indemnified Taxes or Other Taxes imposed or asserted on or attributable to amounts payable under this Section 3.01) payable or paid by the Administrative Agent or such Lender, as the case may be, or required to be withheld or deducted from a payment to the Administrative Agent or such Lender as the case may be, and any penalties, interest and reasonable expenses arising therefrom or with respect thereto, to the extent such Indemnified Taxes or Other Taxes are payable in respect of any payments by or on account of any obligation of the Loan Parties hereunder or under any other Loan Document or otherwise with respect to any Loan Document or activities related thereto, whether or not such Indemnified Taxes or Other Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. A certificate as to the amount of any such payment or liability delivered to the Borrower by a Lender (with a copy to the Administrative Agent), or by the Administrative Agent on its own behalf or on behalf of a Lender, shall be conclusive absent manifest error. (ii) Without limiting the provisions of Section 3.01(a) or 3.01(b), each Lender shall, and do hereby, indemnify the Loan Parties and the Administrative Agent, and shall make payment in respect thereof, within ten (10) days after demand therefor, against any and all Taxes and any and all related losses, claims, liabilities, penalties, interest and expenses (including the fees, charges and disbursements of any counsel for the Loan Parties and the Administrative Agent) incurred by or asserted against the Administrative Agent by any Governmental Authority as a result of the failure by such Lender to deliver, or as a result of the inaccuracy, inadequacy or deficiency of, any documentation required to be delivered by such Lender to the Borrower or the Administrative Agent pursuant to Section 3.01(e). Each Lender hereby authorizes the Administrative Agent to set off and apply any and all amounts at any time owing to such Lender under this Agreement or any other Loan Document against any amount due to the Administrative Agent under this clause (ii). The agreements in this clause (ii) shall survive the resignation and/or replacement of the Administrative Agent, any assignment of rights by, or the replacement of, a Lender, the termination of the Aggregate Commitments and the repayment, satisfaction or discharge of all other Obligations. (d) Evidence of Payments. As soon as practicable after any payment of Indemnified Taxes or Other Taxes by any Loan Party to a Governmental Authority, the Borrower shall deliver to the Administrative Agent the original or a certified copy of a receipt issued by such Governmental Authority evidencing such payment, a copy of the return reporting such payment or other evidence of such payment reasonably satisfactory to the Administrative Agent.


 
58 (e) Status of Lenders. (i) Each Lender shall deliver to the Borrower (with a copy to the Administrative Agent), at the time or times prescribed by applicable Law or reasonably requested by the Borrower or the Administrative Agent, such properly completed and executed documentation prescribed by applicable Law or by the taxing authorities of any jurisdiction and such other reasonably requested information as will permit the Borrower or the Administrative Agent, as the case may be, to determine (A) whether or not payments made by the Borrower hereunder or under any other Loan Document are subject to Taxes, (B) if applicable, the required rate of withholding or deduction, and (C) such Lender’s entitlement to any available exemption from, or reduction of, applicable Taxes in respect of all payments to be made to such Lender by the Borrower pursuant to this Agreement or otherwise to establish such Lender’s status for withholding tax purposes in the applicable jurisdictions. Notwithstanding anything to the contrary in the preceding sentence, the completion, execution and submission of such documentation (other than such documentation set forth in Section 3.01(e)(ii)(A), Section 3.01(e)(ii)(B) and Section 3.01(e)(ii)(C)) shall not be required if in the Lender’s reasonable judgment such completion, execution or submission would materially prejudice the legal or commercial position of such Lender. (ii) Without limiting the generality of the foregoing, in the event that the Borrower is a “United States person” within the meaning of Section 7701(a)(30) of the Code: (A) any Lender that is a “United States person” within the meaning of Section 7701(a)(30) of the Code shall deliver to the Borrower and the Administrative Agent executed copies of IRS Form W-9 or such other documentation or information prescribed by applicable Law or reasonably requested by the Borrower or the Administrative Agent as will enable the Borrower or the Administrative Agent, as the case may be, to determine that such Lender is not subject to backup withholding or information reporting requirements; and (B) each Foreign Lender that is entitled under the Code or any applicable treaty to an exemption from or reduction of withholding tax with respect to payments hereunder or under any other Loan Document shall deliver to the Borrower and the Administrative Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the request of Borrower or the Administrative Agent, but only if such Foreign Lender is legally entitled to do so), whichever of the following is applicable: (I) duly completed executed copies of IRS Form W-8BEN or W-8BEN-E, as applicable, claiming eligibility for benefits of an income tax treaty to which the United States is a party, (II) duly completed executed copies of IRS Form W-8ECI, (III) duly completed executed copies of IRS Form W-8IMY and all required supporting documentation, (IV) in the case of a Foreign Lender claiming the benefits of the exemption for portfolio interest under Section 881(c) of the Code, (x) a certificate to the effect that such Foreign Lender is not (A) a “bank” within the meaning of Section 881(c)(3)(A) of the Code, (B) a “10 percent shareholder” of the Borrower within the meaning of Section 881(c)(3)(B) of the Code, or (C) a “controlled foreign corporation” described in Section 881(c)(3)(C) of the Code and (y) duly completed copies of IRS Form W-8BEN or W-8BEN-E, as applicable, or


 
59 (V) any other form prescribed by applicable Law as a basis for claiming exemption from or a reduction in United States Federal withholding tax duly completed together with such supplementary documentation as may be prescribed by applicable Law to permit the Borrower or the Administrative Agent to determine the withholding or deduction required to be made; and (C) if a payment made to a Lender under any Loan Document would be subject to U.S. Federal withholding Tax imposed by FATCA if such Lender were to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section 1471(b) or 1472(b) of the Code, as applicable), such Lender shall deliver to the Borrower and the Administrative Agent at the time or times prescribed by law and at such time or times reasonably requested by the Borrower or the Administrative Agent such documentation prescribed by applicable Law (including as prescribed by Section 1471(b)(3)(C)(i) of the Code) and such additional documentation reasonably requested by the Borrower or the Administrative Agent as may be necessary for the Borrower and the Administrative Agent to comply with their obligations under FATCA and to determine that such Lender has complied with such Lender’s obligations under FATCA or to determine the amount to deduct and withhold from such payment. Solely for purposes of this clause (C), “FATCA” shall include any amendments made to FATCA after the Closing Date. (iii) Each Lender shall promptly (A) notify the Borrower and the Administrative Agent of any change in circumstances which would modify or render invalid any claimed exemption or reduction, and (B) take such steps as shall not be materially disadvantageous to it, in the reasonable judgment of such Lender, and as may be reasonably necessary (including the re-designation of its Lending Office) to avoid any requirement of applicable Law of any jurisdiction that the Borrower or the Administrative Agent make any withholding or deduction for taxes from amounts payable to such Lender. (iv) Each Lender agrees that, if any form or certification it previously delivered pursuant to this Section 3.01 expires or becomes obsolete or inaccurate in any respect, it shall update such form or certification or promptly notify the Borrower and the Administrative Agent in writing of its legal inability to do so. (f) Treatment of Certain Refunds. Unless required by applicable Law, at no time shall the Administrative Agent have any obligation to file for or otherwise pursue on behalf of a Lender, or have any obligation to pay to any Lender, any refund of Taxes withheld or deducted from funds paid for the account of such Lender. If the Administrative Agent or any Lender determines, in its sole discretion, that it has received a refund of any Taxes or Other Taxes as to which it has been indemnified by any Loan Party or with respect to which any Loan Party has paid additional amounts pursuant to this Section 3.01, it shall pay to such Loan Party an amount equal to such refund (but only to the extent of indemnity payments made, or additional amounts paid, by such Loan Party under this Section 3.01 with respect to the Taxes or Other Taxes giving rise to such refund), net of all out-of-pocket expenses (including Taxes) and net of any loss or gain realized in the conversion of such funds from or to another currency incurred by the Administrative Agent or such Lender, as the case may be, and without interest (other than any interest paid by the relevant Governmental Authority with respect to such refund); provided that each Loan Party, upon the request of the Administrative Agent or such Lender, agrees to repay the amount paid over to such Loan Party (plus any penalties, interest or other charges imposed by the relevant Governmental Authority) to the Administrative Agent or such Lender in the event the Administrative Agent or such Lender is required to repay such refund to such Governmental Authority. This Section 3.01(f) shall not be construed to require the Administrative Agent or any Lender to make available its tax returns (or any other information relating


 
60 to its taxes that it deems confidential) to any Loan Party or any other Person. Notwithstanding anything to the contrary in this Section 3.02(f), in no event will the indemnified party be required to pay any amount to an indemnifying party pursuant to this Section 3.02(f) if the payment of which would place the indemnified party in a less favorable net after-Tax position than the indemnified party would have been in if the Tax subject to indemnification and giving rise to such refund had not been deducted, withheld or otherwise imposed and the indemnification payments or additional amounts with respect to such Tax had never been paid. (g) Definitions. For purposes of this Section 3.01, the term “applicable Law” includes FATCA. 3.02 Illegality. If any Lender determines that any Law has made it unlawful, or that any Governmental Authority has asserted that it is unlawful, for any Lender or its applicable Lending Office to make, maintain or fund Loans whose interest is determined by reference to SOFR, Daily SOFR or Term SOFR, or to determine or charge interest rates based upon SOFR, Daily SOFR or Term SOFR (each an “Affected Loan”), then, upon notice thereof by such Lender to the Borrower (through the Administrative Agent), (a) any obligation of such Lender to make or continue Term SOFR Loans or, solely in the case of Term A-3 Loans or, Term A- 4 Loans or Term A-5 Loans, Daily SOFR Loans, or to convert Base Rate Loans to Term SOFR Loans or, solely in the case of Term A-3 Loans or, Term A-4 Loans or Term A-5 Loans, to Daily SOFR Loans, shall be suspended, and (b) if such notice asserts the illegality of such Lender making or maintaining Base Rate Loans the interest rate on which is determined by reference to the Term SOFR component of the Base Rate, the interest rate on which Base Rate Loans of such Lender shall, if necessary to avoid such illegality, be determined by the Administrative Agent without reference to the Term SOFR component of the Base Rate, in each case until such Lender notifies the Administrative Agent and the Borrower that the circumstances giving rise to such determination no longer exist. Upon receipt of such notice, (i) the Borrower shall, if necessary to avoid such illegality, upon demand from such Lender (with a copy to the Administrative Agent), prepay or, if applicable, convert all Affected Loans of such Lender to Base Rate Loans (the interest rate on which Base Rate Loans of such Lender shall, if necessary to avoid such illegality, be determined by the Administrative Agent without reference to the Term SOFR component of the Base Rate), either on the last day of the Interest Period therefor, if such Lender may lawfully continue to maintain such Term SOFR Loan to such day, or immediately, with respect to any Daily SOFR Loan or if such Lender may not lawfully continue to maintain such Term SOFR Loan to such day and (ii) if such notice asserts the illegality of such Lender determining or charging interest rates based upon SOFR, the Administrative Agent shall during the period of such suspension compute the Base Rate applicable to such Lender without reference to the Term SOFR component thereof until the Administrative Agent is advised in writing by such Lender that it is no longer illegal for such Lender to determine or charge interest rates based upon SOFR. Upon any such prepayment or conversion, the Borrower shall also pay accrued interest on the amount so prepaid or converted, together with any additional amounts required pursuant to Section 3.05. 3.03 Inability to Determine Rates. (a) Subject to Section 3.03(b), if in connection with any request for a Term SOFR Loan or a conversion of Base Rate Loans to Term SOFR Loans or, solely in the case of Term A-3 Loans or, Term A- 4 Loans or Term A-5 Loans, Daily SOFR Loans, or a continuation of any of such Loans, as applicable, or at any time in connection with a Daily SOFR Loan (i) the Administrative Agent determines (which determination shall be conclusive absent manifest error) that (A) no Successor Rate has been determined in accordance with Section 3.03(b), and the circumstances under clause (i) of Section 3.03(b) or the Scheduled Unavailability Date has occurred with respect to Term SOFR or Daily SOFR, as applicable, or (B) adequate and reasonable means do not otherwise exist for determining SOFR, Term SOFR or Daily SOFR or for any


 
61 requested Interest Period with respect to a proposed Term SOFR Loan, or Daily SOFR Loan as applicable, or in connection with an existing or proposed Base Rate Loan, or (ii) the Administrative Agent or the Required Lenders determine that for any reason that Term SOFR for any requested Interest Period with respect to a proposed Loan does not adequately and fairly reflect the cost to such Lenders of funding such Loan, the Administrative Agent will promptly so notify the Borrower and each Lender. Thereafter, (x) the obligation of the Lenders to make or maintain Term SOFR Loans, or to convert Base Rate Loans to Term SOFR Loans or Daily SOFR Loans, shall be suspended (in each case, to the extent of the affected Term SOFR Loans or Daily SOFR Loans or Interest Periods), and (y) in the event of a determination described in the preceding sentence with respect to the Term SOFR component of the Base Rate, the utilization of the Term SOFR component in determining the Base Rate shall be suspended, in each case until the Administrative Agent (or, in the case of a determination by the Required Lenders described in clause (ii) of this Section 3.03(a), until the Administrative Agent upon instruction of the Required Lenders) revokes such notice. Upon receipt of such notice, (i) the Borrower may revoke any pending request for a Borrowing of, or conversion to Daily SOFR Loans, or a Borrowing or continuation of, or conversion to Term SOFR Loans (to the extent of the affected Term SOFR Loans, Daily SOFR Loans or Interest Periods) or, failing that, will be deemed to have converted such request into a request for a Borrowing of or conversion to, as applicable, Base Rate Loans in the amount specified therein and (ii) any outstanding affected Term SOFR Loans and Daily SOFR Loans shall be deemed to have been converted to Base Rate Loans immediately in the case of Daily SOFR Loans or at the end of their applicable Interest Period in the case of Term SOFR Loans. (b) Replacement of SOFR, Term SOFR or Successor Rate. Notwithstanding anything to the contrary in this Agreement or any other Loan Documents, if the Administrative Agent determines (which determination shall be conclusive absent manifest error), or the Borrower or Required Lenders notify the Administrative Agent (with, in the case of the Required Lenders, a copy to the Borrower) that the Borrower or Required Lenders (as applicable) have determined, that: (i) adequate and reasonable means do not exist for ascertaining SOFR or one month, three month and six month interest periods of Term SOFR, including, without limitation, because the Term SOFR Screen Rate is not available or published on a current basis and such circumstances are unlikely to be temporary; or (ii) CME or any successor administrator of the Term SOFR Screen Rate or a Governmental Authority having jurisdiction over the Administrative Agent or such administrator with respect to its publication of SOFR or Term SOFR, in each case acting in such capacity, has made a public statement identifying a specific date after which one month, three month and six month interest periods of Term SOFR, the Term SOFR Screen Rate or SOFR shall or will no longer be made available, or permitted to be used for determining the interest rate of U.S. dollar denominated syndicated loans, or shall or will otherwise cease; provided that, at the time of such statement, there is no successor administrator that is reasonably satisfactory to the Administrative Agent, that will continue to provide such interest periods of Term SOFR or SOFR after such specific date (the latest date on which one month, three month and six month interest periods of Term SOFR, SOFR or the Term SOFR Screen Rate are no longer available permanently or indefinitely, the “Scheduled Unavailability Date”); then, on a date and time determined by the Administrative Agent (any such date, the “SOFR Replacement Date”), which date shall be at the end of an Interest Period or on the relevant interest payment date, as applicable, for interest calculated and, solely with respect to clause (ii) above, no later than the Scheduled


 
62 Unavailability Date, Term SOFR and/or Daily SOFR, as applicable, will be replaced hereunder and under any Loan Document with Daily Simple SOFR for any payment period for interest calculated that can be determined by the Administrative Agent, in each case, without any amendment to, or further action or consent of any other party to, this Agreement or any other Loan Document (the “Successor Rate”). If the Successor Rate is Daily Simple SOFR, all interest payments will be payable on a monthly basis. Notwithstanding anything to the contrary herein, (i) if the Administrative Agent determines that Daily Simple SOFR is not available on or prior to the SOFR Replacement Date, or (ii) if the events or circumstances of the type described in Section 3.03(b)(i) or (ii) have occurred with respect to the Successor Rate then in effect, then in each case, the Administrative Agent and the Borrower may amend this Agreement solely for the purpose of replacing Term SOFR, SOFR or any then current Successor Rate in accordance with this Section 3.03 at the end of any Interest Period, relevant interest payment date or payment period for interest calculated, as applicable, with an alternative benchmark rate giving due consideration to any evolving or then existing convention for similar U.S. dollar denominated credit facilities syndicated and agented in the United States for such alternative benchmark, and, in each case, including any mathematical or other adjustments to such benchmark giving due consideration to any evolving or then existing convention for similar U.S. dollar denominated credit facilities syndicated and agented in the United States for such benchmark. For the avoidance of doubt, any such proposed rate and adjustments shall constitute a “Successor Rate”. Any such amendment executed by the Administrative Agent and the Borrower shall become effective at 5:00 p.m. on the fifth Business Day after the Administrative Agent shall have posted such proposed amendment to all Lenders and the Borrower unless, prior to such time, Lenders comprising the Required Lenders have delivered to the Administrative Agent written notice that such Required Lenders object to such amendment. The Administrative Agent will promptly (in one or more notices) notify the Borrower and each Lender of the implementation of any Successor Rate. Any Successor Rate shall be applied in a manner consistent with market practice; provided that to the extent such market practice is not administratively feasible for the Administrative Agent, such Successor Rate shall be applied in a manner as otherwise reasonably determined by the Administrative Agent. Notwithstanding anything else herein, if at any time any Successor Rate as so determined would otherwise be less than 0.00%, the Successor Rate will be deemed to be 0.00% for the purposes of this Agreement and the other Loan Documents. In connection with the implementation of a Successor Rate, the Administrative Agent will have the right to make Conforming Changes from time to time and, notwithstanding anything to the contrary herein or in any other Loan Document, any amendments implementing such Conforming Changes will become effective without any further action or consent of any other party to this Agreement; provided that, with respect to any such amendment effected, the Administrative Agent shall post each such amendment implementing such Conforming Changes to the Borrower and the Lenders reasonably promptly after such amendment becomes effective. This Section 3.03 shall supersede any provisions in Section 10.01 to the contrary.


 
63 3.04 Increased Costs. (a) Increased Costs Generally. If any Change in Law shall: (i) impose, modify or deem applicable any reserve, special deposit, compulsory loan, insurance charge or similar requirement against assets of, deposits with or for the account of, or credit extended or participated in by, the Administrative Agent or any Lender; (ii) subject the Administrative Agent or any Lender to any Tax of any kind whatsoever with respect to this Agreement or any Term SOFR Loan or any Daily SOFR Loan made by it, or change the basis of taxation of payments to the Administrative Agent or such Lender in respect thereof (except for Indemnified Taxes or Other Taxes covered by Section 3.01 and the imposition of, or any change in the rate of, any Excluded Tax); or (iii) impose on the Administrative Agent or any Lender any other condition, cost or expense (other than Taxes) affecting this Agreement, Term SOFR Loans or Daily SOFR Loans made by such Lender; and the result of any of the foregoing shall be to increase the cost to the Administrative Agent or such Lender of making, maintaining, converting to or continuing any Loan (or of maintaining its obligation to make any such Loan), or to reduce the amount of any sum received or receivable by the Administrative Agent or such Lender hereunder (whether of principal, interest or any other amount) then, upon request of the Administrative Agent or such Lender, the Borrower will pay to the Administrative Agent or such Lender, as the case may be, such additional amount or amounts as will compensate the Administrative Agent or such Lender, as the case may be, for such additional costs incurred or reduction suffered. (b) Capital Requirements. If any Lender determines that any Change in Law affecting such Lender or any Lending Office of such Lender or such Lender’s holding company, if any, regarding capital or liquidity requirements has or would have the effect of reducing the rate of return on such Lender’s capital or on the capital of such Lender’s holding company, if any, as a consequence of this Agreement, the Commitments of such Lender or the Loans made by such Lender to a level below that which such Lender or such Lender’s holding company could have achieved but for such Change in Law (taking into consideration such Lender’s policies and the policies of such Lender’s holding company with respect to capital adequacy and liquidity), then from time to time the Borrower will pay to such Lender such additional amount or amounts as will compensate such Lender or such Lender’s holding company for any such reduction suffered. The Borrower shall not be required to pay such additional amounts unless such amounts are the result of requirements imposed generally on lenders similar to such Lender and not the result of some specific reserve or similar requirement imposed on such Lender as a result of such Lender’s special circumstances. (c) Certificates for Reimbursement. A certificate of the Administrative Agent or a Lender setting forth in reasonable detail the basis for and calculation of the amount or amounts necessary to compensate the Administrative Agent or such Lender or its holding company, as the case may be, as specified in Section 3.04(a) or 3.04(b) and delivered to the Borrower, in detail sufficient to enable the Borrower to verify the computation thereof, shall be conclusive absent manifest error. The Borrower shall pay the Administrative Agent or such Lender, as the case may be, the amount shown as due on any such certificate within ten (10) Business Days after receipt thereof. Any amounts requested to be payable pursuant to this Section 3.04 shall be requested in good faith (and not on an arbitrary and capricious basis) and consistent with similarly situated customers of the Administrative Agent or the applicable Lender after


 
64 consideration of factors as the Administrative Agent or such Lender, as the case may be, then reasonably determines to be relevant. (d) Delay in Requests. Failure or delay on the part of the Administrative Agent or any Lender to demand compensation pursuant to the foregoing provisions of this Section 3.04 shall not constitute a waiver of the Administrative Agent or such Lender’s right to demand such compensation; provided that the Borrower shall not be required to compensate the Administrative Agent or a Lender pursuant to the foregoing provisions of this Section 3.04 for any increased costs incurred or reductions suffered more than six (6) months prior to the date that the Administrative Agent or such Lender, as the case may be, notifies the Borrower of the Change in Law giving rise to such increased costs or reductions and of the Administrative Agent’s or such Lender’s intention to claim compensation therefor (except that, if the Change in Law giving rise to such increased costs or reductions is retroactive, then the six (6) month period referred to above shall be extended to include the period of retroactive effect thereof). (e) [Reserved]. (f) The provisions set forth in Sections 3.04(a) and (b) above shall not apply to the extent any increased cost is already compensated for by payment made by or on behalf of the Borrower pursuant to Section 3.01. 3.05 Compensation for Losses. Upon demand of any Lender (with a copy to the Administrative Agent) from time to time, the Borrower shall promptly compensate such Lender for and hold such Lender harmless from any loss, cost or expense (other than loss of anticipated profits) incurred by it as a result of: (a) any continuation, conversion, payment or prepayment of any Loan other than a Base Rate Loan or Daily SOFR Loan on a day other than the last day of the Interest Period for such Loan (whether voluntary, mandatory, automatic, by reason of acceleration, or otherwise); (b) any failure by the Borrower (for a reason other than the failure of such Lender to make a Loan) to prepay, borrow, continue or convert any Loan other than a Base Rate Loan or Daily SOFR Loan on the date or in the amount notified by the Borrower; (c) [reserved]; or (d) any assignment of a Term SOFR Loan on a day other than the last day of the Interest Period therefor as a result of a request by the Borrower pursuant to Section 10.13. The Borrower shall also pay any customary administrative fees charged by such Lender in connection with the foregoing. 3.06 Mitigation Obligations; Replacement of Lenders. (a) Designation of a Different Lending Office. If any Lender requests compensation under Section 3.04, or the Borrower is required to pay any additional amount to any Lender or any Governmental Authority for the account of any Lender pursuant to Section 3.01, or if any Lender gives a notice pursuant to Section 3.02, then such Lender shall, as applicable, use reasonable efforts to designate a different Lending Office for funding or booking its Loans hereunder or to assign its rights and obligations hereunder to another of its offices, branches or affiliates, if, in the judgment of such Lender, such designation or assignment (i) would eliminate or reduce amounts payable pursuant to Section 3.01 or 3.04, as the case may


 
65 be, in the future, or eliminate the need for the notice pursuant to Section 3.02, as applicable, and (ii) in each case, would not subject such Lender to any unreimbursed cost or expense and would not otherwise be disadvantageous to such Lender. The Borrower hereby agrees to pay all reasonable costs and expenses incurred by any Lender in connection with any such designation or assignment. (b) Replacement of Lenders. If any Lender requests compensation under Section 3.04, or if the Borrower is required to pay any additional amount to any Lender or any Governmental Authority for the account of any Lender pursuant to Section 3.01, or if any Lender’s obligation to make, continue or convert to Affected Loans is suspended pursuant to Section 3.02, the Borrower may replace such Lender in accordance with Section 10.13. 3.07 Survival. All of the Borrower’s obligations under this Article III shall survive termination of the Aggregate Commitments, repayment of all other Obligations hereunder and resignation or replacement of the Administrative Agent or any assignment of rights by, or the replacement of, a Lender. ARTICLE IV CONDITIONS PRECEDENT TO CREDIT EXTENSIONS 4.01 Conditions to Effectiveness of this Agreement. The effectiveness of this Agreement and, if the Borrower shall have requested any Credit Extension be made on the Closing Date, the obligation of each Lender to make its initial Credit Extension hereunder on the Closing Date, if any, are subject to satisfaction or waiver of the following conditions precedent: (a) The Administrative Agent’s receipt of the following, each of which shall be originals or facsimile or electronic copies (followed promptly by originals) unless otherwise specified, each properly executed by a Responsible Officer, each dated the Closing Date (or, in the case of certificates of governmental officials, a recent date before the Closing Date) and each in form and substance reasonably satisfactory to the Administrative Agent: (i) executed counterparts of this Agreement, executed and delivered by the Administrative Agent, the Borrower and each Lender listed on Schedule 2.01; (ii) a Term Note executed by the Borrower in favor of each Lender requesting a Term Note; (iii) such certificates of resolutions or other action, incumbency certificates and/or other certificates of Responsible Officers as the Administrative Agent may reasonably require evidencing the identity, authority and capacity of each Responsible Officer authorized to act as a Responsible Officer in connection with this Agreement and the other Loan Documents; (iv) such documents and certifications as the Administrative Agent may reasonably require to evidence that the Borrower is duly organized or formed, and that the Borrower is validly existing, in good standing and qualified to engage in business in its state of organization and in each jurisdiction where its ownership, lease or operation of properties or the conduct of its business requires such qualification, except to the extent that failure to do so could not reasonably be expected to have a Material Adverse Effect;


 
66 (v) favorable opinions of Skadden, Arps, Slate Meagher & Flom LLP and Ballard Spahr LLP, counsels to the Borrower, addressed to the Administrative Agent and each Lender; and (vi) a certificate signed by a Responsible Officer certifying (A) that the conditions specified in Sections 4.01(e) and (f) have been satisfied; (B) the current Debt Ratings; and (C) that, as of the date of the last financial statements of the Borrower delivered pursuant to the 2021 Credit Agreement, the Borrower was in pro forma compliance (giving pro forma effect to the Term Loans, if any, made on the Closing Date) with the financial covenants contained in Section 7.10. (b) Any fees required to be paid by the Borrower on or prior to the Closing Date pursuant to the Loan Documents and all expenses required to be reimbursed by the Borrower on or prior to the Closing Date pursuant to the Loan Documents shall have been paid; provided that invoices for such expenses have been presented to the Borrower a reasonable period of time (and in any event not less than one (1) Business Day) prior to the Closing Date (including, unless waived by the Administrative Agent, all reasonable, documented, out-of-pocket fees, charges and disbursements of counsel to the Administrative Agent, plus such additional amounts of such fees, charges and disbursements as shall constitute its reasonable estimate of such fees, charges and disbursements incurred or to be incurred by it through the closing proceedings (provided that such estimate shall not thereafter preclude a final settling of accounts between the Borrower and the Administrative Agent)). (c) (i) Upon the reasonable request of any Lender made in writing at least ten (10) Business Days prior to the Closing Date, the Borrower shall have provided to such Lender the documentation and other information so requested by such Lender that satisfies all requirements of regulatory authorities applicable to such Lender and such Lender’s internal policies and procedures in connection with applicable “know your customer” and anti-money-laundering rules and regulations, including, without limitation, the Patriot Act, in each case at least five (5) Business Days prior to the Closing Date and (ii) at least five (5) Business Days prior to the Closing Date, if the Borrower qualifies as a “legal entity customer” under the Beneficial Ownership Regulation it shall have delivered, to each Lender that so requests at least ten (10) Business Days prior to the Closing Date, a Beneficial Ownership Certification in relation to the Borrower. (d) The Administrative Agent’s receipt of an executed copy of a certificate signed by a Responsible Officer certifying the Borrower’s Sustainability Metric Components for the calendar year ended December 31, 2020 (solely for purposes of this Section 4.01(d), reflecting the Boundary Properties that the Borrower has owned and that were in service for the period of two (2) full consecutive calendar years ended December 31, 2020). (e) The representations and warranties of the Borrower contained in Article V shall be true and correct in all material respects (except in the case of a representation or warranty qualified by materiality or Material Adverse Effect or similar language, in which case such representation or warranty shall be true and correct in all respects) on and as of the Closing Date, except to the extent that any such representation or warranty specifically refers to an earlier date, in which case such representation or warranty shall be true and correct in all material respects (except in the case of a representation or warranty qualified by materiality or Material Adverse Effect or similar language, in which case such representation or warranty shall be true and correct in all respects) as of such earlier date. (f) No Default shall exist on the Closing Date, and, if the Borrower shall have requested any Credit Extension be made on such date, no Default would result from such proposed Credit Extension or from the application of the proceeds thereof. (g) If any Credit Extension is to be made on the Closing Date, the Administrative Agent shall have received a Request for Credit Extension in accordance with the requirements hereof.


 
67 Without limiting the generality of the provisions of the last paragraph of Section 9.03, for purposes of determining compliance with the conditions specified in this Section 4.01, each Lender that has signed this Agreement shall be deemed to have consented to, approved or accepted or to be satisfied with, (i) this Agreement and each other document to which it is a party or which it has reviewed and (ii) any other matter required hereunder or thereunder to be consented to or approved by or acceptable or satisfactory to a Lender unless the Administrative Agent shall have received a written notice from such Lender prior to the proposed Closing Date specifying its objection thereto. 4.02 Conditions to All Credit Extensions after the Closing Date. The obligation of each Lender to honor any Request for Credit Extension (other than (x) the extensions of credit, if any, requested by the Borrower to be made on the Closing Date, (y) a Committed Loan Notice requesting only a conversion of Loans to another Type, or a continuation of Term SOFR Loans, and (z) a Borrowing of Incremental Term Loans on the relevant Increase Effective Date) is subject to the following conditions precedent: (a) The representations and warranties of the Loan Parties contained in Article V or any other Loan Document shall be true and correct in all material respects (except in the case of a representation or warranty qualified by materiality or Material Adverse Effect or similar language, in which case such representation or warranty shall be true and correct in all respects) on and as of the date of such Credit Extension (other than such representations and warranties which are expressly made only as of the Closing Date or the FifthSixth Amendment Effective Date, as applicable, including but not limited to those set forth in Section 5.05(c) and Section 5.22), except to the extent that any such representation or warranty specifically refers to an earlier date, in which case such representation or warranty shall be true and correct in all material respects (except in the case of a representation or warranty qualified by materiality or Material Adverse Effect or similar language, in which case such representation or warranty shall be true and correct in all respects) as of such earlier date, and except that for purposes of this Section 4.02, the representations and warranties contained in subsections (a) and (b) of Section 5.05 shall be deemed to refer to the most recent statements furnished pursuant to clauses (a) and (b), respectively, of Section 6.01. (b) No Default shall exist on the date of such Credit Extension, or would result from such proposed Credit Extension or from the application of the proceeds thereof. (c) The Administrative Agent shall have received a Request for Credit Extension in accordance with the requirements hereof. Each such Request for Credit Extension (other than (x) the extensions of credit, if any, requested by the Borrower to be made on the Closing Date, (y) a Committed Loan Notice requesting only a conversion of Loans to another Type, or a continuation of Term SOFR Loans, and (z) a Borrowing of Incremental Term Loans on the relevant Increase Effective Date) submitted by the Borrower shall be deemed to be a representation and warranty that the conditions specified in Sections 4.02(a) and (b) have been satisfied on and as of the date of the applicable Credit Extension.


 
68 ARTICLE V REPRESENTATIONS AND WARRANTIES Each Loan Party represents and warrants to the Administrative Agent and the Lenders that: 5.01 Existence, Qualification and Power. Each Loan Party and each of its Subsidiaries (a) is duly organized or formed, validly existing and, where applicable, in good standing under the Laws of the jurisdiction of its incorporation or organization, (b) has all requisite power and authority and all requisite governmental licenses, authorizations, consents and approvals to (i) own its assets and carry on its business and (ii) execute, deliver and perform its obligations under the Loan Documents to which it is a party and (c) is duly qualified to do business and, where applicable, in good standing under the Laws of each jurisdiction where its ownership, lease or operation of properties or the conduct of its business requires such qualification or license; except in each case referred to in clause (a) (other than with respect to any Loan Party or any Material Subsidiary), clause (b)(i) or clause (c), to the extent that failure to do so could not reasonably be expected to have a Material Adverse Effect. 5.02 Authorization; No Contravention. The execution, delivery and performance by each Loan Party of each Loan Document to which it is party has been duly authorized by all necessary corporate or other organizational action, and do not and will not (a) contravene the terms of any of such Loan Party’s Organization Documents; (b) conflict with or result in any breach or contravention of, or the creation of any Lien under, or require any payment to be made under (i) any Contractual Obligation to which such Loan Party is party or affecting such Loan Party or the properties of such Loan Party or any of its Subsidiaries or (ii) any order, injunction, writ or decree of any Governmental Authority or any arbitral award to which such Loan Party or its property is subject; or (c) violate any Law; except in each case referred to in clause (b) or (c), to the extent such conflict, breach, contravention or violation, or creation of any such Lien or required payment, could not reasonably be expected to have a Material Adverse Effect. 5.03 Governmental Authorization; Other Consents. No approval, consent, exemption, authorization, or other action by, or notice to, or filing with, any Governmental Authority or any other Person is necessary or required in connection with the execution, delivery or performance by, or enforcement against, any Loan Party of this Agreement or any other Loan Document, except for such approvals, consents, exemptions, authorizations or other actions or notices or filings which have already been completed or obtained. 5.04 Binding Effect. This Agreement has been, and each other Loan Document to which each Loan Party is a party, when delivered hereunder, will have been, duly executed and delivered by such Loan Party. This Agreement constitutes, and each other Loan Document to which each Loan Party is a party when so delivered will constitute, a legal, valid and binding obligation of such Loan Party, enforceable against such Loan Party in accordance with its terms, except as such enforcement may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, or other similar laws, now or hereafter in effect, relating to or affecting the enforcement of creditors’ rights generally and except that the remedy of specific performance and other equitable remedies are subject to judicial discretion.


 
69 5.05 Financial Statements; No Material Adverse Effect. (a) The Audited Financial Statements (i) were prepared in accordance with GAAP consistently applied throughout the period covered thereby, except as otherwise expressly noted therein; (ii) fairly present the consolidated financial condition of the Parent Guarantor and its Subsidiaries as of the date thereof and their results of operations for the period covered thereby in accordance with GAAP consistently applied throughout the period covered thereby, except as otherwise expressly noted therein; and (iii) show all material indebtedness and other material liabilities, direct or contingent, of the Parent Guarantor and its Subsidiaries as of the date thereof, including liabilities for taxes, material commitments and material Indebtedness, in each case, to the extent required by GAAP. (b) The unaudited consolidated balance sheet of the Parent Guarantor and its Subsidiaries for the fiscal quarter ended September 30, 2024, and the related unaudited consolidated statements of income or operations, shareholders’ equity and cash flows for the fiscal quarter ended on such date, (i) were prepared in accordance with GAAP consistently applied throughout the period covered thereby, except as otherwise expressly noted therein or as otherwise permitted pursuant to Section 1.03, (ii) fairly present the consolidated financial condition of the Parent Guarantor and its Subsidiaries as of the date thereof and their results of operations for the period covered thereby, subject, in the case of clauses (i) and (ii), to the absence of footnotes and to normal year-end audit adjustments and (iii) show all material indebtedness and other material liabilities, direct or contingent, of the Parent Guarantor and its Subsidiaries as of the date thereof, including liabilities for taxes, material commitments and material Indebtedness, in each case, to the extent required by GAAP. (c) From the date of the Audited Financial Statements through and including the FifthSixth Amendment Effective Date, there has been no event or condition, either individually or in the aggregate, that has had or would reasonably be expected to have a Material Adverse Effect. 5.06 Litigation. There are no actions, suits, proceedings, claims, investigations or disputes pending or, to the knowledge of any Loan Party, threatened or contemplated, at law, in equity, in arbitration or before any Governmental Authority, by or against any Loan Party or any of their respective Subsidiaries or against any of their properties or revenues that (a) affect or pertain to this Agreement or any other Loan Document, or any of the transactions contemplated hereby, or (b) either individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect. 5.07 No Default. No Default has occurred and is continuing or would result from the consummation of the transactions contemplated by this Agreement or any other Loan Document. 5.08 Ownership of Property and Valid Leasehold Interests; Liens. (a) Each of the Loan Parties and each of their respective Subsidiaries has good record and marketable title in fee simple to, or valid leasehold interests in, all real property necessary or used in the ordinary conduct of its business, except for such defects in title or valid leasehold interests as could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. (b) The property of each Loan Party and each of its Subsidiaries is subject to no Liens, other than Liens permitted by Section 7.01.


 
70 5.09 Environmental Compliance. There are no existing violations of Environmental Laws by any Loan Party or any Subsidiary or claims against any Loan Party or any Subsidiary alleging potential liability under, or responsibility for the violation of, any Environmental Law that could, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. 5.10 Insurance. Each Loan Party and each of its Subsidiaries maintain or require the tenants or managers of their owned properties to maintain insurance that complies with the requirements set forth in Section 6.07. 5.11 Taxes. Each Loan Party and its Subsidiaries have filed all Federal, state and other material tax returns and reports required to be filed, and have paid all Federal, state and other material taxes, assessments, fees and other governmental charges levied or imposed upon them or their properties, income or assets otherwise due and payable, except (a) those which are being contested in good faith by appropriate proceedings diligently conducted and for which adequate reserves with respect thereto, to the extent required by GAAP, are maintained on the books of the applicable Person, or (b) where the failure to take any of the foregoing actions could not reasonably be expected to cause, individually or in the aggregate, a Material Adverse Effect. To the knowledge of any Loan Party, there is no proposed tax assessment against such Loan Party or any Subsidiary that would, if made, have a Material Adverse Effect. 5.12 ERISA Compliance. (a) Each Plan is in compliance with the applicable provisions of ERISA, the Code and other Federal or state Laws, except for any such failures to comply as, individually or in the aggregate, could not reasonably be expected to result in a Material Adverse Effect. Each Plan that is intended to qualify under Section 401(a) of the Code has received a favorable determination or opinion letter from the IRS or an application for such a letter is currently being processed by the IRS with respect thereto and, to the knowledge of any Loan Party, nothing has occurred that could reasonably be expected to prevent, or cause the loss of, such qualification. Each Loan Party and each ERISA Affiliate have made all required contributions to each Plan subject to Section 412 of the Code, and no application for a funding waiver or an extension of any amortization period pursuant to Section 412 of the Code has been made with respect to any Plan. (b) There are no pending or, to the knowledge of any Loan Party, threatened claims, actions or lawsuits, or action by any Governmental Authority, with respect to any Plan that could reasonably be expected to have a Material Adverse Effect. There has been no prohibited transaction or violation of the fiduciary responsibility rules with respect to any Plan that has resulted or could reasonably be expected to result in a Material Adverse Effect. (c) (i) No ERISA Event has occurred or is reasonably expected to occur; (ii) no Pension Plan has any Unfunded Pension Liability; (iii) no Loan Party nor any ERISA Affiliate has incurred, or reasonably expects to incur, any liability under Title IV of ERISA with respect to any Pension Plan (other than premiums due and not delinquent under Section 4007 of ERISA); (iv) no Loan Party nor any ERISA Affiliate has incurred, or reasonably expects to incur, any liability (and no event has occurred which, with the giving of notice under Section 4219 of ERISA, would result in such liability) under Sections 4201 or 4243 of ERISA with respect to a Multiemployer Plan; and (v) no Loan Party nor any ERISA Affiliate has engaged in a transaction that could be subject to Sections 4069 or 4212(c) of ERISA; except in each case


 
71 referred to in clauses (i) through (v), to the extent that any such event, individually or in the aggregate, could not reasonably be expected to have a Material Adverse Effect. (d) As of the Closing Date, the Borrower is not and will not be (i) an employee benefit plan subject to Title I of ERISA, (ii) a plan or account subject to Section 4975 of the Code, (iii) using “plan assets” (within the meaning of 29 CFR § 2510.3-101, as modified by Section 3(42) of ERISA) of one or more Benefit Plans in connection with the Loans or the Commitments or (iv) a “governmental plan” within the meaning of ERISA. 5.13 Margin Regulations; Investment Company Act; REIT Status. (a) No Loan Party is engaged and no Loan Party will engage, principally or as one of its important activities, in the business of purchasing or carrying margin stock (within the meaning of Regulation U issued by the FRB), or extending credit for the purpose of purchasing or carrying margin stock. (b) No Loan Party is, and no Loan Party is required to be, registered as an “investment company” under the Investment Company Act of 1940. (c) The Parent Guarantor meets all requirements to qualify as a REIT. 5.14 Disclosure. (a) No report, financial statement, certificate or other information furnished in writing by or on behalf of any Loan Party or any of its Subsidiaries to the Administrative Agent or any Lender in connection with the transactions contemplated hereby and the negotiation of this Agreement or delivered hereunder or under any other Loan Document (in each case, as and when furnished and as modified or supplemented by other information so furnished), together with all such information previously provided and when taken as a whole, contains any untrue statement of a material fact or omits to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were made (together with all such information previously provided and when taken as a whole), not materially misleading; provided, however, that it is understood that no Loan Party makes any representation or warranty with respect to any general economic or specific industry information, any projections, pro forma financial information, financial estimates, forecasts and forward-looking information, except that, with respect to projected financial information concerning the Loan Parties and their respective Subsidiaries furnished in writing by or on behalf of the Borrower to the Administrative Agent or any Lender in connection with the transactions contemplated hereby and the negotiation of this Agreement or delivered hereunder or under any other Loan Document, each Loan Party represents only that such information was prepared in good faith based upon assumptions believed to be reasonable at the time such information was prepared. It is further understood that (i) any projected financial information furnished to the Administrative Agent or any Lender is not to be viewed as facts, is not a guarantee of future performance and is subject to significant uncertainties and contingencies, many of which are beyond a Loan Party’s control, (ii) no assurance is given by such Loan Party that such projections will be realized and (iii) the actual results may differ from such projections and such differences may be material. (b) As of the Closing Date, the information included in the Beneficial Ownership Certification delivered to the Administrative Agent and/or any Lender pursuant to Section 4.01(c), if applicable, is true and correct in all respects.


 
72 5.15 Compliance with Laws. Each of the Loan Parties and each Subsidiary is in compliance in all material respects with the requirements of all Laws and all orders, writs, injunctions and decrees applicable to it or to its properties, except in such instances in which (a) such requirement of Law or order, writ, injunction or decree is being contested in good faith by appropriate proceedings diligently conducted or (b) the failure to comply therewith, either individually or in the aggregate, could not reasonably be expected to result in a Material Adverse Effect. 5.16 Intellectual Property; Licenses, Etc. Each Loan Party and each of its Subsidiaries own, or possess the right to use, all of the trademarks, service marks, trade names, copyrights, patents, patent rights, franchises, licenses and other intellectual property rights (collectively, “IP Rights”) that are reasonably necessary for the operation of their respective businesses, without conflict with the rights of any other Person, except to the extent failure to do so could not reasonably be expected to have a Material Adverse Effect; provided that the foregoing is not a representation or warranty with respect to infringement or other violation of the IP Rights of any other Person (which is addressed in the following sentence of this Section 5.16). To the knowledge of any Loan Party, no slogan or other advertising device, product, process, method, substance, part or other material now employed, or now contemplated to be employed, by such Loan Party or any Subsidiary infringes upon any rights held by any other Person to an extent that such infringement could reasonably be expected to result in a Material Adverse Effect. No claim or litigation regarding any of the foregoing is pending against any Loan Party or any of its Subsidiaries or, to the knowledge of any Loan Party, threatened against such Loan Party or any of its Subsidiaries, which, either individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect. 5.17 Use of Proceeds. The proceeds of the Loans hereunder will be used solely for the purposes specified in Section 6.11. No proceeds of the Loans hereunder will be used for the acquisition of another Person unless the board of directors (or other comparable governing body) or stockholders (or other equity owners), as appropriate, of such other Person has approved such acquisition. 5.18 Taxpayer Identification Number. Each Loan Party’s true and correct U.S. taxpayer identification number is set forth on Schedule 10.02. 5.19 Sanctions. None of the Loan Parties, any Subsidiary of the Loan Parties or, to the knowledge of the chief executive officer, chief financial officer or general counsel of any Loan Party, any director, officer or employee thereof is an individual or entity that is currently (i) the subject of any Sanctions or in violation of any Sanctions or (ii) located, organized or resident in a Designated Jurisdiction. 5.20 Affected Financial Institution. No Loan Party is an Affected Financial Institution.


 
73 5.21 Anti-Corruption Laws. Each Loan Party and each of its Subsidiaries (a) have conducted their businesses for the past two years (or if any Loan Party or Subsidiary was formed within the past two years, for the duration of such Loan Party’s or Subsidiary’s existence) and, to the knowledge of the chief executive officer, chief financial officer, chief operating officer (if any) or general counsel of such Loan Party, their respective directors, officers, agents and employees are, in each case, in compliance in all material respects with the United States Foreign Corrupt Practices Act of 1977, the UK Bribery Act 2010, and other similar applicable anti-money-laundering and anti-corruption legislation in other applicable jurisdictions, in any such case of the foregoing, to the extent applicable to, and binding on, the Loan Parties and their Subsidiaries (collectively, “Anti-Corruption Laws”), and (b) have instituted and maintain policies and procedures reasonably designed to promote and achieve compliance by each Loan Party, its Subsidiaries and, to the knowledge of the chief executive officer, chief financial officer, chief operating officer (if any) or general counsel of such Loan Party, their respective directors, officers, agents and employees with applicable Anti-Corruption Laws and applicable Sanctions. 5.22 Solvency. As of the FifthSixth Amendment Effective Date, immediately after giving effect to the initial Credit Extensions (if any) made on the FifthSixth Amendment Effective Date, (a) the fair value of the assets of the Parent Guarantor and its Subsidiaries, taken as a whole, will exceed their debts and liabilities, subordinated, contingent or otherwise; (b) the present fair saleable value of the property of the Parent Guarantor and its Subsidiaries, taken as a whole, will be greater than the amount that will be required to pay the probable liability of their debts and other liabilities, subordinated, contingent or otherwise, as such debts and other liabilities become absolute and mature; and (c) the Borrower will not have unreasonably small capital with which to conduct the business in which it is engaged as such business is now conducted and is proposed to be conducted following the FifthSixth Amendment Effective Date. ARTICLE VI AFFIRMATIVE COVENANTS So long as any Lender shall have any Commitment hereunder, any Loan or other Obligation hereunder shall remain unpaid or unsatisfied (other than contingent Obligations that are not then due and payable), each Loan Party shall, and shall (except in the case of the covenants set forth in Sections 6.01, 6.02, 6.03 and 6.12) cause each of its Subsidiaries to: 6.01 Financial Statements. Deliver to the Administrative Agent (for distribution to each Lender): (a) as soon as available, but in any event within five (5) Business Days following the date the Parent Guarantor is required to file its Form 10-K with the SEC (without giving effect to any extension of such due date, whether obtained by filing the notification permitted by Rule 12b-25 or any successor provision thereto or otherwise) (commencing with the fiscal year ending December 31, 2024), a consolidated balance sheet of the Group as at the end of such fiscal year, and the related consolidated statements of income or operations, shareholders’ equity and cash flows for such fiscal year, setting forth, commencing with the fiscal year ending December 31, 2025, in each case in comparative form the figures for the previous fiscal year, all in reasonable detail and prepared in accordance with GAAP, such consolidated statements to be audited and accompanied by a report and opinion of an independent certified public accountant of nationally recognized standing, which report and opinion shall be prepared in


 
74 accordance with generally accepted auditing standards and applicable securities laws and shall not be subject to any “going concern” or like qualification or exception or any qualification or exception as to the scope of such audit (provided that, to the extent the components of such consolidated financial statements relating to a prior fiscal period are separately audited by different independent public accounting firms, the audit report of any such accounting firm may contain a qualification or exception as to scope of such consolidated financial statements as they relate to such components); and (b) as soon as available, but in any event within sixty (60) days after the end of the first three fiscal quarters of the Parent Guarantor (or, if earlier, within five (5) Business Days following the date the Parent Guarantor is required to file its Form 10-Q with the SEC (without giving effect to any extension of such due date, whether obtained by filing the notification permitted by Rule 12b-25 or any successor provision thereto or otherwise)) (commencing with the fiscal quarter ending March 31, 2024), an unaudited consolidated balance sheet of the Group as at the end of such fiscal quarter, and the related unaudited consolidated statements of income or operations for such fiscal quarter and for the portion of the Parent Guarantor’s fiscal year then ended, and an unaudited statement of cash flow for the portion of the Parent Guarantor’s fiscal year then ended setting forth, commencing with the fiscal quarter ending June 30, 2025, in each case in comparative form the figures for the corresponding date of the previous fiscal year or the corresponding portion of the previous fiscal year, as applicable, all in reasonable detail, such consolidated statements to be certified by a Responsible Officer as fairly presenting the consolidated financial condition of the Group as of the date thereof and their results of operations for the period covered thereby in accordance with GAAP, subject only to normal year-end audit adjustments and the absence of footnotes. As to any information contained in materials furnished pursuant to Section 6.02(d), the Borrower shall not be separately required to furnish such information under clause (a) or (b) above, but the foregoing shall not be in derogation of the obligation of the Borrower to furnish the information and materials described in clauses (a) and (b) above at the times specified therein. 6.02 Certificates; Other Information. Deliver to the Administrative Agent (for distribution to each Lender): (a) concurrently with the delivery of the financial statements referred to in Sections 6.01(a) and (b) (commencing with the delivery of the financial statements for the fiscal quarter ending March 31, 2024), a duly completed Compliance Certificate signed by a Responsible Officer; (b) promptly after any request by the Administrative Agent, copies of any management letters submitted to the board of directors (or the audit committee of the board of directors) of any Loan Party by independent accountants in connection with an audit of the accounts of the Loan Parties and their respective Subsidiaries; (c) [reserved]; (d) promptly after the same are available, copies of each annual report, proxy or financial statement or other report or communication sent to the stockholders of any Loan Party, and copies of all annual, regular, periodic and special reports and registration statements which such Loan Party may file or be required to file with the SEC under Section 13 or 15(d) of the Securities Exchange Act of 1934, and not otherwise required to be delivered to the Administrative Agent pursuant hereto; (e) promptly, and in any event within five (5) Business Days after receipt thereof by any Loan Party or any Subsidiary thereof, copies of each notice or other correspondence received from the SEC (or comparable agency in any applicable non-U.S. jurisdiction) concerning any investigation by such agency


 
75 regarding financial or other operational results of such Loan Party or any Subsidiary thereof, other than ordinary course or routine notices, correspondence, inquiries, examinations or audits; (f) promptly following any written request therefor, information and documentation reasonably requested by the Administrative Agent or any Lender for purposes of compliance with applicable “know your customer” and anti-money-laundering rules and regulations, including, without limitation, the Patriot Act and the Beneficial Ownership Regulation (to the extent any Loan Party qualifies as a “legal entity customer” under the Beneficial Ownership Regulation and has provided a Beneficial Ownership Certification to any Lender or the Administrative Agent in connection with this Agreement as required by the Beneficial Ownership Regulation); and (g) promptly, such additional information regarding the business, financial or corporate affairs of any Loan Party or any Subsidiary, or compliance with the terms of the Loan Documents, as the Administrative Agent may from time to time reasonably request. Documents required to be delivered pursuant to Section 6.01(a) or (b) or Section 6.02(d) (to the extent any such documents are included in materials otherwise filed with the SEC) may be delivered electronically and if so delivered, shall be deemed to have been delivered on the date (i) on which the Borrower or the Parent Guarantor posts such documents, or provides a link thereto on the Borrower’s or the Parent Guarantor’s website on the Internet at the website address listed on Schedule 10.02; or (ii) on which such documents are posted on the Borrower’s or the Parent Guarantor’s behalf on an Internet or intranet website, if any, to which each Lender and the Administrative Agent have access (whether a commercial, third-party website or whether sponsored by the Administrative Agent); provided that the Borrower shall notify the Administrative Agent (by facsimile or electronic mail), which shall notify each Lender, of the posting of any such documents and, upon request, provide to the Administrative Agent by electronic mail electronic versions (i.e., soft copies) of such documents. The Administrative Agent shall have no obligation to request the delivery or to maintain copies of the documents referred to above, and in any event shall have no responsibility to monitor compliance by the Borrower or the Parent Guarantor with any such request for delivery, and each Lender shall be solely responsible for requesting delivery to it or maintaining its copies of such documents. Each Loan Party hereby acknowledges that (a) the Administrative Agent and/or the Specified Arrangers will make available to the Lenders materials and/or information provided by or on behalf of any Loan Party hereunder (collectively, “Borrower Materials”) by posting the Borrower Materials on IntraLinks or another similar electronic transmission system (the “Platform”) and (b) certain of the Lenders (each, a “Public Lender”) may have personnel that do not wish to receive material non-public information with respect to any Loan Party or its Affiliates, or the respective securities of any of the foregoing, and who may be engaged in investment and other market-related activities with respect to such Persons’ securities. Each Loan Party hereby agrees that so long as such Loan Party is the issuer of any outstanding debt or equity securities that are registered or issued pursuant to a private offering or is actively contemplating issuing any such securities (w) all Borrower Materials that are to be made available to Public Lenders shall be clearly and conspicuously marked “PUBLIC” which, at a minimum, shall mean that the word “PUBLIC” shall appear prominently on the first page thereof, (x) by marking Borrower Materials “PUBLIC,” each Loan Party shall be deemed to have authorized the Administrative Agent, the Arrangers and the Lenders to treat such Borrower Materials as not containing any material non-public information (although it may be sensitive and proprietary) with respect to such Loan Party or its securities for purposes of United States Federal and state securities laws (provided, however, that to the extent such Borrower Materials constitute Information, they shall be treated as set forth in Section 10.07) (y) all Borrower Materials marked “PUBLIC” are permitted to be made available through a portion of the Platform designated “Public Investor”; and (z) the Administrative Agent and the Arrangers shall treat the Borrower Materials that are not marked “PUBLIC” or that are marked “PRIVATE” as being suitable only for posting on a portion of


 
76 the Platform not designated “Public Investor.” Notwithstanding the foregoing, no Loan Party shall be under any obligation to mark any Borrower Materials “PUBLIC.” 6.03 Notices. Promptly following knowledge thereof by a Responsible Officer, notify the Administrative Agent (which shall notify each Lender) of: (a) the occurrence of any Default or Event of Default; (b) any matter that has resulted or could reasonably be expected to result in a Material Adverse Effect; (c) the information set forth in Section 6.13 at the times required therein; (d) any material change in accounting policies or financial reporting practices by any Loan Party or any Subsidiary; and (e) any announcement by Moody’s, S&P or Fitch of any change or possible adverse change in a Debt Rating. Each notice pursuant to this Section 6.03 (other than Section 6.03(e)) shall be accompanied by a statement of a Responsible Officer setting forth details of the occurrence referred to therein and stating what action the applicable Loan Party has taken and proposes to take with respect thereto. Each notice pursuant to Section 6.03(a) shall describe with particularity any and all provisions of this Agreement and any other Loan Document that have been breached. 6.04 Payment of Taxes. Pay and discharge as the same shall become due and payable, all of its tax liabilities, assessments and governmental charges or levies upon it or its properties or assets, unless the same are being contested in good faith by appropriate proceedings diligently conducted and adequate reserves with respect thereto, to the extent required by GAAP, are maintained on the books of the applicable Person, in each case in this Section 6.04, except where the failure to do so could not reasonably be expected to have a Material Adverse Effect. 6.05 Preservation of Existence, Etc. (a) Preserve, renew and maintain in full force and effect its legal existence and, where applicable, good standing under the Laws of the jurisdiction of its organization except in a transaction not prohibited by Section 7.04 or 7.05, or to the extent that failure to do so could not reasonably be expected to have a Material Adverse Effect; (b) take all reasonable action to maintain all rights, privileges, permits, licenses and franchises necessary or desirable in the normal conduct of its business, except to the extent that failure to do so could not reasonably be expected to have a Material Adverse Effect; and (c) preserve or renew all of its registered patents, trademarks, trade names and service marks, the non-preservation of which could reasonably be expected to have a Material Adverse Effect.


 
77 6.06 Maintenance of Properties. (a) Maintain, preserve and protect, or make contractual or other provisions to cause to maintain, preserve or protect, all of its properties and equipment necessary in the operation of its business in good working order and condition, ordinary wear and tear excepted, in each case except where the failure to do so could not reasonably be expected to have a Material Adverse Effect; and (b) make, or make contractual or other provisions to cause to be made, all necessary repairs thereto and renewals and replacements thereof except where the failure to do so could not reasonably be expected to have a Material Adverse Effect. 6.07 Maintenance of Insurance. Maintain, or use reasonable efforts to cause the tenants under all leases to which it is a party as landlord or the manager of its facilities to maintain, insurance with respect to its owned properties and business against loss or damage of the kinds customarily insured against by Persons engaged in the same or similar business and owning similar properties in localities where the applicable Loan Party or the applicable Subsidiary operates, of such types and in such amounts as are customarily carried under similar circumstances by such other Persons (including with respect to any captive insurance subsidiary or self- insurance, a system or systems of self-insurance and reinsurance which accords with the practices of similar businesses). 6.08 Compliance with Laws. Comply in all material respects with the requirements of all Laws and all orders, writs, injunctions and decrees applicable to it or to its business or property, except in such instances in which (a) such requirement of Law or order, writ, injunction or decree is being contested in good faith by appropriate proceedings diligently conducted; or (b) the failure to comply therewith could not reasonably be expected to have a Material Adverse Effect. 6.09 Books and Records. Maintain proper books of record and account, in which full, true and correct entries in conformity with GAAP consistently applied shall be made of all financial transactions and matters involving the assets and business of any Loan Party or its Subsidiary, as the case may be. 6.10 Inspection Rights. Subject to (x) rights of tenants, (y) applicable health and safety laws, and (z) except to the extent disclosure could reasonably be expected to contravene attorney client privilege or similar protection or violate any confidentiality or privacy obligation or otherwise contravene applicable law, permit representatives and independent contractors of the Administrative Agent and each Lender (in each case of a Lender, coordinated through the Administrative Agent) to visit and inspect any of its properties, to examine its corporate, financial and operating records, and make copies thereof or abstracts therefrom, and to discuss its affairs, finances and accounts with its directors, officers, and independent public accountants (provided that the Loan Parties shall have the right to participate in any such discussions), all at such reasonable times during normal business hours and as often as may be reasonably desired, upon reasonable advance notice to the Loan Parties; provided, however, that, excluding any such visits and inspections during the continuation of an Event of Default, only one (1) such visit and inspection by the Administrative Agent during any calendar year shall be at the reasonable expense of the Borrower; provided, further, however, that when an Event of Default exists and is continuing the Administrative Agent or any Lender


 
78 (or any of their respective representatives or independent contractors) may do any of the foregoing at the expense of the Borrower at any time during normal business hours and without advance notice. 6.11 Use of Proceeds. Use proceeds from the Committed Loans for working capital and general corporate purposes, including Investments, dividends and distributions, and acquisitions and developments and, in each case, not in contravention of any applicable Law in any material respect or of any Loan Document. 6.12 REIT Status. The Parent Guarantor shall maintain its qualification as a real estate investment trust under Sections 856 through 860 of the Code. 6.13 Employee Benefits. (a) Comply with the applicable provisions of ERISA and the Code with respect to each Plan, except where the failure to do so could not reasonably be expected to have a Material Adverse Effect and (b) furnish to the Administrative Agent (x) within five (5) Business Days after any Responsible Officer or any ERISA Affiliate knows or has reason to know that, any ERISA Event has occurred that, alone or together with any other ERISA Event could reasonably be expected to result in liability of any Loan Party or any of its ERISA Affiliates in an aggregate amount exceeding the Threshold Amount or the imposition of a Lien, a statement setting forth details as to such ERISA Event and the action, if any, that such Loan Party or ERISA Affiliate proposes to take with respect thereto, and (y) upon request by the Administrative Agent, copies of (i) each Schedule B (Actuarial Information) to the annual report (Form 5500 Series) filed by any Loan Party or any ERISA Affiliate with the Internal Revenue Service with respect to each Pension Plan; (ii) the most recent actuarial valuation report for each Pension Plan; (iii) all notices received by any Loan Party or any ERISA Affiliate from a Multiemployer Plan sponsor or any governmental agency concerning an ERISA Event; and (iv) such other documents or governmental reports or filings relating to any Plan as the Administrative Agent shall reasonably request. 6.14 Anti-Corruption Laws. Conduct its businesses in compliance in all material respects with applicable Anti-Corruption Laws and maintain policies and procedures reasonably designed to promote and achieve compliance by each Loan Party, its Subsidiaries and, to the knowledge of the chief executive officer, chief financial officer, chief operating officer (if any) or general counsel of such Loan Party, their respective directors, officers, agents and employees with applicable Anti-Corruption Laws. ARTICLE VII NEGATIVE COVENANTS So long as any Lender shall have any Commitment hereunder, any Loan or other Obligation hereunder shall remain unpaid or unsatisfied (other than contingent Obligations that are not then due and payable), no Loan Party shall, nor shall it permit any Subsidiary (except Section 7.09 shall apply only to Wholly-Owned Subsidiaries) to, directly or indirectly: 7.01 Liens.


 
79 Create, incur, assume or suffer to exist any Lien upon any of its property, assets or revenues, whether now owned or hereafter acquired, other than the following: (a) Liens pursuant to any Loan Document; (b) Liens securing Indebtedness of the Parent Guarantor and its Subsidiaries permitted under Section 7.03; (c) Liens for Taxes not yet due or which are being contested in good faith and by appropriate proceedings diligently conducted, if adequate reserves with respect thereto, to the extent required by GAAP, are maintained on the books of the applicable Person; (d) carriers’, warehousemen’s, mechanics’, materialmen’s, repairmen’s or other like Liens arising in the ordinary course of business which are not overdue for a period of more than thirty (30) days or which are being contested in good faith and by appropriate proceedings diligently conducted, if adequate reserves with respect thereto, to the extent required by GAAP, are maintained on the books of the applicable Person; (e) pledges or deposits or other Liens arising in the ordinary course of business in connection with workers’ compensation, unemployment insurance and other social security legislation, or to secure statutory obligations, other than any Lien imposed by ERISA; (f) Liens and rights of setoff of banks and securities intermediaries in respect of deposit accounts and securities accounts maintained in the ordinary course of business; (g) the interests of lessees and lessors under leases or subleases of, and the interest of managers or operators with respect to, real or personal property made in the ordinary course of business; (h) Liens on property where the Parent Guarantor or its Subsidiaries is insured against such Liens by title insurance; (i) Liens on property acquired by the Parent Guarantor or any of its Subsidiaries after the date hereof and which are in place at the time such properties are so acquired and not created in contemplation of such acquisition; (j) Liens securing assessments or charges payable to a property owner association or similar entity, which assessments are not yet due and payable or that are being contested in good faith by appropriate proceedings diligently conducted, and for which adequate reserves with respect thereto, to the extent required by GAAP, are maintained on the books of the applicable Person; (k) Liens securing assessment bonds, so long as the Parent Guarantor or its Subsidiaries is not in default under the terms thereof; (l) deposits to secure the performance of bids, trade contracts and leases (other than Indebtedness), statutory obligations, surety bonds (other than bonds related to judgments or litigation), performance bonds and other obligations of a like nature incurred in the ordinary course of business; (m) easements, rights-of-way, restrictions and other similar encumbrances affecting real property which, in the aggregate, are not substantial in amount, and which do not in any case materially detract from the value of the property subject thereto or materially interfere with the ordinary conduct of the business of the applicable Person;


 
80 (n) Liens securing judgments for the payment of money not constituting an Event of Default under Section 8.01(h) or securing appeal or other surety bonds related to such judgments; (o) Liens solely on any cash earnest money deposits made by the Parent Guarantor or any of its Subsidiaries in connection with any letter of intent or purchase agreement; (p) assignments to a reverse Section 1031 exchange trust; (q) licenses of intellectual property granted in the ordinary course of business; (r) Liens on assets of the Borrower or any of its Subsidiaries securing obligations under Swap Contracts; and (s) precautionary UCC filings in respect of operating leases. 7.02 [Reserved]. 7.03 Indebtedness. Create, incur, assume or suffer to exist any Indebtedness of any Loan Party or any of its Subsidiaries, except: (a) (w) Indebtedness under the Loan Documents, (x) the DOC Debt, (y) Guarantees by the Parent Guarantor and the Borrower of the DOC Debt and (z) Indebtedness under the Janus Credit Agreement and Guarantees by the Janus Group under the Janus Credit Agreement; (b) other Indebtedness; provided that (i) at the time of the incurrence of such Indebtedness and immediately after giving effect thereto (including any Liens associated therewith) no Event of Default has occurred and is continuing or would result therefrom and (ii) with respect to obligations of a Loan Party in respect of Swap Contracts, such Swap Contracts shall be (x) entered into in order to manage existing or anticipated risk and not for speculative purposes or (y) (i) for the sale of Equity Interests issued by the Parent Guarantor at a future date that could be discharged solely by (1) delivery of the Parent Guarantor’s Equity Interests, or, (2) solely at Parent Guarantor’s option made at any time, payment of the net cash value of such Equity Interests at the time, irrespective of the form or duration of such agreement, commitment or arrangement and (ii) not for speculative purposes; and (c) (i) Indebtedness between or among Parent Guarantor and any Subsidiary of Parent Guarantor or between or among any Subsidiaries of Parent Guarantor and (ii) Indebtedness owing to any member of the Group (including, for the avoidance of doubt, the Janus Group) as of the FifthSixth Amendment Effective Date or incurred after the FifthSixth Amendment Effective Date pursuant to or in connection with the Janus Management Agreement, in each case, so long as such Indebtedness is subordinated to the Obligations on terms and conditions reasonably acceptable to the Administrative Agent. 7.04 Fundamental Changes. Merge, dissolve, liquidate, consolidate with or into another Person, except that, so long as no Default exists or would result therefrom, (i) any Person may merge with or into, consolidate with or amalgamate with the Borrower in a transaction in which the Borrower shall be the continuing or surviving Person, (ii) any Person (other than Parent Guarantor) may merge with or into, consolidate with or amalgamate with any Subsidiary (other than the Borrower) in a transaction in which the continuing or surviving Person shall be a Subsidiary of the Borrower, (iii) any Subsidiary of the Borrower may merge


 
81 with or into, consolidate with or amalgamate with any Person in order to consummate a Disposition permitted by Section 7.05 or an Investment; (iv) any Subsidiary of the Borrower may merge into, the Parent Guarantor, the Borrower or any other Subsidiary of the Borrower; and (v) any Subsidiary of the Borrower may liquidate or dissolve if the Borrower determines in good faith that such liquidation or dissolution is in the best interests of the Borrower and is not materially disadvantageous to the Lenders. For the avoidance of doubt, in connection with an internal restructuring, (x) DOC OP may merge, consolidate or amalgamate with or into, or distribute or transfer all or substantially all its assets to, DOC or the Borrower and (y) DOC may merge, consolidate or amalgamate with or into, or distribute or transfer all or substantially all its assets to, the Borrower, it being understood and agreed that, in the event the successor or transferee entity in any such transaction expressly assumes the obligations of DOC OP under any DOC Debt, such assumption shall be permitted notwithstanding anything to the contrary in this Article VII and shall not constitute a new incurrence of Indebtedness for purposes of Section 7.03; provided that, the Loan Parties shall provide such customary “know your customer” documentation as the Lenders may reasonably require in connection with such transfer. For avoidance of doubt, in each case to the extent constituting a merger, dissolution, liquidation or consolidation, each of the Janus IPO Transactions is permitted under this Section 7.04. 7.05 Dispositions. Make any Disposition (other than any Disposition to any Loan Party or any Subsidiary) of all or substantially all of the assets (whether now owned or hereafter acquired, including pursuant to a Delaware LLC Division) of any Loan Party and its Subsidiaries, taken as a whole. For avoidance of doubt, in each case to the extent constituting a Disposition, each of the Janus IPO Transactions is permitted under this Section 7.05. 7.06 Restricted Payments. Declare or make, directly or indirectly, any Restricted Payment; provided that, (i) (a) each Loan Party and each Subsidiary may declare or make, directly or indirectly, any Restricted Payment required to qualify and maintain such Loan Party’s qualification as a real estate investment trust under Sections 856 through 860 of the Code, and (b) each Loan Party and each Subsidiary may declare or make, directly or indirectly, any Restricted Payment required to avoid the payment of federal or state income or excise tax; which permitted Restricted Payments under clauses (i)(a) and (i)(b), for the avoidance of doubt, include Restricted Payments from the Borrower or any of its Subsidiaries to its equity holders in order for the Parent Guarantor to comply with the foregoing, (ii) so long as no Default shall have occurred and be continuing or would result therefrom, each Loan Party and each Subsidiary may purchase, redeem, retire, acquire, cancel or terminate Equity Interests issued by such Loan Party or such Subsidiary so long as immediately after giving effect thereto the Parent Guarantor is in compliance on a Pro Forma Basis with the requirements of Section 7.10(e), (iii) so long as no Default shall have occurred and be continuing or would result therefrom, each Loan Party and each Subsidiary may make any payment on account of any return of capital to the Parent Guarantor’s stockholders, partners or members (or the equivalent Person thereof), (iv) each Loan Party and each Subsidiary may declare and make dividend payments, other distributions or other Restricted Payments payable solely in the Equity Interests in such Person, (v) any Subsidiary may at any time make Restricted Payments to the Parent Guarantor, the Borrower or any other Subsidiary and, solely to the extent such Restricted Payments to other holders of its Equity Interests are required by its Organization Documents, to such other holders of Equity Interests, (vi) each Loan Party and each Subsidiary may declare or make, directly or indirectly, any Restricted Payment within sixty (60) days after the date of declaration thereof, if on the date of declaration of such payment, such payment would have been permitted pursuant to another clause of this Section 7.06 and, on the date of such payment, no Default under Section 8.01(a), (f) or (g) shall have occurred and be continuing, (vii) so long as no Event of Default under Section 8.01(a), (f) or (g) shall have occurred and be continuing at the time of such payment, each Loan Party and each Subsidiary thereof may make any payments (including but not limited to management


 
82 fees, expense reimbursement payments, indemnification payments and tax distributions) contemplated by the Janus Management Agreement and (viii) any payments permitted pursuant to Section 7.06(viii) of the Janus Credit Agreement. For avoidance of doubt, in each case to the extent constituting a Restricted Payment after the Fifth Amendment Effective Date, each of the Janus IPO Transactions is permitted under this Section 7.06. 7.07 Change in Nature of Business. Engage in any material line of business substantially different from those lines of business conducted by each Loan Party and its Subsidiaries on the FifthSixth Amendment Effective Date or any business substantially related or incidental thereto. 7.08 Transactions with Affiliates. Enter into any transaction of any kind with any Affiliate of any Loan Party (other than transactions between or among a Loan Party and a Subsidiary (including any entity that becomes a Subsidiary as a result of such transaction) (or any combination thereof)), whether or not in the ordinary course of business, except (i) transactions on fair and reasonable terms substantially as favorable to such Loan Party or such Subsidiary as would be obtainable by such Loan Party or such Subsidiary at the time in a comparable arm’s-length transaction with a Person other than an Affiliate, (ii) payments of compensation, perquisites and fringe benefits arising out of any employment or consulting relationship in the ordinary course of business, (iii) making Restricted Payments permitted by this Agreement, (iv) payments (whether in cash, securities or other property) by any non-Wholly-Owned Subsidiary of the Borrower, including any sinking fund or similar deposit, on account of the purchase, redemption, retirement, acquisition, cancellation or termination of any Equity Interests of such Subsidiary, or on account of any return of capital to such Subsidiary’s stockholders, partners or members (or the equivalent Person thereof), in any such case, made to holders of Equity Interests in such Subsidiary (x) to the extent required pursuant to such Subsidiary’s Organization Documents or (y) to the extent such payment would have been permitted by Section 7.06 had it constituted a Restricted Payment, (v) other transactions expressly permitted by this Agreement, (vi) transactions with Affiliates that are Disclosed Matters (together with any amendments, restatements, extensions, replacements or other modifications thereto that are not adverse to the interests of the Lenders in their capacities as such), (vii) transactions in the ordinary course of business that comply with the requirements of the North American Securities Administrators Association’s Statement of Policy of Real Estate Investment Trusts, (viii) transactions between a Loan Party or Subsidiary and any “taxable REIT subsidiary” (within the meaning of Section 856(l) of the Code) of any Loan Party or Subsidiary, (ix) the Janus IPO Transactions, (x) entry into the Janus Management Agreement and any Permitted Amendment thereof and (xi) transactions pursuant to the Janus Management Agreement. 7.09 Burdensome Agreements. Enter into, assume or otherwise be bound, or permit any Wholly-Owned Subsidiary to enter into, assume or otherwise be bound, by any Negative Pledge other than (i) any Negative Pledge contained in an agreement entered into in connection with any Indebtedness that is permitted pursuant to Section 7.03, which Indebtedness is of a type that customarily includes a Negative Pledge or with respect to which such Negative Pledge is no more restrictive on a Loan Party or such Wholly-Owned Subsidiary in any material respect, when taken as a whole, than this Section 7.09 (as determined in good faith by the Borrower); (ii) any Negative Pledge required or imposed by, or arising under or as a result of, any Law; (iii) Negative Pledges contained in (x) the 2024 Credit Agreement, the agreements set forth on Schedule 7.09 or that are Disclosed Matters; (y) any agreement relating to the Disposition of any Subsidiary or any assets pending such Disposition; provided that, in any such case, the Negative Pledge applies only to the Subsidiary or the assets that are the subject of such Disposition; or (z) any agreement in effect at the time any Person becomes


 
83 a Wholly-Owned Subsidiary so long as such agreement was not entered into in contemplation of such Person becoming a Wholly-Owned Subsidiary and such restriction only applies to such Person and/or its assets, (iv) customary restrictions in leases, licenses and other contracts restricting the assignment thereof, (v) other customary restrictions set forth in agreements relating to assets specified in such agreements and entered into in the ordinary course of business to the extent such restrictions shall solely apply to such specified assets; and (vi) restrictions that apply only to the Equity Interests in, or assets of, any Person other than a Loan Party or a Wholly-Owned Subsidiary, in each case as such agreements, leases or other contracts may be amended from time to time and including any renewal, extension, refinancing or replacement thereof; provided that, with respect to any agreement described in clause (iii), such amendment, renewal, extension, refinancing or replacement does not contain restrictions of the type prohibited by this Section 7.09 that are, in the aggregate, more onerous in any material respect on a Loan Party or any Wholly- Owned Subsidiary than the restrictions, in the aggregate, in the original agreement. 7.10 Financial Covenants. (a) Leverage Ratio. Permit the Leverage Ratio to be greater than 0.60 to 1.00 as of the end of any fiscal quarter. Notwithstanding the foregoing, in connection with the consummation of a Significant Acquisition, the Parent Guarantor shall be permitted to increase the maximum Leverage Ratio to 0.65 to 1.00 for any fiscal quarter in which a Significant Acquisition occurs and for the three (3) consecutive full fiscal quarters immediately thereafter; provided that, solely in the case of any increase pursuant to this sentence, in no event shall the Leverage Ratio exceed 0.65 to 1.00 as of the end of any fiscal quarter or exceed 0.60 to 1.00 for more than four (4) consecutive fiscal quarters in any consecutive five (5) fiscal quarter period. (b) Secured Debt Ratio. Permit the Secured Debt Ratio to be greater than 0.40 to 1.00 as of the end of any fiscal quarter. (c) Fixed Charge Coverage Ratio. Permit the Fixed Charge Coverage Ratio to be less than 1.50 to 1.00 as of the end of any fiscal quarter. (d) Unsecured Leverage Ratio. Permit the Unsecured Leverage Ratio to be greater than 0.60 to 1.00 as of the end of any fiscal quarter. Notwithstanding the foregoing, in connection with the consummation of a Significant Acquisition, the Parent Guarantor shall be permitted to increase the maximum Unsecured Leverage Ratio to 0.65 to 1.00 for any fiscal quarter in which a Significant Acquisition occurs and for the three (3) consecutive full fiscal quarters immediately thereafter; provided that, solely in the case of any increase pursuant to this sentence, in no event shall the Unsecured Leverage Ratio exceed 0.65 to 1.00 as of the end of any fiscal quarter or exceed 0.60 to 1.00 for more than four (4) consecutive fiscal quarters in any consecutive five (5) fiscal quarter period. (e) Consolidated Tangible Net Worth. Permit the Consolidated Tangible Net Worth to be less than $7,700,000,000 as of the end of any fiscal quarter. 7.11 Sanctions. Directly or, to its knowledge, indirectly, use any part of the proceeds of any Credit Extension or lend, contribute or otherwise make available such Credit Extension or the proceeds of any Credit Extension to any Person (i) to fund any activities of or business with any Person, or in any Designated Jurisdiction, that, at the time of such funding, is the subject of Sanctions (except to the extent permitted for a Person that is required to comply with such Sanctions) or (ii) in any other manner that will result in a violation of Sanctions applicable to any party hereto.


 
84 7.12 Anti-Corruption Laws. Directly or, to its knowledge, indirectly use the proceeds of any Credit Extension for any purpose which would violate in any material respect any applicable Anti-Corruption Laws. ARTICLE VIII EVENTS OF DEFAULT AND REMEDIES 8.01 Events of Default. Any of the following shall constitute an Event of Default: (a) Non-Payment. The Borrower or any other Loan Party fails to pay (i) when and as required to be paid herein, any amount of principal of any Loan, or (ii) within five (5) Business Days after the same becomes due, any interest on any Loan, or any fee due hereunder, or (iii) within five (5) Business Days after the same becomes due, any other amount payable hereunder or under any other Loan Document; or (b) Specific Covenants. The Borrower, any other Loan Party or any of their respective Subsidiaries fails to perform or observe any term, covenant or agreement contained in any of (i) Section 6.03(b), 6.05 (solely with respect to the legal existence of the Loan Parties) or 6.11 or Article VII and such failure continues for five (5) consecutive Business Days, or (ii) Section 6.03(a) or Section 6.03(d) and such failure continues for fifteen (15) consecutive Business Days; or (c) Other Defaults. The Borrower, any Loan Party or any of their respective Subsidiaries fails to perform or observe any other covenant or agreement (not specified in Section 8.01(a) or 8.01(b)) contained in any Loan Document on its part to be performed or observed and such failure continues for thirty (30) consecutive days after the receipt by the Borrower of written notice of such failure from the Administrative Agent; provided that, if such failure is of such a nature that can be cured but cannot with reasonable effort be completely cured within thirty (30) days, then such thirty (30) day period shall be extended for such additional period of time (not exceeding ninety (90) additional days) as may be reasonably necessary to cure such failure so long as such Loan Party or its Subsidiaries, as applicable, commence such cure within such thirty (30) day period and diligently prosecute same until completion; or (d) Representations and Warranties. Any representation, warranty, certification or statement of fact made or deemed made by or on behalf of any Loan Party herein, in any other Loan Document, or in any document, certificate or other writing executed by a Responsible Officer and required to be furnished hereunder, shall be incorrect in any material respect when made or deemed made (or, in the case of the representations and warranties in Section 5.14(b) or any representation and warranty that is qualified by materiality, shall be incorrect in any respect when made or deemed made) and, with respect to any representation, warranty, certification or statement (other than the representations and warranties in Section 5.14(b)) not known by such Loan Party at the time made or deemed made to be incorrect, the defect causing such representation or warranty to be incorrect when made or deemed made is not removed within thirty (30) days after the first to occur of (i) the date upon which a Responsible Officer of any Loan Party obtains knowledge thereof or (ii) receipt by the Borrower of written notice thereof from the Administrative Agent; or (e) Cross-Default. (i) The Borrower, the Parent Guarantor or any of their respective Subsidiaries (x) fails (after giving effect to any notice or grace periods applicable thereto) to make any required payment when due (whether by scheduled maturity, required prepayment, acceleration, demand, or otherwise) in respect of any Material Recourse Indebtedness or (y) fails to observe or perform any other


 
85 agreement or condition relating to any such Material Recourse Indebtedness contained in any instrument or agreement evidencing, securing or relating thereto, or any other event occurs, the effect of which default or other event is to cause, with the giving of notice if required, such Material Recourse Indebtedness pursuant to the terms thereof to be demanded or to become due or to require the Borrower, the Parent Guarantor or such Subsidiary to repurchase, prepay, defease or redeem (automatically or otherwise) or make an offer to repurchase, prepay, defease or redeem such Material Recourse Indebtedness pursuant to the terms thereof, prior to its stated maturity; or (ii) there occurs under any Swap Contract an Early Termination Date (as defined in such Swap Contract) resulting from (A) any event of default under such Swap Contract as to which any Loan Party or any Subsidiary is the Defaulting Party (as defined in such Swap Contract) or (B) any Termination Event (as so defined) under such Swap Contract as to which any Loan Party or any Subsidiary is an Affected Party (as so defined) and, in either event, the Swap Termination Value owed by such Loan Party or such Subsidiary as a result thereof is greater than the Threshold Amount; provided that this clause (e) shall not apply to (1) secured Indebtedness that becomes due and payable (or as to which an offer to repurchase, prepay, defease or redeem is required to be made) as a result of the voluntary Disposition of the property or assets securing such Indebtedness, if such Disposition is permitted hereunder and under the documents providing for such Indebtedness and such Indebtedness that has become so due and payable (including as a result of such offer to repurchase, prepay, defease or redeem such Indebtedness) is assumed or repaid in full when and to the extent required under the document providing for such Indebtedness (after giving effect to any notice or grace periods applicable thereto), (2) any redemption, repurchase, conversion or settlement with respect to any convertible debt security which is consummated in accordance with the terms of such convertible debt security, unless such redemption, repurchase, conversion or settlement results from a default thereunder or an event of the type that constitutes an Event of Default or (3) any early payment requirement or unwinding or termination with respect to any Swap Contract (A) not arising out of a default by any Loan Party or any Subsidiary and (B) to the extent that such Swap Termination Value owed has been paid in full by any Loan Party or any of its Subsidiaries when due; or (f) Insolvency Proceedings, Etc. Any Loan Party or any of its Material Subsidiaries institutes or consents to the institution of any proceeding under any Debtor Relief Law, or makes an assignment for the benefit of creditors; or applies for or consents to the appointment of any receiver, trustee, custodian, conservator, liquidator, rehabilitator or similar officer for it or for all or any material part of its property; or any receiver, trustee, custodian, conservator, liquidator, rehabilitator or similar officer is appointed without the application or consent of such Person and the appointment continues undischarged, undismissed or unstayed for sixty (60) calendar days; or any proceeding under any Debtor Relief Law relating to any such Person or to all or any material part of its property is instituted without the consent of such Person and continues undischarged, undismissed or unstayed for sixty (60) calendar days, or an order for relief is entered in any such proceeding; or (g) Inability to Pay Debts; Attachment. (i) Any Loan Party or any of its Material Subsidiaries becomes unable or admits in writing its inability or fails generally to pay its debts as they become due, or (ii) any writ or warrant of attachment or execution or similar process is issued or levied against all or any material part of the property of any such Person and is not released, vacated or fully bonded within thirty (30) days after its issue or levy; or (h) Judgments. There is entered against any Loan Party or any of its Material Subsidiaries (i) a final non-appealable judgment or order that has not been discharged, satisfied, dismissed or vacated for the payment of money in an aggregate amount exceeding the Threshold Amount (to the extent (x) not paid, fully bonded or covered by independent third-party insurance as to which the insurer has not denied coverage or (y) for which such Loan Party or applicable Material Subsidiary has not been indemnified), or (ii) any one or more non-monetary final non-appealable judgments that have not been discharged, dismissed or vacated and that have, or could reasonably be expected to have, individually or in the aggregate, a


 
86 Material Adverse Effect and, in either case of clause (i) or (ii), (A) enforcement proceedings are commenced by any creditor upon such judgment or order, or (B) there is a period of thirty (30) consecutive days during which a stay of enforcement of such judgment, by reason of a pending appeal or otherwise, is not in effect; or (i) ERISA. An ERISA Event occurs with respect to a Pension Plan or Multiemployer Plan which has resulted or could reasonably be expected to result in liability of any Loan Party under Title IV of ERISA to the Pension Plan, Multiemployer Plan or the PBGC in an aggregate amount in excess of the Threshold Amount; or (j) Invalidity of Loan Documents. Any material provision of any Loan Document, at any time after its execution and delivery and for any reason other than as expressly permitted hereunder or thereunder or satisfaction in full of all the Obligations arising under the Loan Documents, ceases to be in full force and effect; or any Loan Party or any of its Subsidiaries contests in writing in any manner the validity or enforceability of any material provision of any Loan Document; or any Loan Party denies in writing that it has any or further liability or obligation under any Loan Document, or purports in writing to revoke, terminate or rescind any material provision of any Loan Document; or (k) Change of Control. There occurs any Change of Control. For purposes of clauses (f), (g), and (h) above (including as it relates to the exercise of remedies set forth below in Section 8.02) no Event of Default shall be deemed to have occurred with respect to a Material Group unless the type of event specified therein has occurred with respect to each Subsidiary that is a member of such Material Group. 8.02 Remedies Upon Event of Default. If any Event of Default occurs and is continuing, the Administrative Agent shall, at the request of, or may, with the consent of, the Required Lenders, take any or all of the following actions: (a) declare the Commitments of each Lender to make Loans to be terminated, whereupon such Commitments shall be terminated; (b) declare the unpaid principal amount of all outstanding Loans, all interest accrued and unpaid thereon, and all other amounts owing or payable hereunder or under any other Loan Document to be immediately due and payable, without presentment, demand, protest or other notice of any kind, all of which are hereby expressly waived by the Loan Parties; (c) [reserved]; and (d) exercise on behalf of itself and the Lenders all rights and remedies available to it and the Lenders under the Loan Documents; provided, however, that upon the occurrence of an Event of Default with respect to any Loan Party pursuant to Section 8.01(f) or (g) or the occurrence of an actual or deemed entry of an order for relief with respect to any Loan Party under the Bankruptcy Code, the obligation of each Lender to make Loans shall automatically terminate, the unpaid principal amount of all outstanding Loans and all interest and other amounts as aforesaid shall automatically become due and payable, in each case without further act of the Administrative Agent or any Lender.


 
87 8.03 Application of Funds. After the exercise of remedies provided for in Section 8.02 (or after the Loans have automatically become immediately due and payable as set forth in the proviso to Section 8.02), any amounts received on account of the Obligations shall, subject to the provisions of Section 2.18, be applied by the Administrative Agent in the following order: First, to payment of that portion of the Obligations constituting fees, indemnities, expenses and other amounts (including fees, charges and disbursements of counsel to the Administrative Agent and amounts payable under Article III) payable to the Administrative Agent in its capacity as such; Second, to payment of that portion of the Obligations constituting fees, indemnities, expenses and other amounts (other than principal and interest) payable to the Lenders (including fees, charges and disbursements of counsel to the respective Lenders and amounts payable under Article III), ratably among them in proportion to the amounts described in this clause Second payable to them; Third, to payment of that portion of the Obligations constituting accrued and unpaid interest on the Loans and fees, premiums and scheduled periodic payments, and any interest accrued thereon, due under any Swap Contract between any Loan Party and any Lender, or any Affiliate of a Lender, ratably among the Lenders (and, in the case of such Swap Contracts, Affiliates of Lenders) in proportion to the respective amounts described in this clause Third payable to them; Fourth, to payment of that portion of the Obligations constituting unpaid principal of the Loans, payment of breakage, termination or other payments, and any interest accrued thereon, due under any Swap Contract between any Loan Party and any Lender, or any Affiliate of a Lender and amounts owing under Treasury Management Agreements, ratably among the Lenders (and, in the case of such Swap Contracts, Affiliates of Lenders) and the Treasury Management Lenders in proportion to the respective amounts described in this clause Fourth held by them; and Last, the balance, if any, after all of the Obligations have been indefeasibly paid in full, to the Borrower or as otherwise required by Law. ARTICLE IX ADMINISTRATIVE AGENT 9.01 Appointment and Authority. Each of the Lenders hereby irrevocably appoints Bank of America to act on its behalf as the Administrative Agent hereunder and under the other Loan Documents and authorizes the Administrative Agent to take such actions on its behalf and to exercise such powers as are delegated to the Administrative Agent by the terms hereof or thereof, together with such actions and powers as are reasonably incidental thereto. Except as otherwise expressly set forth herein and except with respect to Section 9.06, the provisions of this Article IX are solely for the benefit of the Administrative Agent and the Lenders, and no Loan Party shall have any rights as a third-party beneficiary of any of such provisions.


 
88 9.02 Rights as a Lender. The Person serving as the Administrative Agent hereunder shall have the same rights and powers in its capacity as a Lender as any other Lender and may exercise the same as though it were not the Administrative Agent and the term “Lender” or “Lenders” shall, unless otherwise expressly indicated or unless the context otherwise requires, include the Person serving as the Administrative Agent hereunder in its individual capacity. Such Person and its Affiliates may accept deposits from, lend money to, own securities of, act as the financial advisor or in any other advisory capacity for and generally engage in any kind of banking, trust, financial, advisory, underwriting or other business with any Loan Party or any Subsidiary or other Affiliate thereof as if such Person were not the Administrative Agent hereunder and without any duty to account therefor to the Lenders or to provide notice to or obtain consent of the Lenders with respect thereto. 9.03 Exculpatory Provisions. The Administrative Agent shall not have any duties or obligations except those expressly set forth herein and in the other Loan Documents and its duties hereunder shall be administrative in nature. Without limiting the generality of the foregoing, the Administrative Agent and its Related Parties: (a) shall not be subject to any fiduciary or other implied duties, regardless of whether a Default has occurred and is continuing; (b) shall not have any duty to take any discretionary action or exercise any discretionary powers, except discretionary rights and powers expressly contemplated hereby or by the other Loan Documents that the Administrative Agent is required to exercise as directed in writing by the Required Lenders (or such other number or percentage of the Lenders as shall be expressly provided for herein or in the other Loan Documents); provided that the Administrative Agent shall not be required to take any action that, in its opinion or the opinion of its counsel, may expose the Administrative Agent to liability or that is contrary to any Loan Document or applicable Law; and (c) shall not, except as expressly set forth herein and in the other Loan Documents, have any duty to disclose, and shall not be liable for the failure to disclose, any information relating to any Loan Party or any of its Affiliates that is communicated to or obtained by the Person serving as the Administrative Agent or any of its Affiliates in any capacity. The Administrative Agent shall not be liable for any action taken or not taken by it (i) with the consent or at the request of the Required Lenders (or such other number or percentage of the Lenders as shall be necessary, or as the Administrative Agent shall believe in good faith shall be necessary, under the circumstances as provided in Sections 10.01 and 8.02) or (ii) in the absence of its own gross negligence or willful misconduct as determined by a court of competent jurisdiction in a final and non-appealable judgment. The Administrative Agent shall be deemed not to have knowledge of any Default unless and until notice describing such Default is given to the Administrative Agent by the Borrower or a Lender. The Administrative Agent shall not be responsible for or have any duty to ascertain or inquire into (i) any statement, warranty or representation made in or in connection with this Agreement or any other Loan Document, (ii) the contents of any certificate, report or other document delivered hereunder or thereunder or in connection herewith or therewith, (iii) the performance or observance of any of the covenants, agreements or other terms or conditions set forth herein or therein or the occurrence of any Default, (iv) the validity, enforceability, effectiveness or genuineness of this Agreement, any other Loan Document or any other agreement, instrument or document or (v) the satisfaction of any condition set forth


 
89 in Article IV or elsewhere herein, other than to confirm receipt of items expressly required to be delivered to the Administrative Agent. 9.04 Reliance by Administrative Agent. The Administrative Agent shall be entitled to rely upon, and shall not incur any liability for relying upon, any notice, request, certificate, consent, statement, instrument, document or other writing (including any electronic message, Internet or intranet website posting or other distribution) believed by it to be genuine and to have been signed, sent or otherwise authenticated by the proper Person. The Administrative Agent also may rely upon any statement made to it orally or by telephone and believed by it to have been made by the proper Person, and shall not incur any liability for relying thereon. In determining compliance with any condition hereunder to the making of a Loan that by its terms must be fulfilled to the satisfaction of a Lender, the Administrative Agent may presume that such condition is satisfactory to such Lender unless the Administrative Agent shall have received notice to the contrary from such Lender prior to the making of such Loan. The Administrative Agent may consult with legal counsel (who may be counsel for the Loan Parties), independent accountants and other experts selected by it, and shall not be liable for any action taken or not taken by it in accordance with the advice of any such counsel, accountants or experts. 9.05 Delegation of Duties. The Administrative Agent may perform any and all of its duties and exercise its rights and powers hereunder or under any other Loan Document by or through any one or more sub-agents appointed by the Administrative Agent. The Administrative Agent and any such sub-agent may perform any and all of its duties and exercise its rights and powers by or through their respective Related Parties. The exculpatory provisions of this Article IX shall apply to any such sub-agent and to the Related Parties of the Administrative Agent and any such sub-agent, and shall apply to their respective activities in connection with the syndication of the credit facilities provided for herein as well as activities as Administrative Agent. The Administrative Agent shall not be responsible for the negligence or misconduct of any sub-agents except to the extent that a court of competent jurisdiction determines in a final and non-appealable judgment that the Administrative Agent acted with gross negligence or willful misconduct in the selection of such sub-agents. 9.06 Resignation of Administrative Agent. The Administrative Agent may at any time resign as Administrative Agent upon thirty (30) days’ notice to the Lenders and the Borrower. Upon receipt of any such notice of resignation, the Required Lenders shall have the right, subject to the approval (not to be unreasonably withheld or delayed) of the Borrower (unless an Event of Default has occurred and is continuing), to appoint a successor, which shall be a bank with an office in the United States, or an Affiliate of any such bank with an office in the United States; provided that, if any such potential successor is not classified as a “U.S. person” and a “financial institution” within the meaning of Treasury Regulation Section 1.1441-1, then the Borrower shall have the right to prohibit such potential successor from becoming the Administrative Agent in its reasonable discretion. If no such successor shall have been so appointed by the Required Lenders and shall have accepted such appointment within thirty (30) days after the retiring Administrative Agent gives notice of its resignation, then the retiring Administrative Agent may on behalf of the Lenders (and subject to the approval (not to be unreasonably withheld or delayed) of the Borrower (unless an Event of Default has occurred and is continuing)), appoint a successor Administrative Agent meeting the qualifications set forth above; provided that, if any such potential successor is not classified as a “U.S. person” and a “financial institution” within the meaning of Treasury Regulation Section 1.1441-1, then the Borrower shall have the right to prohibit such potential successor from becoming the Administrative Agent in its reasonable discretion; provided, further, that, if the retiring Administrative Agent shall notify the Borrower and the


 
90 Lenders that no qualifying Person has accepted such appointment, then such resignation shall nonetheless become effective in accordance with such notice and (1) the retiring Administrative Agent shall be discharged from its duties and obligations hereunder and under the other Loan Documents and (2) all payments, communications and determinations provided to be made by, to or through the Administrative Agent shall instead be made by or to each Lender directly, until such time as the Required Lenders appoint a successor Administrative Agent as provided for above in this Section 9.06. Upon the acceptance of a successor’s appointment as Administrative Agent hereunder, such successor shall succeed to and become vested with all of the rights, powers, privileges and duties of the retiring (or retired) Administrative Agent, and the retiring Administrative Agent shall be discharged from all of its duties and obligations hereunder or under the other Loan Documents (if not already discharged therefrom as provided above in this Section 9.06). The fees payable by the Borrower to a successor Administrative Agent shall be the same as those payable to its predecessor unless otherwise agreed between the Borrower and such successor. After the retiring Administrative Agent’s resignation hereunder and under the other Loan Documents, the provisions of this Article IX and Section 10.04 shall continue in effect for the benefit of such retiring Administrative Agent, its sub-agents and their respective Related Parties in respect of any actions taken or omitted to be taken by any of them while the retiring Administrative Agent was acting as Administrative Agent. 9.07 Non-Reliance on Administrative Agent, the Arrangers and Other Lenders. Each Lender expressly acknowledges that none of the Administrative Agent or any Arranger has made any representation or warranty to it, and that no act by the Administrative Agent or any Arranger hereafter taken, including any consent to, and acceptance of any assignment or review of the affairs of any Loan Party of any Affiliate thereof, shall be deemed to constitute any representation or warranty by the Administrative Agent or any Arranger to any Lender as to any matter, including whether the Administrative Agent or any Arranger has disclosed material information in its (or its Related Parties’) possession. Each Lender acknowledges that it has, independently and without reliance upon the Administrative Agent or any Arranger or any other Lender or any of their Related Parties and based on such documents and information as it has deemed appropriate, made its own credit analysis and decision to enter into this Agreement. Each Lender also acknowledges that it will, independently and without reliance upon the Administrative Agent, any Arranger or any other Lender or any of their Related Parties and based on such documents and information as it shall from time to time deem appropriate, continue to make its own decisions in taking or not taking action under or based upon this Agreement, any other Loan Document or any related agreement or any document furnished hereunder or thereunder, and to make such investigations as it deems necessary to inform itself as to the business, prospects, operations, property, financial and other condition and creditworthiness of the Loan Parties. Each Lender represents and warrants that (i) the Loan Documents set forth the terms of a commercial lending facility and (ii) it is engaged in making, acquiring or holding commercial loans in the ordinary course and is entering into this Agreement as a Lender for the purpose of making, acquiring or holding commercial loans and providing other facilities set forth herein as may be applicable to such Lender, and not for the purpose of purchasing, acquiring or holding any other type of financial instrument, and each Lender agrees not to assert a claim in contravention of the foregoing. Each Lender represents and warrants that it is sophisticated with respect to decisions to make, acquire and/or hold commercial loans and to provide other facilities set forth herein, as may be applicable to such Lender, and either it, or the Person exercising discretion in making its decision to make, acquire and/or hold such commercial loans or to provide such other facilities, is experienced in making, acquiring or holding such commercial loans or providing such other facilities. 9.08 No Other Duties, Etc. Anything herein to the contrary notwithstanding, none of the Arrangers, Co-Syndication Agents, or Co-Documentation Agents or Senior Managing Agents listed on the cover page hereof shall have any


 
91 powers, duties or responsibilities under this Agreement or any of the other Loan Documents, except in its capacity, as applicable, as the Administrative Agent or a Lender hereunder. 9.09 Administrative Agent May File Proofs of Claim. In case of the pendency of any receivership, insolvency, liquidation, bankruptcy, reorganization, arrangement, adjustment, composition or other judicial proceeding under any Debtor Relief Law relative to the Borrower, the Administrative Agent (irrespective of whether the principal of any Loan shall then be due and payable as herein expressed or by declaration or otherwise and irrespective of whether the Administrative Agent shall have made any demand on the Borrower) shall be entitled and empowered, by intervention in such proceeding or otherwise: (a) to file and prove a claim for the whole amount of the principal and interest owing and unpaid in respect of the Loans and all other Obligations that are owing and unpaid and to file such other documents as may be necessary or advisable in order to have the claims of the Lenders and the Administrative Agent (including any claim for the reasonable compensation, expenses, disbursements and advances of the Lenders and the Administrative Agent and their respective agents and counsel and all other amounts due the Lenders and the Administrative Agent under Sections 2.10 and 10.04) allowed in such judicial proceeding; and (b) to collect and receive any monies or other property payable or deliverable on any such claims and to distribute the same; and any custodian, receiver, assignee, trustee, liquidator, sequestrator or other similar official in any such judicial proceeding is hereby authorized by each Lender to make such payments to the Administrative Agent and, in the event that the Administrative Agent shall consent to the making of such payments directly to the Lenders, to pay to the Administrative Agent any amount due for the reasonable compensation, expenses, disbursements and advances of the Administrative Agent and its agents and counsel, and any other amounts due the Administrative Agent under Sections 2.10 and 10.04. Nothing contained herein shall be deemed to authorize the Administrative Agent to authorize or consent to or accept or adopt on behalf of any Lender any plan of reorganization, arrangement, adjustment or composition affecting the Obligations or the rights of any Lender or to authorize the Administrative Agent to vote in respect of the claim of any Lender in any such proceeding. 9.10 Recovery of Erroneous Payments. Without limitation of any other provision in this Agreement, if at any time the Administrative Agent makes a payment hereunder in error to any Lender, whether or not in respect of an Obligation due and owing by Borrower at such time, where such payment is a Rescindable Amount, then in any such event, each Lender receiving a Rescindable Amount severally agrees to repay to the Administrative Agent forthwith on demand the Rescindable Amount received by such Lender in Same Day Funds in the currency so received, with interest thereon, for each day from and including the date such Rescindable Amount is received by it to but excluding the date of payment to the Administrative Agent, at the greater of the Federal Funds Rate and a rate determined by the Administrative Agent in accordance with banking industry rules on interbank compensation. Each Lender irrevocably waives any and all defenses, including any “discharge for value” (under which a creditor might otherwise claim a right to retain funds mistakenly paid by a third party in respect of a debt owed by another) or similar defense to its obligation to return any Rescindable Amount. The Administrative Agent shall inform each Lender promptly upon determining that any payment made to such Lender comprised, in whole or in part, a Rescindable Amount.


 
92 9.11 Guaranty Matters. The Lenders irrevocably authorize the Administrative Agent to release any Subsidiary Guarantor from its obligations under Article XII in accordance with Section 12.10. Upon request by the Administrative Agent at any time, the Required Lenders will confirm in writing the Administrative Agent’s authority to release any Subsidiary Guarantor from its obligations under Article XII pursuant to this Section 9.11, provided that neither the request nor the delivery of such confirmation shall be a condition to or shall cause any delay in the provision of any release permitted, required or requested in accordance with Section 12.10. ARTICLE X MISCELLANEOUS 10.01 Amendments, Etc. Except as set forth in Section 2.02(f) in respect of Conforming Changes made pursuant to such section, Section 2.15 in respect of an extension of a Maturity Date, Section 2.16 in respect of an Incremental Term Loan Amendment, or Section 3.03 in respect of the replacement of Term SOFR and/or Conforming Changes or other amendments or modifications made pursuant to such section, no amendment or waiver of any provision of this Agreement or any other Loan Document, and no consent to any departure by the Borrower or any other Loan Party therefrom, shall be effective unless in writing signed by the Required Lenders (or such other number or percentage of the Lenders as shall be expressly provided for herein or in the other Loan Documents) and the Borrower or the applicable Loan Party, as the case may be, and acknowledged by the Administrative Agent, and each such waiver or consent shall be effective only in the specific instance and for the specific purpose for which given; provided, however, that no such amendment, waiver or consent shall: (a) extend the expiration date or increase the amount of any Commitment of any Lender (or reinstate any Commitment terminated pursuant to Section 2.07 or Section 8.02) without the written consent of such Lender (it being understood and agreed that a waiver of any condition precedent in Section 4.02 or of any Default or Event of Default is not considered an extension or increase in the Commitments of any Lender); (b) postpone any date fixed by this Agreement or any other Loan Document for any payment (other than mandatory prepayments (if any) with respect to any Loan) of principal, interest, fees or other amounts due to the Lenders (or any of them) hereunder or under any other Loan Document without the written consent of each Lender directly and adversely affected thereby; (c) reduce the principal of, or the rate of interest specified herein on, any Loan, or (subject to clause (iv) of the second proviso to this Section 10.01) any fees or other amounts payable hereunder or under any other Loan Document without the written consent of each Lender directly and adversely affected thereby; provided, however, that only the consent of the Required Class Lenders shall be necessary to amend the definition of “Default Rate” with respect to such Class or to waive any obligation of the Borrower to pay interest at the Default Rate with respect to such Class; (d) change Section 2.14 or Section 8.03 in a manner that would alter the pro rata sharing of payments required thereby without the written consent of each Lender directly and adversely affected thereby;


 
93 (e) change any provision of this Section 10.01 or the definition of “Required Lenders” or “Required Class Lenders” or any other provision hereof specifying the number or percentage of Lenders required to amend, waive or otherwise modify any rights hereunder or make any determination or grant any consent hereunder, without the written consent of each Lender (but any change to the definition of “Required Term A-1 Lenders,” “Required Term A-2 Lenders,” “Required Term A-3 Lenders,” “Required Term A-4 Lenders” or “Required Term A-4-5 Lenders” shall only require the written consent of each Lender under the applicable Term Facility); (f) release all or substantially all of the value of the Guaranteed Obligations of the Guarantor under the Guaranty (except as provided herein) without the written consent of each Lender; or (g) directly and materially adversely affect the rights of Lenders holding Commitments or Loans of one Class differently from the rights of Lenders holding Commitments or Loans of any other Class without the written consent of the applicable Required Class Lenders; and provided, further, that (i) only the written consent of the Borrower and the Required Term A-1 Lenders shall be required to the extent such amendment, waiver or consent shall (x) amend, waive or otherwise modify any of the conditions precedent set forth in Section 4.02 with respect to any Credit Extension under the Term A-1 Facility or (y) impose any greater restriction on the ability of any Term A-1 Lender to assign any of its rights or obligations hereunder with respect to the Term A-1 Facility (and, for the avoidance of doubt, no other Lenders shall have any right to approve or disapprove any such amendment, waiver or consent described in this clause (i)); (ii) only the written consent of the Borrower and the Required Term A-2 Lenders shall be required to the extent such amendment, waiver or consent shall (x) amend, waive or otherwise modify any of the conditions precedent set forth in Section 4.02 with respect to any Credit Extension under the Term A-2 Facility or (y) impose any greater restriction on the ability of any Term A-2 Lender to assign any of its rights or obligations hereunder with respect to the Term A-2 Facility (and, for the avoidance of doubt, no other Lenders shall have any right to approve or disapprove any such amendment, waiver or consent described in this clause (ii)); (iii) only the written consent of the Borrower and the Required Term A-3 Lenders shall be required to the extent such amendment, waiver or consent shall impose any greater restriction on the ability of any Term A-3 Lender to assign any of its rights or obligations hereunder with respect to the Term A-3 Facility (and, for the avoidance of doubt, no other Lenders shall have any right to approve or disapprove any such amendment, waiver or consent described in this clause (iii)); (iv) only the written consent of the Borrower and the Required Term A-4 Lenders shall be required to the extent such amendment, waiver or consent shall (x) amend, waive or otherwise modify any of the conditions precedent set forth in Section 4.02 with respect to any Credit Extension under the Term A-4 Facility or (y) impose any greater restriction on the ability of any Term A-4 Lender to assign any of its rights or obligations hereunder with respect to the Term A-4 Facility (and, for the avoidance of doubt, no other Lenders shall have any right to approve or disapprove any such amendment, waiver or consent described in this clause (iv)); (v) only the written consent of the Borrower and the Required Term A- 5 Lenders shall be required to the extent such amendment, waiver or consent shall (x) amend, waive or otherwise modify any of the conditions precedent set forth in Section 4.02 with respect to any Credit Extension under the Term A-5 Facility or (y) impose any greater restriction on the ability of any Term A-5 Lender to assign any of its rights or obligations hereunder with respect to the Term A- 5 Facility (and, for the avoidance of doubt, no other Lenders shall have any right to approve or disapprove any such amendment, waiver or consent described in this clause (v)); (vi) no amendment, waiver or consent shall, unless in writing and signed by the Administrative Agent in addition to the Lenders required above, affect the rights or duties of the Administrative Agent under this Agreement or any other Loan Document; and (vivii) any fee letter may be amended, or rights or privileges thereunder waived, in a writing executed only by the parties thereto (and, for the avoidance of doubt, no other parties shall have any right to approve or disapprove any such amendment, waiver or consent). Notwithstanding anything to the contrary herein, no Defaulting Lender shall have any right to approve or disapprove any amendment,


 
94 waiver or consent hereunder (and any amendment, waiver or consent which by its terms requires the consent of all Lenders or each affected Lender (or all Lenders of a Class or each affected Lender of a Class) may be effected with the consent of the applicable Lenders other than Defaulting Lenders), except that (x) the Commitment of any Defaulting Lender may not be increased or extended without the consent of such Defaulting Lender and (y) any waiver, amendment or modification requiring the consent of all Lenders or each affected Lender that by its terms affects any Defaulting Lender more adversely than other affected Lenders shall require the consent of such Defaulting Lender. Notwithstanding anything to the contrary herein, (A) the Administrative Agent and the Borrower may, with the consent of the other (but without the consent of any other Person), amend, modify or supplement any Loan Document to correct, amend or cure any ambiguity, inconsistency, omission, mistake or defect or correct any obvious error or any error or omission of an administrative or technical nature so long as such amendment, modification or supplement does not impose additional obligations on any Lender; provided that the Administrative Agent shall promptly give the Lenders notice of, and provide to the Lenders a copy of, any such amendment, modification or supplement, and (B) this Agreement may be amended and restated without the consent of any Lender (but with the consent of the Borrower and the Administrative Agent) if, upon giving effect to such amendment and restatement, such Lender shall no longer be a party to this Agreement (as so amended and restated), the Commitments of such Lender shall have terminated, and such Lender shall have no other commitment or other obligation hereunder and shall have been paid in full all principal, interest and other amounts owing to it or accrued for its account under this Agreement. Notwithstanding the fact that the consent of all the Lenders is required in certain circumstances as set forth above, (x) each Lender is entitled to vote as such Lender sees fit on any reorganization plan that affects the Loans and each Lender acknowledges that the provisions of Section 1126(c) of the Bankruptcy Code supersede the unanimous consent provisions set forth herein and (y) the Required Lenders may consent to allow the Borrower to use cash collateral in the context of a bankruptcy or insolvency proceeding and such determination shall be binding on all of the Lenders. Notwithstanding any provision herein to the contrary, this Agreement may be amended with the written consent of the Required Lenders, the Administrative Agent and the Borrower (i) to add one or more additional term loan facilities to this Agreement and to permit the extensions of credit and all related obligations and liabilities arising in connection therewith from time to time outstanding to share ratably (or on a basis subordinated to the existing facilities hereunder) in the benefits of this Agreement and the other Loan Documents with the obligations and liabilities from time to time outstanding in respect of the existing facilities hereunder, and (ii) in connection with the foregoing, to permit, as deemed appropriate by the Administrative Agent and approved by the Required Lenders, the Lenders providing such additional credit facilities to participate in any required vote or action required to be approved by the Required Lenders or by any other number, percentage or class of Lenders hereunder. In addition, notwithstanding the foregoing, the Borrower may, by written notice to the Administrative Agent from time to time, make one or more offers (each, a “Loan Modification Offer”) to all the Lenders of one or more Classes to make one or more amendments or modifications to (A) allow the maturity of the Accepting Lenders’ (as defined below) Commitments or Loans of such Class(es) to be extended, (B) modify the Applicable Rate and/or fees payable with respect to the Accepting Lenders’ Loans and/or Commitments of such Class(es), (C) modify any covenants or other provisions or add new covenants or provisions with respect to such Class(es) that are agreed between the Borrower, the Administrative Agent and the Accepting Lenders; provided that such modified or new covenants and provisions are applicable only during periods after the applicable Maturity Date that is in effect on the effective date of such Permitted Amendment, and (D) any other amendment to a Loan Document required to give effect to the Permitted Amendments described in clauses (A), (B) and (C) of this paragraph (“Permitted Amendments,” and any


 
95 amendment to this Agreement to implement Permitted Amendments, a “Loan Modification Agreement”) pursuant to procedures reasonably specified by the Administrative Agent and reasonably acceptable to the Borrower. Such notice shall set forth (i) the relevant Class(es) of Lenders to which the Borrower is making the Loan Modification Offer described in such notice, (ii) the terms and conditions of the requested Permitted Amendments and (iii) the date on which such Permitted Amendments are requested to become effective. Permitted Amendments shall become effective only with respect to the Commitments and/or Loans of the relevant Class(es) of the Lenders that accept the applicable Loan Modification Offer (such Lenders, the “Accepting Lenders”) and, in the case of any Accepting Lender, only with respect to such Lender’s Commitments and/or Loans of the relevant Class(es) as to which such Lender’s acceptance has been made. The Borrower and each Accepting Lender shall execute and deliver to the Administrative Agent a Loan Modification Agreement and such other documentation as the Administrative Agent shall reasonably specify to evidence the acceptance of the Permitted Amendments and the terms and conditions thereof, and the Borrower shall also deliver such resolutions, opinions and other documents as reasonably requested by the Administrative Agent. The Administrative Agent shall promptly notify each Lender as to the effectiveness of each Loan Modification Agreement. Each of the parties hereto hereby agrees that (1) upon the effectiveness of any Loan Modification Agreement, this Agreement shall be deemed amended to the extent (but only to the extent) necessary to reflect the existence and terms of the Permitted Amendments evidenced thereby and only with respect to each Accepting Lender’s Commitments and Loans of the relevant Class(es) as to which such Lender’s acceptance has been made, (2) any applicable Lender who is not an Accepting Lender may be replaced by the Borrower in accordance with Section 10.13, and (3) the Administrative Agent and the Borrower shall be permitted to make any amendments or modifications to any Loan Documents necessary to allow any borrowings, prepayments and commitment reductions to be ratable across any relevant Class of commitments to make Loans of such Class, the mechanics for which may be implemented through the applicable Loan Modification Agreement and may include technical changes related to the borrowing and repayment procedures of the Lenders; provided that with the consent of the Accepting Lenders such prepayments and commitment reductions may be applied on a non-ratable basis to the non-Accepting Lenders of the relevant Class(es). Notwithstanding anything herein to the contrary, this Agreement may be amended in connection with Incremental Term Loans, as set forth in Section 2.16(e)(iii). 10.02 Notices; Effectiveness; Electronic Communication. (a) Notices Generally. Except in the case of notices and other communications expressly permitted to be given by telephone (and except as provided in Section 10.02(b) below), all notices and other communications provided for herein shall be in writing and shall be delivered by hand or overnight courier service, mailed by certified or registered mail or sent by facsimile as follows, and all notices and other communications expressly permitted hereunder to be given by telephone shall be made to the applicable telephone number, as follows: (i) if to the Borrower or any other Loan Party or the Administrative Agent, to the address, facsimile number, electronic mail address or telephone number specified for such Person on Schedule 10.02; and (ii) if to any other Lender, to the address, facsimile number, electronic mail address or telephone number specified in its Administrative Questionnaire (including, as appropriate, notices delivered solely to the Person designated by a Lender on its Administrative Questionnaire then in effect for the delivery of notices that may contain material non-public information relating to the Loan Parties).


 
96 Notices and other communications sent by hand or overnight courier service, or mailed by certified or registered mail, shall be deemed to have been given when received; notices and other communications sent by facsimile shall be deemed to have been given when sent (except that, if not given during normal business hours for the recipient, shall be deemed to have been given at the opening of business on the next Business Day for the recipient). Notices and other communications delivered through electronic communications to the extent provided in Section 10.02(b) below, shall be effective as provided in such Section 10.02(b). (b) Electronic Communications. Notices and other communications to the Lenders hereunder may be delivered or furnished by electronic communication (including e-mail and Internet or intranet websites) pursuant to procedures approved by the Administrative Agent; provided that the foregoing shall not apply to notices to any Lender provided pursuant to Article II if such Lender has notified the Administrative Agent that it is incapable of receiving notices under such Article II by electronic communication. The Administrative Agent or the Borrower may each, in its discretion, agree to accept notices and other communications to it hereunder by electronic communications pursuant to procedures approved by it; provided that approval of such procedures may be limited to particular notices or communications. Unless the Administrative Agent otherwise prescribes, (i) notices and other communications sent to an e-mail address shall be deemed received upon the sender’s receipt of an acknowledgement from the intended recipient (such as by the “return receipt requested” function, as available, return e-mail or other written acknowledgement), and (ii) notices or communications posted to an Internet or intranet website shall be deemed received upon the deemed receipt by the intended recipient at its e-mail address as described in the foregoing clause (i) of notification that such notice or communication is available and identifying the website address therefor; provided that, for both clauses (i) and (ii), if such notice, e-mail or other communication is not sent during the normal business hours of the recipient, such notice, e-mail or communication shall be deemed to have been sent at the opening of business on the next business day for the recipient. (c) The Platform. THE PLATFORM IS PROVIDED “AS IS” AND “AS AVAILABLE.” THE AGENT PARTIES (AS DEFINED BELOW) DO NOT WARRANT THE ACCURACY OR COMPLETENESS OF THE BORROWER MATERIALS OR THE ADEQUACY OF THE PLATFORM, AND EXPRESSLY DISCLAIM LIABILITY FOR ERRORS IN OR OMISSIONS FROM THE BORROWER MATERIALS. NO WARRANTY OF ANY KIND, EXPRESS, IMPLIED OR STATUTORY, INCLUDING ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OF THIRD-PARTY RIGHTS OR FREEDOM FROM VIRUSES OR OTHER CODE DEFECTS, IS MADE BY ANY AGENT PARTY IN CONNECTION WITH THE BORROWER MATERIALS OR THE PLATFORM. In no event shall the Administrative Agent or any of its Related Parties (collectively, the “Agent Parties”) have any liability to any Loan Party, any Lender or any other Person for losses, claims, damages, liabilities or expenses of any kind (whether in tort, contract or otherwise) arising out of any Loan Party’s or the Administrative Agent’s transmission of Borrower Materials or notices through the Platform, or any other electronic platform or electronic messaging service, or through the Internet, except to the extent that such losses, claims, damages, liabilities or expenses are determined by a court of competent jurisdiction by a final and non-appealable judgment to have resulted from the gross negligence or willful misconduct of such Agent Party; provided, however, that in no event shall any Agent Party have any liability to any Loan Party, any Lender or any other Person for indirect, special, incidental, consequential or punitive damages (as opposed to direct or actual damages). (d) Change of Address, Etc. Each of the Borrower and any other Loan Party and the Administrative Agent may change its address, facsimile number, telephone number or e-mail address for


 
97 notices and other communications hereunder by notice to the other parties hereto. Each other Lender may change its address, facsimile number, telephone number or e-mail address for notices and other communications hereunder by notice to the Borrower and the Administrative Agent. In addition, each Lender agrees to notify the Administrative Agent from time to time to ensure that the Administrative Agent has on record (i) an effective address, contact name, telephone number, facsimile number and electronic mail address to which notices and other communications may be sent and (ii) accurate wire instructions for such Lender. Furthermore, each Public Lender agrees to cause at least one individual at or on behalf of such Public Lender to at all times have selected the “Private Side Information” or similar designation on the content declaration screen of the Platform in order to enable such Public Lender or its delegate, in accordance with such Public Lender’s compliance procedures and applicable Law, including United States Federal and state securities Laws, to make reference to Borrower Materials that are not made available through the “Public Side Information” portion of the Platform and that may contain material non-public information with respect to any Loan Party or its securities for purposes of United States Federal or state securities Laws. (e) Reliance by Administrative Agent and Lenders. The Administrative Agent and the Lenders shall be entitled to rely and act upon any notices (including telephonic Committed Loan Notices) purportedly given by or on behalf of the Borrower even if (i) such notices were not made in a manner specified herein, were incomplete or were not preceded or followed by any other form of notice specified herein, or (ii) the terms thereof, as understood by the recipient, varied from any confirmation thereof. The Borrower shall indemnify the Administrative Agent, each Lender and the Related Parties of each of them from all losses, costs, expenses and liabilities resulting from the reliance by such Person on each notice purportedly given by or on behalf of the Borrower in accordance with Section 10.02. All telephonic notices to and other telephonic communications with the Administrative Agent may be recorded by the Administrative Agent, and each of the parties hereto hereby consents to such recording. 10.03 No Waiver; Cumulative Remedies. No failure by any Lender or the Administrative Agent to exercise, and no delay by any such Person in exercising, any right, remedy, power or privilege hereunder shall operate as a waiver thereof nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege. The rights, remedies, powers and privileges herein provided are cumulative and not exclusive of any rights, remedies, powers and privileges provided by law. Notwithstanding anything to the contrary contained herein or in any other Loan Document, the authority to enforce rights and remedies hereunder and under the other Loan Documents against any Loan Party and its Subsidiaries or any of them shall be vested exclusively in, and all actions and proceedings at law in connection with such enforcement shall be instituted and maintained exclusively by, the Administrative Agent in accordance with Section 8.02 for the benefit of all the Lenders; provided, however, that the foregoing shall not prohibit (a) the Administrative Agent from exercising on its own behalf the rights and remedies that inure to its benefit (solely in its capacity as Administrative Agent) hereunder and under the other Loan Documents, (b) [reserved], (c) any Lender from enforcing payments of amounts payable to such Lender pursuant to Sections 3.01, 3.04, 3.05 and 10.04 or from exercising setoff rights in accordance with Section 10.08 (subject to the terms of Section 2.14), or (d) any Lender from filing proofs of claim or appearing and filing pleadings on its own behalf during the pendency of a proceeding relative to any Loan Party or any Subsidiary under any Debtor Relief Law; and provided, further, that, if at any time there is no Person acting as Administrative Agent hereunder and under the other Loan Documents, then (i) the Required Lenders shall have the rights otherwise ascribed to the Administrative Agent pursuant to Section 8.02 and (ii) in addition to the matters set forth in clauses (b), (c) and (d) of the preceding proviso


 
98 and subject to Section 2.14, any Lender may, with the consent of the Required Lenders, enforce any rights and remedies available to it and as authorized by the Required Lenders. 10.04 Expenses; Indemnity; Damage Waiver. (a) Costs and Expenses. Each Loan Party shall, jointly and severally, pay (i) all reasonable and documented out-of-pocket expenses incurred by the Administrative Agent and the Arrangers (limited, in the case of legal fees, to the reasonable and documented fees, charges and disbursements of one primary counsel, and, if applicable, one local counsel in each material jurisdiction, for the Administrative Agent), in connection with the syndication of the credit facilities provided for herein, due diligence, the preparation, negotiation, execution, delivery and administration of this Agreement and the other Loan Documents or any amendments, modifications or waivers of the provisions hereof or thereof (whether or not the transactions contemplated hereby or thereby shall be consummated), (ii) [reserved] and (iii) all documented out-of-pocket expenses incurred by the Administrative Agent or any Lender (limited, in the case of legal fees, to the reasonable and documented fees, charges and disbursements of (x) one primary counsel for the Administrative Agent (and, if reasonably required, one counsel for the Administrative Agent per specialty area and one local counsel for the Administrative Agent per applicable jurisdiction) and (y) one additional counsel for all the Lenders (and, if reasonably required, one additional counsel per specialty area and one local counsel per applicable jurisdiction), plus additional counsel for the Lenders as necessary in the event of an actual or potential conflict of interest among the Lenders), in connection with the enforcement or protection of its rights (A) in connection with this Agreement and the other Loan Documents, including its rights under this Section 10.04, or (B) in connection with the Loans made hereunder, including all such reasonable and documented out-of-pocket expenses (subject to the limitations set forth above with respect to legal fees) incurred during any workout, restructuring or negotiations in respect of such Loans. (b) Indemnification by the Loan Parties. Each Loan Party shall, jointly and severally, indemnify the Administrative Agent (and any sub-agent thereof), each Lender, the Agents and their Affiliates and each Related Party of any of the foregoing Persons (each such Person being called an “Indemnitee”) against, and hold each Indemnitee harmless from, any and all losses, claims, damages, penalties, liabilities and related reasonable and documented out-of-pocket expenses (including the reasonable and documented out-of-pocket fees, charges and disbursements of one primary counsel for the Indemnitees; provided that reimbursement for reasonable and documented out-of-pocket fees, charges and disbursements of additional counsel of the Indemnitees will be limited to such specialist counsel as may reasonably be required by the Indemnitees, a single firm of local counsel for the Indemnitees in each material jurisdiction and, in the event of an actual or potential conflict of interest (as reasonably determined by the applicable Indemnitee), one additional firm of counsel to each group of similarly affected Indemnitees), incurred by any Indemnitee or asserted against any Indemnitee by any third party or by any Loan Party arising out of, in connection with, or as a result of (i) the execution or delivery of this Agreement, any other Loan Document or any agreement or instrument contemplated hereby or thereby, the performance by the parties hereto of their respective obligations hereunder or thereunder, the consummation of the transactions contemplated hereby or thereby (including, without limitation, each Lender’s agreement to make Loans or the use or intended use of the proceeds thereof) or, in the case of the Administrative Agent (and any sub-agent thereof) and its Related Parties only, the administration of this Agreement and the other Loan Documents (including in respect of any matters addressed in Section 3.01), (ii) any Loan or the use or proposed use of the proceeds therefrom, (iii) any actual or alleged presence or release of Hazardous Materials on or from any property owned or operated by any Loan Party or any of its Subsidiaries, or any Environmental Liability related in any way to any Loan Party or any of its Subsidiaries, or (iv) any actual or prospective claim, litigation, investigation or proceeding relating to any of the foregoing, whether based on contract, tort or any other theory, whether brought by a third party or by any Loan Party, and regardless of whether any Indemnitee is a party thereto; provided that such indemnity shall not, as to any Indemnitee, be available to the extent that such losses, claims, damages, penalties, liabilities or related expenses


 
99 (A) (x) are determined by a court of competent jurisdiction by final and non-appealable judgment to have resulted from the gross negligence or willful misconduct of such Indemnitee or any of its Related Indemnified Parties or (y) result from a claim brought by any Loan Party against an Indemnitee for breach in bad faith or a material breach of the obligations of such Indemnitee or any of its Related Indemnified Parties hereunder or under any other Loan Document, if any Loan Party has obtained a final and non-appealable judgment in its favor on such claim as determined by a court of competent jurisdiction or (B) arise out of a dispute solely among Indemnitees and not resulting from any act or omission by any Loan Party or any of its Affiliates (other than any such losses, claims, damages, penalties, liabilities or related reasonable and documented out-of-pocket expenses against an Indemnitee in its capacity or in fulfilling its role as an Agent). Notwithstanding the foregoing, Section 3.01 shall be the sole remedy for any indemnification claim in respect of Taxes. No Loan Party shall, except as a result of its indemnification obligations hereunder, and nor shall any of its Related Parties have any liability for any special, indirect, consequential or punitive damages (as opposed to direct or actual damages) arising out of, in connection with, or as a result of, this Agreement, any other Loan Document or any agreement or instrument contemplated hereby, the transactions contemplated hereby or thereby, any Loan or the use of the proceeds thereof. (c) Reimbursement by Lenders. To the extent that any Loan Party for any reason fails to indefeasibly pay any amount required under Section 10.04(a) or 10.04(b) to be paid by it to the Administrative Agent (or any sub-agent thereof) or any Related Party of any of the foregoing and without relieving such Loan Party of its obligations with respect thereto, each Lender severally agrees to pay to the Administrative Agent (or any such sub-agent) or such Related Party, as the case may be, such Lender’s pro rata share (determined as of the time that the applicable unreimbursed expense or indemnity payment is sought based on each Lender’s Applicable Percentage at such time) of such unpaid amount; provided that the unreimbursed expense or indemnified loss, claim, damage, liability or related expense, as the case may be, was incurred by or asserted against the Administrative Agent (or any such sub-agent) in its capacity as such, or against any Related Party of any of the foregoing acting for the Administrative Agent (or any such sub-agent) in connection with such capacity. The obligations of the Lenders under this Section 10.04(c) are subject to the provisions of Section 2.13(d). (d) Waiver of Consequential Damages, Etc. To the fullest extent permitted by applicable Law, each Loan Party shall not assert, and hereby waives, any claim against any of the Administrative Agent (and any sub-agent thereof) and each Lender, the Agents and their Affiliates and each Related Party of any of the foregoing Persons (each such Person being called a “Lender Related Party”), on any theory of liability, for special, indirect, consequential or punitive damages (as opposed to direct or actual damages) arising out of, in connection with, or as a result of, this Agreement, any other Loan Document or any agreement or instrument contemplated hereby, the transactions contemplated hereby or thereby, any Loan or the use of the proceeds thereof. No Lender Related Party shall be liable for any damages arising from the use by unintended recipients of any information or other materials distributed by it through telecommunications, electronic or other information transmission systems in connection with this Agreement or the other Loan Documents or the transactions contemplated hereby or thereby, except to the extent of such Lender Related Party’s gross negligence or willful misconduct as determined by a court of competent jurisdiction in a final, non-appealable judgment. (e) Payments. All amounts due under this Section 10.04 shall be payable not later than ten (10) Business Days after demand therefor (accompanied by backup documentation to the extent available). (f) Survival. The agreements in this Section 10.04 shall survive the resignation of the Administrative Agent, the replacement of any Lender, the termination of the Aggregate Commitments and the repayment, satisfaction or discharge of all the other Obligations.


 
100 10.05 Payments Set Aside. To the extent that any payment by or on behalf of any Loan Party is made to the Administrative Agent or any Lender, or the Administrative Agent or any Lender exercises its right of setoff, and such payment or the proceeds of such setoff or any part thereof is subsequently invalidated, declared to be fraudulent or preferential, set aside or required (including pursuant to any settlement entered into by the Administrative Agent or such Lender in its discretion) to be repaid to a trustee, receiver or any other party, in connection with any proceeding under any Debtor Relief Law or otherwise, then (a) to the extent of such recovery, the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such setoff had not occurred, and (b) each Lender severally agrees to pay to the Administrative Agent upon demand its applicable share (without duplication) of any amount so recovered from or repaid by the Administrative Agent, plus interest thereon from the date of such demand to the date such payment is made at a rate per annum equal to the applicable Overnight Rate from time to time in effect. The obligations of the Lenders under clause (b) of the preceding sentence shall survive the payment in full of the Obligations and the termination of this Agreement. 10.06 Successors and Assigns. (a) Successors and Assigns Generally. The provisions of this Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns permitted hereby, except that neither the Borrower nor any other Loan Party may assign or otherwise transfer any of its rights or obligations hereunder without the prior written consent of the Administrative Agent and each Lender (provided that, for the avoidance of doubt, the rights and obligations of any Loan Party may be assigned to any applicable surviving or successor Loan Party in connection with a transaction permitted by, and consummated in accordance with, Section 7.04) and no Lender may assign or otherwise transfer any of its rights or obligations hereunder except (i) to an assignee in accordance with the provisions of subsection (b) of this Section, (ii) by way of participation in accordance with the provisions of subsection (d) of this Section, or (iii) by way of pledge or assignment or grant of a security interest subject to the restrictions of subsection (f) of this Section (and any other attempted assignment or transfer by any party hereto shall be null and void). Nothing in this Agreement, expressed or implied, shall be construed to confer upon any Person (other than the parties hereto, their respective successors and assigns permitted hereby, Participants to the extent provided in subsection (d) of this Section and, to the extent expressly contemplated hereby, the Related Parties of each of the Administrative Agent and the Lenders) any legal or equitable right, remedy or claim under or by reason of this Agreement. (b) Assignments by Lenders. Any Lender may at any time assign to one or more Eligible Assignees all or a portion of its rights and obligations under this Agreement (including all or a portion of its Commitment(s) and the Loans with respect to any Facility at the time owing to it); provided that, in each case with respect to any Facility, any such assignment shall be subject to the following conditions: (i) Minimum Amounts. (A) in the case of an assignment of the entire remaining amount of the assigning Lender’s applicable Commitment(s) and/or the applicable Loans at the time owing to it, in each case with respect to such Facility, or in the case of an assignment to a Lender, an Affiliate of a Lender or an Approved Fund, no minimum amount need be assigned; and (B) in any case not described in subsection (b)(i)(A) of this Section, the aggregate principal amount of the Commitment and/or outstanding Loans of the assigning Lender subject to each such assignment, in each case with respect to such Facility,


 
101 determined as of the date the Assignment and Assumption with respect to such assignment is delivered to the Administrative Agent or, if “Trade Date” is specified in the Assignment and Assumption, as of the Trade Date, shall not be less than $5,000,000 in the case of any assignment in respect of such Facility unless each of the Administrative Agent and, so long as no Event of Default has occurred and is continuing, the Borrower otherwise consents (each such consent not to be unreasonably withheld or delayed); provided, however, that concurrent assignments with respect to such Facility to members of an Assignee Group and concurrent assignments with respect to such Facility from members of an Assignee Group to a single assignee (or to an assignee and members of its Assignee Group) will be treated as a single assignment for purposes of determining whether such minimum amount has been met with respect to such Facility. (ii) Proportionate Amounts. Each partial assignment shall be made as an assignment of a proportionate part of all the assigning Lender’s rights and obligations under this Agreement with respect to the applicable Loans or the applicable Commitments assigned. Without limiting the generality of the foregoing, to the extent that any unused Commitments remain under a Facility at a time when any Loans are also outstanding under such Facility, any assignment by a Lender with respect to such Facility shall be a ratable assignment by such Lender of its unused Commitments and outstanding Loans under such Facility. (iii) Required Consents. No consent shall be required for any assignment except to the extent required by subsection (b)(i)(B) of this Section and, in addition: (A) the consent of the Borrower (such consent not to be unreasonably withheld or delayed) shall be required unless (1) an Event of Default has occurred and is continuing at the time of such assignment or (2) such assignment is to a Person that is a Lender, an Affiliate of any Lender or an Approved Fund with respect to any Lender; provided that the Borrower shall be deemed to have consented to any such assignment unless it shall object thereto by written notice to the Administrative Agent within ten (10) Business Days after having received notice thereof; and (B) the consent of the Administrative Agent (such consent not to be unreasonably withheld or delayed) shall be required unless such assignment is to a Person that is a Lender, an Affiliate of any Lender or an Approved Fund with respect to any Lender. (iv) Assignment and Assumption. The parties to each assignment shall execute and deliver to the Administrative Agent an Assignment and Assumption, together with a processing and recordation fee in the amount of $3,500; provided, however, that the Administrative Agent may, in its sole discretion, elect to waive such processing and recordation fee in the case of any assignment. The assignee, if it is not a Lender, shall deliver to the Administrative Agent an Administrative Questionnaire. (v) No Assignment to the Loan Parties. No such assignment shall be made to any Loan Party or any of the Loan Parties’ Affiliates or Subsidiaries. (vi) No Assignment to Natural Persons. No such assignment shall be made to a natural person (or a holding company, investment vehicle or trust for, or owned and operated for the primary benefit of, a natural person).


 
102 (vii) No Assignment to Defaulting Lenders. No such assignment shall be made to a Defaulting Lender or any of its Subsidiaries, or any Person who, upon becoming a Lender hereunder, would constitute any of the foregoing Persons described in this clause (vii). (viii) Certain Additional Payments. In connection with any assignment of rights and obligations of any Defaulting Lender hereunder, no such assignment shall be effective unless and until, in addition to the other conditions thereto set forth herein, the parties to the assignment shall make such additional payments to the Administrative Agent in an aggregate amount sufficient, upon distribution thereof as appropriate (which may be outright payment, purchases by the assignee of participations or sub-participations, or other compensating actions, including funding, with the consent of the Borrower and the Administrative Agent, the applicable pro rata share of Loans previously requested but not funded by the Defaulting Lender, to each of which the applicable assignee and assignor hereby irrevocably consent), to (x) pay and satisfy in full all payment liabilities then owed by such Defaulting Lender to the Administrative Agent or any Lender hereunder (and interest accrued thereon) and (y) acquire (and fund as appropriate) its full pro rata share of all Loans in accordance with its relevant Applicable Percentage. Notwithstanding the foregoing, in the event that any assignment of rights and obligations of any Defaulting Lender hereunder shall become effective under applicable Law without compliance with the provisions of this paragraph, then the assignee of such interest shall be deemed to be a Defaulting Lender for all purposes of this Agreement until such compliance occurs. Subject to acceptance and recording thereof by the Administrative Agent pursuant to subsection (c) of this Section, from and after the effective date specified in each Assignment and Assumption, the Eligible Assignee thereunder shall be a party to this Agreement and, to the extent of the interest assigned by such Assignment and Assumption, have the rights and obligations of a Lender under this Agreement, and the assigning Lender thereunder shall, to the extent of the interest assigned by such Assignment and Assumption, be released from its obligations under this Agreement (and, in the case of an Assignment and Assumption covering all of the assigning Lender’s rights and obligations under this Agreement, such Lender shall cease to be a party hereto) but shall continue to be entitled to the benefits of Sections 3.01, 3.04, 3.05, and 10.04 with respect to facts and circumstances occurring prior to the effective date of such assignment; provided that, except to the extent otherwise expressly agreed by the affected parties, no assignment by a Defaulting Lender will constitute a waiver or release of any claim of any party hereunder arising from that Lender’s having been a Defaulting Lender. Upon request, the Borrower (at its expense) shall execute and deliver Note(s) with respect to the applicable Facility or Facilities to the assignee Lender. Any assignment or transfer by a Lender of rights or obligations under this Agreement that does not comply with this subsection shall be treated for purposes of this Agreement as a sale by such Lender of a participation in such rights and obligations in accordance with subsection (d) of this Section. (c) Register. The Administrative Agent, acting solely for this purpose as a non-fiduciary agent of the Borrower (and such agency being solely for tax purposes), shall maintain at the Administrative Agent’s Office a copy of each Assignment and Assumption delivered to it (or the equivalent thereof in electronic form) and a register for the recordation of the names and addresses of the Lenders, and the Commitments of, and principal amounts (and stated interest) of the Loans owing to, each Lender pursuant to the terms hereof from time to time (the “Register”). The entries in the Register shall be conclusive absent manifest error, and the Borrower, the Administrative Agent and the Lenders shall treat each Person whose name is recorded in the Register pursuant to the terms hereof as a Lender hereunder for all purposes of this Agreement, notwithstanding notice to the contrary. In addition, the Administrative Agent shall maintain on the Register information regarding the designation, and revocation of designation, of any Lender as a Defaulting Lender. The Register shall be available for inspection by the Borrower and any Lender (with respect to its own interest only), at any reasonable time and from time to time upon reasonable prior notice.


 
103 (d) Participations. Any Lender may at any time, without the consent of, or notice to, the Borrower or the Administrative Agent, sell participations to any Person (other than a natural person (or a holding company, investment vehicle or trust for, or owned and operated for the primary benefit of, a natural person), a Defaulting Lender (or any of its Subsidiaries, or any Person who, upon becoming a Lender hereunder, would constitute a Defaulting Lender or any of its Subsidiaries) or any Loan Party or any of the Loan Parties’ Affiliates or Subsidiaries) (each, a “Participant”) in all or a portion of such Lender’s rights and/or obligations under this Agreement (including all or a portion of its Commitments and/or the Loans owing to it); provided that (i) such Lender’s obligations under this Agreement shall remain unchanged, (ii) such Lender shall remain solely responsible to the other parties hereto for the performance of such obligations and (iii) the Borrower, the Administrative Agent and the Lenders shall continue to deal solely and directly with such Lender in connection with such Lender’s rights and obligations under this Agreement. Any agreement or instrument pursuant to which a Lender sells such a participation shall provide that such Lender shall retain the sole right to enforce this Agreement and to approve any amendment, modification or waiver of any provision of this Agreement; provided that such agreement or instrument may provide that such Lender will not, without the consent of the Participant, agree to any amendment, waiver or other modification described in clauses (a) through (e) of the first proviso to Section 10.01 that affects such Participant. Subject to subsection (e) of this Section, the Borrower agrees that each Participant shall be entitled to the benefits of Sections 3.01, 3.04 and 3.05 to the same extent as if it were a Lender and had acquired its interest by assignment pursuant to subsection (b) of this Section (it being understood that the documentation required under Section 3.01(e) shall be delivered to the Lender who sells the participation) to the same extent as if it were a Lender and had acquired its interest by assignment pursuant to Section 10.06(b); provided that such Participant agrees to be subject to the provisions of Sections 3.01, 3.04, 3.05, 3.06 and 10.13 and any requirements or limitations contained therein as if it were an assignee under subsection (b) of this Section. Each Lender that sells a participation agrees, at the Borrower’s request and expense, to use reasonable efforts to cooperate with the Borrower to effectuate the provisions of Sections 3.06 and 10.13 with respect to any Participant. To the extent permitted by law, each Participant also shall be entitled to the benefits of Section 10.08 as though it were a Lender; provided such Participant agrees to be subject to Section 2.14 as though it were a Lender. Each Lender that sells a participation shall, acting solely for this purpose as a non-fiduciary agent of the Borrower, maintain a register on which it enters the name and address of each Participant and the principal amounts (and stated interest) of each Participant’s interest in the Loans or other obligations under the Loan Documents (the “Participant Register”); provided that no Lender shall have any obligation to disclose all or any portion of the Participant Register (including the identity of any Participant or any information relating to a Participant’s interest in any commitments, loans or its other obligations under any Loan Document) to any Person except to the extent that such disclosure is necessary to establish that such commitment, loan or other obligation is in registered form under Section 5f.103-1(c) of the United States Treasury Regulations. The entries in the Participant Register shall be conclusive absent manifest error, and such Lender shall treat each Person whose name is recorded in the Participant Register as the owner of such participation for all purposes of this Agreement notwithstanding any notice to the contrary. For the avoidance of doubt, the Administrative Agent (in its capacity as Administrative Agent) shall have no responsibility for maintaining a Participant Register. (e) Limitations upon Participant Rights. A Participant shall not be entitled to receive any greater payment under Section 3.01 or 3.04 than the applicable Lender would have been entitled to receive with respect to the participation sold to such Participant, unless the sale of the participation to such Participant is made with the Borrower’s prior written consent. A Participant that would be a Foreign Lender if it were a Lender shall not be entitled to the benefits of Section 3.01 unless the Borrower is notified of the


 
104 participation sold to such Participant and such Participant agrees, for the benefit of the Borrower, to comply with Section 3.01(e) as though it were a Lender. (f) Certain Pledges. Any Lender may at any time pledge, assign or grant a security interest in, all or any portion of its rights under this Agreement (including under its Note(s), if any) to secure obligations of such Lender, including any pledge or assignment or grant of a security interest to secure obligations to a Federal Reserve Bank or other central banking authority; provided that no such pledge or assignment or grant of a security interest shall release such Lender from any of its obligations hereunder or substitute any such pledgee or assignee or grantee for such Lender as a party hereto. 10.07 Treatment of Certain Information; Confidentiality. Each of the Administrative Agent and the Lenders agrees to maintain the confidentiality of the Information (as defined below), except that Information may be disclosed (a) on a need-to-know basis to its Affiliates and to its and its Affiliates’ respective partners, directors, officers, employees, agents, advisors, consultants, service providers and representatives (it being understood that the Persons to whom such disclosure is made will be informed of the confidential nature of such Information and instructed to keep such Information confidential), (b) to the extent required or requested by any governmental agency or regulatory authority purporting to have jurisdiction over it or its Affiliates (including any self-regulatory authority, such as the National Association of Insurance Commissioners), (c) to the extent required by applicable Laws or by any subpoena or similar legal process, (d) to any other party hereto, (e) in connection with the exercise of any remedies hereunder or under any other Loan Document or any action or proceeding relating to this Agreement or any other Loan Document or the enforcement of rights hereunder or thereunder, (f) subject to an agreement containing provisions substantially the same as (or no less restrictive than) those of this Section 10.07, to (i) any assignee of or Participant in, or any prospective assignee of or Participant in, any of its rights or obligations under this Agreement or any Eligible Assignee invited to be a Lender pursuant to Section 2.16(c), (ii) any actual or prospective counterparty (or its advisors) to any swap or derivative transaction relating to the Borrower and its obligations or (iii) any actual or potential insurer or reinsurer, (g) with the consent of the Borrower, (h) to the extent such Information (x) becomes publicly available other than as a result of a breach of this Section 10.07 or (y) becomes available to the Administrative Agent or any Lender or any of their respective Affiliates on a nonconfidential basis from a source other than the Borrower that the Administrative Agent or any such Lender reasonably believes is not bound by a duty of confidentiality to the Borrower, (i) to any rating agency in connection with rating the Borrower or its Subsidiaries or the credit facilities provided hereunder (provided such rating agencies are advised of the confidential nature of such information and agree to keep such information confidential), (j) on a confidential basis to the CUSIP Service Bureau or any similar agency in connection with the application, issuance, publishing and monitoring of CUSIP numbers or other market identifiers with respect to the credit facilities provided hereunder or (k) to any Person that would qualify as an Eligible Assignee hereunder (without giving effect to the consent required under Section 10.06(b)(iii)) providing financing to the disclosing Lender, to the extent reasonably required by such Person (provided such other Persons are advised of the confidential nature of such information and agree to keep such information confidential). In addition, the Administrative Agent and the Lenders may disclose the existence of this Agreement and customary information about this Agreement to market data collectors, similar service providers to the lending industry and service providers to the Agents and the Lenders in connection with the administration of this Agreement, the other Loan Documents, and the Commitments. For purposes of this Section 10.07, “Information” means all information received from or on behalf of the Borrower or any Subsidiary relating to the Borrower or any Subsidiary or any of their respective businesses, other than any such information that is available to the Administrative Agent or any Lender on a nonconfidential basis prior to disclosure by the Borrower or any Subsidiary; provided that, in the case of information received from the Borrower or any Subsidiary after the date hereof, such information is clearly


 
105 identified at the time of delivery as confidential. Any Person required to maintain the confidentiality of Information as provided in this Section 10.07 shall be considered to have complied with its obligation to do so if such Person has exercised the same degree of care to maintain the confidentiality of such Information as such Person would accord to its own or its other similarly situated customers’ confidential information. Each of the Administrative Agent and the Lenders acknowledges that (a) the Information may include material non-public information concerning any Loan Party or a Subsidiary, as the case may be, (b) it has developed compliance procedures regarding the use of material non-public information and (c) it will handle such material non-public information in accordance with applicable Law, including United States Federal and state securities Laws. 10.08 Right of Setoff. If an Event of Default shall have occurred and be continuing, each Lender and each of their respective Affiliates is hereby authorized at any time and from time to time, to the fullest extent permitted by applicable Law, to set off and apply any and all deposits (general or special, time or demand, provisional or final, in whatever currency) at any time held and other obligations (in whatever currency) at any time owing by such Lender or any such Affiliate to or for the credit or the account of the applicable Loan Party against any and all of the Obligations of such Loan Party now or hereafter existing under this Agreement or any other Loan Document to such Lender, irrespective of whether or not such Lender shall have made any demand under this Agreement or any other Loan Document and although such obligations of such Loan Party may be contingent or unmatured or are owed to a branch or office of such Lender different from the branch or office holding such deposit or obligated on such indebtedness; provided that, in the event that any Defaulting Lender shall exercise any such right of setoff, (x) all amounts so set off shall be paid over immediately to the Administrative Agent for further application in accordance with the provisions of Section 2.18 and, pending such payment, shall be segregated by such Defaulting Lender from its other funds and deemed held in trust for the benefit of the Administrative Agent and the Lenders, and (y) such Defaulting Lender shall provide promptly to the Administrative Agent a statement describing in reasonable detail the Obligations owing to such Defaulting Lender as to which it exercised such right of setoff. The rights of each Lender and its Affiliates under this Section 10.08 are in addition to other rights and remedies (including other rights of setoff) that such Lender or its Affiliates may have. Each Lender agrees to notify the Borrower and the Administrative Agent promptly after any such setoff and application; provided that the failure to give such notice shall not affect the validity of such setoff and application. 10.09 Interest Rate Limitation. Notwithstanding anything to the contrary contained in any Loan Document, the interest paid or agreed to be paid under the Loan Documents shall not exceed the maximum rate of non-usurious interest permitted by applicable Law (the “Maximum Rate”). If the Administrative Agent or any Lender shall receive interest in an amount that exceeds the Maximum Rate, the excess interest shall be applied to the principal of the Loans or, if it exceeds such unpaid principal, refunded to the Borrower. In determining whether the interest contracted for, charged, or received by the Administrative Agent or a Lender exceeds the Maximum Rate, such Person may, to the extent permitted by applicable Law, (a) characterize any payment that is not principal as an expense, fee, or premium rather than interest, (b) exclude voluntary prepayments and the effects thereof, and (c) amortize, prorate, allocate, and spread in equal or unequal parts the total amount of interest throughout the contemplated term of the Obligations hereunder.


 
106 10.10 Integration; Effectiveness. This Agreement and the other Loan Documents constitute the entire contract among the parties relating to the subject matter hereof and supersede any and all previous agreements and understandings, oral or written, relating to the subject matter hereof. Except as provided in Section 4.01, this Agreement shall become effective when it shall have been executed by the Administrative Agent and when the Administrative Agent shall have received counterparts hereof that, when taken together, bear the signatures of each of the other parties hereto. 10.11 Survival of Representations and Warranties. All representations and warranties made hereunder and in any other Loan Document or any document, certificate or other writing executed by a Responsible Officer and required to be furnished hereunder shall survive the execution and delivery hereof and thereof. Such representations and warranties have been or will be relied upon by the Administrative Agent and each Lender, regardless of any investigation made by the Administrative Agent or any Lender or on their behalf and notwithstanding that the Administrative Agent or any Lender may have had notice or knowledge of any Default at the time of any Credit Extension, and shall continue in full force and effect as long as any Loan or any other Obligation hereunder shall remain unpaid or unsatisfied. 10.12 Severability. If any provision of this Agreement or the other Loan Documents is held to be illegal, invalid or unenforceable, (a) the legality, validity and enforceability of the remaining provisions of this Agreement and the other Loan Documents shall not be affected or impaired thereby and (b) the parties shall endeavor in good faith negotiations to replace the illegal, invalid or unenforceable provisions with valid provisions the economic effect of which comes as close as possible to that of the illegal, invalid or unenforceable provisions. The invalidity of a provision in a particular jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. Without limiting the foregoing provisions of this Section 10.12, if and to the extent that the enforceability of any provisions in this Agreement relating to Defaulting Lenders shall be limited by Debtor Relief Laws, as determined in good faith by the Administrative Agent, then such provisions shall be deemed to be in effect only to the extent not so limited. 10.13 Replacement of Lenders. If any Lender requests compensation under Section 3.04, or if the Borrower is required to pay any additional amount to any Lender or any Governmental Authority for the account of any Lender pursuant to Section 3.01, or if any Lender’s obligation to make, continue or convert to Affected Loans is suspended pursuant to Section 3.02, or if any Lender is a Defaulting Lender, or if any Lender does not consent to any amendment or waiver of any provision hereof or of any other Loan Document for which its consent is required under Section 10.01 after Required Lenders or applicable Required Class Lenders have consented thereto, then the Borrower may, at its sole expense and effort, upon notice to such Lender and the Administrative Agent, require such Lender to assign and delegate, without recourse (in accordance with and subject to the restrictions contained in, and consents required by, Section 10.06), all of its interests, rights and obligations under this Agreement and the related Loan Documents to an assignee that shall assume such obligations (which assignee may be another Lender, if a Lender accepts such assignment); provided that: (a) the assignment fee specified in Section 10.06(b) shall have been paid to or waived by the Administrative Agent;


 
107 (b) such Lender shall have received payment of an amount equal to the outstanding principal of its Loans, accrued interest thereon, accrued fees and all other amounts payable to it hereunder and under the other Loan Documents (including any amounts under Section 3.05) from the assignee (to the extent of such outstanding principal and accrued interest and fees) or the Borrower (in the case of all other amounts); (c) in the case of any such assignment resulting from (i) a claim for compensation under Section 3.04 or payments required to be made pursuant to Section 3.01, such assignment will result in a reduction in such compensation or payments thereafter, (ii) a suspension of a Lender’s obligation to make, continue or convert to Affected Loans pursuant to Section 3.02, the applicable assignee shall not be subject to a similar suspension and (iii) a Lender not consenting to any amendment or waiver hereunder or under any Loan Document for which its consent is required under Section 10.01, the applicable assignee shall have consented to such amendment or waiver; and (d) such assignment does not conflict with applicable Laws. A Lender shall not be required to make any such assignment or delegation if, prior thereto, as a result of a waiver by such Lender or otherwise, the circumstances entitling the Borrower to require such assignment and delegation cease to apply. Each party hereto agrees that (i) an assignment required pursuant to this Section 10.13 may be effected pursuant to an Assignment and Assumption executed by the Borrower, the Administrative Agent and the assignee and (ii) the Lender required to make such assignment need not be a party thereto in order for such assignment to be effective and shall be deemed to have consented to and be bound by the terms thereof; provided that, following the effectiveness of any such assignment, the other parties to such assignment agree to execute and deliver such documents necessary to evidence such assignment as reasonably requested by the applicable Lender; provided, further, that any such documents shall be without recourse to or warranty by the parties thereto. 10.14 Governing Law; Jurisdiction; Etc. (a) GOVERNING LAW. THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK, WITHOUT REGARD TO CONFLICTS OF LAWS PRINCIPLES THAT WOULD REQUIRE THE APPLICATION OF THE LAWS OF ANOTHER JURISDICTION. (b) SUBMISSION TO JURISDICTION. EACH PARTY HERETO IRREVOCABLY AND UNCONDITIONALLY SUBMITS, FOR ITSELF AND ITS PROPERTY, TO THE EXCLUSIVE JURISDICTION OF THE COURTS OF THE STATE OF NEW YORK SITTING IN THE BOROUGH OF MANHATTAN AND OF THE UNITED STATES DISTRICT COURT OF THE SOUTHERN DISTRICT OF NEW YORK SITTING IN THE BOROUGH OF MANHATTAN, AND ANY APPELLATE COURT FROM ANY THEREOF, IN ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT, OR FOR RECOGNITION OR ENFORCEMENT OF ANY JUDGMENT, AND EACH OF THE PARTIES HERETO IRREVOCABLY AND UNCONDITIONALLY AGREES THAT ALL CLAIMS IN RESPECT OF ANY SUCH ACTION OR PROCEEDING MAY BE HEARD AND DETERMINED IN SUCH NEW YORK STATE COURT OR, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, IN SUCH FEDERAL COURT. EACH OF THE PARTIES HERETO AGREES THAT A FINAL JUDGMENT IN ANY SUCH ACTION OR PROCEEDING SHALL BE CONCLUSIVE AND MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON THE JUDGMENT OR IN ANY OTHER MANNER PROVIDED BY LAW. NOTHING IN THIS AGREEMENT OR IN ANY OTHER LOAN DOCUMENT SHALL AFFECT ANY RIGHT THAT THE ADMINISTRATIVE AGENT OR ANY


 
108 LENDER MAY OTHERWISE HAVE TO BRING ANY ACTION OR PROCEEDING RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT AGAINST THE BORROWER OR ANY OTHER LOAN PARTY OR ITS PROPERTIES IN THE COURTS OF ANY JURISDICTION. (c) WAIVER OF VENUE. EACH PARTY HERETO IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY OBJECTION THAT IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT IN ANY COURT REFERRED TO IN SECTION 10.14(b). EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, THE DEFENSE OF AN INCONVENIENT FORUM TO THE MAINTENANCE OF SUCH ACTION OR PROCEEDING IN ANY SUCH COURT. (d) SERVICE OF PROCESS. EACH PARTY HERETO IRREVOCABLY CONSENTS TO SERVICE OF PROCESS IN THE MANNER PROVIDED FOR NOTICES IN SECTION 10.02. NOTHING IN THIS AGREEMENT WILL AFFECT THE RIGHT OF ANY PARTY HERETO TO SERVE PROCESS IN ANY OTHER MANNER PERMITTED BY APPLICABLE LAW. 10.15 Waiver of Jury Trial. EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY). EACH PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PERSON HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PERSON WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 10.15. 10.16 No Advisory or Fiduciary Responsibility. In connection with all aspects of each transaction contemplated hereby (including in connection with any amendment, waiver or other modification hereof or of any other Loan Document), the Borrower and each other Loan Party acknowledges and agrees, and acknowledges its Subsidiaries’ understanding, that: (i) (A) the arranging and other services regarding this Agreement provided by the Administrative Agent, the Lenders and the Arrangers are arm’s-length commercial transactions between the Borrower and each other Loan Party, on the one hand, and the Administrative Agent, the Lenders and the Arrangers, on the other hand, (B) the Borrower and each other Loan Party has consulted its own legal, accounting, regulatory and tax advisors to the extent it has deemed appropriate, and (C) the Borrower and each other Loan Party is capable of evaluating, and understands and accepts, the terms, risks and conditions of the transactions contemplated hereby and by the other Loan Documents; (ii) (A) the Administrative Agent, each Lender and each Arranger each is and has been acting solely as a principal and, except as expressly agreed in writing by the relevant parties, has not been, is not, and will not be acting as an advisor, agent or fiduciary for the Borrower or any other Loan Party or any of its Affiliates, or any other Person and (B) neither the Administrative Agent, any Lender nor any Arranger has any obligation to the Borrower or any other Loan Party or any of its Affiliates with respect to the transactions contemplated hereby except


 
109 those obligations expressly set forth herein and in the other Loan Documents; and (iii) the Administrative Agent, the Lenders and the Arrangers and their respective Affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Borrower and each other Loan Party and its Affiliates, and neither the Administrative Agent, any Lender nor any Arranger has any obligation to disclose any of such interests to the Borrower or any other Loan Party or its Affiliates. To the fullest extent permitted by law, the Borrower and each other Loan Party hereby waives and releases any claims that it may have against the Administrative Agent, the Lenders and the Arrangers with respect to any breach or alleged breach of agency or fiduciary duty in connection with any aspect of any transaction contemplated hereby. 10.17 USA Patriot Act and Beneficial Ownership Regulation Notice. Each Lender that is subject to the Patriot Act (as hereinafter defined) and the Administrative Agent (for itself and not on behalf of any Lender) hereby notifies the Borrower and each other Loan Party that, pursuant to the requirements of the USA Patriot Act (Title III of Pub. L. 107–56 (signed into law October 26, 2001)) (the “Patriot Act”) and the Beneficial Ownership Regulation, as applicable, it is required to obtain, verify and record information that identifies the Borrower and each other Loan Party, which information includes the name and address of the Borrower and each other Loan Party and other information that will allow such Lender or the Administrative Agent, as applicable, to identify the Borrower and each other Loan Party in accordance with the Patriot Act and the Beneficial Ownership Regulation, as applicable. 10.18 Delivery of Signature Page. Each Lender to become a party to this Agreement on the date hereof shall do so by delivering to the Administrative Agent a counterpart of this Agreement duly executed by such Lender. 10.19 Judgment Currency. If, for the purposes of obtaining judgment in any court, it is necessary to convert a sum due hereunder or under any other Loan Document in one currency into another currency, the rate of exchange used shall be that at which in accordance with normal banking procedures the Administrative Agent could purchase the first currency with such other currency on the Business Day preceding that on which final judgment is given. The obligation of the Borrower and each other Loan Party in respect of any such sum due from it to the Administrative Agent or any Lender hereunder or under the other Loan Documents shall, notwithstanding any judgment in a currency (the “Judgment Currency”) other than that in which such sum is denominated in accordance with the applicable provisions of this Agreement (the “Agreement Currency”), be discharged only to the extent that on the Business Day following receipt by the Administrative Agent or such Lender, as the case may be, of any sum adjudged to be so due in the Judgment Currency, the Administrative Agent or such Lender, as the case may be, may in accordance with normal banking procedures purchase the Agreement Currency with the Judgment Currency. If the amount of the Agreement Currency so purchased is less than the sum originally due to the Administrative Agent or any Lender from the Borrower or any other Loan Party in the Agreement Currency, the Borrower and each other Loan Party agrees, as a separate obligation and notwithstanding any such judgment, to indemnify the Administrative Agent or such Lender, as the case may be, against such loss. If the amount of the Agreement Currency so purchased is greater than the sum originally due to the Administrative Agent or any Lender in such currency, the Administrative Agent or such Lender, as the case may be, agrees to return the amount of any excess to the Borrower or such other Loan Party (or to any other Person who may be entitled thereto under applicable law). All of the Borrower’s and each other Loan Party’s obligations under this Section 10.19 shall survive termination of the Aggregate Commitments and repayment of all other Obligations hereunder.


 
110 10.20 Acknowledgement and Consent to Bail-In of Affected Financial Institutions. Solely to the extent any Lender that is an Affected Financial Institution is a party to this Agreement and notwithstanding anything to the contrary in any Loan Document or in any other agreement, arrangement or understanding among any such parties, each party hereto acknowledges that any liability of any Lender that is an Affected Financial Institution arising under any Loan Document, to the extent such liability is unsecured, may be subject to the Write-Down and Conversion Powers of the applicable Resolution Authority and agrees and consents to, and acknowledges and agrees to be bound by: (a) the application of any Write-Down and Conversion Powers by the applicable Resolution Authority to any such liabilities arising hereunder which may be payable to it by any Lender that is an Affected Financial Institution; and (b) the effects of any Bail-In Action on any such liability, including, if applicable: (i) a reduction in full or in part or cancellation of any such liability; (ii) a conversion of all, or a portion of, such liability into shares or other instruments of ownership in such Affected Financial Institution, its parent undertaking, or a bridge institution that may be issued to it or otherwise conferred on it, and that such shares or other instruments of ownership will be accepted by it in lieu of any rights with respect to any such liability under this Agreement or any other Loan Document; or (iii) the variation of the terms of such liability in connection with the exercise of the Write-Down and Conversion Powers of the applicable Resolution Authority. 10.21 Electronic Execution; Electronic Records; Counterparts. This Agreement, any Loan Document and any other Communication, including Communications required to be in writing, may be in the form of an Electronic Record and may be executed using Electronic Signatures. Each of the Loan Parties and each of the Administrative Agent and each Lender Party agrees that any Electronic Signature on or associated with any Communication shall be valid and binding on such Person to the same extent as a manual, original signature, and that any Communication entered into by Electronic Signature, will constitute the legal, valid and binding obligation of such Person enforceable against such Person in accordance with the terms thereof to the same extent as if a manually executed original signature was delivered. Any Communication may be executed in as many counterparts as necessary or convenient, including both paper and electronic counterparts, but all such counterparts are one and the same Communication. For the avoidance of doubt, the authorization under this paragraph may include, without limitation, use or acceptance of a manually signed paper Communication which has been converted into electronic form (such as scanned into PDF format), or an electronically signed Communication converted into another format, for transmission, delivery and/or retention. The Administrative Agent and each of the Lender Parties may, at its option, create one or more copies of any Communication in the form of an imaged Electronic Record (“Electronic Copy”), which shall be deemed created in the ordinary course of such Person’s business, and destroy the original paper document. All Communications in the form of an Electronic Record, including an Electronic Copy, shall be considered an original for all purposes, and shall have the same legal effect, validity and enforceability as a paper record. Notwithstanding anything contained herein to the contrary, the Administrative Agent is not under any obligation to accept an Electronic Signature in any form or in any format unless expressly agreed to by such Person pursuant to procedures approved by it; provided, further, without limiting the foregoing, (a) to the extent the Administrative Agent has agreed to accept such Electronic Signature, the Administrative Agent and each of the Lender Parties shall be entitled to rely on any such Electronic Signature purportedly given


 
111 by or on behalf of any Loan Party and/or any Lender Party without further verification and (b) upon the reasonable request of the Administrative Agent or any Lender Party, any Electronic Signature shall be promptly followed by such manually executed counterpart. 10.22 [Reserved]. 10.23 Lender Representations. (a) Each Lender (x) represents and warrants, as of the Closing Date or such later date such Person became a Lender party hereto, to, and (y) covenants, from the Closing Date or such later date such Person became a Lender party hereto to the date such Person ceases being a Lender party hereto, for the benefit of, the Administrative Agent and the Arrangers and their respective Affiliates and not, for the avoidance of doubt, to or for the benefit of any Loan Party, that at least one of the following is and will be true: (i) such Lender is not using “plan assets” (within the meaning of Section 3(42) of ERISA or otherwise) of one or more Benefit Plans with respect to such Lender’s entrance into, participation in, administration of and performance of the Loans, the Commitments or this Agreement, the transaction exemption set forth in one or more PTEs, such as PTE 84-14 (a class exemption for certain transactions determined by independent qualified professional asset managers), PTE 95-60 (a class exemption for certain transactions involving insurance company general accounts), PTE 90-1 (a class exemption for certain transactions involving insurance company pooled separate accounts), PTE 91-38 (a class exemption for certain transactions involving bank collective investment funds) or PTE 96-23 (a class exemption for certain transactions determined by in-house asset managers), is applicable with respect to such Lender’s entrance into, participation in, administration of and performance of the Loans, the Commitments and this Agreement, (A) such Lender is an investment fund managed by a “Qualified Professional Asset Manager” (within the meaning of Part VI of PTE 84-14), (B) such Qualified Professional Asset Manager made the investment decision on behalf of such Lender to enter into, participate in, administer and perform the Loans, the Commitments and this Agreement, (C) the entrance into, participation in, administration of and performance of the Loans, the Commitments and this Agreement satisfies the requirements of subsections (b) through (g) of Part I of PTE 84-14 and (D) to the best knowledge of such Lender, the requirements of subsection (a) of Part I of PTE 84-14 are satisfied with respect to such Lender’s entrance into, participation in, administration of and performance of the Loans, the Commitments and this Agreement, or such other representation, warranty and covenant as may be agreed in writing between the Administrative Agent, in its sole discretion, and such Lender. (b) In addition, unless either (1) subclause (i) in the immediately preceding clause (a) is true with respect to a Lender or (2) a Lender has provided another representation, warranty and covenant in accordance with subclause (iv) in the immediately preceding clause (a), such Lender further (x) represents and warrants, as of the Closing Date or such later date such Person became a Lender party hereto, to, and


 
112 (y) covenants, from the Closing Date or such later date such Person became a Lender party hereto to the date such Person ceases being a Lender party hereto, for the benefit of, the Administrative Agent and the Arrangers and their respective Affiliates and not, for the avoidance of doubt, to or for the benefit of any Loan Party, that none of the Administrative Agent or the Arrangers or any of their respective Affiliates is a fiduciary with respect to the assets of such Lender involved in such Lender’s entrance into, participation in, administration of and performance of the Loans, the Commitments and this Agreement (including in connection with the reservation or exercise of any rights by the Administrative Agent or the Arrangers under this Agreement, any Loan Document or any documents related hereto or thereto). 10.24 Acknowledgement Regarding Any Supported QFCs. To the extent that the Loan Documents provide support, through a guarantee or otherwise, for any Swap Contract or any other agreement or instrument that is a QFC (such support, “QFC Credit Support,” and each such QFC, a “Supported QFC”), the parties acknowledge and agree as follows with respect to the resolution power of the Federal Deposit Insurance Corporation under the Federal Deposit Insurance Act and Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act (together with the regulations promulgated thereunder, the “U.S. Special Resolution Regimes”) in respect of such Supported QFC and QFC Credit Support (with the provisions below applicable notwithstanding that the Loan Documents and any Supported QFC may in fact be stated to be governed by the laws of the State of New York and/or of the United States or any other state of the United States): (a) In the event a Covered Entity that is party to a Supported QFC (each, a “Covered Party”) becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer of such Supported QFC and the benefit of such QFC Credit Support (and any interest and obligation in or under such Supported QFC and such QFC Credit Support, and any rights in property securing such Supported QFC or such QFC Credit Support) from such Covered Party will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if the Supported QFC and such QFC Credit Support (and any such interest, obligation and rights in property) were governed by the laws of the United States or a state of the United States. In the event a Covered Party or a BHC Act Affiliate of a Covered Party becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under the Loan Documents that might otherwise apply to such Supported QFC or any QFC Credit Support that may be exercised against such Covered Party are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if the Supported QFC and the Loan Documents were governed by the laws of the United States or a state of the United States. Without limitation of the foregoing, it is understood and agreed that rights and remedies of the parties with respect to a Defaulting Lender shall in no event affect the rights of any Covered Party with respect to a Supported QFC or any QFC Credit Support. (b) As used in this Section 10.24, the following terms have the following meanings: “BHC Act Affiliate” of a party means an “affiliate” (as such term is defined under, and interpreted in accordance with, 12 U.S.C. 1841(k)) of such party. “Covered Entity” means any of the following: (i) a “covered entity” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 252.82(b); (ii) a “covered bank” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 47.3(b); or (iii) a “covered FSI” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 382.2(b). “Default Right” has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. §§ 252.81, 47.2 or 382.1, as applicable.


 
113 “QFC” has the meaning assigned to the term “qualified financial contract” in, and shall be interpreted in accordance with, 12 U.S.C. 5390(c)(8)(D). 10.25 Cashless Settlement. Notwithstanding anything to the contrary contained in this Agreement, any Lender may exchange, continue or rollover all or a portion of its Loans of any Class in connection with any refinancing, extension, loan modification or similar transaction with respect to such Class of Loans that is permitted by the terms of this Agreement, pursuant to a cashless settlement mechanism approved by the Borrower, the Administrative Agent and such Lender. 10.26 Appointment of Borrower. Each of the Loan Parties hereby appoints the Borrower to act as its agent for all purposes of this Agreement, the other Loan Documents and all other documents and electronic platforms entered into in connection herewith and agrees that any notice or communication delivered by the Administrative Agent or a Lender to the Borrower shall be deemed delivered to each Loan Party. 10.27 Keepwell. Each Loan Party that is a Qualified ECP Guarantor at the time the Guaranty or the grant of a Lien under the Loan Documents, in each case, by any Loan Party becomes effective with respect to any Swap Obligation, hereby jointly and severally, absolutely, unconditionally and irrevocably undertakes to provide such funds or other support to each Loan Party with respect to such Swap Obligation as may be needed by such Loan Party from time to time to honor all of its obligations under the Loan Documents in respect of such Swap Obligation (but, in each case, only up to the maximum amount of such liability that can be hereby incurred without rendering such Qualified ECP Guarantor’s obligations and undertakings under this Article XI voidable under applicable Law relating to fraudulent conveyance or fraudulent transfer, and not for any greater amount). The obligations and undertakings of each Qualified ECP Guarantor under this Section 10.27 shall remain in full force and effect until the Obligations have been indefeasibly paid and performed in full. Each Loan Party intends this Section 10.27 to constitute, and this Section 10.27 shall be deemed to constitute, a guarantee of the obligations of, and a “keepwell, support, or other agreement” for the benefit of, each Loan Party for all purposes of the Commodity Exchange Act. ARTICLE XI CONTINUING GUARANTY 11.01 Guaranty. The Guarantor hereby absolutely and unconditionally, jointly and severally guarantees, as primary obligor and as guaranty of payment and performance and not merely as a guaranty of collection, prompt payment when due, whether at stated maturity, by required prepayment, upon acceleration, demand or otherwise, and at all times thereafter, of any and all Obligations (for the Guarantor, subject to the proviso in this sentence, its “Guaranteed Obligations”); provided that (a) the Guaranteed Obligations of the Guarantor shall exclude any Excluded Swap Obligations with respect to the Guarantor and (b) the liability of the Guarantor individually with respect to this Guaranty shall be limited to an aggregate amount equal to the largest amount that would not render its obligations hereunder subject to avoidance under Section 548 of the Bankruptcy Code of the United States or any comparable provisions of any applicable state law or other applicable Law. Without limiting the generality of the foregoing, the Guaranteed Obligations shall include any such indebtedness, obligations, and liabilities, or portion thereof, which may be or hereafter become unenforceable or compromised or shall be an allowed or disallowed claim under any proceeding or case commenced by or against any debtor under any Debtor Relief Laws. The Administrative Agent’s books and records showing the amount of the Obligations shall be admissible in evidence in any action or


 
114 proceeding, and shall be binding upon the Guarantor, and conclusive for the purpose of establishing the amount of the Obligations. This Guaranty shall not be affected by the genuineness, validity, regularity or enforceability of the Obligations or any instrument or agreement evidencing any Obligations, or by the existence, validity, enforceability, perfection, non-perfection or extent of any collateral therefor, or by any fact or circumstance relating to the Obligations which might otherwise constitute a defense to the obligations of the Guarantor, or any of them, under this Guaranty, and the Guarantor hereby irrevocably waives any defenses it may now have or hereafter acquire in any way relating to any or all of the foregoing (other than a defense as to the payment in full of the Guaranteed Obligations). 11.02 Rights of Lenders. The Guarantor consents and agrees that the Administrative Agent and each the other Lenders may, at any time and from time to time, without notice or demand, and without affecting the enforceability or continuing effectiveness hereof: (a) amend, extend, renew, compromise, discharge, accelerate or otherwise change the time for payment or the terms of the Obligations or any part thereof; (b) take, hold, exchange, enforce, waive, release, fail to perfect, sell, or otherwise dispose of any security for the payment of this Guaranty or any Obligations; (c) apply such security and direct the order or manner of sale thereof as the Administrative Agent or any of the Lenders in their sole discretion may determine; and (d) release or substitute one or more of any endorsers or other guarantors of any of the Obligations. Without limiting the generality of the foregoing, the Guarantor consents to the taking of, or failure to take, any action which might in any manner or to any extent vary the risks of the Guarantor under this Guaranty or which, but for this provision, might operate as a discharge of the Guarantor. 11.03 Certain Waivers. The Guarantor waives (a) any defense arising by reason of any disability or other defense of the Borrower, or the cessation from any cause whatsoever (including any act or omission of the Administrative Agent or any other Lender) of the liability of the Borrower (other than as to the payment in full of the Guaranteed Obligations); (b) any defense based on any claim that the Guarantor’s obligations exceed or are more burdensome than those of the Borrower; (c) the benefit of any statute of limitations affecting the Guarantor’s liability hereunder; (d) any right to proceed against the Borrower, proceed against or exhaust any security for the Obligations, or pursue any other remedy in the power of the Administrative Agent or any other Lender whatsoever; (e) any benefit of and any right to participate in any security now or hereafter held by the Administrative Agent or any other Lender; and (f) to the fullest extent permitted by law, any and all other defenses or benefits that may be derived from or afforded by applicable Law limiting the liability of or exonerating guarantors or sureties (other than as to the payment in full of the Guaranteed Obligations). The Guarantor expressly waives all setoffs and counterclaims and all presentments, demands for payment or performance, notices of nonpayment or nonperformance, protests, notices of protest, notices of dishonor and all other notices or demands of any kind or nature whatsoever with respect to the Obligations, and all notices of acceptance of this Guaranty or of the existence, creation or incurrence of new or additional Obligations. 11.04 Obligations Independent. The obligations of the Guarantor hereunder are those of primary obligor, and not merely as surety, and are independent of the Obligations and the obligations of any other guarantor, and a separate action may be brought against the Guarantor to enforce this Guaranty whether or not the Borrower or any other person or entity is joined as a party.


 
115 11.05 Subrogation. The Guarantor shall not exercise any right of subrogation, contribution, indemnity, reimbursement or similar rights with respect to any payments it makes under this Guaranty until all of the Obligations have been paid in full in cash (other than contingent Obligations that are not then due and payable) and the Commitments are terminated. If any amounts are paid to the Guarantor in violation of the foregoing limitation, then such amounts shall be held in trust for the benefit of the Administrative Agent and the other Lenders and shall forthwith be paid to the Administrative Agent and the other Lenders to reduce the amount of the Obligations, whether matured or unmatured. 11.06 Termination; Reinstatement. This Guaranty is a continuing and irrevocable guaranty of all Guaranteed Obligations now or hereafter existing and shall remain in full force and effect until the earlier of (i) the payment in cash of all Guaranteed Obligations and the Commitments and the Facilities with respect to the Guaranteed Obligations are terminated (other than contingent indemnification obligations as to which no claim has been asserted) and (ii) the release of the Guarantor pursuant to Section 10.01(f). Notwithstanding the foregoing, this Guaranty shall continue in full force and effect or be revived, as the case may be, if any payment by or on behalf of the Borrower or the Guarantor is made, or any of the Administrative Agent or the other Lenders exercises its right of setoff, in respect of the Obligations and such payment or the proceeds of such setoff or any part thereof is subsequently invalidated, declared to be fraudulent or preferential, set aside or required (including pursuant to any settlement entered into by any of the Administrative Agent or the other Lenders in their discretion) to be repaid to a trustee, receiver or any other party, in connection with any proceeding under any Debtor Relief Laws or otherwise, all as if such payment had not been made or such setoff had not occurred and whether or not the Administrative Agent or the other Lenders are in possession of or have released this Guaranty and regardless of any prior revocation, rescission, termination or reduction. The obligations of the Guarantor under this Section 11.06 shall survive termination of this Guaranty. 11.07 Stay of Acceleration. If acceleration of the time for payment of any of the Obligations is stayed, in connection with any case commenced by or against the Guarantor or the Borrower under any Debtor Relief Laws, or otherwise, all such amounts shall nonetheless be payable by the Guarantor immediately upon demand by the Administrative Agent or the Lenders. 11.08 Condition of Borrower. The Guarantor acknowledges and agrees that it has the sole responsibility for, and has adequate means of, obtaining from the Borrower such information concerning the financial condition, business and operations of the Borrower as the Guarantor requires, and that none of the Administrative Agent or any other Lender has any duty, and the Guarantor is not relying on the Administrative Agent or any other Lender at any time, to disclose to it any information relating to the business, operations or financial condition of the Borrower (the Guarantor waiving any duty on the part of the Administrative Agent or any other Lender to disclose such information and any defense relating to the failure to provide the same).


 
116 ARTICLE XII SUBSIDIARY GUARANTOR CONTINUING GUARANTY 12.01 Guaranty. Each Subsidiary Guarantor hereby absolutely and unconditionally, jointly and severally guarantees, as primary obligor and as guaranty of payment and performance and not merely as a guaranty of collection, prompt payment when due, whether at stated maturity, by required prepayment, upon acceleration, demand or otherwise, and at all times thereafter, of any and all Obligations (for each Subsidiary Guarantor, subject to the proviso in this sentence, its “Guaranteed Obligations”); provided that (a) the Guaranteed Obligations of such Subsidiary Guarantor shall exclude any Excluded Swap Obligations with respect to such Subsidiary Guarantor and (b) the liability of such Subsidiary Guarantor individually with respect to this Guaranty shall be limited to an aggregate amount equal to the largest amount that would not render its obligations hereunder subject to avoidance under Section 548 of the Bankruptcy Code of the United States or any comparable provisions of any applicable state law or other applicable Law. Without limiting the generality of the foregoing, the Guaranteed Obligations shall include any such indebtedness, obligations, and liabilities, or portion thereof, which may be or hereafter become unenforceable or compromised or shall be an allowed or disallowed claim under any proceeding or case commenced by or against any debtor under any Debtor Relief Laws. The Administrative Agent’s books and records showing the amount of the Obligations shall be admissible in evidence in any action or proceeding, and shall be binding upon each Subsidiary Guarantor, and conclusive for the purpose of establishing the amount of the Obligations. This Guaranty shall not be affected by the genuineness, validity, regularity or enforceability of the Obligations or any instrument or agreement evidencing any Obligations, or by the existence, validity, enforceability, perfection, non-perfection or extent of any collateral therefor, or by any fact or circumstance relating to the Obligations which might otherwise constitute a defense to the obligations of any Subsidiary Guarantor, or any of them, under this Guaranty, and each Subsidiary Guarantor hereby irrevocably waives any defenses it may now have or hereafter acquire in any way relating to any or all of the foregoing (other than a defense as to the payment in full of the Guaranteed Obligations). 12.02 Rights of Lenders. Each Subsidiary Guarantor consents and agrees that the Administrative Agent and each the other Lenders may, at any time and from time to time, without notice or demand, and without affecting the enforceability or continuing effectiveness hereof: (a) amend, extend, renew, compromise, discharge, accelerate or otherwise change the time for payment or the terms of the Obligations or any part thereof; (b) take, hold, exchange, enforce, waive, release, fail to perfect, sell, or otherwise dispose of any security for the payment of this Guaranty or any Obligations; (c) apply such security and direct the order or manner of sale thereof as the Administrative Agent or any of the Lenders in their sole discretion may determine; and (d) release or substitute one or more of any endorsers or other guarantors of any of the Obligations. Without limiting the generality of the foregoing, each Subsidiary Guarantor consents to the taking of, or failure to take, any action which might in any manner or to any extent vary the risks of such Subsidiary Guarantor under this Guaranty or which, but for this provision, might operate as a discharge of such Subsidiary Guarantor. 12.03 Certain Waivers. Each Subsidiary Guarantor waives (a) any defense arising by reason of any disability or other defense of the Borrower, or the cessation from any cause whatsoever (including any act or omission of the Administrative Agent or any other Lender) of the liability of the Borrower (other than as to the payment in full of the Guaranteed Obligations); (b) any defense based on any claim that such Subsidiary Guarantor’s


 
117 obligations exceed or are more burdensome than those of the Borrower; (c) the benefit of any statute of limitations affecting such Subsidiary Guarantor’s liability hereunder; (d) any right to proceed against the Borrower, proceed against or exhaust any security for the Obligations, or pursue any other remedy in the power of the Administrative Agent or any other Lender whatsoever; (e) any benefit of and any right to participate in any security now or hereafter held by the Administrative Agent or any other Lender; and (f) to the fullest extent permitted by law, any and all other defenses or benefits that may be derived from or afforded by applicable Law limiting the liability of or exonerating guarantors or sureties (other than as to the payment in full of the Guaranteed Obligations). Each Subsidiary Guarantor expressly waives all setoffs and counterclaims and all presentments, demands for payment or performance, notices of nonpayment or nonperformance, protests, notices of protest, notices of dishonor and all other notices or demands of any kind or nature whatsoever with respect to the Obligations, and all notices of acceptance of this Guaranty or of the existence, creation or incurrence of new or additional Obligations. 12.04 Obligations Independent. The obligations of each Subsidiary Guarantor hereunder are those of primary obligor, and not merely as surety, and are independent of the Obligations and the obligations of any other guarantor, and a separate action may be brought against such Subsidiary Guarantor to enforce this Guaranty whether or not the Borrower or any other person or entity is joined as a party. 12.05 Subrogation. No Subsidiary Guarantor shall exercise any right of subrogation, contribution, indemnity, reimbursement or similar rights with respect to any payments it makes under this Guaranty until all of the Obligations have been paid in full in cash (other than contingent Obligations that are not then due and payable) and the Commitments are terminated. If any amounts are paid to any Subsidiary Guarantor in violation of the foregoing limitation, then such amounts shall be held in trust for the benefit of the Administrative Agent and the other Lenders and shall forthwith be paid to the Administrative Agent and the other Lenders to reduce the amount of the Obligations, whether matured or unmatured. 12.06 Termination; Reinstatement. This Guaranty is a continuing and irrevocable guaranty of all Guaranteed Obligations now or hereafter existing and shall remain in full force and effect until the earlier of (i) the payment in cash of all Guaranteed Obligations and the Commitments and the Facilities with respect to the Guaranteed Obligations are terminated (other than contingent indemnification obligations as to which no claim has been asserted) and (ii) the release of the applicable Subsidiary Guarantor pursuant to Section 12.10. Notwithstanding the foregoing, this Guaranty shall continue in full force and effect or be revived, as the case may be, if any payment by or on behalf of the Borrower or the applicable Guarantor is made, or any of the Administrative Agent or the other Lenders exercises its right of setoff, in respect of the Obligations and such payment or the proceeds of such setoff or any part thereof is subsequently invalidated, declared to be fraudulent or preferential, set aside or required (including pursuant to any settlement entered into by any of the Administrative Agent or the other Lenders in their discretion) to be repaid to a trustee, receiver or any other party, in connection with any proceeding under any Debtor Relief Laws or otherwise, all as if such payment had not been made or such setoff had not occurred and whether or not the Administrative Agent or the other Lenders are in possession of or have released this Guaranty and regardless of any prior revocation, rescission, termination or reduction. The obligations of each Subsidiary Guarantor under this Section 12.06 shall survive termination of this Guaranty.


 
118 12.07 Stay of Acceleration. If acceleration of the time for payment of any of the Obligations is stayed, in connection with any case commenced by or against any Subsidiary Guarantor or the Borrower under any Debtor Relief Laws, or otherwise, all such amounts shall nonetheless be payable by such Subsidiary Guarantor immediately upon demand by the Administrative Agent or the Lenders. 12.08 Condition of Borrower. Each Subsidiary Guarantor acknowledges and agrees that it has the sole responsibility for, and has adequate means of, obtaining from the Borrower such information concerning the financial condition, business and operations of the Borrower as such Subsidiary Guarantor requires, and that none of the Administrative Agent or any other Lender has any duty, and neither Subsidiary Guarantor is relying on the Administrative Agent or any other Lender at any time, to disclose to it any information relating to the business, operations or financial condition of the Borrower (each Subsidiary Guarantor waiving any duty on the part of the Administrative Agent or any other Lender to disclose such information and any defense relating to the failure to provide the same). 12.09 Subordination. Each Subsidiary Guarantor hereby subordinates the payment of all obligations and indebtedness of the Borrower owing to such Subsidiary Guarantor, whether now existing or hereafter arising, including but not limited to any obligation of the Borrower to such Subsidiary Guarantor as subrogee of the Administrative Agent, on behalf of the Lenders, or resulting from such Subsidiary Guarantor’s performance under this Guaranty, to the indefeasible payment in full in cash of all Guaranteed Obligations. If the Administrative Agent so requests, after the occurrence and during the continuance of an Event of Default, any such obligation or indebtedness of the Borrower to any Subsidiary Guarantor shall be enforced and performance received by such Subsidiary Guarantor as trustee for the Administrative Agent, on behalf of the Lenders, and the proceeds thereof shall be paid over to the Administrative Agent, on behalf of the Lenders, on account of the Guaranteed Obligations, but without reducing or affecting in any manner the liability of such Subsidiary Guarantor under this Guaranty. 12.10 Release of Subsidiary Guarantors. A Subsidiary Guarantor shall be automatically released from this Guaranty, and any Liens granted by such Subsidiary Guarantor in respect of the Obligations shall be automatically released, if: (a) (i) such Subsidiary Guarantor is not a Wholly-Owned Subsidiary or ceases to be a Wholly-Owned Subsidiary of the Parent Guarantor in a transaction not prohibited by this Agreement or (ii) the Borrower otherwise requests such release and, in the case of each of clauses (a)(i) and (a)(ii), after giving effect to any such release, such Subsidiary Guarantor shall not be a borrower or a guarantor, or otherwise have a payment obligation, in respect of any Enterprise Unsecured Debt and (b) the Administrative Agent shall have received a certificate of the Borrower signed by a Responsible Officer certifying that, as of the date of such release, (x) the matters set forth in clause (a)(i) or (a)(ii), as applicable, are true and correct, (y) no Default or Event of Default shall then exist or would occur as a result of such releases and (z) the representations and warranties contained in Article V and in the other Loan Documents are true and correct in all material respects (except in the case of a representation or warranty qualified by materiality or Material Adverse Effect or similar language, in which case such representation or warranty shall be true and correct in all respects) on and as of the date of release of such Subsidiary Guarantor (other than such representations and warranties which are expressly made only as of as of the Closing Date or the FifthSixth Amendment Effective Date, as applicable, including but not limited to those set forth in Section 5.05(c) and Section 5.22), except to the extent that such representations and warranties specifically refer to an earlier date, in which case they were true and correct in all material respects (except in the case of a representation or warranty qualified by materiality or Material Adverse Effect or similar language, in which case such representation or warranty shall have been true and correct in all respects) as of such earlier date, and except that for purposes of this Section 12.10, the representations


 
119 and warranties contained in subsections (a) and (b) of Section 5.05 shall be deemed to refer to the most recent statements furnished pursuant to subsections (a) and (b), respectively, of Section 6.01. The Administrative Agent agrees to furnish to the Borrower, promptly after the Borrower’s request and at the Borrower’s sole cost and expense, any release, termination, or other agreement or document as is reasonably necessary or advisable to evidence the foregoing release or as may be reasonably requested by the Borrower.


 


 

EXHIBIT 31.1
 
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
 
I, Scott M. Brinker, certify that:
 
1. I have reviewed this quarterly report on Form 10-Q of Healthpeak Properties, Inc. for the period ended September 30, 2026;
 
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
4 
Date: November 3, 2026/s/ SCOTT M. BRINKER
Scott M. Brinker
President and Chief Executive Officer
(Principal Executive Officer)



EXHIBIT 31.2
 
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
 
I, Kelvin O. Moses, certify that:
 
1. I have reviewed this quarterly report on Form 10-Q of Healthpeak Properties, Inc. for the period ended September 30, 2026;
 
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
4 
Date: November 3, 2026/s/ KELVIN O. MOSES
Kelvin O. Moses
Chief Financial Officer
(Principal Financial Officer)



EXHIBIT 32.1
 
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
 
Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Healthpeak Properties, Inc., a Maryland corporation (the “Company”), hereby certifies, to his knowledge, that:
 
(i) the accompanying quarterly report on Form 10-Q of the Company for the period ended September 30, 2026 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
 
(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date: November 3, 2026/s/ SCOTT M. BRINKER
Scott M. Brinker
President and Chief Executive Officer
(Principal Executive Officer)
 
A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Company specifically incorporates it by reference.



EXHIBIT 32.2
 
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
 
Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Healthpeak Properties, Inc., a Maryland corporation (the “Company”), hereby certifies, to his knowledge, that:
 
(i) the accompanying quarterly report on Form 10-Q of the Company for the period ended September 30, 2026 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
 
(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date: November 3, 2026/s/ KELVIN O. MOSES
Kelvin O. Moses
Chief Financial Officer
(Principal Financial Officer)
 
A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Company specifically incorporates it by reference.